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Abstract 
During the course of this PhD, several libraries of potential PET imaging agents were 
synthesised for testing their affinity and selectivity for sphingosine-1-phosphate 5 
receptors (S1P5). These receptors are located within oligodendrocytes and are proposed 
to have a major role in the re-myelination of neurons. Imaging of these receptors could 
lead to new treatments and diagnostic tools for the management of demyelinating 
disorders, such as multiple sclerosis (MS). The libraries of compounds were subject to 
biological evaluation and two lead compounds, fluorobenzamides 89 and 94, were 
identified as being the most potent and selective for S1P5 receptors. The synthesis of a 
further compound that was described in the literature as having high affinity for S1P5 was 
adapted to allow for the preparation of precursor 124 for 11C-labelling. The radiosynthesis 
of compound [11C]33 was then optimised. 
 
An improved synthesis of AB5186, an imaging agent for the translocator protein (TSPO), 
was developed. TSPO has been shown to be involved in inflammatory processes and is a 
biomarker for many inflammatory diseases. Evaluation of AB5186 led to the synthesis of a 
higher affinity compound LW223 (155), which was not sensitive to the single nucleotide 
polymorphism present in TSPO. A synthesis of LW223 (155) was developed that allowed 
for the production of two potential precursors for radiofluorination. Investigation of the 
radiochemistry showed a chloro-precursor was the most efficient for 18F-labelling. 
 
Finally, an investigation into a polymer-supported nitrite reagent approach for the 
synthesis of benzotriazole derived α-amino acids allowed the preparation of a variety of 
functionalised compounds in relatively few steps. Further derivatisation of these 
compounds led to the discovery of a benzotriazole derived α-amino acid 212 with strong 
fluorescence in the visible region. 
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1 Introduction 
1.1 Molecular Imaging 
Molecular imaging describes a wide range of medical imaging techniques including 
magnetic resonance imaging (MRI), optical imaging and nuclear imaging. These 
techniques provide different methods to produce an image: magnetism, sound, and in the 
case of nuclear imaging, radiolabelled molecules that decay to produce signals. The term 
molecular imaging is often broadly used and can be interpreted in one of two ways: 
imaging using molecules or the imaging of molecules.1 A more precise definition would be 
the non-invasive visualisation and measurement of in vivo biological processes at the 
cellular and molecular level via specific imaging probes.2 
Molecular imaging has the ability to produce ‘real time’ images, useful for monitoring the 
progression of disease or for measuring the efficacy of a drug. Nuclear imaging 
approaches, such as positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) are the most sensitive techniques used for molecular 
imaging and benefit from an unlimited depth penetration.3 These methods require the use 
of a radiolabelled molecule to measure the in vivo distribution of a radiotracer via the 
external detection of high energy light in the form of gamma radiation from the decay of 
the radionuclide.  
In planar imaging, the radiation from a patient is collected and the data shown as if the 
radiation had been emitted from a single plane.3 However, contrast of the image is 
reduced and images of interest at a particular depth are obscured by images above and 
below that area. Computed tomography overcomes this problem by using mathematical 
algorithms to convert the data; the term tomography is used to describe the image of a 
slice and so a tomographic image is a two-dimensional representation of an image within 
a particular plane of a three-dimensional object.  
1.2 Positron Emission Tomography 
1.2.1 Principles of Positron Emission Tomography 
PET is a nuclear medicine imaging technology that is based on the positron decay 
process.4 This type of radioactive decay occurs in radionuclides that have an excess of 
protons: the nucleus becomes more stable by the transformation of a proton into a 
neutron through the loss of an anti-electron called a positron (β+) and a neutrino (ν). A 
consequence of the matter-antimatter relationship between the positron and the electron 
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is that the emitted positron will soon encounter an ‘ordinary’ electron. On emission from 
the nucleus, the positron travels a short distance in the surrounding tissue, expending its 
kinetic energy in inelastic collisions, before annihilating by combining with an electron.4 
This distance travelled is referred to as the positron range. After annihilation, 511 keV of 
energy for each particle in the form of gamma radiation is released. The two gamma rays 
are equal in energy and emitted simultaneously in opposite directions. The PET apparatus 
utilises this decay process by injecting a patient with a radioactive tracer and surrounding 
them with a ring of scintillations detectors (Figure 1). These detectors have the ability to 
absorb the incoming photons and convert the energy into an electric signal. When 
simultaneous arrival of gamma rays is detected, the point of origin of this annihilation is 
assumed to lie on a line connecting the two signals, known as the line of response (LOR). 
Measurements of multiple sets of LORs allow for reconstruction of an image showing the 
distribution of the radionuclide.5 
 
Figure 1: Positron decay and annihilation processes in PET 
(Reprinted with permission from Angew. Chem. Int. Ed., 2008, 47, 8998‒9033. Copyright 
2008 John Wiley and Sons)6 
A major challenge in the reconstruction of the PET image is the location of the origin of 
decay. Two fundamental sources of error exist.5 The first is that the reconstructed image 
is based on the location of the positronium (β+-β− complex) and, thus, does not take into 
account the positron range. The second is that, depending on the energy of the positron 
upon annihilation, the two gamma rays emitted will not be exactly 180° to one another due 
to conservation of momentum; this error can be as much as ±6°. These processes are 
fundamental to PET methodology and limit the spatial resolution of this technique to 
between 1.5‒3.0 mm, independent of any new PET apparatus and detection methods. 
Notwithstanding, this resolution is substantially better than that accomplished on a SPECT 
imaging system.  
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Another factor that has to be taken into account when locating the origin of decay is the 
type of coincidence that is detected by the PET apparatus. True coincidence (Figure 2a) is 
the desired detection event, whereby a positronium annihilates to form two non-collinear 
gamma rays. This can be complicated by Compton scattering of one of the gamma rays 
causing an incorrect LOR to be calculated (Figure 2b). Accidental or random coincidences 
can also be detected, in which the LOR is incorrectly calculated due to two separate 
disintegrations (Figure 2c). Only true coincidences will provide accurate spatial 
information and, in practice, different practical and mathematical techniques are used to 
reduce the scattered and accidental coincidences.5 A further source of error comes from 
the gamma ray penetrating into the detector ring before interacting. Although not a 
problem when arriving along the diameter from the middle of the detector ring, if the 
annihilation event occurs at an acute angle, it may travel through several detection 
crystals before being absorbed. This phenomenon is referred to as ‘radial astigmatism’ 
and can become more of a challenge to overcome in preclinical microPET systems.7 
 
Figure 2: Types of coincidences detected by a PET apparatus: (a) True coincidences; (b) 
scatter; (c) accidental coincidences. 
 
1.2.2 Types of PET Imaging Systems 
Although it is extremely useful at providing a detailed image of the target and the 
physiological process at the molecular level, PET does not afford any anatomical 
information. For this reason PET is often combined with other types of imaging in a 
technique known as multi-modality imaging (MMI).8 PET is often combined with X-ray 
computed tomography (CT), as this is an operationally simple process where the two 
machines can be placed beside one another. These scans can be performed sequentially 
and on a single patient bed, allowing for quick collection and analysis of physiological and 
anatomical data. The limitations of this technique are the poor soft tissue contrast and 
attenuation correction, which can cause error due to patient movement.9 
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Combination of PET with magnetic resonance imaging (MRI) has been highly desirable 
due the superiority of MRI for the acquisition of soft tissue analysis. This MMI technique 
can also considerably reduce the dose of ionising radiation administered to a patient, as 
the CT scan constitutes 60‒80% of the radiation dose.10 However, the major challenge in 
this technology is the development of a PET scanner that can operate in close proximity to 
a strong magnetic field.11 With recent improvements in PET and MRI equipment, this MMI 
technology is becoming more widely used, but more studies into improving the attenuation 
correction are required.12 
Both PET/CT and PET/MRI systems are currently used in smaller preclinical scanners 
known as microPET. These scanners are capable of small animal imaging in the field of 
radiotracer development.13 As the system is more compact, the whole of the animal can 
be scanned at once, rather than just a small section and this also improves the spatial 
resolution. As mentioned previously, it should be noted that the incidence of radial-
astigmatism increases due to the disintegrations occurring closer to the detection ring.7 
One of the current drawbacks of the PET scanner is that photon detection is an inefficient 
process, with only 1% of the photons emitted from a patient being detected. This is due to 
the axial field of view (FOV) in current scanners being less than 25 cm. This limitation 
means that a ‘full-body’ scan requires several scans and radiotracer distribution can only 
be measured from one position at a time. A recent development in the field of PET is the 
construction of the first ‘total-body’ PET/CT scanner by the EXPLORER Consortium.14 In 
total-body PET, the FOV is extended to cover the entire length of the body and allows for 
simultaneous distribution data to be acquired. Also, unlike current PET scanners, the 
majority of emitted photons would be collected resulting in high sensitivity and signal to 
noise ratio of a radiotracer.15 In such a system, the administered dose of radiotracer could 
be much lower and this would enable the imaging of short half-life radionuclides without 
the necessity for an on-site cyclotron. Recently, the first human imaging studies have 
been carried out with a total-body PET scanner; however, this technology is currently 
limited by high cost of manufacture.14 
1.2.3 Radionuclides Used in PET Imaging 
There are many different radionuclides used in PET imaging. Ideally the radioisotope 
chosen would decay by mostly positron emission and not by electron capture as well as 
having a half-life comparable to that of the process being imaged. A short half-life 
radionuclide might not be around long enough for sufficient data to be collected; however, 
those with a long half-life would linger in the patient for too long. Some of the more 
common radionuclides for PET imaging are shown below (Table 1).4 The most common 
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radionuclides used in PET imaging are carbon-11 and fluorine-18. Since carbon is the 
main constituent in most organic molecules, replacement of carbon-12 with carbon-11 
produces only an isotope effect as a radiolabelled imaging agent. The shorter half-life of 
carbon-11 currently limits its use to centres and hospitals with an on-site cyclotron. 
However, this may change as PET technology becomes more advanced. The short half-
life of carbon-11 can be an advantage, allowing for several automated productions in a 
single day, whereas fluorine-18 usually requires a 24 h wait for the radioactivity to decay. 
Although fluorine is not as common in naturally occurring compounds as carbon, 
replacement of a hydroxyl group or hydrogen atom with fluorine-18 is common. The 
fluorine atom is similar in size to a hydrogen atom and it has the added advantage that the 
carbon–fluorine bond is the strongest in organic chemistry and is, therefore, unlikely to be 
metabolised resulting in the loss of the radiolabel.4 Fluorine-18 benefits from a longer half-
life of 110 minutes which in turn allows for a more complex synthesis and longer in vivo 
studies. However, a common misconception exists surrounding fluorine-18 that states: the 
low positron energy produced (0.64 MeV) results in higher resolution images since the 
positron range will be decreased. Although the positron range is decreased for the 
positron from fluorine-18 decay, this does not affect the spatial resolution in PET. Instead, 
the errors previously described (see section 1.2) account for the current limit of spatial 
resolution in PET technology.7 Nevertheless, the positron range may play a more 
important role in radionuclide selection as the photon detector crystals and PET imaging 
systems become more advanced. 
Table 1: Commonly used radionuclides for PET imaging 
Nuclide Half-life (min) Type of Emission Max. Energy (MeV) 
11C 20.3 β+ 0.97 
18F 110 β+ 0.64 
13N 10 β+ 1.20 
15O 2 β+ 1.74 
64Cu 762 β+ / electron capture 0.66 
68Ga 68.1 β+ / electron capture 1.90 
76Br 972 β+ / electron capture 4.00 
124I 60192 β+ / electron capture 2.14 
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1.2.4 Production of Radionuclides 
1.2.4.1 The cyclotron 
The cyclotron is a type of particle accelerator, first developed by Ernest Lawrence at the 
beginning of the 1930s.16 Cyclotrons are capable of accelerating a charged particle beam 
to a high enough energy to initiate nuclear reactions and are responsible for the discovery 
and generation of many radionuclides used in nuclear medicine. The acceleration 
chamber of the cyclotron consists of two hollow D-shaped electrodes (‘dees’) located 
between the poles of an electromagnet with a magnetic field applied perpendicular to the 
plane of the electrodes.17 Ions are produced from an ion source at the centre of the 
acceleration chamber and the magnetic field influences a Lorentz force causing them to 
travel in circular orbits. These ions are accelerated by an oscillating electric field between 
the ‘dees’. The diameter of the orbit increases as the speed of the ions increases, which 
causes the ion beam to travel in a spiral. This allows for the production of a high energy 
ion beam, with proton energies of the most powerful cyclotrons in the region of 70 MeV. 
However, for the routine production of most radionuclides for medical imaging, proton 
beam energies below 30‒40 MeV are more than sufficient. As it exits the cyclotron, this 
beam can be directed at a target containing a gas or liquid that will take part in the nuclear 
reaction, producing the desired radionuclide. 
1.2.4.2 Production of the fluorine-18 nuclide 
Production of fluorine-18 can be brought about by a variety of different nuclear reactions, 
the most effective of which is the 18O(p,n)18F reaction of 18O-enriched water (Table 2).18 
This method produces aqueous [18F]fluoride, which can be used for nucleophilic 
radiolabelling procedures. The high molar activity can be easily achieved even with low 
energy cyclotrons, requiring short irradiation times. For electrophilic radiofluorinations, 
[18F]F2 is required and can be produced via two methods from different gas targets. These 
processes are hindered due to adsorption of [18F]F2 on the walls of the target, so to 
circumvent this, [19F]F2 is added to the target. This affects the molar activity of the [18F]F2 
due to higher concentrations of non-radioactive fluorine and is referred to as carrier-added 
(c.a.). The 20Ne(d,α)18F reaction produces c.a. [18F]F2 in low molar activities, however, 
Hess et al. reported an improved target system involving a two-step irradiation.19 Firstly, 
oxygen-18 gas is irradiated with a proton beam to form fluorine-18, which is deposited on 
the target inner surface. After cryogenic recovery of the oxygen-18, elemental fluorine gas 
and krypton are added and a short proton irradiation enables isotopic exchange of the 
deposited [18F]F2. This method can produce up to 0.6 GBq μmol−1 activities and enables 
recovery of the valuable oxygen-18 gas for further productions. 
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Table 2: Different approaches for the production of 18F 
Reaction 18O(p,n)18F 16O(3He,p)18F 20Ne(d,α)18F 18O(p,n)18F 
Target [18O]H2O H2O 
Ne (200 µmol 
F2) 
[18O]O2, Kr (50 
µmol F2) 
Product [18F]F−(aq) [18F]F−(aq) [18F]F2 [18F]F2 
Yield (GBq μAh−1) 2.22 0.26 0.40 1.0 
Molar Activity 
(GBq μmol−1) 
≈ 600 ≈ 50 ≈ 0.1 ≈ 0.6 
 
1.2.4.3 Production of the carbon-11 nuclide 
Due to the short half-life of carbon-11, production of this nuclide and its reactive forms 
generates added challenges. The most commonly used process for the production of 
carbon-11 is the 14N(p,α)11C nuclear reaction. Addition of small quantities of hydrogen or 
oxygen gas to the target enables the production of [11C]CH4 or [11C]CO2, respectively. 
Although, in the case of the latter, trace quantities of oxygen present in the N2 have been 
shown to be sufficient without further addition of O2 gas.20 Irradiation to form [11C]CO2 
often results in simultaneous production of [11C]CO, however, this can easily be 
cryogenically separated. Since the nuclear reaction involves irradiation of a nitrogen gas 
target (a non-carbon containing material), this process is capable of producing [11C]CH4 
and [11C]CO2 in high specific activities. However, a challenge in the production of high 
specific activity carbon-11 is preventing the introduction of naturally abundant carbon-12. 
This can be introduced from impurities in the target gas or even from the valves and seals 
within the target. 
Of the forms of carbon-11 produced from the cyclotron, [11C]CO2 is the most versatile, 
owing to its ease of separation and high production yield.21 Another advantage is the 
prospect for chemical transformations, with [11C]CO2 being the source of a variety of 
different secondary precursors, the most commonly used is [11C]MeI.22 Production of 
[11C]MeI can be carried out using two different methods from [11C]CO2, known as the ‘wet’ 
method and the ‘gas phase’ method (Figure 3). In the ‘wet’ method, reduction of [11C]CO2 
takes place using lithium aluminium hydride (LAH) in organic solvent to form 
[11C]methanol and conversion to [11C]MeI takes place using hydrogen iodide. Although 
this method returns high radiochemical yields, the specific activity is low due to trace 
amounts of organic solvent and LAH absorbing CO2 from the atmosphere and carrying 
this into the reaction mixture.23 The ‘gas phase’ method avoids the use of LAH and 
instead produces [11C]methane via reduction with H2 and free radical iodination with I2 in a 
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circulating gas phase. This also avoids the use of hydrogen iodide and prevents tubing 
deterioration within the apparatus. This method is capable of producing specific activities 
of [11C]MeI up to 4,700 GBq μmol−1.24 
 
Figure 3: Production of [11C]MeI and [11C]MeOTf 
 
1.2.5 Radiolabelling Methods 
1.2.5.1 Radiochemistry Techniques 
The incorporation of a radionuclide into a small molecule or peptide is important for 
imaging physiological processes using PET.25 The non-radioactive form of the compound 
can be independently tested to confirm affinity for a particular target or, in the case of 
carbon-11, modifying the synthesis of an existing drug or tracer allows for a 
[11C]methylation. Incorporation of a radionuclide can take place using a variety of different 
methods, but these can be grouped into two main categories: covalent attachment and 
chelation of a radionuclide. Covalent attachment is the most common method for 
incorporation of carbon-11 or fluorine-18 and for small molecules. This has the advantage 
that the carbon–fluorine and carbon–carbon bonds are strong and unlikely to be 
metabolised. However, this method requires the synthesis of an appropriate precursor for 
labelling, longer reaction times at higher temperatures and can be a challenge if trying to 
label a large biomolecule such as a peptide.26 Previously, chelation of the PET nuclide 
gallium-68 using a 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) chelator allowed 
for quick radiolabelling of NOTA-peptides.27 Further work in this field expanded the use of 
NOTA for the chelation of [18F]AlF (Scheme 1).28 
 
Scheme 1: [18F]AlF chelation attachment 
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The radiolabelling of any compound has practical challenges due to the presence of 
radiation from the positron decay process.6 As such, these reactions have to take place 
behind appropriate shielding, usually several inches of lead. Production of a radiotracer 
can be performed using two practical methods: a manual or an automated synthesis. In 
manual synthesis, the reaction is carried out in the same way as a standard organic 
chemistry reaction, but with the operator standing behind lead shielding and limiting the 
time they spend manipulating the radioactivity to reduce their overall dose. This method 
has the advantage that a reaction can be carried out in the same manner as the non-
radioactive synthesis and, therefore, should require little optimisation. The disadvantage is 
that, in order to protect the safety of the operator, only low levels of radiation should be 
used. Another shortcoming is that, as with many non-radioactive syntheses, the operator 
requires a certain level of skill and knowledge in order to carry out a successful production 
of the radiotracer. Therefore, for the routine production of radiotracers in a clinical setting, 
most radiosyntheses are carried out on automated systems.29 These synthesisers benefit 
from the ability to be controlled remotely and so an operator can perform a reaction using 
high levels of radiation without any risk to health. Once a synthesis is optimised, this 
process is highly reproducible and requires minimal input from the operator. Indeed, many 
synthesisers exist that employ a cassette-based system that allows for routine production 
by trained technical staff. Since this automation is intrinsic to the production of PET 
radiotracers for the clinic, it is highly desirable for optimisation of a radiotracer still 
undergoing preclinical evaluation to be produced in this way. This can aid the translation 
of a radiotracer to a clinical setting. 
1.2.5.2 Preparation of radiotracers 
An added challenge in the preparation of radiotracers is in the quantity of radionuclide 
produced by the cyclotron. Even for very large quantities of radiation, this is in the 
nanomolar to picomolar range.6 As the non-radioactive components of the reaction are 
often in such high stoichiometric excess, this gives the reaction pseudo-first-order kinetics 
with respect to the radionuclide. This has the advantage that reactions that would 
generally require days to go to completion can be complete within minutes. The 
consequence of this is that trace impurities in reagents and solvent can greatly affect the 
reaction; if a reaction with a trace impurity is faster than that of a desired precursor then 
no product may be formed.6 Since the product is formed in such small quantities, 
traditional methods of characterisation, such as nuclear magnetic resonance (NMR) 
spectroscopy cannot be used. Instead, high performance liquid chromatography (HPLC) 
and thin-layer chromatography (TLC), using radioactivity detectors is employed. The 
radiotracer is quantified by its radiochemical yield (RCY): the radioactivity of product 
expressed as a percentage of the starting radioactivity, which is decay corrected to the 
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start of synthesis and is identical to the concept of chemical yield.30 Another important 
value is the specific activity (As), which is defined as the measured activity per gram of 
compound, usually expressed in GBq mg−1. The theoretical maximum value of As is never 
reached due to isotopic dilution by the naturally occurring isotope.6 However, a particularly 
low specific activity would imply a high level of isotopic dilution and, thus, the toxicological 
effect of any administered radioisotope would be greater. However, most radiotracers fall 
into the <1.5 μg level of administration and pose no toxicological threat to the patient.31 
1.2.5.3 Common labelling methods for fluorine-18 
There are two broad categories of reactions to incorporate fluorine-18: direct fluorination 
using [18F]fluoride or [18F]F2 from the cyclotron and indirect fluorination, which requires a 
multi-step approach. Direct fluorination can be further split into electrophilic fluorination 
methods using [18F]F2 and nucleophilic reactions using [18F]fluoride. As mentioned 
previously (see section 1.2.4.2), electrophilic methods suffer from poor specific activity 
due to the presence of a fluorine-19 carrier. Since this means that the maximum possible 
RCY for the radiofluorination would be 50%, these methods are not as popular. 
Notwithstanding, electrophilic aromatic substitution of electron-rich aryl systems has been 
shown to be effective, but can suffer from poor regioselectivity due to their high 
reactivity.32 Conversion of [18F]F2 into the less reactive [18F]AcOF enables a more 
regioselective reaction to take place and this has been used for the synthesis of cyclic 
RGD peptide 2 for in vivo studies of αvβ3 integrin (Scheme 2). This radiotracer is used for 
the study of tumour status.33 The lower reactivity prevents the di-fluorination of peptide 1 
and enables separation of the desired ortho-substituted product in 27% RCY and specific 
activity of 32.8 GBq μmol−1. 
 
Scheme 2: Radiosynthesis of [18F]fluorinated cyclo(RGDfMeV) (2) 
 
Electrophilic fluorination is also performed through the demetalation of organometallic 
compounds.34 Organotin precursors are commonly used for this transformation and this 
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method has improved regioselectivity due to the presence of a functional handle attached 
to the molecule. The tin–carbon bond is strong enough to withstand many reaction 
conditions and can be incorporated early in the synthesis.35 Furthermore, the toxicity of tin 
has not been an issue in translation of fluorine-18 radiopharmaceuticals to the clinic, with 
organotin precursor 3 for [18F]fluoro-L-DOPA (4) a good example (Scheme 3).36,37 
However, recent work by Makaravage et al. has shown that arylstannanes can be 
radiofluorinated with [18F]fluoride in the presence of a copper catalyst.38 This study used 
the radiotracer [18F]fluoro-L-DOPA (4) as an example substrate. Avoiding the use of an 
electrophilic source of fluorine-18 in the synthesis of electron-rich aryl systems has 
become more popular, as better specific activity and radiochemical yield can be achieved 
from [18F]fluoride. 
 
Scheme 3: Radiosynthesis of [18F]fluoro-L-DOPA (4) from organotin precursor 3 
 
Aliphatic nucleophilic substitution reactions with [18F]fluoride are amongst the most 
straightforward and proceed via an SN2 reaction.34 [18F]Fluoride from the cyclotron is 
highly solvated, so addition of a phase transfer catalyst (such as Kryptofix 222® or 
tetrabutylammonium hydrogencarbonate) followed by removal of water leaves an exposed 
fluoride, which is highly nucleophilic.39 A precursor with a good leaving group is required 
for these reactions and is often in the form of a tosylate or triflate. This method was used 
in the production of cis-4-[18F]fluoro-L-proline (7a), a radiotracer for imaging increased 
collagen synthesis (Scheme 4). Direct nucleophilic [18F]fluorination of a tosylate precursor 
to form 6a is followed by deprotection in triflic acid.40 Further study of this fluorination 
reaction revealed that high temperature during the radiofluorination step caused a 
competing SN1 mechanism which resulted in a mixture of cis- and trans-isomers.41 
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Scheme 4: Radiosynthesis of cis-4-[18F]fluoro-L-proline (7a) and competing SN1 reaction at 
high temperature to form trans-4-[18F]fluoro-L-proline (7b) 
 
Nucleophilic aromatic substitution (SNAr) reaction with [18F]fluoride plays an important role 
in the radiofluorination of arenes. However, for the success of this reaction it is important 
to have a highly electron-withdrawing group, such as a nitro or cyano in the ortho- or para-
position to the leaving group. Effective leaving groups for SNAr include the nitro and 
trimethylammonium groups.42 Halogens can also be used as leaving groups for SNAr 
reactions. para-Nitrophenyl halides show reactivity for radiofluorination with Cl > Br and 
the nitro group remaining intact.43 These reactions are limited by the need for very 
electron-deficient aryl systems, however, radiofluorination of more electron-rich arenes 
can be performed using diaryliodonium salts. These reactions are believed to proceed via 
an SNAr mechanism and the radiofluorination occurs preferentially at the electron-deficient 
arene.44 Further studies showed that regioselectivity could also be controlled by the steric 
bulk of the ortho-substituent.45 The use of a 2-thienyl group has been shown as a method 
for incorporation of fluorine-18 in more electron-rich systems, such as anisole (Scheme 
5).46 
 
Scheme 5: Radiosynthesis of ortho-[18F]fluoroanisole (9) using heteroaromatic iodonium 
salt 8 
 
Diaryliodonium salts are also used in the synthesis of prosthetic groups for the indirect 
radiofluorination of larger molecules. Gao et al. reported the synthesis of 4-
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[18F]fluorophenylboronic acid (14) that could be used to 18F-label polypeptides via an 
aqueous Suzuki-Miyaura coupling (Scheme 6).47 Radiofluorination of a symmetrical 
diaryliodonium species 12 allowed for the synthesis of 18F-labelled iodobenzene 13. 
Subsequent Miyaura borylation gave boronic acid 14 in 5‒10% overall RCY. Many other 
methods exist that use prosthetic group approaches, with some of the most prevalent 
being ‘click chemistry’ reactions between alkynes and azides.48 
 
Scheme 6: Synthesis of 4-[18F]fluorophenylboronic acid (14) 
 
Transition metal-free methodology for the selective radiofluorination of unmodified 
peptides was reported by Verhoog et al. (Scheme 7).49 Halogen exchange of compound 
15 with [18F]fluoride in the presence of AgOTf afforded 18F-labelled compound 16. 
Subsequent cyclisation with oxone® and Tf2O provided 18F-labelled Umemoto reagent 17 
in 5% activity yield, calculated from [18F]fluoride. The authors showed that it was possible 
to radiofluorinate cysteine residues of unmodified peptides with the [18F]trifluoromethyl 
group. It was proposed that the soft nature of the sulfonium leaving group and of the thiol 
nucleophile guided the selectivity of the reaction. 
 
Scheme 7: Radiosynthesis of 18F-labelled Umemoto reagent 17 
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With the rise in interest of C–H functionalisation in organic chemistry, this methodology is 
becoming increasingly more common in the field of radiochemistry.50‒52 In 2019, Lee et al. 
reported a Pd-mediated C–H radiofluorination of 8-methylquinoline derivatives using 
Ag[18F]F, based on earlier work using fluorine-19 (Scheme 8).53,54 The authors found that it 
was possible to automate this synthesis using a GE TRACERlab FXFN module, providing 
18F-analogue 19 in 4% RCY with a specific activity of 39 GBq mmol−1. This is 
demonstrated as a proof-of-concept, with the manual synthesis returning 19 in 21% RCY. 
Recently, Chen et al. reported the direct [18F]fluorination of C–H arenes via organic 
photoredox catalysis. This reaction required the use of an acridinium-based photooxidant 
and a 450 nm laser under an atmosphere of oxygen. The methodology was shown to be 
effective for electron rich arenes featuring a strong directing group such as anisole.55 
 
Scheme 8: Radiofluorination of 8-methylquinoline (18) 
 
1.2.5.4 Common labelling methods for carbon-11 
The most popular method for incorporation of carbon-11 is the N-, O- and S-methylation of 
organic compounds. Since these motifs are found in abundance in drug-like molecules, 
often, very little modification of a known compound needs to take place to allow for a 
successful radiomethylation. The most commonly used reagent for this transformation is 
[11C]MeI; however, [11C]MeOTf is finding increased use due to its high reactivity and 
volatility.56 This reagent is used in the routine production of [11C]DTBZ (21), a radiotracer 
for imaging the vesicular monoamine transporter 2 (VMAT2) in neurodegenerative 
disease (Scheme 9).57 Due to the short half-life of carbon-11, radiosyntheses that have 
two or more reactive sites and require protecting group removal are commonly 
disfavoured. As a general rule, the time taken for a radiosynthesis should not exceed 
three half-lives of the radioisotope used.6 
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Scheme 9: Production of the radiotracer [11C]DTBZ (21) 
 
The use of transition metal catalysis has also been translated to 11C-labelling applications. 
Since the quantities of the transition metal catalyst are in high stoichiometric quantities 
with respect to the source of carbon-11, these reactions are often referred to as ‘transition 
metal-mediated’.58 One of the most widely used is the palladium-mediated Stille coupling 
with [11C]MeI. This allows for 11C-methylation of aryl and vinyl organotin species; however, 
it is susceptible to isotopic dilution if a trimethylstannane is used as a leaving group.58 
Ketones can be obtained from the Stille coupling if carbon monoxide is present in the 
reaction. Therefore, the use of either [11C]MeI or [11C]CO allows the synthesis of different 
products from the same precursor (Scheme 10).59,60 
 
Scheme 10: Radiosynthesis of 11C-labelled products 23 and 24 from organotin precursor 22 
 
Since organotin precursors are known to be toxic, the Suzuki-Miyaura reaction from aryl 
or alkyl boronates is often utilised.61 Given the versatility of the Suzuki-Miyaura reaction, 
its application is widespread in the production of radiotracers. Indeed, this method is used 
in the production of [11C]cetrozole (26), a PET imaging probe for aromatase imaging in the 
brain.62 
27 
 
Scheme 11: Suzuki-Miyaura reaction of boronic ester precursor 25 to form [11C]Cetrozole 
(26) 
 
The use of [11C]CO2 as the reactive form of carbon-11 is an attractive option, as this 
bypasses the need to transform the reagent extensively after production from the 
cyclotron and can provide high yielding reactions. The radiosynthesis of [11C]acetate, a 
tracer used in the diagnosis of prostate cancer, is produced from passing [11C]CO2 
through a loop coated with the Grignard reagent MeMgBr.63 A RCY of 65% can be 
achieved in a total reaction time of 5 min using this process.64 The problems associated 
with using the Grignard reaction are contamination with atmospheric CO2 and hydrolysis 
of the air sensitive organometallic reagent, which can unfavourably affect the specific 
activity. 
1.2.6 Clinical Applications of Radiotracers 
1.2.6.1 Applications of 18F-labelled tracers 
The most commonly used PET radiotracer is [18F]fluoro-2-deoxyglucose (FDG) (27).65 
[18F]FDG enters cells via plasma membrane transporters and becomes irreversibly 
trapped in most tissues. Since tumour cells have a higher rate of metabolic activity, the 
[18F]FDG accumulates in tumour cells rather than normal tissue, in a similar manner to 
glucose. As such, [18F]FDG has found widespread use in oncology as a tool for the 
diagnosis of cancer.66 Rather uniquely for a radiotracer, [18F]FDG works by a metabolic 
trapping mechanism: [18F]FDG metabolism is inhibited due to a lack of 2-hydroxyl group 
and accumulates. When the fluorine-18 nuclide decays by positron emission, it transforms 
to the oxygen-18 nuclide and can then be metabolised and excreted. [18F]FDG is limited 
as a diagnostic tool due to high uptake in brain and bladder tissues, making it impractical 
for the imaging of brain and prostate cancers. Shown below is a PET/CT scan of a patient 
post-hysterectomy after presenting with a neuroendocrine cervical carcinoma (Figure 4).67 
The CT image shows the anatomical data (Figure 4a), while the PET image shows the 
location of increased metabolic activity (Figure 4b). The fused image shows the location of 
metastases in the mediastinum, liver and abdominal lymphatic chain (Figure 4c). 
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Figure 4: [18F]FDG PET/CT scan: (a) CT image; (b) PET image; (c) fused images 
(Reprinted with permission from Korean J. Radiol., 2012, 13, 760‒770. Copyright 2012 
The Korean Society of Radiology)67 
Another routinely used 18F-tracer in the clinic is the bone-seeking agent [18F]NaF.68 Most 
[18F]NaF is taken up in bone after only a single pass of the blood and uptake is 10 times 
higher in areas of regenerating bone, compared with healthy bone tissue.69 As such, 
[18F]NaF has found use in the metabolic evaluation of benign bone and joint diseases (e.g. 
the detection of bone remodelling in the early stages of osteoarthritis) and in diagnosis of 
malignant diseases.70 As [18F]fluoride can be generated in high specific activity from the 
cyclotron, the reformulation to [18F]NaF is simple and high yielding. 
Despite [18F]FDG and [18F]NaF being amongst the most commonly used 18F-labelled 
radiotracers in a clinical setting, many others also exist. The previously mentioned 
[18F]fluoro-L-DOPA (see section 1.2.5.3) is a radiofluorinated analogue of L-DOPA, a 
precursor in the biosynthesis of dopamine. [18F]Fluoro-L-DOPA can cross the blood-brain 
barrier (BBB), unlike dopamine, and can then be transformed to [18F]fluoro-dopamine.71 
Since disturbances in dopamine metabolism are characteristic of neurodegenerative 
diseases such as Parkinson’s, tracing the dopaminergic pathway can provide early 
diagnosis and aid with monitoring disease progression. Other tracers that are seeing 
increased use are the previously described cis-4-[18F]fluoro-L-proline (7a) and trans-4-
[18F]fluoro-L-proline (7b). However, it is the former that shows greater incorporation into 
proteins and is used to better understand the synthesis of collagen in connective tissues.72 
(a) (b) (c)
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1.2.6.2 Applications of 11C-labelled tracers 
A common carbon-11 PET radiotracer is Pittsburgh compound B (PiB) which is used to 
image beta-amyloid plaques in neuronal tissue.73 These plaques are found in the brains of 
patients with Alzheimer’s disease (AD) and so [11C]PiB (29) can be used for differential 
diagnosis of AD and other dementias. The first radiosynthesis of [11C]PiB involved a 
MOM-protected phenol precursor and used [11C]MeI as the source of carbon-11.74 This 
synthesis required forcing conditions for the methylation and subsequent deprotection of 
the phenyl alcohol, so only low radiochemical yields were achieved. A new radiosynthesis 
is now used that utilises [11C]MeOTf and requires no base, allowing for direct N-
methylation from an unprotected precursor 28 (Scheme 12). 
 
Scheme 12: Radiosynthesis of [11C]PiB (29) 
 
The previously mentioned [11C]acetate is another radiotracer that is used in the detection 
of cancer.75 It is used in studies of prostate, bladder and brain cancers, amongst others.76 
These are areas where [18F]FDG is not able to differentiate tumour cells due to being part 
of the excretion pathway or having increased uptake. [11C]Acetate is readily metabolised 
into acetyl-CoA, an important molecule in the Krebs cycle. This is taken up into cells that 
over-express fatty acid synthetase (FAS), such as tumour cells.75 The figure below shows 
a PET/CT scan of a prostate cancer patient with increased uptake of [11C]acetate near the 
pubic symphysis (Figure 5).77 
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Figure 5: PET scan of a cancer patient. (A) Coronal whole-body PET image; (B–D) Axial 
[11C]acetate PET/CT images 
(This research was originally published in J. Nucl. Med., 2016, 57, 30S‒37S. Copyright 
2019 SNMMI)77 
Another important radiotracer is the 11C-labelled amino acid [11C]methionine. Since 
methionine is a vital amino acid in protein synthesis, it can be used to study cancerous 
tissue.78 Most studies using [11C]methionine focus on brain tumours, as unlike [18F]FDG 
this does not accumulate in healthy brain tissue. A commonly used tracer in the 
assessment of prostate cancer is 11C-labelled choline. Since there is not much bladder 
uptake, [11C]choline can assess tumours in the prostate.79 [11C]Choline is also the 
precursor in the biosynthesis of the neurotransmitter acetylcholine, which is impaired in 
many neurodegenerative diseases; however, as with [11C]methionine, [11C]choline is also 
a biomarker of brain tumours and is not taken up in the healthy brain tissue.80 
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1.3 Sphingosine-1-Phosphate 5 Receptor (S1P5) 
1.3.1 Multiple Sclerosis 
Multiple Sclerosis (MS) is an immune mediated disorder that affects over 2 million people 
worldwide.81 In the UK alone, approximately 120,000 people have MS, with over 6000 
new cases diagnosed per year.82 A recent study showed a high prevalence of MS in the 
Orkney and Shetland islands with a marked increase in prevalence in Orkney over the last 
30 years.83 Work by Mokry et al. has identified a lowered vitamin D level with increased 
susceptibility to MS, suggesting that low levels of UV-B sunlight in these northerly areas 
may explain this prevalence.84 However, these studies are yet to address whether vitamin 
D sufficiency can indeed delay MS onset. Over 70% of cases of MS are with females, 
indicating a sex difference in prevalence.82 Although, the exact cause of MS is currently 
unknown. 
Multiple sclerosis affects the central nervous system (CNS) and is thought to result from 
demyelination by autoreactive T-cells.85 Some of the main characteristics of MS are the 
formation of plaques in the CNS and the destruction of myelin sheaths of neurons. A loss 
of myelin disrupts the communication between cells and causes a wide range of 
symptoms, such as: extreme tiredness, blurring of vision and problems with balance 
amongst many others. In MS, these symptoms are unpredictable and can develop and 
increase over time, or come and go periodically. A healthy myelin sheath will increase the 
speed of impulses by increasing the resistance and decreasing the capacitance. The 
signals propagate by saltatory conduction where the action potential jumps from one 
uninsulated node of Ranvier to the next (Figure 6).86 Voltage-gated ion channels are found 
more abundantly at these nodes of Ranvier so action potentials are not generated along 
the areas covered by the myelin sheath. Along an unmyelinated axon, the electrical 
impulse would move as a continuous wave, but the action potential propagation would 
decay as the current leaks across the membrane. 
32 
 
Figure 6: Myelin sheath saltatory conduction 
(Reprinted with permission from Glial Physiology and Pathophysiology, John Wiley & 
Sons, Ltd, Chichester, 2013, p. 245‒319. Copyright 2013 John Wiley and Sons)86 
A distinctive feature of multiple sclerosis is the formation of the sclerotic plaque that forms 
in the CNS.87 This most commonly affects the white matter (so named due to the high lipid 
content of myelin) in the optic nerve, brain stem and spinal cord. This feature is a result of 
inflammation, demyelination and remyelination followed by oligodendrocyte depletion and 
neuronal and axon deterioration. However, the exact cause and underlying mechanism of 
action have yet to be elucidated.88 Oligodendrocytes are a type of neuroglia: i.e. they are 
non-neuronal cells that maintain homeostasis; they are specialised to form the myelin 
sheaths surrounding neurons.86 As demyelination occurs, the oligodendrocytes repair the 
myelin sheath of axons, however, remyelinated neurons have a thinner sheath and 
repeated demyelination leads to the formation of sclerotic plaque. This results in a loss of 
speed of conduction between neurons and, hence, a loss of communication between 
cells. 
Diagnosis of multiple sclerosis is complicated, as currently there is no single test that can 
confirm or deny the presence of the disease. The diagnosis follows a set of guidelines 
known as the McDonald criteria and these are updated regularly, with the last update 
occurring in 2017.89 Neurological examination, blood tests and examination of spinal fluid 
are commonly used methods, but now MRI is increasingly used in MS diagnosis as it is 
capable of showing lesions of sclerotic plaque.90 However, by the time these plaques are 
visible by MRI, the damage is often very severe. Thus, a tool is needed that can represent 
the pathology in patients before the detection of lesions is visible. 
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1.3.2 Sphingosine-1-Phosphate Receptors 
Sphingosine-1-phosphate (S1P) (Figure 7) is a lysophospholipid derived from the cell 
membrane that acts as an extracellular signal. S1P plays a fundamental role in cell growth 
and apoptosis in the CNS and the immune and cardiovascular systems. It acts by 
engaging with high-affinity S1P receptors.91 There are currently five known different S1P 
receptors (S1P1–S1P5) that specifically bind S1P with low nanomolar affinities. S1P1–S1P3 
are predominantly expressed in immune cells and the cardiovascular system, where S1P1 
is highly expressed on T-cells and B-cells.92 S1P4 is expressed in the hematopoietic 
system and S1P5 is expressed in the neural and glial cells, including astrocytes and 
oligodendrocytes.93 
 
Figure 7: Sphingosine-1-phosphate (S1P) 
 
The distribution of S1P5 suggests that it may play an important role in regulating the 
myelination process.94 Indeed, S1P activation of S1P5 has been shown to promote the 
survival of myelin-forming mature oligodendrocytes.94 On that basis, the development of 
new selective agonists of the S1P5 receptor may be beneficial for the treatment of 
neurodegenerative diseases such as MS. If so, minimal S1P1 interaction would be 
favourable since this will decrease the risk of immune suppression and cardiovascular 
effects.91 
1.3.3 S1P Receptor Agonists 
1.3.3.1 Agonists for S1P5 receptors 
In 2010, a group from Novartis published a paper reporting the synthesis of various 
benzamide compounds that proved to be potent and selective S1P5 receptor agonists.95 
These compounds were discovered by using high-throughput screening techniques to 
assess their in vitro potency towards S1P1, S1P4 and S1P5 receptors. To guide the 
optimisation process of these compounds, docking experiments of the benzamide 
compounds into homology models of the S1P receptors were carried out (Figure 8). 
Crucially, they found that the 2,6-dimethyl substituted aniline substituent causes twisting in 
the molecule, leading to effective binding within the proposed pockets. In the S1P5 
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receptor complex, the amide forms a hydrogen bond with threonine and the benzamide 
phenyl ring lies in a large hydrophobic pocket surrounded by phenylalanine, leucine and 
tryptophan. The aniline ring forms a T-shaped interaction with a phenylalanine residue 
and hydrophobic interactions with leucine. The ortho-methyl substituents fill a small pocket 
formed by tyrosine, valine and leucine residues. After the synthesis of various analogues 
of these benzamide compounds was complete, they were assayed for S1P5, S1P1 and 
S1P4 activation. Some of the more promising structures (31‒33) are shown below (Figure 
9). 
 
Figure 8: A) Longitudinal and B) transverse views of the S1P5 homology model with the 
benzamide compound docked. 
(Reprinted with permission from ChemMedChem, 2010, 5, 1693‒1696. Copyright 2010 
John Wiley and Sons)95 
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Figure 9: Potent benzamide agonists of S1P5 
 
A paper in 2015 reported the discovery of an orally bioavailable selective S1P5 receptor 
agonist, 34 (Figure 10).96 This compound was discovered through the application of a 
parallel synthesis, based on previous structures from the literature, followed by high 
throughput screening to identify compounds for structure activity relationship (SAR) 
experiments. Although it shows high potency for the S1P5 receptor, it is not as selective as 
the benzamide compounds reported by Mattes et al. However, significant work 
determined the drug-like properties of the compound, supporting its suitability for in vivo 
studies of the biology of S1P5.96 
 
Figure 10: S1P5 receptor agonist 34 
 
1.3.3.2 Agonists for S1P1–S1P4 receptors 
In 2016, Gilmore et al. reported the discovery of a series of ethanolamine-based agonists 
of S1P1 (Figure 11).97 They discovered a novel polar headgroup consisting of an 
ethanolamine scaffold with a terminal carboxylic acid, mimicked the structure of S1P. 
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Through SAR studies, they synthesised compound 35, which had desirable 
pharmacokinetic and pharmacodynamic properties and has progressed to advanced 
studies for consideration as a clinical development candidate. 
 
Figure 11: 5-Substitued trifluoromethyloxazole ethanolamine 35 
 
Also in 2016, Hur et al., reported the synthesis of a benzo[b]thiophene-based selective 
S1P4 receptor agonist, 36 (Figure 12).98 S1P4 is expressed primarily in lymphoid tissues 
and suppresses T-cell proliferation, but is believed to possess additional functions.85 
Compound 36 has an EC50 of 200 nM for S1P4 and exhibits no activity for S1P1‒3,5. 
Interestingly, many of the selective S1P4 agonists reported in the literature have an overall 
“L-shaped” structure, suggesting that this backbone is specific for S1P4 activation. 
 
Figure 12: Benzo[b]thiophene-based selective S1P4 receptor agonist 36 
 
1.3.4 S1P Receptor Imaging Using PET 
The drug fingolimod (37) (FTY720, trade name gilenya) is a compound that was approved 
by the European Medicines Agency in 2011 for the treatment of relapsing MS.99 The 
compound is structurally very similar to S1P and was developed from SAR studies of the 
antibiotic myriocin. Fingolimod (37) is phosphorylated in the cell by sphingosine kinases to 
the active form (38) (Scheme 13).91 Fingolimod-phosphate acts as an agonist for the S1P2 
and S1P5 receptors, however, it is also a functional antagonist of S1P1 and leads to the 
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sequestering of lymphocytes in lymph nodes preventing them from moving to sites of 
autoimmunity, transplanted organs and the CNS – averting a relapse in MS.99 
 
Scheme 13: Phosphorylation of fingolimod (37) with sphingosine kinases 
 
Recent work by Shaikh et al. has generated various fluorinated structural analogues of 
fingolimod in an effort to develop a radiotracer (Scheme 14).91 This was to study the organ 
distribution and pharmacokinetics of fingolimod and the S1P receptor biodistribution using 
PET. After testing the in vitro and in vivo biological activity of the radiotracer, in vivo 
biodistribution/PET imaging took place. PET revealed fast uptake and elimination of the 
tracer by the liver and the kidneys. An increased uptake was observed in S1P relevant 
tissues: the lungs and myocardium, as well as in the spleen. 
 
Scheme 14: Radiofluorination of fingolimod analogue precursor 39 
 
Rosenberg et al., reported the synthesis and in vitro and in vivo evaluation of a S1P1 PET 
tracer (Scheme 15).100 After their screening process, they found a compound with a 2.63 
nM potency for S1P1 and selectivity >100-fold for S1P1 over S1P2/3. This was successfully 
18F-labelled from the tosyl precursor 41 in both high yield and specific activity. The data 
collected suggests that uptake of this tracer reflects the expression of S1P1 and has 
potential for use in quantifying S1P1 expression in response to inflammation. 
38 
 
Scheme 15: Radiosynthesis of S1P1 PET tracer 42 
 
1.4 The Translocator Protein (TSPO) 
1.4.1 Function and Distribution of TSPO 
Since its discovery in 1977 by Braestrup and Squires, the translocator protein 18 kDa 
(TSPO) has been a major focus of research.101 TSPO is expressed in a variety of different 
tissues and is involved in a number of cellular processes, including cholesterol transport, 
inflammation, tumour progression and, Parkinson’s and Alzheimer’s diseases.102 In 
particular, TSPO is expressed at high levels in tissues that synthesise and distribute 
steroids, but in the CNS, TSPO expression is restricted mostly to glial cells.103 At the 
subcellular level, TSPO localisation is mainly in the outer mitochondrial membrane.104 This 
protein used to be known as the peripheral benzodiazepine receptor (PBR), however, it 
was renamed to TSPO to better describe its nature and function.103 
Microglia are a type of glial cell located in the brain and spinal cord and act as brain-
resident macrophages, maintaining local neurons and circuits.105 These immune cells 
exist in their inactive form, but undergo change to an activated state in response to CNS 
inflammation that stimulates them to function as phagocytes.106 Activation of microglia has 
been associated with a range of different neurodegenerative disorders such as MS, 
Parkinson’s and Alzheimer’s diseases amongst others. The receptor density of TSPO 
located in microglia cells in a healthy state is negligible, however, in response to CNS 
insults, expression of TSPO dramatically increases.106 In vivo imaging of TSPO could 
therefore be an excellent target for understanding and treating diseases associated with 
neuro-inflammation. 
The levels of TSPO expression are highest in steroid producing cells of the adrenal 
glands, testes and ovaries.102 The expression in these tissues has led to the discovery 
that TSPO is responsible for the transport of cholesterol across the outer mitochondrial 
membrane, where it can be converted to pregnenolone before it is metabolised into 
specific steroids in a process called de novo steroidogenesis.107 Indeed, studies have 
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shown that modulation of TSPO with the TSPO-specific ligand PK11195 (41), induced 
steroid hormone production in adrenocortical cell lines.108 There is controversy in this 
area, as a report has shown that TSPO gene deletion in testicular Leydig cells had no 
effect on the production of testosterone.109 However, studies to the contrary have been 
published (including embryonic lethality associated with TSPO gene deletion). As such, 
more research is required in this area.110,111 TSPO is over-expressed in prostate cancer 
tissue and tumour cells have been shown to induce de novo steroidogenesis to evade the 
immune response.112 The tumour-induced androgen synthesis results in resistance to 
androgen deprivation therapy and leads to the development of lethal metastatic castration 
resistant prostate cancer (mCRPC).113 Thus, PET imaging of TSPO could give insight into 
the development of mCRPC and provide better tools for early detection. 
1.4.2 Imaging agents for TSPO 
The most widely used ligand for PET imaging of TSPO is the isoquinoline carboxamide 
[11C]PK11195 (41) (Figure 13).114 Its widespread use notwithstanding, [11C]PK11195 (41) 
suffers from poor brain uptake and displays weak signal to noise ratio, complicating its 
quantification.115 Additionally, the use of a 11C-label limits the use of this tracer to facilities 
with an on-site cyclotron. Furthermore, labelling of this compound can be challenging due 
to its short half-life. Other attempts have been made to develop more effective imaging 
agents, however, except for PK11195 (41), the in vitro binding of these second-generation 
compounds (e.g. 42 and 43) to human brain tissue is variable between different 
individuals due to TSPO single nucleotide polymorphism (rs6971).116,117 These 
compounds can be categorised as high-affinity (HAB), low-affinity (LAB) or mixed-affinity 
binders (MAB).118 
 
Figure 13: PK11195 (41) and second generation TSPO radiotracers 
 
Considering this, Blair et al., in 2015, reported the synthesis, biological evaluation and 
physiochemical properties of a novel 3-fluoromethylquinoline-2-carboxamide, AB5186 
(45), for PET imaging of TSPO (Scheme 16).119 Studies conducted previously in the 
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Sutherland group had revealed the rigidity and steric factors caused by the bulky amide 
and benzene moiety allowed for efficient binding to TSPO.120 Competition binding assays 
measuring the displacement of PK11195 (41) revealed that AB5186 (45) has low 
nanomolar affinity for TSPO (Ki = 2.8 nM). The key physiochemical parameters of AB5186 
(45) (Pm, Km and %PPB) were also found to be optimal for use as an imaging agent.119 A 
radiofluorination method was developed, involving a halogen exchange reaction from the 
chloride precursor 44. This was treated with [18F]fluoride and Kryptofix® 222 at 100 °C for 
12 min to afford [18F]AB5186 (45) in a RCY of 38 ± 19% (n = 7).119 
 
Scheme 16: Radiosynthesis of [18F]AB5186 (45) 
 
To investigate the behaviour of [18F]AB5186 (45) in vivo, ex vivo autoradiography was 
performed using glioma bearing mice and showed specific binding of [18F]AB5186 (45) to 
TSPO in tumour tissue.119 [18F]AB5186 (45) could image TSPO in an intracranial glioma 
bearing mouse (Figure 14) and a PET scan was also successfully performed on a healthy 
baboon to show that [18F]AB5186 (45) was indeed capable of penetrating the blood-brain 
barrier (BBB) of a non-human primate. 
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Figure 14: (a) PET image of a glioma bearing mouse following [18F]AB5186 (45) injection; (b) 
H&E staining of the tumour which stains dark blue 
(This research was originally published in Chem. Sci., 2015, 6, 4772‒4777. Published by 
The Royal Society of Chemistry) 
In 2019, Qiao et al. reported the radiosynthesis of a TSPO radiotracer (R,S)-[18F]GE387 
(47) (Scheme 17).121 In order to test the affinity of this compound, a separation of the two 
enantiomers from the racemic material was desired. The use of a chiral derivatisation 
group to separate the diastereomers proved unsuccessful and the authors resorted to 
supercritical fluid chromatography to obtain the enantiopure compounds. The authors 
reported that the (S)-enantiomer showed low binding sensitivity to the polymorphism 
present in TSPO, using assays based on human embryonic cell lines. Their studies show 
that (S)-47 binds with similar affinity to PK11195 and a LAB:HAB ratio of 1.3. 
Radiofluorination of the precursor 46 occurred after 20 min at 100 °C and the radiolabelled 
product was isolated in 20.8 ± 4.5% RCY and with a molar activity of 93.2 ± 50.6 GBq 
μmol−1 (n = 9). Further biological evaluation of this radiotracer is ongoing. 
 
Scheme 17: Radiosynthesis of (R,S)-[18F]GE387 (47) 
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2 Results and Discussion 
2.1 New Selective PET Imaging Agents for the 
Sphingosine-1-Phosphate 5 Receptor 
2.1.1 Project Aims 
The focus of this work was to develop tools to allow an understanding of the 
interdependence of S1P5 receptors in demyelination, in particular, to focus on the design 
of PET imaging agents that act as S1P5 agonists in the human brain. The first main 
objective was to synthesise a small library of compounds that specifically target the S1P5 
receptor. Using the benzamide compounds previously described by Mattes et al. as the 
basis for potential imaging agents (Figure 15), a synthetic route towards fluoride 
analogues of these compounds would be developed.95 Crystal structure docking 
experiments carried out on the literature benzamide compounds showed that the methyl 
group at the top of the molecule was furthest from the binding pocket. As such, it was 
proposed that an ideal radiotracer would have the fluorine atom in this position. The 
libraries of compounds would be based on three of the most promising compounds from 
the literature: benzamide 31, phthalazinone 32 and 3-methyl benzamide 33 (Figure 15). 
The most promising compounds would be assessed by physicochemical analysis using 
HPLC methodology and then tested for their affinity and selectivity for S1P5.122 A 
precursor would be synthesised that would allow for 11C-labelling of the most potent 
compound in the literature study, 3-methyl benzamide 33, as this would provide insight 
into the behaviour of these compounds as PET radiotracers. 
 
Figure 15: S1P5 selective benzamide analogues 
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2.1.2 Synthesis of Fluoro-Benzamide Library 
2.1.2.1 Proposed route 
To incorporate a functional handle that could be used for late-stage fluorination of these 
compounds, a route was proposed that would allow access to fluorinated analogues of 31. 
This began with the para-nitration of 2,6-dimethylaniline (48) to give aniline 49 and 
subsequent SNAr reaction with benzoic acid 50 to give compound 51 (Scheme 18). 
Ullmann condensation reactions with various alcohols could be used to incorporate the 
ether substituent and amidation of the carboxylic acid group would provide the nitrated 
analogues 53. The nitro group would then be reduced to an amine and the compound 54 
could be fluorinated via diazonium salt 55 according to literature precedent.123 
 
Scheme 18: Proposed route for functionalised derivatives 
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2.1.2.2 Optimisation of the synthetic route 
Prior to nitration of aniline 48, synthesis of benzamide 31 began in order to optimise the 
literature route. Multi-gram quantities of the required benzoic acid 50 were synthesised 
from the corresponding dihalobenzene 57 using a literature procedure (Scheme 19).124 
The carboxylation of the 1,3-dihalobenzene proceeded via directed ortho-metalation 
(DoM). Initially, LDA regioselectively deprotonated the halobenzene between the two 
halogens: both the fluorine and the bromine act as directing groups and enhance the 
acidity of the mutually ortho-hydrogen atom. Subsequent addition of CO2 as the 
electrophile followed by acidic work-up afforded the desired benzoic acid 50 in a 
quantitative yield. 
 
Scheme 19: DoM of dihalobenzene 57 and subsequent carboxylation to form 50 
 
The next step involved the synthesis of the core structure 59 via an SNAr reaction between 
benzoic acid 50 and 2,4,6-trimethylaniline (58) (Table 3). The first attempt employed 
conditions described in the Novartis paper, using LDA to deprotonate aniline 58 and 
allowing the reaction to warm to room temperature to perform the SNAr reaction with 50 
(entry 1).95 After 20 h, only a 28% conversion to the product was observed by 1H NMR 
spectroscopy. Substitution of LDA for LiHMDS, according to a similar literature reaction, 
allowed for a 100% conversion to the product after 72 h (entry 2).125 However, this method 
only returned the desired product in 13% yield. It was proposed that the slow conversion 
in this reaction was due to the desired site of nucleophilic attack of 50 being ortho- to the 
deprotonated carboxylic acid, combined with the nucleophile being ortho,ortho-
disubstituted. Consequently, it was found that heating the reaction to 40 °C allowed for a 
faster conversion and the desired SNAr product 59 was isolated in 94% yield (entry 3). 
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Table 3: SNAr reaction to form core structure 59 
 
Entry Reagents Temperature Time Yield 
1 LDA, THF −78 °C to rt 20 h 28% conversion 
2 LiHMDS, THF −78 °C to rt 72 h 13% 
3 LiHMDS, THF −78 to 40 °C 16 h 94% 
 
To incorporate the ether substituent, the bromide of 59 was used in an Ullmann 
condensation reaction with isopropanol (Scheme 20). Ullmann condensations between an 
aryl halide and alcohol or amine nucleophile have been shown to work well with a variety 
of different copper catalysts, including sources of Cu(0), Cu(I) and Cu(II).126 The 
mechanism of this reaction is widely disputed, however, the reactivity for the aryl halide is 
in the order I > Br > Cl, which implies the copper catalyst is somehow involved in its 
activation.127 Aryl bromides have been shown to be more reactive when they possess an 
electron-withdrawing group in the ortho-position, making aryl bromide 59 an ideal 
substrate.128 In this reaction, initial deprotonation of isopropanol with NaH was performed 
before addition of aryl bromide 59 and copper powder. After 20 h, the reaction was 
complete and ether-bearing product 60 was isolated in 69% yield. 
Following the Ullmann condensation reaction, the carboxylic acid of 60 was converted to 
an amide to give benzamide 31 (Scheme 20). This reaction utilised the coupling reagent 
CDMT (2-chloro-4,6-dimethoxy-1,3,5-triazine), which in the presence of NMM, formed the 
reactive intermediate 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride 
(DMTMM) in situ.129 Reaction of carboxylic acid 60 with DMTMM via an SNAr mechanism 
yielded the activated ester, which upon addition of NH4OH, formed the benzamide product 
31 in 74% yield. 
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Scheme 20: Ullmann condensation and subsequent amidation to form benzamide 31 
 
2.1.2.3 Synthesis using nitrated analogue 
The first step in this synthesis involved the para-nitration of 2,6-dimethylaniline (48) to 
form 49. This could not be achieved using a traditional one-step approach with nitric and 
sulfuric acids, as the aniline becomes protonated in acidic conditions. This anilinium cation 
acts as a meta director, forming both meta- and para-nitrated products. Instead, a three-
step process was utilised. Following a literature procedure, the amine was first protected 
with a tosyl group, using p-toluenesulfonyl chloride in pyridine to afford product 61 in 98% 
yield (Scheme 21).130 Regioselective electrophilic aromatic substitution at the para 
position was performed using sodium nitrite under acidic conditions and afforded a single 
nitrated product 62 in 64% yield. The tosyl group was removed using sulfuric acid to afford 
2,6-dimethyl-4-nitroaniline (49) in 98% yield. 
 
Scheme 21: para-Nitration of aniline 48 
 
The reaction of nitrated aniline 49 with benzoic acid 50 was first attempted at 40 °C 
(Scheme 22). When no conversion to product was observed after 16 h, the reaction was 
heated under reflux. After a further 12 h, still no conversion could be observed. It was 
assumed that the explanation for no reaction was due to 49 being a very poor nucleophile: 
the presence of a para-nitro group made the aromatic ring very electron-deficient; 
furthermore, the aniline was poorly soluble in THF. The reaction was attempted again by 
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heating under reflux in toluene; however, no reaction was observed and so a different 
synthetic route was required. 
 
Scheme 22: Attempted SNAr reaction using aniline 49 
 
2.1.2.4 Synthesis of a brominated analogue 
A new synthesis was devised providing two different routes for the synthesis of 
brominated analogue 64 (Scheme 23). The first route would start with direct bromination 
of aniline 48 using methodology developed within the Sutherland group.131,132 This method 
utilises the readily available ionic liquid [BMIM]NTf2 and FeCl3 to form the powerful Lewis 
acid catalyst Fe(NTf2)3 in situ. Since the triflimide ligands are highly delocalised, this 
provides a strong Lewis acidic Fe3+ cation. The iron catalyst accelerates electrophilic 
aromatic substitution with NBS by coordinating with the oxygen carbonyl atom of the 
succinimide. In this reaction the ionic liquid can also act as the solvent, accelerating the 
rate of reaction. After the synthesis of aniline 63, the three steps described earlier could 
be used to provide brominated analogue 64. It was believed that selectivity of the Ullmann 
reaction for the aryl bromide on the lower ring could be achieved due to this ring featuring 
an electron-withdrawing group ortho- to the bromine atom. A Miyaura borylation reaction 
could be used to install a pinacol boronic ester, which can in turn be transformed into 
fluorinated analogue 66 by utilising literature methods for both the radioactive and non-
radioactive fluorination.133,134 This methodology uses a nucleophilic source of fluoride and 
a copper catalyst. A second route could also be attempted that would use the 
aforementioned three steps to access benzamide 67 directly from aniline 48. This would 
then be brominated using the same method to provide brominated analogue 64, which 
could be manipulated as previously described. 
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Scheme 23: Alternative routes to target 64 
 
Bromination of 48 was first attempted at room temperature using conditions described in 
the literature (Scheme 24).131 After 16 h of reaction time, there was no evidence of any 
product being formed. Therefore, the reaction was heated to 60 °C and full conversion to 
the desired product was observed after 48 h, giving aniline 63 in 53% yield. The SNAr 
reaction between benzoic acid 50 and aniline 63 was unsuccessful using the previously 
optimised conditions and yielded no product. When the reaction was heated under reflux 
and allowed to react over a longer period of 72 h, still no conversion was observed. It was 
assumed that the bromine atom had a similar deactivating effect on aniline 63 as the nitro 
group had on the previously described reaction. Thus, synthesis of brominated analogue 
64 was attempted via the alternative route. 
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Scheme 24: Bromination of aniline 48 and attempted SNAr reaction with 63 
 
Reaction of aniline 48 with benzoic acid 50 occurred as expected using the previously 
optimised conditions and afforded 69 in 83% yield (Scheme 25). The subsequent Ullmann 
condensation with isopropanol and the following amidation reaction occurred in 48% and 
92% yields, respectively. To perform the bromination reaction, it was necessary to dilute 
the reaction mixture in dichloromethane, as benzamide 67 was poorly soluble in the ionic 
liquid. Bromination of 67 yielded an inseparable mixture of mono- and di-brominated 
products. Further inspection of the 1H NMR spectrum of the mixture showed that the 3H 
multiplet corresponding to the three aryl protons of the upper ring was still present. 
Therefore, the mixture of products contained bromine in the C-3 and C-5 positions of the 
lower ring. It was not possible to determine which position was the initial site of 
bromination, so further analysis of this reaction was performed. 
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Scheme 25: Bromination of 67 to form target 64 
 
The previously synthesised benzamide 31 was subjected to the bromination reaction 
conditions (Scheme 26a). Using 0.8 equivalents of NBS, it was possible to control the rate 
of bromination to synthesise a single mono-brominated product 72 in 77% yield. It was 
initially believed that examination of the structure of 31, using NOE NMR experiments 
would provide insight into the site of bromination. However, the NOE difference spectra 
from irradiation of the signals of the isopropanol protons and of the ortho-methyl groups of 
the upper ring were inconclusive. Consequently, brominated product 72 was recrystallised 
from a mixture of CH2Cl2 and hexane and a small molecule crystal structure was obtained 
(Scheme 26b). This clearly showed only bromination of the C-3 position and also 
demonstrated the significant twisting of the two aryl rings across the bridging nitrogen 
atom. 
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Scheme 26: (a) Bromination reaction and (b) crystal structure of brominated product 72 
 
Given the successful incorporation of bromine into the structure, it was proposed that an 
iodine atom could be introduced using the same method and NIS (Scheme 27). This was 
proposed as a target, as this could be used as a SPECT radiotracer if labelled with 
[123I]iodide. An iodinated compound may also have more favourable pharmacokinetics, 
due to the added lipophilicity of the iodine atom. Under the same conditions used for the 
bromination only low conversion to product was observed after 16 h. By heating to 40 °C 
and adding 1 equivalent of NIS at the start of the reaction, before further addition of 0.4 
equivalents after 16 h, it was possible to achieve full conversion to the product. Although 
NIS is a better electrophile than NBS due to the weaker nitrogen-iodine bond, the 
increased size of the iodine may have hindered this reaction. Hence, the reaction time 
was increased compared with the bromination conditions and iodinated analogue 73 was 
isolated in 31% yield. 
 
Scheme 27: Synthesis of iodinated analogue 73 
(a) (b)
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2.1.2.5 Incorporation of fluorine at an earlier stage of the synthesis 
Since it was not possible to synthesise brominated analogue 64 due to the lower ring 
being more electron rich, a new route was proposed (Scheme 28). This involved the direct 
incorporation of fluorine via an SNAr reaction between commercially available fluoroaniline 
74 and benzoic acid 50, with the rest of the synthesis proceeding as previously described. 
The obvious drawback to using this method was that fluorine was not incorporated in the 
final step and therefore the route would not be applicable to a radiosynthesis. 
Notwithstanding, it was deemed more crucial to synthesise derivatives that could be 
tested for their affinity and selectivity for S1P5 receptors. If there were any promising 
compounds after biological screening, time could then be spent on synthesising an 
appropriate precursor for radiofluorination. 
 
Scheme 28: Proposed route towards fluorinated analogues 
 
One of the more promising benzamide compounds synthesised by Novartis featured a 
methyl group in the C-3 position of the benzamide ring (33). To provide a fluorinated 
analogue of this compound, benzoic acid 78 would need to be synthesised from the 
corresponding dihalobenzene 77 (Scheme 29). The reaction proceeded as previously 
described for 50 and benzoic acid 78 was isolated in a quantitative yield. The following 
SNAr reaction with fluoroaniline 74 proceeded in an excellent yield to afford the des-methyl 
derivative 75. However, the yield was reduced somewhat for the 3-methyl derivative, 
yielding product 79 in 68% yield. 
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Scheme 29: Carboxylation and SNAr reaction of 3-H and 3-Me analogues 
 
To produce a small library of fluorobenzamide derivatives, the ether was varied by 
performing an Ullmann condensation reaction with various alcohols (Scheme 30). The 
isopropoxy (80) and methoxy (81) derivatives were synthesised in 44% and 71%, 
respectively, to provide fluorinated analogues of compounds previously synthesised in the 
Novartis paper.95 However, to better explore the structure activity relationship of these 
compounds, other novel structures were synthesised. Isobutyl and n-butyl ethers were 
synthesised successfully in 68% and 70% yields, respectively, but reaction with tert-
butanol afforded the debrominated product 84 in 58% yield. This was due to the poor 
nucleophilicity of the tert-butanol anion and so the reaction followed a proto-decupration 
mechanism instead. A similar result was observed when using isopropylamine as the 
coupling partner. Coupling of aryl bromide 75 with 3-fluoropropan-1-ol took place in THF 
rather than neat reaction conditions and provided terminal alkene product 86, which was 
isolated in 46% yield. It was proposed that the desired product had been synthesised, but 
under the conditions of the reaction the alkene formed via an E1cB mechanism. Reaction 
of 3-methyl derivative 79 with methanol and also with isobutanol provided the products 87 
and 88 in 71% and 68% yields, respectively. However, reaction with isopropanol or more 
sterically hindered alcohols was not successful and yielded debrominated analogue 84. It 
was proposed that the ortho,ortho-disubstitution of this aryl bromide made this position 
less accessible. 
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Scheme 30: Ullmann condensation reaction with various alcohols 
 
The amidation reaction to form the final fluorobenzamide products was straightforward 
and high yielding, affording the products in good to excellent yields (Scheme 31). The 
yield of the reaction was independent of the size of the ether substituent installed, but as 
sufficient quantities of the compounds had been synthesised for biological screening, no 
further optimisation of the reaction was considered. 
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Scheme 31: Amidation reaction to form final products 
 
2.1.3 Synthesis of 3-Substituted Benzamide Library 
2.1.3.1 Synthesis of aryl bromide 98 
The unexpected site of bromination observed in the reaction to form 72 (see section 
2.1.2.4) inspired a new class of compounds. Since the bromination occurred in the C-3 
position of the benzamide ring, this reaction could be used to provide aryl derivatives of 
potent compound 33, described in the literature by Mattes et al.95 The previously 
synthesised aryl bromide 59 was subjected to the Ullmann condensation reaction using 
methanol to give methoxy derivative 96 in 97% yield (Scheme 32). This was then 
successfully converted to benzamide 97 in 95% yield and then bromination using NBS 
gave brominated analogue 98 in 77% yield. Several attempts were made to incorporate a 
boronic ester in the structure via a Miyaura borylation reaction, which could then be used 
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as a precursor for fluorination. However, the reaction returned only the debrominated 
product 97 via a proto-depalladation mechanism. 
 
Scheme 32: Synthesis of aryl bromide 98 and attempted Miyaura borylation 
 
2.1.3.2 Suzuki-Miyaura reaction 
It was proposed that a Suzuki-Miyaura reaction would be a robust method for 
incorporating a range of aryl groups, containing either fluoride or methoxy substituents.135 
These compounds would have an advantage on those from the previous library, as the 
fluorine-18 or carbon-11 nuclide could be incorporated in the final step.47,136 Consequently, 
a screening of reaction conditions took place using 4-fluorophenylboronic acid (100) as a 
coupling partner (Table 4). The initial reaction took place using Pd(PPh3)4 as the catalyst, 
with KH2PO4 as the base in DMF (entry 1). After 16 h, it was clear that none of the desired 
product had formed and analysis of the 1H NMR spectrum of the crude material showed 
only starting material and evidence of decomposition. It was proposed that decomposition 
may have been due to the high temperature, so the reaction was attempted again at 80 °C 
and the base was substituted for K3PO4 (entry 2). Although there was not the same 
evidence of decomposition, after 48 h there was only the presence of starting material in 
the reaction. Changing the base to K2CO3 and using similar conditions yielded the same 
result (entry 3). The catalyst was changed to PdCl2(dppf), due to its reported air and 
moisture sensitivity and enhanced reactivity compared to other palladium catalysts.137 
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When Cs2CO3 was used as a base in dioxane, full conversion of starting material was 
achieved in 16 h (entry 4). This provided a 3:1 mixture of coupled product 101 and 
debrominated analogue 97 in 92% yield. Since proto-depalladation had taken place, it 
implied that there was ineffective transmetalation in the reaction and it was believed this 
may have been due to poor solubility of the base in dioxane. Since Suzuki-Miyaura 
reactions can take place in aqueous media, a small quantity of water was added to the 
reaction mixture to improve the solubility of Cs2CO3 and the desired product was isolated 
as a single product in 71% yield (entry 5).138 
Table 4: Optimisation of Suzuki-Miyaura reaction 
 
Entry Catalyst Base Solvent Temperature/Time Yield 
1 Pd(PPh3)4 KH2PO4 DMF Δ, 16 h n/a 
2 Pd(PPh3)4 K3PO4 DMF 80 °C, 48 h n/a 
3 Pd(PPh3)4 K2CO3 DMF 80 °C, 48 h n/a 
4 PdCl2(dppf) Cs2CO3 dioxane 80 °C, 16 h *92%* 
5 PdCl2(dppf) Cs2CO3 dioxane/H2O 80 °C, 16 h 71% 
*A mixture of 101 and 97 
 
With the optimised conditions now in hand, a library of 3-substituted products were 
synthesised (Scheme 33). Boronic acids featuring fluoride and methoxy substituents were 
used for the coupling to provide non-radioactive forms of the fluorine-18 and carbon-11 
radiotracers, respectively. Most of the products were obtained in good yields, however 
compound 106 bearing a fluoropyridine motif was isolated in 18% yield. Nevertheless, 
there was sufficient quantity of material to use for biological screening. 
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Scheme 33: Library of 3-substituted benzamides 
 
2.1.4 Synthesis of Fluorophthalazinone Library 
2.1.4.1 Proposed route 
A third library of compounds was synthesised based on the selective phthalazinone 
agonist described by Mattes et al.95 This series of compounds would be constructed from 
the previously synthesised fluoro-intermediate 75 (Scheme 34). An esterification followed 
by a Stille coupling reaction would afford the enol ether product 109, which would then be 
hydrolysed in situ to for the keto ester 110. Reaction with hydrazine would form the 
phthalazinone core structure and then further derivatives could be made by performing a 
regioselective bromination and following Suzuki-Miyaura reaction, as described for the 
previous library of compounds. 
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Scheme 34: Proposed route towards fluorophthalazinone derivatives 
 
2.1.4.2 Esterification reaction 
The first step towards the synthesis of the phthalazinone core was esterification of 75 
(Table 5). Initially, reaction with thionyl chloride and MeOH was attempted (entry 1).139 
After 18 h, a 50% conversion to product was observed by 1H NMR spectroscopy, but after 
the addition of further equivalents of thionyl chloride, decarboxylation had occurred. 
Esterification was then attempted using oxalyl chloride, catalytic DMF and MeOH in a two-
step process (entry 2).120 As these conditions were milder, it was proposed that this 
procedure would prevent decarboxylation through the in situ formation of the Vilsmeier 
reagent, providing a stable intermediate for the formation of the acid chloride. On a small 
scale, 108 was formed in 61% yield, however, upon scale-up significant decarboxylation 
was observed. Eventually a method for the synthesis of 108 that was scalable was 
achieved using TMS-diazomethane in THF over 16 h (entry 3).95 No decarboxylation was 
observed and the product was isolated in 88% yield. 
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Table 5: Methyl ester synthesis conditions 
 
Entry Reagents Temperature Time Yield 
1 SOCl2, MeOH 0 °C to rt 48 h n/a 
2 
1. (COCl)2, DMF 
(cat.) CH2Cl2 
2. MeOH, CH2Cl2 
0 °C to Δ 24 h n/a 
3 
TMS-diazomethane 
THF 
0 °C to rt 16 h 88% 
 
2.1.4.3 Construction of the phthalazinone core 
Next the phthalazinone core was assembled. This began with a Stille coupling using alkyl 
tin 113 and Pd(PPh3)4 (Scheme 35). Initial reaction using 10 mol% of catalyst stalled after 
24 h of reaction time, giving only 64% conversion to 109. A second attempt using 5 mol% 
of catalyst followed by a further 5 mol% after 5 h allowed for complete conversion to enol 
ether product 109 and hydrolysis immediately followed using 1 M HCl. After initial 
purification, there was still evidence of alkyl tin impurities in the product. Washing with 
aqueous KF solution was not successful in removing the impurities. However, via a 
second column with 10% K2CO3 (w/w) in silica as the stationary phase, it was possible to 
remove all traces of the tin byproducts. Keto ester product 110 was isolated in 90% yield 
over the two steps. The final step in forming the phthalazinone was the reaction of 110 
with hydrazine, which afforded product 111 in 89% yield upon first attempt. 
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Scheme 35: Synthesis of the fluorophthalazinone derivative 111 
 
2.1.4.4 Synthesis of final compounds 
The bromination of phthalazinone 111 used the same conditions as the attempt in the 
previous library of compounds and returned brominated analogue 114 in 94% yield 
(Scheme 36). As this series of compounds already had a fluorine atom incorporated as 
the potential site for radiolabelling, the choice of boronic acid coupling partners could be 
more varied. A library of seven compounds were synthesised in good yields, however, the 
coupling of 4-bromophenylboronic acid to form 116 occurred in a lower yield of 21%. 
Since this reagent was also an aryl bromide, there was a competing reaction between two 
of the boronic acids, forming byproducts. The synthesis of an iodinated analogue of the 
fluorophthalazinone may have resolved this issue, due to the greater order of reactivity for 
the aryl iodine. However, the iodination reaction was shown to be not as efficient on the 
benzamide 67 and the quantity of phthalazinone product obtained was sufficient for further 
studies. 
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Scheme 36: Bromination and Suzuki-Miyaura reaction to form final fluorophthalazinones 
 
2.1.5 Investigation of Physicochemical Properties 
The key physicochemical properties of the three libraries of potential radiotracers were 
assessed in order to rank the compounds for biological screening and to give insight into 
which structures may have more favourable pharmacokinetics. These compounds were 
intended to target receptors that lie within the central nervous system, so ability to 
penetrate the blood-brain barrier (BBB) would be crucial. Established methodology by 
Tavares et al. to determine radiotracer properties using HPLC was employed.122 This 
allowed for rapid testing of the compounds, as the process was automated and multiple 
compounds could be assessed during a single run. The properties examined were the 
partition coefficient (log P), permeability (Pm), membrane partition coefficient (Km) and 
plasma protein binding (%PPB). 
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2.1.5.1 Partition coefficient 
The partition coefficient (log P) is defined as the ratio of concentration of a substance in 
two immiscible phases at equilibrium and therefore is a good measure of lipophilicity.140 It 
is determined experimentally and traditionally measured using the “shake flask” method: 
calculated from the ratio of concentration of compound in octanol and water (Figure 16). 
One of the disadvantages of this method is that it is quite time-consuming, which made 
using the HPLC methodology desirable. Values for log P were obtained by comparison of 
the retention times of the unknown compounds with those of known standards on a C18 
column. Compounds require a good balance of lipophilicity to have good probability of 
penetrating the BBB, thus the value for log P is an important selection criterion for 
radiotracer development.141,142 
 
Figure 16: Equation for the calculation of log P 
 
2.1.5.2 Permeability and membrane partition coefficient 
Another important factor in penetration of the BBB is the ability of a compound to cross 
brain capillary endothelial cells. This factor can be greatly affected by solute-membrane 
interactions and is known as the membrane partition coefficient (Km). This provides 
information about the solute’s free energy of interaction (ΔGm) with the fluid membrane 
according to the below equation (Figure 17).143 This property can be measured using 
immobilised artificial membrane (IAM) chromatography, as this can model the solute-
membrane interactions. IAM columns consist of monolayers of phospholipids covalently 
bonded to the surface of silica.144 Permeability (Pm) of drug via passive diffusion is directly 
proportional to Km and depends upon the size of the molecule. 
 
Figure 17: Equation to show the relationship between ΔGm and Km 
 
2.1.5.3 Plasma protein binding 
When a compound enters the bloodstream it interacts with plasma proteins, with two of 
the most common being human serum albumin (HSA) and α1-acid glycoprotein (AGP). A 
radiotracer with high percentage plasma protein binding (%PPB) means less compound is 
log P = log  
 Concentration Octanol
 Concentration Water
  
∆Gm =  −RT ln(Km) 
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available to cross the BBB and results in higher nuclear image noise from deposition of 
the tracer in the peripheral organs and build-up in the blood. The %PPB can be 
determined by measuring the retention time of compounds using HPLC and a column 
coated with HSA.145 
2.1.5.4 Physicochemical properties of S1P5 compounds 
The HPLC methodology developed by Tavares et al. established a range of ideal values 
based on analysis of ten known radiotracers (Table 6).122 Ideally the compounds tested 
would fall below these values; however, the purpose of this screening process was to 
rapidly assess and rank the libraries of compounds. All three libraries of compounds were 
submitted to this methodology, including iodinated analogue 73 (Table 7). 
Table 6: Ideal values for physicochemical properties 
Physicochemical Property Ideal Value 
log P < 4.0 
Pm < 0.5 
Km < 250 
%PPB < 95% 
 
Table 7: Physicochemical analysis of S1P5 compounds 
Compound log P Pm Km %PPB 
 
5.35 0.319 101 99% 
 
4.56 0.223 64.4 99% 
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Compound log P Pm Km %PPB 
 
5.74 0.487 101 100% 
 
5.89 0.509 168 100% 
 
6.14 0.646 223 100% 
 
5.22 0.285 89.6 100% 
 
5.01 0.233 70.5 99% 
 
6.21 0.518 178 100% 
 
6.16 0.650 246 100% 
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Compound log P Pm Km %PPB 
 
5.97 0.539 210 100% 
 
6.08 0.514 195 100% 
 
5.79 0.378 148 100% 
 
5.95 0.465 190 100% 
 
5.88 0.446 182 100% 
 
5.03 0.211 79.9 99% 
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Compound log P Pm Km %PPB 
 
5.69 0.562 210 100% 
 
5.53 0.477 193 100% 
 
5.49 0.499 189 100% 
 
5.82 0.561 250 100% 
 
6.03 0.618 273 100% 
 
5.76 0.611 268 100% 
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Compound log P Pm Km %PPB 
 
6.20 0.786 355 100% 
 
6.39 0.578 253 100% 
 
2.1.5.5 Analysis of physicochemical properties of S1P5 compounds 
Following the testing of the three libraries of compounds, the values were assessed and 
compared. The log P value obtained for many of the compounds was above the ideal limit 
of 4.0, with the exception of compound 89. The compounds from fluorobenzamide library 
that did not feature longer alkyl chains had more ideal properties. Unsurprisingly, the 
further extension of the aromatic system present in the other two libraries of compounds 
was shown to increase the lipophilicity of the compounds. The benzamide analogue 73, 
featuring an iodine atom, also had a much increased log P value due to the presence of 
an aromatic iodine substituent.146 The membrane partition coefficient and permeability 
values obtained were mainly good across the libraries, with the fluorophthalazinone library 
having slightly increased values. The most promising compounds from this screening 
process were fluorobenzamides 89 and 93. Analysis of the plasma protein binding 
showed that all of the compounds possessed values of 99% or 100%. This seemed 
unlikely, indeed study of a different class of compound described in a later chapter (see 
section 2.2.3.2) using the same methodology showed that the experimentally determined 
value for plasma protein binding was too high when compared to other methods. 
Consequently, it was believed that the HPLC column used to obtain these results was 
now unreliable and these values were not used to assess or rank the compounds. 
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2.1.6 Synthesis of a Carbon-11 Precursor 
2.1.6.1 Proposed route 
Whilst the three libraries of novel S1P5 agonists were screened for their biological 
properties, a carbon-11 precursor based on an existing benzamide agonist from the 
literature was proposed (Scheme 37). The compound chosen was the 3-methyl derivative 
33 that was shown to have particularly high affinity and selectivity for S1P5. This tracer 
would allow for initial investigation of the ability of this class of compounds to act as 
radiotracers to image S1P5. Biological data already existed for this compound, so a 
successful radiosynthesis would allow for evaluation of in vivo distribution. The phenol 
precursor 124 was proposed as a desirable target, as methylation of phenols using 
[11C]MeI or [11C]MeOTf is a robust, commonly used radiosynthesis. Indeed, this is the 
method of radiolabelling the PET radioligand [11C]DTBZ and allows for a fully automated 
synthesis.57,147 To access precursor 124, benzamide 33 would be synthesised from 
benzoic acid 77 using the previously described chemistry. Demethylation of the methoxy 
group using BBr3 would provide the phenol for precursor 124. 
 
Scheme 37: Proposed route towards carbon-11 precursor 124 
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2.1.6.2 Precursor synthesis via demethylation of 33 
Synthesis of benzamide 33 was a high yielding process and gram-scale preparation was 
easily possible. Since this was the non-radioactive form of the proposed carbon-11 
radiotracer and would be necessary for early preclinical work, rapid synthesis was 
advantageous. Initial reaction of 33 with the demethylating reagent BBr3 returned the 
phenol product 124 in 41% yield; however, the product contained some inseparable 
impurities and the yield was not reproducible on a larger scale. With this in mind, 
optimisation of the demethylation step took place. 
 
Scheme 38: Synthesis of demethylated precursor 124 
 
Conditions were altered in order to optimise the demethylation reaction (Table 8). To 
remove impurities and increase the rate of demethylation using BBr3, the reaction was 
heated under reflux (entry 1). After 4 h, there was no evidence of product present and the 
starting material had begun to decompose under the reaction conditions. An attempt to 
prevent decomposition, where the reaction was cooled to −78 °C before warming room 
temperature was also unsuccessful (entry 2). Several other literature procedures for the 
demethylation of 33 were attempted, but these either resulted in no reaction or partial 
decomposition of the starting material.148‒150 A different approach was considered to avoid 
the use of a demethylation reaction. 
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Table 8: Optimisation of demethylation reaction 
 
Entry Reagents Temperature Time Yield 
1 BBr3, CH2Cl2 0 °C to Δ 4 h n/a 
2 BBr3, CH2Cl2 −78 °C to rt 24 h n/a 
3 AlCl3, CH2Cl2 0 °C to rt 16 h n/a 
4 BF3·OEt2, CH2Cl2 0 °C to rt 16 h n/a 
5 LiCl, DMF 100 °C 24 h n/a 
6 NaSEt, DMF 100 °C 16 h n/a 
 
2.1.6.3 Use of an allyl protecting group 
Rather than use a methyl group as protection for the alcohol, an allyl group was 
considered, as this could be removed using milder conditions to provide phenol precursor 
124. This moiety could be introduced through an Ullmann condensation reaction with allyl 
alcohol (Scheme 39). Initial reaction of aryl bromide 122 with allyl alcohol showed total 
conversion of starting material after 24 h, with a small amount of impurity also present in 
the reaction mixture. Formation of the desired product 125 was confirmed by 1H NMR 
spectroscopy and isolated in 77% yield. However, rearrangement to a new compound 
took place after 1 h in a chloroform solution, prior to full characterisation. Further analysis 
of this solution confirmed the presence of rearranged product 126, supported by the 
appearance of individual signals for the two diastereotopic sp3 hydrogen atoms on the allyl 
group at 2.27 and 2.73 ppm in the 1H NMR spectrum. Analysis of the 13C NMR spectrum 
of 126 also confirmed the presence of a ketone carbonyl group. It was proposed that this 
compound had formed via an aromatic Claisen rearrangement, but no tautomerisation to 
the phenol product had taken place due the ortho-methyl group. In ortho,ortho-
disubstituted allyl phenols a para-substituted allyl product forms via a tandem Claisen and 
Cope rearrangement.151 However, the additional steric congestion at the C-5 position of 
the benzamide ring was proposed to make this transformation unfavourable. The 
synthesis was performed again and the product used immediately in the following 
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amidation step, but only conversion to the rearranged product 126 was evident and no 
amidation had taken place. Examination of the neat product immediately post-synthesis 
showed that the rearrangement was slowly taking place at room temperature and 
accelerated when in solution in chloroform. After 1 h of standing neat at room 
temperature, a 10% conversion to rearranged product 126 was observed using 1H NMR 
spectroscopy and after 24 h, the neat sample had formed a 1:1 ratio of 125 and 126. The 
rearranged product 126 was formed quantitatively from 125 upon standing in a solution in 
chloroform after 2 h. 
 
Scheme 39: Attempted synthesis of allyl ether 125 
 
An alternative approach to allyl ether 128 was considered by initially conducting 
amidation, followed by the Ullmann reaction (Scheme 40). Amidation of 122 occurred as 
expected in a quantitative yield; however, when subjected to the Ullman condensation 
conditions, no conversion to any product was observed. This may be due to the amide 
group not being as electron-withdrawing or inhibiting oxidative addition of the copper 
catalyst.127 
 
Scheme 40: Amidation of 122 prior to Ullmann condensation reaction 
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2.1.6.4 Use of a PMB protecting group 
A new protecting group approach was considered for the synthesis of phenol precursor 
124. Next, a para-methoxybenzyl (PMB) group was used (Scheme 41). Ullmann 
condensation reaction with PMB alcohol took place in THF instead of neat alcohol for 
improved solubility and reduction in cost of materials. This reaction showed full conversion 
of starting material after 24 h, although none of the desired compound was formed and 
instead rearranged product 130 was isolated in 40% yield. The structure of 130 was 
confirmed by the presence of individual signals for the two diastereotopic hydrogen atoms 
in the benzyl position at 2.72 and 3.35 ppm in the 1H NMR spectrum. Additionally, as for 
the rearranged compound 126, analysis of the 13C NMR spectrum of 130 also confirmed 
the presence of a ketone carbonyl group. 
 
Scheme 41: Ullmann condensation reaction with PMB-OH 
 
2.1.6.5 Use of a benzyl protecting group 
To investigate the role the electronics of the benzyl group plays in the rearrangement 
reaction, the Ullmann condensation reaction was attempted with benzyl alcohol (Scheme 
42). After 24 h, full conversion to the desired product had taken place and benzyl ether 
131 was isolated in 74% yield. No rearrangement of this product was observed by 1H 
NMR spectroscopy and the isolated product was still >95% pure after >72 h in chloroform 
at room temperature. It was proposed that benzyl group was not as efficient at stabilising 
a partial positive charge in the benzylic position compared to the PMB group, due to the 
absence of an electron-donating group. Subsequent amidation of 131 gave benzamide 
132, which was isolated in 92% yield. Deprotection of the benzyl group via hydrogenation 
was successful and the phenol precursor 124 was isolated in 87% yield. To show that this 
precursor was capable to undergo radiosynthesis with [11C]MeI, standard methylation 
conditions were used to access non-radioactive benzamide 33 in 80% yield. Importantly, 
no impurities were observed to be formed in the methylation reaction, indicating precedent 
for a clean radiosynthesis. 
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Scheme 42: Ullmann condensation reaction with BnOH and synthesis of precursor 124 
 
2.1.6.6 Methylation of precursor 124 
Another potential source of carbon-11 is the methylating reagent [11C]MeOTf. This is a 
more powerful methylating reagent than [11C]MeI and it is possible to perform 
methylations on weakly nucleophilic functional groups. As such, methylations using 
MeOTf tend to be much faster: an important factor to consider with the short half-life of the 
carbon-11 radionuclide.56 Trial of this reagent prior to radiosynthesis would advise of its 
suitability for methylation of precursor 124. Reaction of precursor 124 with MeOTf, using 
conditions similar to that of the MeI reaction, returned benzamide 33 in 33% yield 
(Scheme 43). Despite the lower yield obtained, this reaction produced no side products 
and so MeOTf could still be considered as a reagent for radiomethylation. 
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Scheme 43: Methylation of precursor 124 using MeOTf 
 
2.1.7 Radiochemistry 
2.1.7.1 Establishing an HPLC method 
The limiting reagent of a radiomethylation reaction is the source of carbon-11; therefore, 
separation of the remaining precursor from the methylated product would need to take 
place. Many radiomethylations with carbon-11 avoid the use of semi-preparative HPLC for 
the purification of the radiotracer, instead adopting for a solid-phase extraction (SPE) 
method.147,152‒154 HPLC purification and reformulation from the eluent can be a lengthy 
process and due to the much shorter half-life of the carbon-11 radionuclide, this can 
significantly affect the specific activity of the product. On the other hand, SPE purification 
allows for quick trapping and elution from a small cartridge and can decrease the time 
required for purification. This also allows easy automation and reproducibility of the 
reaction – an important factor when taking a radiopharmaceutical through to clinical use. 
Nevertheless, a good separation of both precursor 124 and product 33 would need to be 
achieved in order to properly analyse the reaction and advise on the method of separation 
used in the synthesis. A sample was prepared containing a 1:1 mix of standard/precursor 
and examined by reverse phase HPLC (Figure 18). It was found that a mixture of 62% 
acetonitrile in water provided a good separation, but the product was only eluted from the 
column after 11 min due to its lipophilicity. 
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Figure 18: HPLC chromatogram of (a) precursor 124 and (b) benzamide 33, using a C18 
column and 62% acetonitrile in water as the eluent 
 
2.1.7.2 Synthesis of [11C]MeI and [11C]MeOTf 
The radioactive synthesis was carried out using a Synthra Wolpertinger synthesiser; the 
graphics overlay for this synthesiser is shown in Appendix I. The [11C]MeI required for the 
reaction was synthesised through a gas phase synthesis and its production was optimised 
prior to attempts of the radiomethylation reaction (Scheme 44). [11C]CO2 was produced via 
the 14N(p,α)11C nuclear reaction by cyclotron irradiation of a target containing [14N]N2.58 
The gas phase synthesis required little optimisation and an irradiation of the cyclotron 
target to produce approximately 10 GBq of [11C]CO2 was sufficient for the synthesis of 5 
GBq of [11C]MeI after 15 min. Production of [11C]MeOTf was not as successful, as initial 
attempts at its synthesis led to the activity being trapped inside the triflate oven. Further 
investigation found that the type of activated carbon used in the column was not allowing 
de-adsorption of [11C]MeOTf. Switching to a less active form of carbon for the column 
allowed de-adsorption to take place, providing 3‒4 GBq of [11C]MeOTf. 
 
Scheme 44: Gas phase synthesis of [11C]MeI and [11C]MeOTf 
 
2.1.7.3 Radiolabelling of precursor 124 
To optimise the reaction conditions, HPLC and reformulation was bypassed and the 
reaction vessel was connected directly to a dispensing vial. The reaction mixture was then 
analysed with HPLC on a C18 column, using both UV and gamma detectors. Any 
unreacted [11C]MeI or [11C]MeOTf quickly reacts with water in the eluent, forming 
[11C]MeOH. This was easily visible on the gamma trace of the HPLC and provided 
(a)
(b)
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quantitative conversion analysis of the reaction. For the first reactions, [11C]MeOTf was 
used as the source of carbon-11, with no base added due the enhanced reactivity 
compared to [11C]MeI (Table 9).155 Cooling of the reaction mixture should increase the 
trapping of [11C]MeOTf, but after 5 min of reaction time at room temperature, no 
conversion to product was observed in the HPLC trace (entry 1). Heating the reaction to 
100 °C for 10 min showed no improvement (entry 2). Adding TBAOH as a base at 40 °C 
for 5 min showed no conversion to product and increasing the reaction time and 
temperature was also unsuccessful (entries 3 and 4). The source of carbon-11 was 
changed to [11C]MeI and NaOH was used as a base in THF. The GM counter in the 
reaction vial showed that trapping was efficient at 40 °C and 60 °C, but still no conversion 
was observed (entries 5 and 6). Using conditions similar to the non-radioactive reaction 
was difficult, as K2CO3 was not soluble in the reaction solvent and solid would cause 
blockages in the automated synthesiser. However, K2CO3 was mixed with precursor 124 
prior to injecting into the reaction vial to try and emulate these conditions. After 10 min, 
there was no product (entry 7). Addition of a 1 M TBAOH solution in THF showed a 
promising 2% conversion and heating the reaction to 80 °C, enabled 38% conversion after 
10 min (entries 8 and 9). Literature procedures have shown that the use of TBAF 
enhances the efficiency of N- and O-methylations, as it is highly soluble in organic 
solvents compared to many other bases.156,157 Using TBAF in THF at 80 °C gave 72% 
conversion of [11C]MeI after 5 min (entry 10). Changing the solvent to cyclohexanone and 
heating the reaction to 120 °C gave 83% conversion (entry 11). To further optimise this 
process, the reaction time was reduced to 0 min, i.e. transferring the reaction immediately 
after trapping of [11C]MeI (entry 12). This gave 94% conversion, which was more than 
sufficient to begin purification. 
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Table 9: Optimisation of reaction conditions 
 
Entry 
Carbon-
11 Source 
Base Solvent Temperature Time* Conversion 
1 [11C]MeOTf None Cyclohexanone −20 °C‒rt 5 min 0% 
2 [11C]MeOTf None Cyclohexanone −20‒100 °C 10 min 0% 
3 [11C]MeOTf TBAOH Cyclohexanone 40 °C 5 min 0% 
4 [11C]MeOTf TBAOH Cyclohexanone 60 °C 10 min 0% 
5 [11C]MeI NaOH THF 40 °C 5 min 0% 
6 [11C]MeI NaOH THF 80 °C 10 min 0% 
7 [11C]MeI K2CO3 THF 40 °C 10 min 0% 
8 [11C]MeI TBAOH THF 40 °C 5 min 2% 
9 [11C]MeI TBAOH THF 0‒80 °C 10 min 38% 
10 [11C]MeI TBAF THF 80 °C 5 min 72% 
11 [11C]MeI TBAF Cyclohexanone 120 °C 5 min 83% 
12 [11C]MeI TBAF Cyclohexanone 120 °C 0 min 94% 
* Time for reaction after 3 min of trapping [11C]MeI 
 
2.1.7.4 Purification and reformulation of product 
The optimised conditions showed 94% conversion to desired product [11C]33. There was 
no residual [11C]MeI observed from the analysis, however, the remaining 6% impurities 
had similar retention times to the product (Figure 19). Consequently, SPE purification of 
the labelled product would be difficult, despite the absence of other radioimpurities. 
Purification using a C18 cartridge was unsuccessful at removing both the radioimpurities 
and unreacted precursor. Use of an HLB cartridge allowed separation of the precursor 
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from the product, but not removal of the radioimpurities and so purification using HPLC 
was considered. 
 
Figure 19: HPLC gamma trace of the reaction mixture using the optimised conditions, using 
a C18 column and 62% acetonitrile in water as the eluent. [11C]33 can be seen at a retention 
time of 13.3 min 
 
The preclinical analysis of the S1P5 carbon-11 radiotracer will be carried out by 
collaborators at the University of Edinburgh. Consequently, a radiosynthesis was to be 
developed that could be transcribed to the radiochemistry unit at Edinburgh, since 
transport of carbon-11 tracers is currently impractical given its short half-life. The 
synthesiser used in Edinburgh is a TRACERlab FXC PRO; the graphics overlay is shown 
in Appendix II. This differs slightly from the Synthra Wolpertinger in its method of [11C]MeI 
synthesis, but also in the method of purification and reformulation. Reformulation on the 
Synthra takes place by evaporation of the HPLC fraction and then addition of the desired 
formulation, whereas the FXC PRO passes the HPLC fraction to an SPE cartridge for 
formulation. With this in mind, the purification and reformulation on the Synthra was 
adjusted to mimic that of the FXC PRO. 
Semi-preparative HPLC was applied to the reaction and product [11C]33 successfully 
separated from its impurities (Figure 20). As the product was very lipophilic, this took over 
30 min to elute from the column and needed to be diluted with 26 mL of water to prevent 
breakthrough on the SPE cartridge. Since this was not the intended purpose of this part of 
the synthesiser, it took over 20 min to transfer the mixture on the SPE for formulation. The 
compound was successfully reformulated and 80 MBq of clean product was isolated from 
a starting activity of approximately 5 GBq of [11C]MeI. This reaction took over 60 min to 
complete and so such a small amount of activity isolated was expected. However, this 
provided precedent for the reaction to take place on the FXC PRO where the transfer from 
HPLC to SPE would be much faster. 
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Figure 20: Semi-preparative (a) radio and (b) UV HPLC chromatograms of the reaction 
mixture, using a C18 column and 62% acetonitrile in water as the eluent. [11C]33 can be seen 
at a retention time of 32 min 
 
2.1.8 Biological Evaluation 
2.1.8.1 The [35S]GTPγS binding assay 
The [35S]GTPγS assay is an in vitro assay used to determine binding to G protein coupled 
receptors (GPCRs). This assay measures the level of G protein activation following 
agonist activation of GPCRs.158 The mechanism of GPCRs involves initial formation of a 
Gαβγ heterotrimer with GDP bound to the Gα subunit (Figure 21). A major function of βγ 
is inhibition of the Gα subunit. Activation of this receptor by an agonist leads to the 
dissociation of GDP and binding of GTP to the Gα subunit. Dissociation of the βγ takes 
place allowing activation of Gα, which is then able to interact with effector systems.158 The 
G protein heterotrimer is reformed by the enzyme GTPase by hydrolysis of GTP to GDP 
and recombination of the βγ subunit. 
 
 
(a)
(b)
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Figure 21: Mechanism of GPCR activation and GDP/GTP exchange 
 
In the [35S]GTPγS binding assay, GTP is substituted for 35S labelled GTP (Figure 22). 
Then GTPase enzyme is not able to hydrolyse this [35S]GTPγS to GDP and, therefore, 
accumulation of bound Gα([35S]GTPγS) take place. The assay measures the level of G-
protein activation following binding of an agonist, thus, binding affinity of an agonist can be 
measured from the quantity of sulphur-35. To perform this assay, the sample is filtered 
and scintillation fluid is used to measure the level of radioactivity present on the filter. 
 
Figure 22: Principle of the [35S]GTPγS binding assay 
 
2.1.8.2 Optimisation of the assay protocol 
Before screening of the compounds could take place, optimisation of the assay protocol 
was carried out using the endogenous compound S1P and fluorobenzamide 66. 
Preliminary data was collected using a protocol described in the literature by DeLapp et al. 
and the assay was carried out by filtration using a cell harvester.159 The S1P5 protein 
obtained was a solution of cell membranes and this was diluted as required. To determine 
the level of agonist stimulation on the protein, comparison of the total and basal binding 
was determined. A 10 μM solution of S1P was used for the total binding and no compound 
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was added for the basal. After incubation and filtration there was no significant difference 
in the two values and the quantity of radiation was unexpectedly low. It was proposed that 
the [35S]GTPγS may not have bound to the protein, so saponin was added to the solution 
of protein to permeabilise the membranes and release more free protein. This increased 
the radiation counts slightly, but there was still little difference between the total and basal 
binding. Analysis of the documentation of the S1P5 protein membranes showed that they 
were incapable of surviving one freeze-thaw cycle: i.e. the frozen sample of protein would 
need using straight after thawing and it was impossible to aliquot and refreeze without 
denaturing the protein. Further analysis showed that a much higher quantity of protein 
would be needed for the assay and this may have also explained the low counts of 
radiation. New assay conditions using a higher concentration of protein were developed. 
Using S1P and fluorobenzamide 66, the new conditions were attempted. To better 
visualise the affinity binding curves, nine different concentrations of each sample were 
used in the assay and the experiments were carried out in non-binding 96 well plates. 
Affinity binding curves were fitted for the data and significant difference between total and 
basal binding was observed (Figure 23). 
 
Figure 23: Non-linear fit of S1P5 affinity data for (a) S1P and (b) fluorobenzamide 66 
 
2.1.8.3 Evaluation of S1P agonist libraries 
With the optimal conditions for the assay now in hand, the three libraries of compounds 
could be tested for their affinity for S1P5. The limiting factor in screening all of the 
compounds was the S1P receptor membranes. There was a sufficient quantity of S1P5 
cell membranes to test all of the compounds, but the most potent compounds would be 
tested for their affinity for the S1P1‒3 receptors. Another screening factor was the relative 
potency of a particular concentration for each compound versus that of the endogenous 
compound S1P. An ideal radiotracer would have the same potency (100%) as S1P, so 
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this would competitively bind for the S1P5 receptors. If this value was too low, little or no 
binding of the tracer to S1P5 would take place, given the abundance of the endogenous 
compound. Likewise, a value that was too high would mean that this tracer could not be 
displaced by S1P and poor imaging of the distribution would occur, as no competitive 
binding for the receptor would take place. 
After the first set of assays, any compound with an EC50 value above 35 nM was excluded 
from further screening (Table 10). This left six compounds: three from the 
fluorobenzamide library, two from the library of 3-aryl substituted compounds and one 
compound featuring a phthalazinone core. Since there was sufficient quantity of cell 
membranes to test the selectivity of these six compounds, the values for potency relative 
to S1P was disregarded in this screening process. To measure their selectivity, the 
compounds were tested for their affinity towards the S1P1‒3 receptors. The most potent 
compound for S1P5, allyl derivative 93, showed high affinity for S1P1 and S1P3 in the 20‒
30 nM range. This selectivity for S1P5 was too poor to consider this as a desirable target. 
The compound from the fluorophthalazinone library and the 3-substituted compounds 102 
and 106 also showed high affinity for S1P1. The two most promising candidates from this 
screening process were the fluorobenzamides 89 and 94, with the former exhibiting better 
%potency for S1P5 and better selectivity; the latter showing higher affinity for S1P5. With 
the biological evaluation of these compounds completed, work began examining potential 
routes towards radiofluorination. 
Table 10: Biological evaluation of S1P agonist libraries with most promising compounds 
highlighted in red 
Compound 
EC50 (nM) 
S1P5 
%Potency 
EC50 (nM) 
S1P1 
EC50 (nM) 
S1P2 
EC50 (nM) 
S1P3 
S1P 10.7 100% n/a n/a 42.6 
 
419 105% n/a n/a n/a 
 
39.8 108% >10000 >10000 >10000 
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Compound 
EC50 (nM) 
S1P5 
%Potency 
EC50 (nM) 
S1P1 
EC50 (nM) 
S1P2 
EC50 (nM) 
S1P3 
 
180 137% n/a n/a n/a 
 
234 140% n/a n/a n/a 
 
49 102% n/a n/a n/a 
 
6.66 164% 25.6 >10000 27.6 
 
22.3 183% 104 >10000 2030 
 
2240 154% n/a n/a n/a 
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Compound 
EC50 (nM) 
S1P5 
%Potency 
EC50 (nM) 
S1P1 
EC50 (nM) 
S1P2 
EC50 (nM) 
S1P3 
 
72.3 129% n/a n/a n/a 
 
77.8 154% n/a n/a n/a 
 
954 136% n/a n/a n/a 
 
4880 102% n/a n/a n/a 
 
29.8 120% 76.0 >10000 >10000 
 
612 142% n/a n/a n/a 
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Compound 
EC50 (nM) 
S1P5 
%Potency 
EC50 (nM) 
S1P1 
EC50 (nM) 
S1P2 
EC50 (nM) 
S1P3 
 
23.4 175% 0.336 >10000 172 
 
31.4 92% 5.221 >10000 197 
 
3260 62% n/a n/a n/a 
 
3834 134% n/a n/a n/a 
 
>10000 90% n/a n/a n/a 
 
8490 101% n/a n/a n/a 
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Compound 
EC50 (nM) 
S1P5 
%Potency 
EC50 (nM) 
S1P1 
EC50 (nM) 
S1P2 
EC50 (nM) 
S1P3 
 
7350 53% n/a n/a n/a 
 
>10000 27% n/a n/a n/a 
 
49.2 45% n/a n/a n/a 
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2.1.9 Lead Compound Fluorination 
2.1.9.1 Synthesis of a precursor for fluorobenzamide 89 
The most promising analogue in terms of potency and selectivity for S1P5 was 
fluorobenzamide 89. As the synthesis of this library of compounds required incorporation 
of fluorine in an early step, a new route to access a precursor was considered. It was 
proposed that using ipso-defluoroborylation from aryl fluoride 89, it would be possible to 
synthesise boronic ester 133. This could then be radiofluorinated using established 
methodology.133 
 
Scheme 45: Proposed route to precursor 133 for radiofluorination 
 
Firstly, a literature method by Zhao et al. that used a palladium catalyst and B2Pin2 was 
attempted that did not require glovebox conditions (Table 11).160 The mechanism of this 
reaction involved activation of B2Pin2 and oxidative addition of the palladium into the C–F 
bond. Transmetalation takes place followed by reductive elimination to afford the boronic 
ester. Reaction of aryl fluoride 89 under these reaction conditions showed no conversion 
to any product after 16 h (entry 1). Instead, analysis of the 1H NMR spectrum of the crude 
material showed only decomposition of the starting material. This reaction was attempted 
once more at a lower temperature, but a similar result was observed (entry 2). The 
authors report that this reaction does not work well with compounds bearing ester and 
amide functional groups, so this may explain the lack of reactivity. A different literature 
method using a copper catalyst and PCy3 ligand was attempted (entry 3).161 This reaction 
did not form any product and instead only returned starting material. Heating the reaction 
under reflux resulted in decomposition (entry 4). The proposed mechanism for this 
reaction involves electron donation from a copper species into the aryl fluroide.161 This 
may explain why electron-rich aryl fluoride 89 did not undergo the reaction and indeed the 
authors do not report reaction with electron-rich aryl systems. 
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Table 11: Defluoroborylation reaction of aryl fluoride 89 
 
Entry Reagents Temperature Yield 
1 
B2Pin2, Pd2(dba)3, LiHMDS, 
toluene 
80 °C n/a 
2 
B2Pin2, Pd2(dba)3, LiHMDS, 
toluene 
40 °C n/a 
3 B2Pin2, CuCl, PCy3, CsF, toluene 50 °C n/a 
4 B2Pin2, CuCl, PCy3, CsF, toluene Δ n/a 
 
2.1.9.2 Synthesis of a precursor for fluorobenzamide 94 
The ipso-defluoroborylation to form a precursor for fluorobenzamide 89 was unsuccessful 
and so a new method to access a precursor for the other biologically active 
fluorobenzamide, 94 was proposed (Scheme 46). This required the synthesis of 3-methyl 
analogue 134 using the three established steps towards the benzamide core. It was 
proposed that the iron(III)-catalysed iodination of 134 would result in iodide 135 and this 
could be converted to the boronic ester via a Miyaura borylation reaction to provide a 
precursor for radiofluorination. 
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Scheme 46: Synthesis of boronate precursor 136 by iodination of 134 
 
Synthesis of 3-methyl analogue 134 was straightforward using the previously described 
methodology (Scheme 47). The SNAr reaction between benzoic acid 77 and aniline 48 
returned aryl bromide 137 in 95% yield; subsequent Ullmann condensation and amidation 
occurred in 71% and 92% yields, respectively. It was believed that NIS would be a more 
selective reagent for the upper aryl ring than NBS due to the larger atomic radius of the 
iodine atom. Nevertheless, the earlier reactions with NIS were not as efficient as those 
with NBS and so the bromination of 134 was attempted. After 16 h, conversion to mono- 
and di-brominated products 139 and 140 were observed. These products were isolated as 
an inseparable mixture in a 1:1 ratio. The mono-brominated product was identified as 139, 
due to the presence of a 3H multiplet in the 1H NMR spectrum that corresponded to the 
three hydrogen atoms of the upper ring and disappearance of the two doublets 
corresponding to C-3 and C-5 of the benzamide ring. This confirmed the theory that, due 
to being more electron rich, this lower ring would be halogenated first. 
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Scheme 47: Synthesis of benzamide 134 and attempted bromination 
 
For the initial reaction of 138 with NIS, THF was chosen as the solvent as this dissolved 
the reagents well and was capable of being heated to a higher temperature than 
dichloromethane (Table 12). The first attempts at the reaction used 1.0 equivalents of NIS 
and, after 16 h, showed no conversion to product at room temperature or under reflux 
(entries 1 and 2). Addition of 2.0 equivalents of NIS followed by heating under reflux for 20 
h showed a 50% conversion of starting material to mono- and di-iodinated products (entry 
3). The di-iodinated product 141 also showed iodination of the C-5 position in the 
benzamide ring. An attempt was made to separate the mono-iodinated compound, but 
only the di-iodinated product could be separated leaving a mixture of desired product 135 
and starting material 134. To push this reaction to completion and avoid as little di-
iodination as possible, 2.0 equivalents of NIS were added followed by a further equivalent 
after 16 h (entry 4). After 20 h, full conversion of starting material was observed and 
iodinated product 135 was isolated in 5% yield; however, insufficient material was 
obtained for the subsequent Miyaura borylation of 135 to compound 136. 
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Table 12: Optimisation of iodination reaction 
 
Entry NIS equivalents Temperature Time Yield 
1 1.0 rt 16 h n/a 
2 1.0 Δ 16 h n/a 
3 2.0 Δ 20 h n/a 
4 3.0 Δ 20 h 5% 
 
2.1.10 Conclusions 
In summary, several routes towards fluoride analogues of the S1P5 agonists described by 
Mattes et al. were investigated. A library of compounds was synthesised bearing an aryl 
fluoride moiety, through incorporation of the fluorine atom in an early step. An Ullmann 
condensation reaction was used to vary the ether side-chain and two compounds were 
synthesised that contained a methyl group in the C-3 position of the benzamide ring. A 
second library of compounds were synthesised, inspired by a serendipitous discovery 
made when attempting to prepare a precursor from the previous library. This bromination 
occurred in the C-3 position of the benzamide ring and so by utilising the Suzuki-Miyaura 
reaction to install fluorine and methoxy-bearing aryl rings, analogues of the most potent 
compound described in the literature could be synthesised. This library of compounds 
contained potential sites for fluorine-18 or carbon-11 radionuclides. A final library of 
compounds were synthesised based on a phthalazinone structure reported in the 
literature. These compounds also incorporated fluorine early in the synthesis and were 
further functionalised by the same bromination and subsequent Suzuki-Miyaura reaction 
as the previous library of compounds. 
All three libraries of compounds were tested to obtain their physicochemical properties 
prior to biological screening. A [35S]GTPγS binding assay was used to determine the 
affinity and selectivity of these libraries for S1P5 receptors. The two fluorobenzamide 
compounds 89 and 94 were identified as being the most favourable in terms of their 
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affinity and selectivity for S1P5, having relatively good physicochemical properties. A route 
towards a potential precursor for fluorobenzamide 89 was proposed that used an ipso-
defluoroborylation to form boronic ester 133, however, the reaction conditions were too 
harsh and not ideal for electron-rich aryl fluorides. A proposed route towards a potential 
precursor for fluorobenzamide 94 was proposed that began with iodination of benzamide 
134 to form an aryl iodide that could be transformed into boronic ester 136. Competing di-
iodination made this reaction hard to control; however, it was possible to isolate aryl iodide 
135 in 5% yield. 
Attempts to synthesise a potential precursor for carbon-11 radiotracer [11C]33 led to 
several unexpected rearrangement reactions. However, the use of a benzyl protecting 
group allowed for the synthesis of phenol 124 which could easily be methylated with MeI 
or MeOTf to give the non-radioactive compound 33. Radiosynthesis of carbon-11 
radiotracer [11C]33 would allow our collaborators to image S1P5 at the University of 
Edinburgh and the reaction was optimised on a Synthra Wolpertinger module. A 94% 
conversion to product was observed by radio-HPLC. This reaction was then purified using 
a method that could be used by the FXC PRO module in Edinburgh. This successfully 
provided a route towards radiochemically pure benzamide [11C]33, but would require 
adjustment to suit a different synthesiser and provide a superior radiochemical yield. 
2.1.11 Future Work 
Future work carried out at the University of Edinburgh will involve the synthesis of carbon-
11 radiotracer [11C]33 using an FXC PRO module. Since this reaction has already been 
optimised, this work will involve tailoring the purification to fit the synthesiser. Once a 
radiosynthesis has been established, preclinical work investigating the distribution and 
metabolism of this radiotracer in vivo will begin. A carbon-11 radiotracer that specifically 
targets S1P5 can then begin to study the role this receptor plays in repair of neurons. 
Optimisation of the iodination reaction to form mono-iodinated analogue 135 would allow 
for a larger quantity to be synthesised and the subsequent borylation and fluorination can 
be attempted. Attempting the iodination using different solvents may prove more effective, 
including the use of ionic liquid as the solvent. Other methods could be employed that use 
silver triflimide as a catalyst. This has been shown to be an effective catalyst for the 
iodination of arenes using NIS.125 The larger size of the silver atom improves 
regioselectivity of the iodination reaction and may prevent unwanted iodination in the 
sterically congested benzamide ring. 
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To synthesise a potential precursor for fluorobenzamide 89, selective bromination of 142 
could provide brominated analogue 143 (Scheme 48). With this C-3 position blocked and 
the lower ring more electron-deficient, iodination of the upper ring may be more efficient. 
With the enhanced reactivity of the aryl iodide over the bromide, Miyaura borylation should 
provide boronic ester 145 selectively. The bromine could then be removed via 
hydrogenation to give boronic ester precursor 133. 
 
Scheme 48: Proposed synthesis of a precursor for radiofluorination 
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2.2 Synthesis of LW223: A PET Imaging Agent for TSPO 
2.2.1 Project Aims 
Following the initial success of AB5186 (45) through the early stages of preclinical testing 
(see section 1.4.2), larger quantities were required for human clinical trials. This required 
the synthesis of both AB5186 (45) and the chloride precursor 44 on a multi-gram scale. 
Therefore, work was carried out on improving the overall nine-step synthesis. Although 
the radiosynthesis was efficient, there was concern that when applied to an automated 
system, there may be difficulty in separating the radioactive product from the unreacted 
precursor compound. Thus, another objective was to investigate other potential 
precursors to improve automation of the radiofluorination step. 
The first goal was to use the same nine-step procedure used by Blair et al., (Scheme 49) 
and synthesise both AB5186 (45) and the chloride precursor 44 to assess further, the 
binding profile in human tissue.119 Work began by assessment and optimisation of the 
route and synthesis of 44 on a large enough scale to investigate the incorporation of a 
different leaving group for the final radiofluorination step. 
 
Scheme 49: Published synthesis of AB5186 (45)119 
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2.2.2 Synthesis and Evaluation of AB5186 
2.2.2.1 Initial synthesis 
The first stage of this project involved using the same route as Blair et al., to synthesise 
AB5186 (45).119 This began with a one-pot two component reaction between 2-
aminobenzophenone (146) and diethyl acetylenedicarboxylate (147) using indium(III) 
chloride as a catalyst to form quinoline 148 in a quantitative yield (Scheme 50).162 This 
reaction was performed neat and used indium(III) chloride as a Lewis acid to activate the 
carbonyl of 147. The next step involved a sodium borohydride reduction in methanol to 
reduce 148 to lactol 152 in 78% yield. The order of addition was important for this 
reaction, as initial attempts involving addition of starting material 148 to a solution of 
NaBH4 in methanol and THF were very low yielding. It was believed this was due to 
decomposition of material through the slow addition of small quantities of 148 into a 
solution containing large quantities of NaBH4. A reversal of the order of addition, adding 
NaBH4 to 148, resulted in a much better yield. 
 
Scheme 50: Initial coupling and reduction 
 
Lactol 152 was then oxidised to lactone 149 using manganese(IV) oxide in 83% yield over 
4 h (Scheme 51). To switch the lactone from the C-3 to the C-2 position (153), lactone 149 
was subjected to lithium aluminium hydride (LAH) reduction. The work-up for this reaction 
reported in the literature involved addition of 1 M aqueous hydrochloric acid followed by 
extraction with ethyl acetate. Work-up methods with LAH can often form aluminium 
emulsions that cause separation difficulties, further complicated in this case by the 
presence of the over-reduced quinoline. Instead of using an acidic work up, the Fieser 
method was employed (quenched with water, basified and filtered).163 After subsequent 
re-oxidation of the nitrogen-carbon bond using 10% palladium on carbon in methanol, 150 
was achieved in 80% yield. This was then treated with the same manganese(IV) dioxide 
conditions and through chelation control of the manganese with the nitrogen of the 
quinoline, gave desired lactone 153 in 92% yield. 
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Scheme 51: Changing to an alternate lactone isomer 
 
The next step of the route was the trimethylaluminium-mediated incorporation of 
diethylamine and concurrent formation of the 3-hydroxymethyl group under reflux to form 
151 in 61% yield. Trimethylaluminium is a powerful, highly pyrophoric reagent. Thus, 
before this reaction was attempted, a similar reaction using the more stable and milder 
Lewis acid aluminium(III) chloride was attempted (Scheme 52). This reaction reached 
completion after 15 h under these milder conditions, at room temperature and formed 151 
in an improved yield of 88%. The final steps were chlorination using thionyl chloride and 
halogen-exchange using potassium fluoride and 18-crown-6. The 18-crown-6 was used to 
coordinate the potassium counter-ion, resulting in a more reactive fluoride nucleophile. 
This 18-crown-6 also acted as a phase transfer catalyst, allowing transport of the fluoride 
anions into the organic phase where the reaction took place. Given the hygroscopic 
nature of this crown ether, it was important to perform this fluorination under anhydrous 
conditions. These steps proceeded according to the literature in a quantitative yield and 
60% yield, respectively.119 
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Scheme 52: Synthesis of chloride precursor and successive fluorination 
 
2.2.2.2 Optimisation of the route 
Following the successful substitution of aluminium(III) chloride for trimethylaluminium and 
the subsequent synthesis of AB5186 (45), further optimisation of the route was 
investigated. Initial analysis identified the switching of the lactone orientation, from diester 
148 to lactone 149 (Scheme 51), as inefficient and an area that could be significantly 
improved. It was hypothesised that a direct reduction of the diester to the diol 150 would 
be possible using LAH as the reducing agent.  
This reduction was attempted using LAH and the same conditions for the following Pd/C 
oxidation (Scheme 53). As previously mentioned, LAH reaction work-up procedures can 
be problematic due to the formation of complex aluminium emulsions. Therefore, the 
Fieser work-up was used to yield 150 in 78% yield over two steps. This improvement, 
along with the use of aluminium(III) chloride, meant that the multi-gram synthesis of 
AB5186 (45) was possible, requiring three fewer steps and with a higher overall yield 
(38% over five steps). 
99 
 
Scheme 53: Direct reduction of 148 to 150 (shown in red) and previous route via lactone 149 
(shown in blue) 
 
2.2.2.3 New leaving groups for fluorination 
Now that it was possible to quickly generate a large quantity of alcohol 151, work began to 
investigate different leaving groups for the fluorination. The first leaving group investigated 
was a tosylate (Table 13), however, when tosylation at both room temperature and under 
reflux was attempted, no conversion was observed (entries 2 and 3). This was most likely 
due to the size of the tosyl group and the steric bulk around the ortho,ortho-disubstituted 
benzyl alcohol. With this in mind, mesylation was attempted using the relatively smaller 
mesyl chloride (entry 4). Analysis of the reaction mixture showed no starting material and 
the formation of a new product. Instead of forming the mesylate, the chloride was isolated 
in 86% yield. In this case, it was assumed that the mesylate had formed, but been 
displaced by the chloride ion present. The reaction to form the mesylate was attempted 
again at room temperature, in the presence of 4-dimethylaminopyridine (DMAP). It was 
proposed that the milder conditions would leave the mesylate intact (entry 5). 
Unfortunately, the same result was observed and the chloride compound was isolated. 
Considering these results, the formation of a triflate was attempted using triflic anhydride, 
a reagent that has no chloride counter ion (entry 6). No conversion to product was 
observed and the alcohol 151 decomposed under the reaction conditions. Acetic 
anhydride was then used to form an acetate (entry 7). This successfully formed 154 in 
83% yield. However, when 154 was subjected to typical fluorination conditions, no product 
was formed. 
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Table 13: Attempted synthesis of a new precursor 
 
Entry 
Leaving 
Group 
Conditions Temperature Yield 
Fluorination 
Yield 
1 Cl SOCl2, CH2Cl2 ∆ 100%, 44 60% 
2 OTs 
TsCl, NEt3, 
CH2Cl2 
rt 0% n/a 
3 OTs 
TsCl, NEt3, 
CH2Cl2 
∆ 0% n/a 
4 OMs 
MsCl, NEt3, 
CH2Cl2 
∆ 86% 44 n/a 
5 OMs 
MsCl, NEt3, 
DMAP, CH2Cl2 
rt 74%, 44 n/a 
6 OTf 
Tf2O, DIPEA, 
CH2Cl2 
−78 °C to rt 0% n/a 
7 OAc 
Ac2O, NEt3, 
DMAP, CH2Cl2 
rt 83%, 154 0% 
 
2.2.2.4 Biological Assessment of AB5186 
Access to multi-gram quantities of AB5186 (45) allowed biological assessment to be 
carried out. Specifically, the evaluation of the specific binding in human brain and heart 
tissue samples to assess sensitivity to the single nucleotide polymorphism (rs6971). By 
using samples that were known to be high-affinity binders (HAB), low-affinity binders 
(LAB) and mixed (MAB), it was possible to quantify the level of sensitivity. Following 
testing by our colleagues at the University of Edinburgh, it was shown that AB5186 (45) 
was indeed sensitive to the polymorphs of TSPO (Figure 24), albeit to a lesser extent than 
some of the other second generation TSPO ligands (see section 1.4.2): the LAB/HAB ratio 
of PBR28 in human brain and heart tissue was 48 when compared in the same assay. It 
was clear that a new molecular target was necessary and a re-evaluation of the structure 
was therefore considered. 
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Figure 24: Mean AB5186 (45) binding affinity curves in (a) human brain and (b) human heart, 
showing high (black), low (red) and mixed (blue) affinity binding 
 
2.2.3 Synthesis and Evaluation of LW223 
2.2.3.1 Initial synthesis 
After reconsidering the structure of AB5186 (45), a new compound, LW223 (155) was 
proposed, featuring a sec-butyl chain in the amide part of the molecule (Figure 25). This 
particular functionality is observed in PK11195 (41) as a racemic mixture, but studies by 
Shah et al. showed that the (R)-enantiomer of PK11195 (41) shows 2-fold greater affinity 
than the (S)-enantiomer for the known binding sites in vitro.164 Thus, the (R)-enantiomer of 
155 was proposed as the desired target. 
 
Figure 25: New proposed structure (155) and PK11195 (41) 
 
It was envisioned that the synthesis of LW223 (155) could be performed with only a small 
alteration to that of AB5186 (45): changing the amine from diethylamine to (R)-N-methyl-
sec-butylamine (156) for the ring opening of the lactone 153. Initial optimisation work was 
carried out with the racemic amine, as this was cheaper and more readily available. 
Attempts to open lactone 153 using amine 156 using the same conditions were 
unsuccessful. The reaction showed no conversion of starting material; increasing the time 
and the temperature of the reaction also had no effect. It was believed that amine 156 was 
   
(a) (b) 
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too sterically hindered to react with the lactone. Subsequently, it was proposed that using 
a less sterically hindered primary amine may be more successful. 
 
Scheme 54: Attempted ring opening reaction 
 
Ring opening of the lactone using (R)-sec-butylamine (158) was more successful, with the 
reaction reaching completion after 16 h under reflux. However, despite full conversion of 
starting material 153, only a low yield of 30% was achieved for this process. It was 
believed that some of the product was being lost in the acidic work-up, which was used to 
remove the excess amine. Subsequently, this aqueous step of the work-up was removed 
and instead the reaction was filtered to remove solid impurities. The amine was then 
evaporated in vacuo. This adapted procedure afforded 159 in 75% yield for both the 
racemic and enantiomeric reactions (Scheme 55). 
 
Scheme 55: Lactone ring opening using amine 158 
 
With the ring-opened product 159 now in hand, attempts were made to complete the rest 
of the synthesis. The nitrogen of the amide would need to be methylated prior to the 
chlorination of the compound to form the precursor. This was not without challenge: any 
N-methylation procedures may also involve a competing O-methylation reaction. 
Consequently, it was proposed to first protect the alcohol of 159. Prior investigation into 
an optimal leaving group for AB5186 (45) (Table 13) provided insight into which protecting 
groups could be installed, in particular, the synthesis of acetate 154. The same conditions 
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used for the AB5186 (45) route were effective in synthesising acetate 160 from alcohol 
159 in 89% yield (Scheme 56). 
 
Scheme 56: Synthesis of acetate 160 
 
Acetate 160 was subjected to standard methylation conditions (Table 14), using 
iodomethane (1 equivalent) and sodium hydride in DMF (entry 1). At room temperature, 
no conversion of starting material was observed, but when the reaction was heated to 60 
°C, there was full conversion of the starting material to the deprotected alcohol 159 (entry 
2). Since these conditions resulted in removal of the acetate, but no methylation, silver 
oxide was added to the reaction in an attempt to remove any HI generated and allow the 
reaction to be carried out at a lower temperature (entry 3). This did improve the 
methylation, however, it still resulted in deprotection of the alcohol and the di-methylated 
product 161 was obtained in 41% yield (Table 14). Literature procedures using nBuLi and 
MeI to methylate amides in the presence of esters have been reported.165‒167 With this in 
mind, these conditions were applied to acetate 160 (entry 4). After 1 h of reaction at −78 
°C, only the deprotected alcohol 159 was returned in 75% yield. Another method reported 
by Monteiro et al. describes the use of trimethyloxonium tetrafluoroborate as a methylating 
agent in the presence of esters.168 When this method was applied (entry 5), the di-
methylated product 161 was produced in 36% yield. 
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Table 14: Attempted methylation reaction 
 
Entry Reagents Solvent Temperature Product Yield 
1 MeI, NaH DMF rt n/a n/a 
2 MeI, NaH DMF 60 °C 159 35% 
3 
MeI, NaH, 
Ag2O 
DMF rt 161 41% 
4 nBuLi, MeI THF −78 °C 159 75% 
5 
tBuOK, 
Me3OBF4 
CH2Cl2 rt 161 36% 
 
The N-H hydrogen atom was believed to be of a very similar pKa to that of the O-H. 
Nevertheless, careful control of the quantity of reagents could result in mono-methylation 
of one of the groups. Using the alcohol 159 and maintaining the quantity of MeI and NaH 
to 0.9 equivalents, the reaction was carried out at 0 °C in THF to improve the solubility of 
the reagents (Scheme 57). After 1 h, there was evidence of three products from the 
reaction, including a mono-methylated compound in 32% yield. This was confirmed as the 
O-methylated compound 162 by the absence of the broad triplet in the 1H NMR spectrum. 
The di-methylated compound 161 and alcohol 159 were also obtained from this reaction in 
27% and 19% yield, respectively. 
 
Scheme 57: Methylation with 0.9 equivalents of MeI and NaH 
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With methylation of the amide being complicated by the presence of the alcohol, the route 
was redesigned so that the methylation was performed as a final step. Chlorination of 159 
occurred as expected in 85% yield after 16 h (Scheme 58) and subsequent fluorination, 
using previously described conditions, gave 164 in 92% yield. The final methylation step, 
using standard conditions returned LW223 (155) in 91% yield after 3 h. Methylation also 
resulted in the appearance of rotamers in the 1H and 13C NMR spectra. This was observed 
most dramatically for the hydrogen atom of the chiral centre of the sec-butyl chain splitting 
into two peaks. This appeared as two separate signals at 3.60 ppm and 4.88 ppm (Figure 
26). It was believed that the appearance of rotamers was due to restricted rotation of the 
amide bond as a result of a more sterically hindered side chain. It was not possible to 
coalesce the rotamer peaks in the 1H NMR spectrum, despite heating the sample to 100 
°C in DMSO-d6. However, the ratio of the rotamers did change from a 3:1 mixture to 1:1. 
 
Scheme 58: Initial synthesis of LW223 (155) 
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Figure 26: Expansion of the 1H NMR spectrum of LW223 (155) in CDCl3 
 
Although this route was successful in producing the desired compound for testing, due to 
the fluorination being the penultimate step, another approach would be required for 
radiofluorination. Although many 18F-labelled tracers are produced in a two-step method 
(e.g. [18F]FDG or [18F]FMISO), the steps that follow radiofluorination tend to be removal of 
protecting groups and are very fast. Consequently, this route would require re-
examination depending on the success of human tissue affinity testing. 
2.2.3.2 Biological assessment of LW223 
LW223 (155) was next tested by our collaborators in human tissue samples for sensitivity 
to the genetic polymorphism (rs6971) in TSPO. In human brain and heart tissue, the 
affinity of LW223 (155) for TSPO demonstrated no significant difference between the HAB 
and LAB, giving a ratio of 1 (Figure 27). Furthermore, the mean binding affinity (Ki) of 
LW223 (155) in human brain tissue was shown to be 0.6 nM, twice the potency of 
PK11195 (41) (1.2 nM). In human heart tissue, the Ki value of 1.7 nM for LW223 (155) 
was found to be the same as PK11195 (41). 
 
Figure 27: Mean LW223 (155) binding affinity curves in (a) human brain and (b) human heart 
showing high (black), low (red) and mixed (blue) affinity binding 
 
   
(a) (b) 
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Given the promising affinity results, the physicochemical properties of LW223 (155) were 
assessed using the previously described HPLC methodology (see section 2.1.5).122 These 
values were determined alongside those of PK11195 (41) and AB5186 (45) (Table 15). As 
expected, the physicochemical properties of LW223 (155) were not as ideal as those of 
AB5186 (45), since adding the sec-butyl chain resulted in a more lipophilic compound. 
However, the log P, Km and Pm were within the predicted ideal properties of a radiotracer 
(see section 2.1.5.4).122 The %PPB was very high for LW223 (155), however, the values 
obtained for PK11195 (41) and AB5186 (45) were also higher when compared with 
previously calculated values (92% and 90%, respectively).119,169 Correcting this value, 
using PK11195 (41) and AB5186 (45) as standards to conform with previous studies, 
returns a %PPB of 92%. 
Table 15: Physicochemical properties of LW223 
Compound log P %PPB Km Pm 
PK11195 (41) 3.98 97% 184 0.52 
AB5186 (45) 3.74 96% 124 0.35 
LW223 (155) 4.17 98% 195 0.56 
 
2.2.3.3 Synthesis of a precursor for LW223 (155) 
As the majority of properties for LW223 (155) were found to be positive, work began on 
adapting the synthesis so as to allow for late stage radiofluorination. Previous work carried 
out within the Sutherland group investigated iodinated quinoline derived compounds for 
SPECT imaging.170,171 Amongst the compounds reported were some featuring N-
methylated amides with sec-butyl chains. This N-methylation was performed in the 
absence of any other groups that could potentially react. Thus an adaptation of this 
synthesis was attempted in order to develop an appropriate precursor. Utilisation of this 
literature route would allow access to 3-methyl quinolone 167 (Scheme 59). A radical 
bromination could provide the potential precursor 168, which then could either be 
converted to the chloro-compound or used directly for a final step fluorination. 
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Scheme 59: Proposed synthesis of a precursor (168) to perform a late stage fluorination 
 
The first step was the construction of the quinoline ring via a Combes quinoline synthesis 
using conditions developed by Bradbury et al. (Scheme 60).172,173 This two part reaction 
consisted of condensation of aniline with diethyl oxalpropionate (166) to form imine 169 
using catalytic tosic acid. The reaction took place under Dean-Stark conditions in order to 
remove water that was generated. Imine 169 was not isolated, but instead immediately 
subjected to acid-mediated cyclisation using polyphosphoric acid at 120 °C, forming 
quinoline 170 in 60% yield over the two steps. 
 
Scheme 60: Synthesis of quinoline 170 
 
The next step was the incorporation of the phenyl ring onto the quinoline. To perform this, 
a bromination reaction was first employed, using phosphorus oxybromide (POBr3) in the 
presence of potassium carbonate (Scheme 61). This reaction was completed in 2 h and 
gave 171 in 86% yield. The incorporation of a bromine atom now allowed the use of a 
Suzuki-Miyaura reaction with benzeneboronic acid.135 In the literature, this reaction took 
48 h to go to completion and required an additional portion of boronic acid and base. It 
was believed that this slow conversion was due to oxidation of the palladium catalyst by 
dissolved oxygen in the solvent of the reaction. Consequently, the reaction mixture was 
degassed under argon before addition of Pd(PPh3)4 (3 mol%) and full conversion of the 
reaction was confirmed after 16 h, giving 172 in 78% yield. To prepare the compound for 
an amide coupling, the ester was then converted to the acid in a hydrolysis reaction, using 
standard conditions, to give 173 in 98% yield. 
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Scheme 61: Synthesis of acid 173 
 
Acid 173 was submitted to an amide coupling with sec-butylamine to form amide 174, with 
conditions described in an earlier chapter (see section 2.1.4.2). This involved formation of 
the acid chloride intermediate with oxalyl chloride, followed by reaction with amine 158 
(Table 16). The literature synthesis used 15 equivalents of the racemic amine and 
produced 174 in 70% yield (entry 1).170 Since the compound of interest was a single 
enantiomer, a more conservative approach was required. Initially, the same reaction 
conditions were used, however, the equivalents of the amine were reduced to 1.5. The 
reaction did go to completion, but the yield was affected, giving 174 in 40% yield (entry 2). 
A different literature method by Cappelli et al. used 1.1 equivalents of amine alongside 20 
equivalents of triethylamine to convert the acid chloride to the product.174 When these 
conditions were applied, there was only a small amount of conversion to the desired 
product, with the reaction returning mostly starting material (entry 3). Considering all of 
these attempts required two-steps – conversion to the acid chloride followed by addition of 
the amine – a new method employing the coupling reagent HBTU in a single step was 
investigated (entry 4). After only 4.5 h of reaction time, full conversion to the desired 
product was observed and amide coupled product 174 was isolated in 91% yield. These 
optimised conditions only required 1.1 equivalents of chiral amine and had the advantage 
of taking less time and being a more operationally simple method. 
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Table 16: Amide coupling reaction 
 
Entry Conditions 
Equivalents of 
Amine 
Yield 
*1* 
1. (COCl)2, cat. DMF 
CH2Cl2, 0‒50 °C, 2 h      
2. amine, CH2Cl2          
0‒50 °C, 16 h 
15 70% 
2 
1. (COCl)2, cat. DMF 
CH2Cl2, 0‒50 °C, 2 h      
2. amine, CH2Cl2          
0‒50 °C, 16 h 
1.5 40% 
3 
1. (COCl)2, cat. DMF 
CH2Cl2, 0‒50 °C, 2 h     
2. NEt3, amine, CH2Cl2  
0‒50 °C, 16 h 
1.1 30% conversion 
4 
HBTU, amine, DIPEA 
DMF, 50 °C, 4.5 h 
1.1 91% 
*Racemic amine used 
 
The proposed mechanism for the HBTU coupling is shown below (Scheme 62).175 
Deprotonation of the carboxylic acid gives carboxylate 176, which can in turn perform 
nucleophilic attack of the uronium moiety of HBTU (177). Intermediate 178 then 
undergoes further reaction with benzotriazole 179, producing the OBt activated ester 181 
and tetramethylurea (180) as a by-product. Subsequent reaction of 181 with the amine 
gives amide coupled product 182. The order of reagent addition for this reaction was 
important: if the amine is added too early, a side-reaction can take place between the 
amine and HBTU to form guanidinium by-product 183. It was found that the addition of 
amine after 0.5 h of reaction time was sufficient to avoid formation of this unwanted by-
product. 
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Scheme 62: Mechanism of the HBTU coupling 
 
With the amide coupled product now in hand, the methylation of the amide could now take 
place. Using a standard procedure with iodomethane and sodium hydride, the methylation 
was complete within 3 h and gave 167 in 94% yield (Scheme 63). As with the initial 
synthesis of LW223 (155), after the methylation of 174, the appearance of rotamers was 
observed in the 1H and 13C NMR spectra. 
A chloride precursor proved to be an effective substrate for the radiofluorination and 
synthesis of [18F]AB5186 (45). For these reasons, it was believed that a chloro-derivative 
of LW223 (155) would also be an effective precursor. Therefore, a method for chlorination 
of the 3-methyl moiety was next studied. Examples in the literature used Wohl-Ziegler 
bromination conditions, substituting NBS for NCS.176,177 An initial attempt using dibenzoyl 
peroxide and NCS in CCl4 only returned starting material 167 (Scheme 63). Variation of 
the radical initiator to either AIBN or the cyclohexane derivative, AHCN was ineffective 
and it was believed that the stronger N-Cl bond of NCS was preventing reaction. By 
utilising NBS, with the comparatively weaker N-Br bond (due to its larger size and poorer 
overlap of bonding orbitals), it was proposed that a radical-initiated bromination followed 
by a SN2 reaction using LiCl would yield the chlorinated precursor. Bromination proceeded 
very well, using Wohl-Ziegler conditions and gave 168 in 67% yield. Due to limited 
availability and toxicity issues, the solvent CCl4 was substituted with CHCl3, which 
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provided 168 in an increased yield of 83%. The subsequent chlorination of 168 took place 
using LiCl anhydrous conditions and gave the chloro-precursor in 73% yield. 
 
Scheme 63: Synthesis of chloro-precursor 184 
 
Following synthesis of chloride 184, fluorination with potassium fluoride was next 
investigated. Chloro-precursor 184 was subjected to the same conditions as previously 
used for the fluorination of AB5186 (45) (Scheme 64). After reflux for 96 h, only 9% 
conversion to product was observed by 1H NMR spectroscopy. Although a good leaving 
group for the fluorination of AB5186 (45), the additional steric-bulk of the sec-butyl chain 
obviously makes this an inefficient process. Consequently, the fluorination reaction was 
attempted using bromo-precursor 168. After reflux for 72 h, total conversion to the product 
was observed and LW223 (155) was isolated in 53% yield. In this case, the weaker 
carbon-halogen bond partially compensates for the steric hindrance associated with this 
reaction, allowing formation of the product in moderate yield. 
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Scheme 64: Non-radioactive fluorination of precursors 
 
Whilst the non-radioactive reaction to form LW223 (155) from the chloro-precursor was 
unsuccessful, this did not mean that it would be unsuitable for radiosynthesis. These 
reactions are pseudo-first-order with respect to the [18F]fluoride (see section 1.2.5.2) and, 
therefore, act differently to the non-radioactive process. Consequently, both the chloro- 
and bromo-precursors were considered for radiosynthesis. 
2.2.3.4 Conformational isomerism of LW223 
The appearance of rotamers in the NMR spectra of LW223 (155) was not too surprising 
given the combined steric hindrance associated with the quinolone substituents and the 
bulky sec-butyl chain of the amide. However, what was initially unexpected was the 
appearance of two peaks in the HPLC chromatogram. These two peaks were initially in a 
3:1 ratio, but upon standing in solution in an acetonitrile and water mixture, re-equilibrated 
to an approximate 1:1 ratio. This re-equilibration of the peaks, combined with the data 
collected from other standard analytical methods, suggested that the two peaks were as a 
result of conformational isomerism of LW223 (155), rather than that of an impurity. Indeed 
this phenomenon has been previously reported in the literature, including by Geffe et al., 
who describe a formamide that produced double bands in TLC, as well as two peaks by 
HPLC.178 As with LW223 (155), their compounds also showed no coalescence of 1H NMR 
signals when heated to 150 °C. This phenomenon was proposed to be due to the 
hindered rotation around the amide bond, similar to that of DMF where the two sets of 
methyl group hydrogen atoms show two distinct peaks in the 1H NMR spectrum. However, 
unlike DMF, heating the NMR sample did not overcome the energy barrier to rotation, due 
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to the amide nitrogen possessing a larger group, causing steric congestion. To confirm 
this theory, an LCMS of LW223 (155) was performed (Figure 28). This displayed good 
separation of the two peaks and mass analysis showed that their masses were identical. 
 
Figure 28: (a) LCMS chromatogram of LW223 (155), using 10‒90% MeCN/0.1% formic 
acid(aq) on a C18 HPLC column at 1.2 mL min−1; (b) mass spectrum of peak at 12.49 min; (c) 
mass spectrum of peak at 12.72 min 
 
It was not expected that the two peaks of LW223 (155) were as a result of racemisation of 
the stereocentre given that the compound only possesses one stereogenic centre and 
separation of enantiomers is not possible using standard analytical HPLC. Nevertheless, 
analytical chiral HPLC analysis of LW223 (155) was considered to confirm the 
enantiopurity and corroborate the amide rotamer hypothesis. To perform the chiral HPLC, 
racemic LW223 derivative 185 was synthesised as described before using racemic amine 
158 (Figure 29a). This was then analysed by chiral HPLC using an AD-H column and 
2.5% isopropanol in hexane. The double peaks made analysis of the two enantiomers 
challenging, however, using a 1 mL min−1 flow rate gave four peaks, eluting over 15 min 
(Figure 29a). The same conditions were then applied to the analysis of the (R)-enantiomer 
(Figure 29b). This chromatogram showed that the two outer peaks (retention times 27.1 
and 38.4 min) corresponded to the (S)-enantiomer and the inner peaks were the (R)-
enantiomer. Indeed, small quantities of the (S)-enantiomer were present in the chiral 
sample, however, the enantiomeric excess of (R)-LW223 (155) was calculated as 99%. 
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Figure 29: Chiral HPLC chromatograms of (a) racemic LW223 (185) and (b) (R)-LW223 (155), 
using 2.5% isopropanol in hexane on an AD-H column at 1.0 mL min−1 
 
2.2.4 Radiosynthesis of [18F]LW223 
2.2.4.1 Establishing an HPLC method 
As the limiting reagent in the radioactive synthesis would be [18F]fluoride, the remaining 
precursor would need to be separated from the product post-synthesis, usually with semi-
preparative HPLC. The synthesiser used for the reaction and purification would only allow 
an isocratic flow, therefore an isocratic HPLC method was established. With its superior 
reactivity, bromo-precursor 168 was chosen for this initial work. A sample was prepared 
Peak Ret. Time Area Area%
1 27.256 15118 21.597
2 30.509 21743 31.061
3 32.330 24215 34.593
4 38.171 8925 12.749
Peak Ret. Time Area Area%
1 27.145 21940 0.264
2 30.679 7486077 49.204
3 32.224 7378647 50.289
4 38.379 29955 0.243
(a)
(b)
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containing a 1:1 mix of LW223/precursor and examined by HPLC. The aim of this 
experiment was to find conditions for effective separation of the fluorinated product. Extra 
time spent separating the product during the radiosynthesis would result in less activity, 
due to the short half-life of the 18F nuclide, but also a wider peak would mean the product 
would be collected in a greater volume of solvent, which would make reformulating the 
product more difficult. Therefore optimal conditions for the elution of LW223 (155) were 
crucial. It was found that a mixture of 70% acetonitrile in water provided good separation 
of the two compounds. 
 
Figure 30: HPLC chromatogram of LW223 (155) and bromo-precursor 168, using a C18 
column and 70% acetonitrile in water as the eluent 
 
2.2.4.2 Drying of [18F]fluoride 
The radioactive synthesis was carried out using a TRACERlab FXFN synthesiser (GE 
Healthcare); the graphics overlay for this synthesiser is shown in Appendix III. The 
[18F]fluoride was produced via the 18O(p,n)18F nuclear reaction by cyclotron irradiation of a 
target containing [18O]H2O. This was then separated from the water by trapping on an ion 
exchange resin. The radioactivity trapped on the separation cartridge could then be 
measured using a Geiger-Muller (GM) counter. To elute the [18F]fluoride, a solution of 
K2CO3 and Kryptofix 222® (Figure 31) was passed over the resin and transferred to the 
reaction vessel. The Kryptofix 222® fulfils a similar role to the 18-crown-6 used in the non-
radioactive synthesis (see section 2.2.2.1), however, the cryptand is more strongly 
complexing, possessing a very slow de-complexation rate that results in a high binding 
strength.179 This more superior complexing reagent was used for the radiosynthesis, as 
efficiency of binding potassium cations was crucial to allow for rapid radiolabelling. 
LW223
Bromo-precursor
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Figure 31: Kryptofix 222® 
 
After transfer of [18F]fluoride to the reaction vessel, it was then required to evaporate the 
solution and dry quantitatively to remove any remaining water. If the reaction was not dry, 
hydroxide ions are formed and compete with the nucleophilic fluorination, reducing the 
radiochemical yield. Drying was implemented by azeotropic distillation with acetonitrile, 
applying vacuum and a flow of anhydrous nitrogen gas. It was then possible to measure 
the radioactivity trapped in the reaction vial using another GM counter. Acetonitrile was 
chosen as the solvent for the reaction, as this was aprotic and dissolved both bromo-
precursor 168 and LW223 (155). Since the reaction would take place under reflux in a 
sealed vial resistant to pressure changes, it was possible to heat the reaction above the 
boiling point of the solvent and so a higher boiling point solvent would only be needed for 
more extreme conditions. 
2.2.4.3 Labelling 
Initially, HPLC was omitted from the synthesis to allow for optimisation of the 
radiolabelling process. The reaction mixture was then sent directly into a dispensing vial 
so the radioactivity could be measured and the sample could be analysed with HPLC on a 
C18 column, using both UV and gamma detectors. Since unreacted [18F]fluoride would be 
retained on the C18 column and therefore not show on the gamma detector, analysis of the 
samples using radio-TLC was also considered. For these test reactions, only a small 
amount of radioactivity was required, thus, an [16O]H2O rinse of the cyclotron target, used 
for an earlier production of medical tracers was sufficient to deliver between 0.5‒1.0 GBq 
of [18F]fluoride. The smaller quantity of radiation would allow for two reactions to take 
place in a single day. The first reaction was carried out using similar conditions to the non-
radioactive synthesis (Table 17). After 10 min of reaction at 80 °C, a sample of the mixture 
was injected into an analytical HPLC. This showed no evidence of the product on the 
gamma trace (entry 1). An increase in reaction time and temperature showed a small 
improvement, but when the solvent was switched to DMSO there was no longer any 
product formed (entries 2‒3). 
Further examination of the bromo-precursor showed that small quantities of hydrolysed 
compound had formed during storage at −20 °C after some months. Although this impurity 
was small, this may explain the poor conversion to the product observed in the reaction. 
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Following re-purification of bromide 168 by silica chromatography, the reaction was 
attempted again using acetonitrile at 110 °C for 10 min (entry 4). This showed promising 
conversion and was unaffected by the reduction in reaction time to 5 min (entry 5). 
Overall, the optimised procedure allowed an 88% conversion after a reaction time of 5 
min. 
Table 17: Optimisation of reaction conditions 
 
Entry Solvent Temperature Time Conversion 
1 MeCN 80 °C 10 min 0% 
2 MeCN 100 °C 15 min 40% 
3 DMSO 120 °C 15 min 0% 
4 MeCN 110 °C 10 min 91% 
5 MeCN 110 °C 5 min 88% 
 
2.2.4.4 Purification and reformulation 
After optimisation of the reaction conditions, HPLC was incorporated into the method. 
Following the reaction, the mixture was passed through an Al2O3 cartridge to absorb any 
remaining fluoride prior to injection into the HPLC. Only trace quantities of the product 
were observed on the gamma trace of the HPLC, despite having high radioactivity in the 
reaction vial. It was believed that [18F]LW223 (155) may have also been retained on the 
Al2O3 cartridge, a theory which was confirmed by passing non-radioactive LW223 (155) 
through a cartridge using the same conditions. Ultimately it was decided to remove the 
Al2O3 cartridge from the method, as the conversion from [18F]fluoride had already been 
shown to be efficient. 
The purpose of this radiotracer would be to image TSPO in vivo, therefore, the 
acetonitrile/water mixture of the HPLC fraction collected would be reformulated into saline 
with a minimum amount of ethanol prior to injection. To perform this reformulation, the 
HPLC fraction was collected in a round-bottomed flask containing 20 mL of water with 
stirring. This diluted the acetonitrile in the solution from 70% to around 10‒15%. This 
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solution was then pushed through a C18 solid phase extraction (SPE) cartridge, retarding 
the product on the cartridge and passing the water and acetonitrile to waste. This was 
washed once more with water to remove any remaining acetonitrile, before eluting the 
product with ethanol and diluting with saline. Initially, [18F]LW223 (155) was reformulated 
with 10% ethanol in saline, however, it was found this could be reduced to 5% with no loss 
in radioactivity. 
2.2.4.5 Productions of [18F]LW223 
After optimisation of the radiosynthesis and formulation, three productions of [18F]LW223 
(155) were performed using bromo-precursor 168. An irradiation of the target for 1 min at 
65 µA was used to produce the [18F]fluoride for these syntheses. Consistent radiochemical 
yields (non-decay corrected) were obtained for each production, with an average of 49% 
(Table 18). As per the new nomenclature rules for radiopharmaceuticals, these 
radiochemical yields were decay corrected according to the formula: At = A0 × 𝑒
−λt, where 
At is the activity at time t and λ is the decay constant, calculated for fluorine-18 as 1.05 × 
10−4 s−1.30 This gave an average radiochemical yield of 60% and radiochemical purity was 
shown to be greater than 99%, based on the gamma trace of the analytical HPLC. Molar 
activity (Am) was calculated by running known concentrations of non-radioactive LW223 
(155) on the same HPLC system, giving activity per µmol. Accordingly, specific activity 
(As) was calculated from this value to give activity per mg. 
Table 18: Productions of [18F]LW223 (155) from bromo-precursor 168 
Production 
Starting 
Activity 
(GBq) 
End 
Activity 
(GBq) 
Non-Decay 
Corrected 
RCY 
Decay 
Corrected 
RCY 
Am 
(GBq 
µmol−1) 
As 
(GBq 
mg−1) 
1 2.89 1.52 53% 65% 4.57 13.1 
2 2.89 1.43 50% 61% 10.5 29.9 
3 2.89 1.28 44% 54% 7.90 22.6 
Average - - 49% ± 3% 60% ± 3% 7.65 ± 1.71 21.9 ± 4.86 
 
It was expected that bromo-precursor 168 would be more effective than the chloride 
analogue 184, however, it was deemed prudent to check the efficiency of the 
radiosynthesis from this precursor using the same method. Using exactly the same 
conditions, chloro-precursor 184 returned a decay corrected radiochemical yield of 59%, 
very similar to that of bromo-precursor 168 (Table 19). Moreover, the As calculated for this 
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synthesis was 48.1 GBq mg−1, twice that of the previous syntheses. The reactivity of the 
chloride versus that of the bromide did not impede the reaction. Based on these results 
and its enhanced stability, the chloride was chosen as the precursor for the preclinical 
trials of [18F]LW223 (155). Further productions of [18F]LW223 (155) from chloro-precursor 
184 were of a much higher starting activity (irradiation for 10 min at 65 µA), so the 
radiochemical yields are not directly comparable to previous productions. However, these 
still gave good and consistent yields for [18F]LW223 (155) with improved As. 
Table 19: Productions of [18F]LW223 (155) from chloro-precursor 184 
Production 
Starting 
Activity 
(GBq) 
End 
Activity 
(GBq) 
Non-
Decay 
Corrected 
RCY 
Decay 
Corrected 
RCY 
Am 
(GBq 
µmol−1) 
As 
(GBq 
mg−1) 
1 2.89 1.39 48% 59% 16.9 48.1 
2 27.0 7.68 28% 35% 58.2 165.9 
3 27.0 7.75 29% 35% 52.2 149.1 
4 27.0 5.14 19% 23% 29.7 84.8 
5 27.0 7.54 28% 34% 61.3 175.0 
 
2.2.5 Preclinical Studies 
With radiofluorination optimised, preclinical evaluation of the radiotracer began. This work 
was carried out by collaborators at the University of Edinburgh. Small animals injected 
with [18F]LW223 (155) were scanned in a microPET system and images were produced 
that showed uptake in tissues associated with high levels of TSPO (Figure 32). Uptake in 
the heart and lungs was high, but since levels of TSPO are low in healthy brain tissue, 
only a small amount of uptake was observed in the brain. Elimination of the tracer was 
shown to be via the intestines. To show that [18F]LW223 (155) was reversibly binding to 
TSPO and to also assess the specific binding, displacement studies were carries out 
using non-radioactive PK11195 (41). After 60 min post-injection of PK11195 (41), the 
signal had reduced considerably from the heart and lungs, with uptake in the surrounding 
tissue low. This demonstrated that [18F]LW223 (155) was indeed reversibly binding to 
TSPO and that non-specific binding was low. 
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Figure 32: Displacement study of [18F]LW223 (155) using PK11195 (41). Bound [18F]LW223 
(155) can be shown to be reversibly binding to the target after injection of PK11195 (41) 60 
min post injection 
 
2.2.6 Conclusions 
An optimised synthesis towards the potential TSPO radiotracer AB5186 (45) was 
designed, which allowed for multi-gram quantities of the precursor and non-radioactive 
compound to be produced. Following biological evaluation, it was found that AB5186 (45) 
was sensitive to the single nucleotide polymorphism that afflicts many second generation 
TSPO radiotracers. As such, a new structure was proposed and the compound LW223 
(155) was synthesised, albeit using a method that would not allow late-stage 
radiosynthesis. After biological evaluation showed that LW223 (155) was not sensitive to 
the single nucleotide polymorphism, a new synthesis was designed that allowed for the 
synthesis of two potential precursors. A radiofluorination method was designed and 
optimised from bromo-precursor 168 to produce [18F]LW223 (155) in 60% ± 6% decay 
corrected radiochemical yield and a radiochemical purity of greater than 99% (n = 3). 
Comparison of the radiosynthesis from both precursors showed that there was very little 
difference in efficiency and therefore, chloro-precursor 184 was chosen for the preclinical 
work of [18F]LW223 (155) due to its superior stability. Preclinical studies have shown that 
[18F]LW223 (155) images TSPO in vivo, consistent with the known expression of the 
receptor; clearance studies using non-radioactive PK11195 (41), show that this binding to 
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TSPO is reversible. Future work has been proposed that includes preclinical imaging of 
TSPO in myocardial infarction and also investigating the role of TSPO in prostate cancer 
using [18F]LW223 (155). 
2.2.7 Future Work 
Following the preclinical evaluation of [18F]LW223 (155), future work will involve the 
preparation of this tracer for phase I clinical trials. The safety and dosimetry properties of 
the tracer will be established. Toxicology for a radiotracer often falls into a lower category 
for pharmaceuticals due to the small dose of compound administered. For example, only 
1.5 µg of a tracer is injected in a 250 MBq dose, if the tracer has a molecular weight of 
300 g mol−1 and Am of 50 GBq µmol−1.31 The major difference for radiotracers, compared 
to other pharmaceuticals, is that an estimate of the radiation dosimetry is required. 
Following the success of these studies, phase II clinical trials can begin. 
Further preclinical work, carried out by collaborators at The Beatson Institute for Cancer 
Research, will look at using [18F]LW223 (155) to image TSPO and investigate the role that 
this protein plays in de novo androgen biosynthesis in prostate cancer cells. These 
studies will provide insight into the in vivo mechanism of the development of lethal 
metastatic castration-resistant prostate cancer and allow for early detection in 
patients.113,180 
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2.3 Novel Benzotriazole Derived α-Amino Acids 
2.3.1 Project Aims 
In 2008, Filimonov et al. developed the synthesis of stable aryl diazonium tosylate salts by 
using a polymer-supported nitrite reagent under mild acidic conditions.181 These 
diazonium salts could be used for a variety of transformations and previous work by Sloan 
et al. has shown that, by utilising this reagent, it was possible to incorporate radioactive 
[125I]iodine into aryl amines via these stable diazonium salts in a one-pot process.182 
Within the Sutherland group, further application of this reaction for the synthesis of more 
complex molecular imaging agents was explored.183 Amongst many other targets, this led 
to the attempted synthesis of AT-1012: a selective antagonist for the α3β4 nicotinic 
acetylcholine receptor (nAChR).184 However, instead of the expected outcome, a 
diazotisation-cyclisation product was observed in the form of a benzotriazole (Scheme 
65).183 
 
Scheme 65: Attempted iodination of AT-1012 
 
Traditionally the synthesis of benzotriazoles has involved the mono-diazotisation of 1,2-
aryldiamines, using sodium nitrite and acidic conditions, followed by intramolecular 
cyclisation.185 More recently, N-substituted benzotriazoles have been synthesised via 
“click” chemistry: a [3+2] cycloaddition of azides with benzynes, using mild conditions.186 
Other methods include: 1,7-palladium migration via C-H activation, followed by 
intramolecular cyclisation, allowing the regioselective synthesis of benzotriazoles, and 
also the use of alkyl nitrites under catalyst-free and mild conditions.187 However, many of 
these approaches are limited by the need for high temperatures, the use of acidic 
conditions, nitrite reagents that can decay to toxic nitrogen oxides, or the need to have 
highly functionalised starting materials. To overcome some of the drawbacks of these 
other approaches and encouraged by the success of this earlier incidental reaction, 
Faggyas et al. developed methodology towards the preparation of N-substituted 
benzotriazoles from 1,2-aryldiamines via diazotisation and intramolecular cyclisation, 
using the polymer-supported nitrite reagent and p-tosic acid (Scheme 66).188 
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Scheme 66: Synthesis of N-substituted benzotriazoles from 1,2-aryldiamines 
 
Previously within the Sutherland group, various fluorescent α-amino acid derivatives have 
been developed, however, one of the drawbacks of these compounds is the rather lengthy 
synthesis required.189‒191 Inspired by the use of the polymer-supported nitrite reagent 
approach for the synthesis of benzotriazoles, it was envisaged that this methodology 
would allow easy and quick access to a range of benzotriazole derived α-amino acids 
(Figure 33). Access to these compounds in relatively few steps would allow for greater 
diversification of the structure and for the investigation of the fluorescent properties of this 
class of compound. 
 
Figure 33: Proposed benzotriazole substituted α-amino acids 
 
2.3.2 Synthesis of Benzotriazole Derived α-Amino Acids 
2.3.2.1 Synthesis of the unsubstituted benzotriazole derived α-amino acid 
The first goal was the preparation of the unsubstituted benzotriazole derived α-amino acid 
(186). Beginning from the naturally occurring L-amino acid would allow introduction of the 
correct stereochemistry from the beginning of the synthesis, thus avoiding the need for 
asymmetric synthesis later in the route. It was proposed that starting from the cheap and 
readily available Cbz-L-asparagine (192), a Hofmann rearrangement could be performed 
followed by an esterification to yield the amine 191 (Scheme 67). This could be coupled 
with ortho-fluoronitrobenzene (190) in a SNAr reaction and then be reduced to the aryl 
amine 188. Next would come the key step: diazotisation and intramolecular cyclisation to 
form the protected benzotriazole substituted α-amino acid 187, followed by deprotection of 
the amine and acid groups to give 186. 
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Scheme 67: Proposed retrosynthesis of the benzotriazole derived α-amino acid 
 
With this proposed route in mind, the synthesis of 191 began from Cbz-L-asparagine 
(192). Previous work within the Sutherland group involved optimisation of this 
transformation.192 Initially, (bis(trifluoroacetoxy)iodo)benzene was used in various solvent 
systems, but the best results were achieved by using the hypervalent iodine reagent 
(diacetoxyiodo)benzene in a mixed solvent system. It was then possible to perform a 
Hofmann rearrangement of 192 to 193 in a quantitative yield (Scheme 68).193 This was 
followed by an esterification using thionyl chloride and methanol to yield 191, again 
quantitatively.194 
 
Scheme 68: Hofmann rearrangement and esterification193,194 
 
Amine 191 was used in a nucleophilic aromatic substitution reaction, with ortho-
fluoronitrobenzene (190) and triethylamine (Scheme 69), and gave nitrobenzene product 
189 in 89% yield according to literature conditions.195 Nitrobenzene 189 was reduced 
using tin(II) chloride to form aryl amine 188, using literature conditions developed by 
Bellamy.196 Methanol was used as the solvent instead of ethanol to avoid unwanted 
transesterification. Completion of the reaction was evident from thin-layer chromatography 
(TLC), as product 188 stained brightly with ninhydrin. Due to the reactivity and instability 
of 188, this was used immediately in the next step without extensive characterisation. The 
key step in this synthesis was the transformation of 188 to benzotriazole 187. The 
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polymer-supported nitrite reagent was prepared beforehand by ion exchange of Amberlyst 
A26 resin with sodium nitrite. Treatment of 188 with the polymer-supported nitrite reagent 
and p-tosic acid gave benzotriazole 187 in 59% yield. The final step in the synthesis was 
the deprotection of the α-amino acid portion of 187. To remove the benzyl carbonate 
protecting group and hydrolyse the methyl ester, 187 was heated in 6 M aqueous 
hydrochloric acid for 20 h. Recrystallisation from methanol and diethyl ether gave 186 as 
the hydrochloric acid salt in 94% yield. 
 
Scheme 69: Synthesis of the unsubstituted benzotriazole α-amino acid 
 
2.3.2.2 Synthesis of substituted benzotriazole derived α-amino acids 
Given the success of the synthesis of amino acid 186, work then began on the synthesis 
of analogues, using other ortho-fluoronitrobenzenes for the SNAr reaction with 191. The 
ortho-fluorobenzene featuring a methoxy substituent was prepared beforehand via an O-
methylation using potassium carbonate and iodomethane at room temperature for 16 h.197 
However, this literature procedure was improved by heating the reaction to reflux, allowing 
completion in 3 h (Scheme 70). The SNAr reaction consistently gave excellent yields with 
a range of ortho-fluoronitrobenzenes bearing either electron-withdrawing or electron-
donating groups (Scheme 71). One of the advantages of this reaction is how well ortho-
fluoronitrobenzenes work as electrophiles: having a leaving group ortho to the electron 
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withdrawing nitro group greatly activates the ring towards nucleophilic attack, with the 
fluorine atom being a particularly good leaving group for SNAr reactions. 
 
Scheme 70: Methylation reaction to form 195 
 
 
Scheme 71: SNAr reaction of derivatives 
 
Each analogue was reduced with tin(II) chloride and gave good yields for most of the 
derivatives. However, a more modest yield was observed for the methoxy analogue 
(Table 20). Since the other derivatives contained electron-withdrawing groups, it is 
presumed that the electron-donating effect of the methoxy group contributed to a more 
electron-rich aromatic ring, which in turn was not able to receive electrons from the tin(II) 
chloride. Nevertheless, the reaction gave enough product to proceed with the subsequent 
step. The anilines were then subjected to the one-pot diazotisation and cyclisation by 
reaction with the polymer-supported nitrite reagent and p-tosic acid. This gave 
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benzotriazoles 187‒204 in modest to good yields. Again, the electron-donating methoxy 
derivative 201 was produced in 39% yield, despite full conversion of the starting material. 
Various conditions were trialled for this reaction, using fewer equivalents of reagents and 
varying reaction time. However, the best yield was achieved using the initial method. 
Table 20: Reduction and cyclisation of derivatives 
 
Entry R Yield for 1st Step Yield for 2nd Step 
1 H, 187 83% 59% 
2 5-CF3, 200 85% 57% 
3 6-MeO, 201 59% 39% 
4 5,6-Dichloro, 202 89% 80% 
5 5-Me-6-Cl, 203 65% 78% 
6 5-Br, 204 76% 66% 
 
The final step in the synthesis involved the acid mediated deprotection and gave all the 
target compounds in good yields. The two slightly lower yields for α-amino acids 205 and 
209 were most probably due to the difficulty in purification of these by recrystallisation.  
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Scheme 72: Deprotection of benzotriazole α-amino acids 
 
2.3.2.3 Analysis of fluorescent properties 
With the deprotected benzotriazoles now in hand, the optical properties of these 
compounds were assessed. The UV-visible absorption were recorded for each compound 
(Figure 34), using 5 μM and 10 μM solutions in methanol. This revealed the absorption 
maximum for each amino acid which was used for excitation. 
 
Figure 34: Graph showing UV absorption data for substituted benzotriazole α-amino acids 
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It was immediately clear from the emission spectra that none of these compounds were 
fluorescent (Figure 35). This was expected due to the limited size of the conjugated 
system and indeed the main purpose of the synthesis of this library of compounds was to 
showcase the versatility of the synthetic route. The fluorescence emission does however 
provide preliminary data on which of these compounds should be further investigated. 
Analysis provided values for the Stokes shift: an important factor in fluorescence imaging, 
as this shows the difficulty with which the excitation light can be separated from the probe 
emission.198 Another useful factor is the molar extinction coefficient (ε), determined from 
the absorption spectrum using the Beer-Lambert Law. This value is defined as how well a 
substance absorbs light at a particular wavelength and contributes to the measure of 
brightness for potential fluorophores. 
 
Figure 35: Graph showing fluorescence emission for substituted benzotriazole α-amino 
acids 
 
Of the compounds tested, 6-methoxy derivative 209 had the highest molar extinction 
coefficient of 8320 cm−1 M−1 and a Stokes shift of 52 nm (Table 21). Compound 207 
showed a Stokes shift of 70 nm; however, showed very weak fluorescence. 
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Table 21: Optical properties for library of benzotriazole α-amino acids 
Compound 
Absorption 
maximum 
(nm) 
Molar 
Extinction 
Coefficient 
(ε) (cm−1 
M−1) 
Emission 
maximum 
(nm) 
Stokes shift 
(nm) 
 
255 4857 312 57 
 
262 5750 315 53 
 
286 8320 338 52 
 
273 5000 343 70 
 
288 4720 316 28 
 
265 5601 318 53 
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2.3.3 Further Functionalisation and Analysis 
2.3.3.1 Functionalisation of the 6-methoxy analogue 
With 6-methoxy analogue 209 showing more promising fluorescence emission properties 
and having a strong directing group for electrophilic aromatic substitution in the form of the 
methoxy group, work then began on the further functionalisation of this compound. By 
utilising the aforementioned bromination reaction, using iron(III) chloride and the ionic 
liquid [BMIM]NTf2 to generate Fe(NTf2)3 in situ, it was proposed that with the more active 
para-position blocked, bromination would occur in one of the two ortho-positions to the 
methoxy group.131,199 It was expected that, of the two positions, bromination would be 
more likely at the C-5 position of the benzotriazole given that it is the least hindered. 
Reaction of 201 with NBS in the presence of FeCl3 (5 mol%) and [BMIM]NTf2 gave 210 in 
85% yield as the only product (Scheme 73). 
 
Scheme 73: Bromination of 201 
 
Confirmation of the outcome of this reaction was obtained from 1H NMR spectroscopy 
(Figure 36). The 1H NMR spectrum of 210 clearly showed two doublets in the aromatic 
region with ortho-coupling constants (Figure 36a) and disappearance of the broad singlet 
observed in starting material 201 (Figure 36b). This regiochemistry can be explained by 
possible coordination of the NBS-iron catalyst with the amino acid moiety of 201, directing 
bromination to the C-7 position. 
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Figure 36: Expansion of the aromatic region of the 1H NMR spectrum of (a) 201 and (b) 210 
 
Although unexpected, this product was still an ideal substrate for further functionalisation 
by palladium cross-coupling reactions. A Suzuki-Miyaura reaction was proposed, as this 
uses fairly mild conditions and could be used to introduce an aromatic ring and extend the 
conjugation of the amino acid side chain.135,200 With this in mind, 210 was subjected to a 
Suzuki-Miyaura reaction with 4-methoxyphenylboronic acid using similar conditions to 
previously described reactions (see section 2.1.3.2). In this reaction, potassium fluoride 
was used as the base, since caesium carbonate would likely cause hydrolysis of the ester 
(Scheme 74). The reaction was complete after 24 h and successfully produced 211 in 
66% yield. 
 
Scheme 74: Suzuki-Miyaura reaction to form 211 
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The final step in this synthesis was the deprotection of 211 to form parent amino acid 212. 
Initially, it was proposed that using the same deprotection as the previous analogues may 
not be appropriate, given the harsh acidic conditions may result in some demethylation of 
the aryl methoxy groups of 211. Instead a milder two-step approach was proposed, using 
caesium carbonate to hydroylse the ester followed by a short reaction with 6 M 
hydrochloric acid to remove the benzyl carbamate.201 The hydrolysis was successful, 
proceeding in 94% yield (Scheme 75), however, despite the milder conditions, amino 
group deprotection with 6 M HCl resulted in small quantities of demethylation giving a mix 
of products that were inseparable. It was then proposed that hydrogenation of the amino 
group may be a better method for deprotection of the benzyl carbamate. Standard 
conditions of 10% palladium on carbon under a hydrogen atmosphere were applied, 
initially using ethyl acetate as the solvent. After 24 h none of the desired product was 
observed. However, when the solvent was changed to tetrahydrofuran, full conversion to 
the desired product was observed, giving 212 in 73% yield. 
 
Scheme 75: Deprotection of 211 
 
2.3.3.2 Analysis of fluorescent properties 
The photophysical properties of α-amino acid 212 were recorded at 10 μM concentration 
in methanol (Figure 37). The absorption spectrum showed a maximum of 283 nm, while 
the emission spectrum revealed strong fluorescence, with the major band at 432 nm. This 
data showed that 212 possessed a MegaStokes shift of 148 nm. The quantum yield (ΦF) 
describes the efficiency of the fluorescence and is defined as the ratio of the number of 
photons emitted to the number of photons absorbed. This was calculated for 212 as 0.09, 
using anthracene and L-tryptophan as standards. By finding the product of the quantum 
yield and the molar extinction coefficient (ε), the brightness of 212 was calculated as 856 
cm−1 M−1 (Figure 38). 
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Figure 37: 212 absorption and emission spectra 
 
 
Figure 38: Optical properties of 212 
 
2.3.4 Synthesis of More Conjugated Benzotriazole α-Amino Acids 
2.3.4.1 Dibenzofuran analogue of 212 
Given the difference in fluorescent properties that were observed with the addition of an 
aromatic ring to form 212, work began on modifying the structure further. Indeed, one of 
the potential drawbacks of 212 may be the twisting of the molecule due to the di-ortho-
substituted biaryl system: ideally these two rings would adopt a planar confirmation, 
allowing charge transfer across the aryl system and thus enhancing the fluorescence 
further.200 It was proposed that conformational restriction of the aryl system to form a 
dibenzofuran (Figure 39) would produce an α-amino acid with enhanced photophysical 
properties. 
 
λabs. = 283 nm 
λemi. = 432 nm 
ε = 9516 cm−1 M−1 
ΦF = 0.09 
Brightness = 856 cm−1 M−1 
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Figure 39: Dibenzofuran benzotriazole α-amino acid target 
 
Forming a dibenzofuran after synthesis of the benzotriazole looked to be a challenging 
reaction, however, conditions developed by Zhao et al. (Scheme 76) show that ortho-
arylphenols with electron withdrawing groups in the para-position are good substrates for 
C-H cycloetherification.202 With this in mind, a synthesis was proposed towards a 
dibenzofuran featuring an ortho-fluoronitro moiety for use in the SNAr reaction. 
Bromination of phenol 194, using NBS and the iron(III) triflimide method proved to 
unselective and gave mono-brominated compounds 213 and 214 in a 2.5:1 ratio. Although 
the regiochemistry was not important, these two regioisomers were inseparable. Attempts 
at the same reaction at a lower temperature (0 °C) gave the same ratio of compounds and 
iodination (switching NBS for NIS) produced only a small amount of di-iodinated product. 
This lack of selectivity is likely due to the similar steric hindrance of both ortho-postions 
(i.e. the similar size of H versus F). With this in mind, a final iodination attempt was made 
using NIS and silver triflimide (AgNTf2) instead of the ionic liquid, [BMIM]NTf2. This 
method was developed by Racys et al., who showed that the larger size of the silver atom 
aided the regioselectivity by tuning down the reactivity.125 The reaction, however, showed 
no sign of any product and so the proposed route was re-examined. 
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Scheme 76: Proposed synthesis of a dibenzofuran and attempted bromination 
 
Since the attempted bromination of 201 to form 210 was selective, a new approach was 
considered in which the dibenzofuran would be prepared after the benzotriazole unit 
(Scheme 77). This would involve bromination of a protected phenol 215, followed by a 
Suzuki-Miyaura coupling and selective deprotection of the alcohol, before attempting the 
C-H cycloetherification to form a dibenzofuran 219. The choice of protecting group for the 
alcohol would be important, as this would need to be orthogonal to both the methyl ester 
and the benzyl carbamate and would also need to remain intact throughout the route. 
 
Scheme 77: New route towards dibenzofuran analogue (P = protecting group) 
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The silyl protecting group, TBDMS was first considered, as this could be easily 
deprotected using TBAF at a later stage. The initial attempt at TBDMS protection of 194 
used TBDMS-Cl and imidazole in dichloromethane, stirring at room temperature for 24 h 
and gave 220 in 70% yield. In order to improve upon this result, the second attempt also 
used 10 mol% of DMAP. Having an amine in the para-position pushing electrons into the 
aromatic system makes DMAP a more effective nucleophile than just pyridine itself. It can 
be used to activate the TBDMSCl, facilitating nucleophilic attack of the phenolic alcohol of 
194. These conditions gave 220 in 94% yield after 16 h (Scheme 78). Compound 220 was 
then submitted to the SNAr reaction conditions with 3-aminoalanine 191. Conversion of the 
starting material was slow, and the reaction took 48 h. However, instead of the desired 
product, the only compound isolated was deprotected coupled amino acid, 221 in 45% 
yield. This deprotection may have been caused by the presence of fluoride generated 
from the SNAr reaction. Therefore a different approach was considered. 
 
Scheme 78: Synthesis of 221 and attempted coupling with 191 
 
Given that the attempted SNAr reaction of 220 gave 221 in a moderate yield, this 
suggested that a protecting group may not be necessary for the route. Reaction of phenol 
194 with 191 gave the desired SNAr product in 49% yield (Scheme 79) and reduction of 
the nitro group with tin(II) chloride to form 222 proceeded as expected, in 83% yield. 
Attempted diazotisation and cyclisation of 222 with the polymer-supported nitrite reagent 
and p-tosic acid was unsuccessful. After 3 h, there was no starting material visible in the 
1H NMR spectrum of the crude material, nor was there any evidence of the desired 
product, 223. Attempts to cool down the reaction and add fewer equivalents of reagents 
led to no improvement, as it seemed that the starting material was decomposing during 
the reaction. This was possibly due to the hydroxyl group interference with the 
diazotisation step. 
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Scheme 79: Attempted synthesis of benzotriazole amino acid 223 
 
Since protection of the alcohol seemed necessary, a MOM group was next considered. 
Although MOM groups can be removed using acid, it was expected that the reduction 
could be performed using non-acidic conditions and the mild conditions of the cyclisation 
should leave the group unaltered. Initial protection of phenol 194 to give MOM-protected 
224 was performed using MOMBr and DIPEA in dichloromethane (Scheme 80). This 
successfully gave 224 in 99% yield. The subsequent SNAr reaction of 224 with 3-
aminoalanine 191 occurred well to give 225 in 83% yield, using the same conditions as 
previous reactions. To perform the reduction of the nitro group, tin(II) chloride in the 
presence of pyridine was used. This procedure has been used previously with compounds 
containing acid-labile moieties, such as Boc-protecting groups.203 Unfortunately the 
reduction of 225 was very slow, taking 48 h to go to completion. None of the desired 
product was observed. Instead, deprotected product 222 was formed in 66% yield. 
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Scheme 80: Use of MOM-protected phenol 224 for the attempted synthesis of 226 
 
The final attempt at using a protecting group involved the incorporation of a PMB group. 
The initial synthesis of 227 was performed using PMBCl and potassium carbonate in DMF 
at 80 °C. This provided 227 in 65% yield after 2 h. This yield was improved by changing 
the solvent to acetone, reducing the temperature and the addition of catalytic 
tetrabutylammonium iodide. Since PMBCl is not as reactive on its own due to the chloride 
leaving group, this additive allows for the in situ generation of the iodide which is more 
reactive and allows the reaction to be carried out faster at a lower temperature. The yield 
of 227 improved to 93% after 2 h (Scheme 81). Conversion of 227 into 228 via the SNAr 
coupling occurred successfully in 86% yield. The use of tin(II) chloride to reduce the nitro 
group was very slow and after 72 h, only a small conversion to the desired product was 
observed. Other methods of reduction that would not affect the other functionality of 228 
were investigated. A reaction with sodium dithionite and potassium carbonate in 95% 
aqueous ethanol at room temperature was attempted, however, none of the desired 
product was formed after 16 h. Only hydrolysis of the starting material was observed. A 
reaction with sodium sulphide in a 3:1 ethanol:water mixture was also attempted, 
however, a similar result to the previous reaction was observed. 
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Scheme 81: The use of a PMB protecting group for the synthesis of 228 
 
2.3.4.2 Other methods of dibenzofuran synthesis 
The difficulties encountered in the previous syntheses were associated with the phenol 
protecting groups and their influence on the proposed route. It was envisioned that the 
bromo-substituted analogue 204 previously synthesised could be used as a potential aryl 
halide for a Suzuki-Miyaura reaction (Scheme 82). Through this, an ortho-hydroxyl group 
could be introduced, providing a potential substrate for the attempted synthesis of a 
dibenzofuran. Another advantage of this approach was that the reactions leading up to the 
synthesis of 204 were well established and highly yielding. Reaction of bromide 204 with 
2-hydroxyphenylboronic acid under the previously developed conditions gave coupled 
product 229 in 93% yield (Scheme 82). 
 
Scheme 82: Synthesis of 229 via a Suzuki-Miyaura reaction 
 
With the desired biaryl compound now in hand, methods to perform the cycloetherification 
were investigated. It was believed that the method by Zhao et al. provided an approach to 
a dibenzofuran that did not require reagents that could cleave the protecting groups of 
229.202 Despite the starting material now lacking a strongly electron-withdrawing group 
para to the alcohol, this reaction was attempted. The method used a copper(II) bromide 
catalyst, pivalic acid and caesium carbonate in DMSO under reflux (Scheme 83). After a 
16 h reaction at 120 °C, there was no evidence of any starting material or product and it 
seemed that the conditions were causing decomposition of 229. The authors had shown 
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that the reaction was able to proceed using potassium carbonate as well as caesium 
carbonate, although not as effectively.202 Consequently an attempt at a cyclisation using 
potassium carbonate was attempted, however, the same decomposition of material was 
observed. In a last attempt the reaction was performed at a lower temperature (50 °C) and 
monitored closely over a 5 h period. Although there was only a small amount of hydrolysis 
observed, there was no conversion to the desired product, even after 2 h. After 5 h, it 
appeared that there was decomposition of material, as only a small amount of starting 
material remained with no sign of any desired product. 
 
Scheme 83: Attempted synthesis of a dibenzofuran analogue 230 
 
2.3.4.3 Synthesis of 231 and analysis of its fluorescent properties 
As a dibenzofuran analogue was not synthesised, it was decided to analyse the 
fluorescence properties of the 2-hydroxy compound 231. Since there was not the same 
concern for demethylation of this compound as for 212, deprotection in 6 M HCl was 
investigated. Addition of dioxane to the reaction mixture led to better solubilisation of the 
starting material. This reduced the reaction time to 4 h and gave 231 in 97% yield. 
 
Scheme 84: Deprotection to form α-amino acid 231 
 
The absorbance and emission spectra of amino acid 231 was then recorded at 10 μM in 
methanol (Figure 40). Despite the highly conjugated aryl system, amino acid 231 showed 
weak fluorescence. Twisting across the biaryl rings and poor orbital overlap across the 
conjugated system as a result of having an ortho-substituted aryl ring may explain this 
lack of intensity. Future work may involve a solvatochromic study for this compound, since 
many promising fluorophores feature phenolic alcohols that exhibit different levels of 
fluorescence when analysed in different solvents and pH.204,205 Nevertheless, the Stokes 
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shift of 231 was found to be 80 nm and the molar extinction coefficient was calculated at 
5670 cm−1 M−1. 
 
Figure 40: 231 absorption and emission spectra 
 
2.3.5 Conclusions 
In summary, a small library of substituted α-amino acid benzotriazoles were synthesised 
via diazotisation and intramolecular cyclisation of diarylamines, using a polymer-supported 
nitrite reagent and p-tosic acid as the key step. This reaction was most efficient for 
compounds featuring an electron-withdrawing group on the aryl ring. Analysis of the 
optical properties for these compounds showed that they were not fluorescent, possibly 
due to the absence of an extended conjugated system, and so methods to further 
functionalise these compounds were investigated. The 6-methoxy analogue, 201, proved 
a good substrate for performing electrophilic aromatic substitution reactions, as it 
contained a strong directing group. This was successfully brominated to form a single 
regioisomer. Suzuki-Miyaura reaction with 4-methoxyphenylboronic acid followed by a 
mild, two-step deprotection method, gave amino acid 212. This α-amino acid 
benzotriazole showed very promising optical properties: a Stokes shift of 139 nm and 
strong fluorescence in the visible region (432 nm). Attempts to optimise these properties 
further involved avoiding twisting of the biaryl system in 212 by forming a dibenzofuran. 
Several approaches were implemented, however, none resulted in the desired product. 
Synthesis of compound 229 enabled attempts at C-H cycloetherification, but the various 
reaction conditions proved too harsh for the substrate. Notwithstanding, the compound 
was deprotected to form parent amino acid 231 so that the optical properties could be 
assessed. Future work has been proposed that describes several potential new 
approaches towards a dibenzofuran analogue, but also a variation on the structure of 212 
that could be used to further assess how the electronics of the aromatic system affect the 
optical properties of these α-amino acids. 
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2.3.6 Future work 
2.3.6.1 Variation of the electronics of 212 
Given the promising fluorescent properties of 212, future work will investigate the 
incorporation of alternative aryl groups through the late-stage Suzuki-Miyaura reaction. 
Amino acid 212 with a p-methoxy substituent was prepared as it was thought that the 
electron-rich substituent would suitably complement the electron-withdrawing triazole 
moiety and provide the molecule with strong push-pull properties. Such is the case with 
many promising fluorophores.206,207 However, taking into account the methoxy group 
already present on the benzotriazole aryl ring, it would be desirable to install an electron-
withdrawing group to enhance the push-pull dynamic in this structure (Figure 41). 
 
Figure 41: Proposed future target 
 
2.3.6.2 Potential synthetic routes towards a dibenzofuran analogue 
The conditions used for the cycloetherification to form a dibenzofuran proved too harsh for 
the Suzuki-Miyaura product, 229 (see section 2.3.4.2). However, the cyclisation reaction 
may have failed due to the absence of an electron-withdrawing group para to the hydroxyl 
group. To test this theory, the Suzuki-Miyaura reaction between 204 and a boronic acid 
featuring a nitro group should be investigated (Scheme 85). Compound 232 could then be 
used in a cycloetherification reaction. 
 
Scheme 85: Proposed synthesis of a cycloetherification substrate 
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Likewise, earlier in this chapter, the synthesis of compound 221 was described (see 
section 2.3.4.1). Although at the time the focus was on the synthesis of the benzotriazole, 
coupled product 234 could instead be used for a cycloetherification. Bromination of 221 
via an electrophilic aromatic bromination would potentially be more difficult due to the 
electron-withdrawing effect of the nitro group, however the alcohol is strongly electron-
donating and moreover, this reduction in reactivity may result in better regiochemical 
control (Scheme 86). A Suzuki-Miyaura reaction using either the 4-methoxy or other 
boronic acids would give compound 234, which could be subjected to the 
cycloetherification conditions. The advantage of this method is that, so long as the second 
aryl ring was symmetrical, only a single product would be formed. 
 
Scheme 86: New approach to cycloetherification 
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3 Experimental 
3.1 General 
All reagents and starting materials were obtained from commercial sources and used as 
received. All reactions were performed under an atmosphere of air unless otherwise 
stated. All dry solvents were purified using a PureSolv 500 MD solvent purification system. 
Brine is defined as a saturated solution of aqueous sodium chloride. Flash column 
chromatography was carried out using Merck Geduran Si 60 (40‒63 μm). Merck 
aluminium-backed plates pre-coated with silica gel 60 (UV254) were used for thin layer 
chromatography and were visualised under ultraviolet light and by staining with KMnO4, 
ninhydrin or vanillin. 1H NMR and 13C NMR spectra were recorded on a Bruker DPX 400 
spectrometer or Bruker 500 spectrometer with chemical shift values in ppm relative to 
tetramethysilane (δH 0.00 and δC 0.0) or residual chloroform (δH 7.26 and δC 77.2) as the 
standard. Assignment of 1H and 13C NMR signals are based on 2-dimensional COSY, 
HSQC and DEPT experiments. Infrared spectra were recorded using a Shimadzu FTIR-
84005 spectrometer and mass spectra were obtained using a JEOL JMS-700 
spectrometer or a Bruker MicroTOFq high resolution mass spectrometer. Melting points 
were determined on a Gallenkamp melting point apparatus. Optical rotations were 
determined as solutions irradiating with the sodium D line (λ = 589 nm) using an Autopol V 
polarimeter. [α]D values are given in units 10−1 deg cm2 g−1. UV-Vis spectra were recorded 
on a Perkin Elmer Lamda 25 instrument. Fluorescence spectra were recorded on a 
Shimadzu RF-5301PC spectrofluorophotometer and emission data were measured using 
an excitation slit width of 3 nm and emission slit width of 3 nm. Quantum yield data were 
measured using anthracene and L-tryptophan as standard references. 
3.2 S1P5 Experimental 
General Procedure A: Carboxylation of Dihalobenzenes124 
To a solution of freshly distilled diisopropylamine (1.7 equiv.) in tetrahydrofuran (2.0 
mL/mmol) in an oven dried flask under argon at −10 °C was added n-butyllithium (1.6 
equiv.; 2.5 M in hexanes). The mixture was stirred for 0.5 h, before cooling to −78 °C. The 
dihalobenzene (1.0 equiv.) was then added dropwise. After 1 h of stirring, CO2 was 
bubbled into the reaction via syringe (a pellet of dry ice was added to a 10 mL syringe). 
The addition was continued for 0.3 h and then the reaction mixture was allowed to reach 
room temperature over 2 h. The mixture was diluted with water (2.0 mL/mmol) and 
extracted with a 1 M aqueous sodium hydroxide solution (3 × 2.0 mL/mmol). The aqueous 
layers were then back-extracted with ethyl acetate (4.0 mL/mmol) and the organic layer 
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discarded. The aqueous layers were acidified to pH 1 using a 6 M aqueous hydrochloric 
acid solution and subsequently extracted with ethyl acetate (6.0 mL/mmol). The organic 
layer was then washed with brine (6.0 mL/mmol), dried (MgSO4), filtered and concentrated 
in vacuo to afford the product. 
General Procedure B: Nucleophilic Aromatic Substitution of 2-Fluorobenzoic Acids 
The benzoic acid (1.0 equiv.) was dissolved in tetrahydrofuran (4.5 mL/mmol) under an 
atmosphere of argon. The aniline (2.0 equiv.) was added and the mixture cooled to −78 
°C. Lithium bis(trimethylsilyl)amide (3.0 equiv.; 1.0 M in tetrahydrofuran) was then slowly 
added over 0.1 h. The reaction mixture was then allowed to reach room temperature 
before heating to 40 °C and stirring for 16 h. The reaction was quenched with water (2.5 
mL/mmol) and acidified to pH 2 with 10% aqueous hydrochloric acid. The mixture was 
then extracted with ethyl acetate (3 × 5.0 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The resulting residue was then purified by flash column chromatography, eluting 
with 20‒40% ethyl acetate in petroleum ether (40‒60) to afford the benzoic acid 
derivative. 
General Procedure C: Ullmann Condensation of 2-Bromobenzoic Acids95 
Sodium hydride (3.0 equiv.; 60% in mineral oil) was added to a dry flask under argon. The 
sodium hydride was then washed with hexane (2 × 3.3 mL/mmol) to remove the oil and 
the flask cooled to 0 °C. The required dry alcohol (3.3 mL/mmol) was added to the 
reaction vessel carefully over 0.1 h and then stirred for 0.5 h. The benzoic acid derivative 
(1.0 equiv.) was added followed by the addition of copper powder (0.4 equiv.) and the 
reaction mixture heated to 80 °C for 18 h. The reaction mixture was cooled to room 
temperature and filtered through a pad of Celite®. The filtrate was concentrated in vacuo 
and taken up in water (3.3 mL/mmol). The mixture was acidified to pH 2 using 10% 
aqueous hydrochloric acid and extracted with dichloromethane (3 × 5.0 mL/mmol). The 
organic layer was dried (MgSO4), filtered and concentrated in vacuo. The resulting residue 
was then purified by flash column chromatography, eluting with 20% ethyl acetate in 
petroleum ether (40‒60) to afford the ether product. 
General Procedure D: Amidation of Benzoic Acid Ether Derivatives95 
The benzoic acid ether derivative (1.0 equiv.) was dissolved in tetrahydrofuran (3.0 
mL/mmol) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (1.2 equiv.) and N-methylmorpholine 
(3.0 equiv.) were added. The mixture was then stirred for 2 h at room temperature. The 
precipitate was filtered and ammonium hydroxide (9.0 mL/mmol) was added to the filtrate. 
The reaction mixture was stirred for 0.5 h at room temperature and then filtered. 2 M 
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Sodium hydroxide (9.0 mL/mmol) was added to the filtrate and the crude product was 
extracted with ethyl acetate (3 × 9.0 mL/mmol). The organic layer was dried (MgSO4), 
filtered and concentrated in vacuo. The resulting residue was then purified by flash 
column chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to 
afford the benzamide product. 
General Procedure E: Bromination of Benzamide and Phthalazinone Derivatives131 
To a dry flask under argon was added iron(III) choride (5 mol%) and [BMIM]NTf2 (2.0 
equiv.) and the mixture stirred for 0.5 h. The derivative (1.0 equiv.) was then added as a 
solution in dichloromethane (2.5 mL/mmol) and N-bromosuccinimide (0.8 equiv.) was 
added slowly to the mixture. After 1 h of stirring at room temperature, N-bromosuccinimide 
(0.25 equiv.) was added and the reaction stirred for a further 1 h. The mixture was diluted 
with ethyl acetate (5.0 mL/mmol) and filtered through a short pad of silica. The filtrate was 
then washed with 1 M sodium thiosulfate (2 × 10 mL/mmol) and brine (10 mL/mmol). It 
was dried (MgSO4), filtered and concentrated in vacuo. The resulting residue was then 
purified by flash column chromatography, eluting with 20% ethyl acetate in petroleum 
ether (40‒60) to afford the brominated product. 
General Procedure F: Suzuki-Miyaura Reaction of Benzamide and Phthalazinone 
Bromides 
To a reaction vessel containing the aryl bromide (1.0 equiv) in 1,4-dioxane (15 mL/mmol) 
and water (1.1 mL/mmol) was added [1,1ʹ-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1:1) (5 mol%), the boronic acid 
(1.6 equiv.) and caesium carbonate (3.0 equiv). The reaction mixture was then sealed and 
degassed under argon for 0.2 h, before heating to 80 °C for 2‒16 h. The reaction mixture 
was cooled and filtered through Celite®, washed with ethyl acetate (50 mL/mmol). The 
filtrate was washed with water (3 × 50 mL/mmol) and brine (50 mL/mmol) and the organic 
layer dried (MgSO4), filtered and concentrated in vacuo. The resulting residue was then 
purified by flash column chromatography to afford the coupled product. 
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N-Tosyl-2,6-dimethylaniline (61)130 
 
2,6-Dimethylaniline (6.10 mL, 49.5 mmol) and p-toluenesulfonyl chloride (11.3 g, 59.4 
mmol) were supended in pyridine (120 mL) and heated under reflux for 5 h. The reaction 
was quenched with 2 M aqueous hydrochloric acid (250 mL) and extracted with diethyl 
ether (3 × 100 mL). The organic layer was then dried (MgSO4), filtered and concentrated 
in vacuo. Toluene (50 mL) was added to the residue and the resulting suspension 
concentrated in vacuo to afford N-tosyl-2,6-dimethylaniline (61) as a white solid (13.4 g, 
98%). Mp 123‒125 °C, lit.130 124‒126 °C; δH (400 MHz, CDCl3) 2.04 (6H, s, 2-CH3 and 6-
CH3), 2.42 (3H, s, 4ʹ-CH3), 6.08 (1H, br s, NH), 7.00 (2H, d, J 7.5 Hz, 3-H and 5-H), 7.05‒
7.12 (1H, m, 4-H), 7.24 (2H, d, J 8.2 Hz, 3ʹ-H and 5ʹ-H), 7.60 (2H, d, J 8.2 Hz, 2ʹ-H and 6ʹ-
H); δC (101 MHz, CDCl3) 18.7 (2 × CH3), 21.6 (CH3), 127.2 (2 × CH), 127.8 (CH), 128.8 (2 
× CH), 129.6 (2 × CH), 132.6 (C), 137.7 (2 × C), 137.8 (C) 143.7 (C); m/z (ESI) 298 
(MNa+. 100%). 
N-Tosyl-2,6-dimethyl-4-nitroaniline (62)130 
 
N-Tosyl-2,6-dimethylaniline (61) (5.00 g, 18.1 mmol) was suspended in glacial acetic acid 
(100 mL), water (100 mL) and concentrated nitric acid (21 mL). Sodium nitrite (2.50 g, 
36.3 mmol) was added and the reaction mixture was heated at 140 °C for 6 h. The 
reaction mixture was cooled to room temperature and then stored in a refrigerator 
overnight. The resulting colourless crystals were filtered and washed repeatedly with 
water until the washings were neutral to afford N-tosyl-2,6-dimethyl-4-nitroaniline (62) as 
colourless crystals (3.69 g, 64%). Mp 163‒165 °C, lit.130 165‒167 °C; δH (400 MHz, 
CDCl3) 2.16 (6H, s, 2-CH3 and 6-CH3), 2.45 (3H, s, 4ʹ-CH3), 6.13 (1H, br s, NH), 7.29 (2H, 
d, J 8.2 Hz, 3ʹ-H and 5ʹ-H), 7.60 (2H, d, J 8.2 Hz, 2ʹ-H and 6ʹ-H), 7.89 (2H, s, 3-H and 5-
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H); δC (126 MHz, CDCl3) 19.1 (2 × CH3), 21.6 (CH3), 123.6 (2 × CH), 127.1 (2 × CH), 
130.0 (2 × CH), 137.2 (2 × C), 138.7 (C), 139.2 (C), 144.5 (C), 146.3 (C); m/z (ESI) 343 
(MNa+. 100%). 
2,6-Dimethyl-4-nitroaniline (49)130 
 
N-Tosyl-2,6-dimethyl-4-nitroaniline (62) (3.00 g, 9.40 mmol) was dissolved in sulfuric acid 
(15 mL) and water (1 mL) and heated at 40 °C for 16 h. The reaction mixture was poured 
slowly into an ice/water/sodium hydroxide mixture (300 mL). This was then extracted with 
ethyl acetate (3 × 100 mL), dried (MgSO4), filtered and concentrated in vacuo to afford 
2,6-dimethyl-4-nitroaniline (49) as yellow crystals (1.52 g, 98%). Mp 167‒169 °C, lit.130 
165‒167 °C; δH (400 MHz, CDCl3) 2.22 (6H, s, 2 × CH3), 4.29 (2H, br s, NH2), 7.90 (2H, s, 
3-H and 5-H); δC (126 MHz, CDCl3) 17.5 (2 × CH3), 120.5 (2 × C), 124.6 (2 × CH), 138.3 
(C), 149.3 (C); m/z (ESI) 189 (MNa+. 100%). 
4-Bromo-2,6-dimethylaniline (63)208 
 
To a small dry vial fitted with a magnetic stirrer was added iron(III) chloride (0.0040 g, 
0.025 mmol) and [BMIM]NTf2 (0.30 mL, 1.0 mmol). The mixture was stirred at room 
temperature for 0.5 h, before adding 2,6-dimethylaniline (0.061 mL, 0.50 mmol). N-
Bromosuccinimide (0.098 g, 0.55 mmol) was then added in three portions over 1 h and 
the reaction mixture was heated to 60 °C for 48 h. The reaction mixture was cooled to 
room temperature and taken up in 5% ethyl acetate in hexane and sonicated for 0.1 h. 
The resulting solution was washed with 1 M aqueous sodium thiosulfate (50 mL) and brine 
(50 mL), dried (MgSO4), filtered and then concentrated in vacuo. The crude material was 
purified by flash column chromatography, eluting with 5‒15% diethyl ether in petroleum 
ether (40‒60) to afford 4-bromo-2,6-dimethylaniline (63) as an orange solid (0.053 g, 
53%). Mp 46‒49 °C, lit.208 44‒48 °C; δH (500 MHz, CDCl3) 2.15 (6H, s, 2-CH3 and 6-CH3), 
3.57 (2H, br s, NH2), 7.06 (2H, s, 3-H and 5-H); δC (126 MHz, CDCl3) 17.4 (2 × CH3), 
109.4 (C), 123.6 (2 × C), 130.5 (2 × CH), 141.8 (C); m/z (ESI) 200 (MH+. 100%). 
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2-Bromo-6-fluoro-3-methylbenzoic acid (78)124 
 
The reaction was carried out according to general procedure A using diisopropylamine 
(3.75 mL, 27.0 mmol) n-butyllithium (10.2 mL, 25.5 mmol, 2.5 M in hexanes) and 2-bromo-
4-fluorotoluene (1.95 mL, 15.9 mmol) in tetrahydrofuran (30 mL). This afforded 2-bromo-6-
fluoro-3-methylbenzoic acid (78) as a white solid (3.70 g, 100%). The spectroscopic data 
were consistent with the literature.124 Mp 104‒106 °C; δH (500 MHz, CDCl3) 2.42 (3H, s, 3-
CH3), 7.05 (1H, t, J 8.6 Hz, 5-H), 7.31 (1H, dd, J 8.6, 5.9 Hz, 4-H), 11.39 (1H, br s, OH); 
δC (101 MHz, CDCl3) 22.7 (CH3), 114.7 (CH, d, 2JCF 20.8 Hz), 121.7 (C, d, 3JCF 4.0 Hz), 
123.7 (C, d, 2JCF 19.4 Hz), 132.8 (CH, d, 3JCF 8.3 Hz), 134.9 (C, d, 4JCF 3.7 Hz), 157.6 (C, 
d, 1JCF 252.6 Hz), 169.8 (C); m/z (EI) 232 (M+. 100%), 215 (55), 153 (38), 107 (38), 84 
(34).  
2-Bromo-6-fluorobenzoic acid (50)209 
 
The reaction was carried out according to general procedure A using diisopropylamine 
(2.70 mL, 19.4 mmol) n-butyllithium (7.48 mL, 18.7 mmol, 2.5 M in hexanes) and 1-bromo-
3-fluorobenzene (1.28 mL, 11.4 mmol) in tetrahydrofuran (20 mL). This afforded 2-bromo-
6-fluorobenzoic acid (50) as a white solid (2.49 g, 100%). Mp 148‒150 °C, lit.209 152‒154 
°C; δH (400 MHz, CDCl3) 7.14 (1H, ddd, J 9.3, 8.5, 1.0 Hz, 5-H), 7.33 (1H, td, J 8.5, 5.8 
Hz, 4-H), 7.45 (1H, dt, J 8.1, 0.9 Hz, 3-H); δC (126 MHz, CDCl3) 115.2 (CH, d, 2JCF 21.5 
Hz), 120.5 (C, d, 3JCF 3.6 Hz), 123.2 (C, d, 2JCF 19.0 Hz), 129.0 (CH, d, 4JCF 3.5 Hz), 132.6 
(CH, d, 3JCF 9.1 Hz), 159.9 (C, d, 1JCF 256.3 Hz), 168.5 (C); m/z (EI) 218 (M+. 100%), 201 
(98), 94 (58), 83 (30), 75 (24). 
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2-Bromo-6-(mesitylamino)benzoic acid (59)95 
 
The reaction was carried out according to general procedure B using 2-bromo-6-
fluorobenzoic acid (50) (1.00 g, 4.57 mmol) and 2,4,6-dimethylaniline (1.36 mL, 9.13 
mmol) in tetrahydrofuran (20 mL), followed by treatment with lithium 
bis(trimethylsilyl)amide (13.7 mL, 13.7 mmol, 1.0 M in tetrahydrofuran). The crude 
material was purified by flash column chromatography, eluting with 20% ethyl acetate in 
petroleum ether (40‒60) to afford 2-bromo-6-(mesitylamino)benzoic acid (59) as a brown 
solid (1.44 g, 94%). The spectroscopic data were consistent with the literature.95 Mp 169‒
171 °C; δH (400 MHz, CDCl3) 2.15 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.31 (3H, s, 4ʹ-CH3), 6.18 
(1H, dd, J 7.8, 1.8 Hz, 5-H), 6.89‒7.00 (4H, m, 3-H, 4-H, 3ʹ-H and 5ʹ-H); δC (101 MHz, 
CDCl3) 18.1 (2 × CH3), 21.0 (CH3), 112.2 (CH), 113.1 (C), 122.8 (CH), 123.4 (C), 129.3 (2 
× CH), 133.5 (CH), 134.0 (C), 136.2 (2 × C), 136.5 (C), 150.3 (C), 172.5 (C); m/z (EI) 333 
(M+. 100%), 315 (55), 300 (64), 208 (25), 135 (21). 
2-Bromo-6-[(2ʹ,6ʹ-dimethylphenyl)amino]benzoic acid (69) 
 
The reaction was carried out according to general procedure B using 2-bromo-6-
fluorobenzoic acid (50) (0.300 g, 1.37 mmol) and 2,6-dimethylaniline (0.337 mL, 2.74 
mmol) in tetrahydrofuran (8 mL), followed by treatment with lithium bis(trimethylsilyl)amide 
(4.11 mL, 4.11 mmol, 1.0 M in tetrahydrofuran). The crude material was purified by flash 
column chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to 
afford 2-bromo-6-[(2,6-dimethylphenyl)amino]benzoic acid (69) as a brown solid (0.367 g, 
83%). Mp 176‒178 °C; νmax/cm−1 (neat) 3356 (NH/OH), 2921 (CH), 1644 (CO), 1556 
(C=C), 1484, 1429, 1239, 772; δH (500 MHz, CDCl3) 2.19 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 6.18 
(1H, dd, J 8.0, 1.3 Hz, 5-H), 6.96 (1H, t, J 8.0 Hz, 4-H), 6.99 (1H, dd, J 8.0, 1.3 Hz, 3-H), 
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7.07‒7.16 (3H, m, 3ʹ-H, 4ʹ-H and 5ʹ-H); δC (126 MHz, CDCl3) 18.2 (2 × CH3), 112.2 (CH), 
113.4 (C), 123.0 (CH), 123.4 (C), 126.8 (CH), 128.7 (2 × CH), 133.5 (CH), 136.4 (2 × C), 
136.7 (C), 149.8 (C), 172.0 (C); m/z (ESI) 318.0128 ([M−H]−. C15H1379BrNO2 requires 
318.0135). 
2-Bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoic acid (75) 
 
The reaction was carried out according to general procedure B using 2-bromo-6-
fluorobenzoic acid (50) (1.00 g, 4.56 mmol) and 4-fluoro-2,6-dimethylaniline (1.17 mL, 
9.13 mmol) in tetrahydrofuran (20 mL), followed by treatment with lithium 
bis(trimethylsilyl)amide (13.7 mL, 13.7 mmol, 1.0 M in tetrahydrofuran). The crude 
material was purified by flash column chromatography, eluting with 20% ethyl acetate in 
petroleum ether (40‒60) to afford 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]benzoic acid (75) as a brown solid (1.53 g, 99%). Mp 148‒150 °C; 
νmax/cm−1 (neat) 2953 (NH/OH), 2920 (CH), 1672 (CO), 1595 (C=C), 1560, 1481, 1451, 
1242, 858, 767; δH (500 MHz, CDCl3) 2.18 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 6.15 (1H, dd, J 7.8, 
1.4 Hz, 5-H), 6.85 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 6.97 (1H, t, J 7.8 Hz, 4-H), 7.00 (1H, 
dd, J 7.8, 1.4 Hz, 3-H); δC (126 MHz, CDCl3) 18.4 (2 × CH3), 111.9 (CH), 113.2 (C), 115.1 
(2 × CH, d, 2JCF 21.9 Hz), 123.2 (C), 123.5 (CH), 132.5 (C, d, 
4JCF 2.8 Hz), 133.7 (CH), 
138.9 (2 × C, d, 3JCF 8.9 Hz), 150.1 (C), 161.0 (C, d, 
1JCF 245.3 Hz), 172.1 (C); m/z (EI) 
337.0122 (M+. C15H1379BrFNO2 requires 337.0114), 319 (72%), 293 (58), 212 (100). 
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2-Bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-3-methylbenzoic acid (79) 
 
The reaction was carried out according to general procedure B using 2-bromo-6-fluoro-3-
methylbenzoic acid (78) (0.500 g, 2.15 mmol) and 4-fluoro-2,6-dimethylaniline (0.553 mL, 
4.30 mmol) in tetrahydrofuran (10 mL), followed by treatment with lithium 
bis(trimethylsilyl)amide (6.45 mL, 6.45 mmol, 1.0 M in tetrahydrofuran). The crude 
material was purified by flash column chromatography, eluting with 20% ethyl acetate in 
petroleum ether (40‒60) to afford 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]benzoic acid (79) as a brown solid (0.103 g, 68%). Mp 130‒132 °C; 
νmax/cm−1 (neat) 2955 (NH/OH), 2924 (CH), 1696 (CO), 1606 (C=C), 1565, 1491, 1215, 
1129, 1019, 862, 757; δH (400 MHz, CDCl3) 2.17 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.32 (3H, s, 
3-CH3), 6.08 (1H, d, J 8.5 Hz, 5-H), 6.82 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 7.01 (1H, d, J 8.5 
Hz, 4-H); δC (101 MHz, CDCl3) 18.4 (2 × CH3), 23.0 (CH3), 112.0 (CH), 115.0 (2 × CH, d, 
2JCF 21.8), 116.8 (C), 124.2 (C), 128.1 (C), 133.0 (C, d, 
4JCF 2.8 Hz), 134.1 (CH), 138.6 (2 
× C, d, 3JCF 8.6 Hz), 146.2 (C), 160.7 (C, d, 
1JCF 245.0 Hz), 173.2 (C); m/z (ESI) 350.0197 
([M−H]−. C16H1479BrFNO2 requires 350.0197). 
2-Isopropoxy-6-(mesitylamino)benzoic acid (60)95 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.0792 g, 1.98 mmol, 60% in mineral oil), isopropanol (2.4 mL), 2-bromo-6-
(mesitylamino)benzoic acid (59) (0.220 g, 0.660 mmol) and copper powder (0.0168 g, 
0.264 mmol). The crude material was purified by flash column chromatography, eluting 
with 20% ethyl acetate in petroleum ether (40‒60) to afford 2-isopropoxy-6-
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(mesitylamino)benzoic acid (60) as an orange solid (0.142 g, 69%). The spectroscopic 
data were consistent with the literature.95 Mp 148‒150 °C; δH (400 MHz, CDCl3) 1.50 (6H, 
d, J 6.1 Hz, OCH(CH3)2), 2.13 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.31 (3H, s, 4ʹ-CH3), 4.82 (1H, 
sept, J 6.1 Hz, OCH(CH3)2), 5.91 (1H, dd, J 8.3, 0.8 Hz, 5-H), 6.20 (1H, br d, J 8.3 Hz, 3-
H), 6.94 (2H, s, 3ʹ-H and 5ʹ-H), 7.07 (1H, t, J 8.3 Hz, 4-H), 9.91 (1H, br s, NH), 12.03 (1H, 
br s, OH); δC (101 MHz, CDCl3) 18.1 (2 × CH3), 21.0 (CH3), 22.1 (2 × CH3), 74.2 (CH), 
99.8 (C), 100.0 (CH), 107.1 (CH), 129.1 (2 × CH), 134.1 (CH), 134.5 (C), 136.3 (C), 136.6 
(2 × C), 152.9 (C), 158.2 (C), 169.3 (C); m/z (EI) 313 (M+. 91%), 253 (100), 252 (22), 238 
(54). 
6-(Mesitylamino)-2-methoxybenzoic acid (96)95 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.720 g, 18.0 mmol, 60% in mineral oil), methanol (20 mL), 2-bromo-6-
(mesitylamino)benzoic acid (59) (2.00 g, 5.98 mmol) and copper powder (0.152 g, 2.39 
mmol). The crude material was purified by flash column chromatography, eluting with 20% 
ethyl acetate in petroleum ether (40‒60) to afford 6-(mesitylamino)-2-methoxybenzoic acid 
(96) as an orange solid (1.62 g, 95%). The spectroscopic data were consistent with the 
literature.95 Mp 83‒85 °C; δH (500 MHz, CDCl3) 2.14 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.31 (3H, 
s, 4ʹ-CH3), 4.04 (3H, s, OCH3), 5.96 (1H, d, J 8.3 Hz, 5-H), 6.22 (1H, d, J 8.3 Hz, 3-H), 
6.95 (2H, s, 3ʹ-H and 5ʹ-H), 7.10 (1H, t, J 8.3 Hz, 4-H), 9.93 (1H, s, NH), 11.50 (1H, br s, 
OH); δC (126 MHz, CDCl3) 18.1 (2 × CH3), 21.0 (CH3), 56.8 (CH3), 97.7 (CH), 98.6 (C), 
107.4 (CH), 129.2 (2 × CH), 134.3 (CH), 134.4 (C), 136.4 (C), 136.5 (2 × C), 152.8 (C), 
159.9 (C), 169.1 (C); m/z (ESI) 308 (MNa+. 100%). 
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6-[(2ʹ,6ʹ-Dimethylphenyl)amino]-2-isopropoxybenzoic acid (70) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.0564 g, 1.41 mmol, 60% in mineral oil), isopropanol (1.6 mL), 2-bromo-6-[(2,6-
dimethylphenyl)amino]benzoic acid (69) (0.150 g, 0.468 mmol) and copper powder 
(0.0119 g, 0.187 mmol). The crude material was purified by flash column chromatography, 
eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 6-[(2ʹ,6ʹ-
dimethylphenyl)amino]-2-isopropoxybenzoic acid (70) as an orange solid (0.067 g, 48%). 
Mp 84‒86 °C; νmax/cm−1 (neat) 3230 (NH/OH), 2980 (CH), 1695 (CO), 1576 (C=C), 1458, 
1248; δH (500 MHz, CDCl3) 1.50 (6H, d, J 6.1 Hz, OCH(CH3)2), 2.18 (6H, s, 2ʹ-CH3 and 6ʹ-
CH3), 4.82 (1H, sept, J 6.1 Hz, OCH(CH3)2), 5.90 (1H, dd, J 8.4, 0.6 Hz, 5-H), 6.22 (1H, br 
d, J 8.4 Hz, 3-H), 7.08 (1H, t, J 8.4 Hz, 4-H), 7.10‒7.16 (3H, m, 3ʹ-H, 4ʹ-H and 5ʹ-H), 9.99 
(1H, br s, NH), 12.03 (1H, br s, OH); δC (126 MHz, CDCl3) 18.2 (2 × CH3), 22.1 (2 × CH3), 
74.2 (CH), 99.8 (C), 100.3 (CH), 107.1 (CH), 126.7 (CH), 128.4 (2 × CH), 134.1 (CH), 
136.9 (2 × C), 137.2 (C), 152.5 (C), 158.2 (C), 169.3 (C); m/z (ESI) 322.1402 (MNa+. 
C18H21NNaO3 requires 322.1414). 
6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-isopropoxybenzoic acid (80) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.0532 g, 1.33 mmol, 60% in mineral oil), isopropanol (1.6 mL), 2-bromo-6-[(4ʹ-fluoro-
2ʹ,6ʹ-dimethylphenyl]amino)benzoic acid (75) (0.150 g, 0.444 mmol) and copper powder 
(0.0112 g, 0.177 mmol). The crude material was purified by flash column chromatography, 
eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 6-[(4ʹ-fluoro-2ʹ,6ʹ-
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dimethylphenyl)amino]-2-isopropoxybenzoic acid (80) as an orange solid (0.062 g, 44%). 
Mp 99‒101 °C; νmax/cm−1 (neat) 3250 (NH/OH), 2982 (CH), 1697 (CO), 1578 (C=C), 1458, 
1252; δH (400 MHz, CDCl3) 1.50 (6H, d, J 6.1 Hz, OCH(CH3)2), 2.16 (6H, s, 2ʹ-CH3 and 6ʹ-
CH3), 4.83 (1H, sept, J 6.1 Hz, OCH(CH3)2), 5.87 (1H, dd, J 8.4, 0.8 Hz, 5-H), 6.24 (1H, br 
d, J 8.4 Hz, 3-H), 6.83 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 7.10 (1H, t, J 8.4 Hz, 4-H), 9.89 
(1H, br s, NH), 12.04 (1H, br s, OH); δC (101 MHz, CDCl3) 18.4 (2 × CH3), 22.1 (2 × CH3), 
74.3 (CH), 100.0 (C), 100.5 (CH), 106.8 (CH), 114.8 (2 × CH, d 2JCF 21.7 Hz), 133.0 (C, d, 
4JCF 2.8 Hz), 134.2 (CH), 139.2 (2 × C, d, 
3JCF 8.7 Hz), 152.7 (C), 158.3 (C), 160.9 (C, d, 
1JCF 244.9 Hz), 169.3 (C); m/z (ESI) 340.1306 (MNa+. C18H20FNNaO3 requires 340.1319). 
2-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoic acid (84) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.018 g, 0.44 mmol, 60% in mineral oil), tert-butanol (0.8 mL), 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]benzoic acid (75) (0.050 g, 0.15 mmol) and copper powder (0.0040 
g, 0.060 mmol). The crude material was purified by flash column chromatography, eluting 
with 20% ethyl acetate in petroleum ether (40‒60) to afford 2-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]benzoic acid (84) as a brown solid (0.022 g, 58%). Mp 225‒228 °C; 
νmax/cm−1 (neat) 3325 (NH/OH), 2857 (CH), 1651 (CO), 1578 (C=C), 1506, 1443, 1265, 
750; δH (400 MHz, CDCl3) 2.19 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 6.19 (1H, dd, J 7.8, 0.7 Hz, 3-
H), 6.67 (1H, td, J 7.8, 0.7 Hz, 5-H), 6.86 (2H, d, J 9.0, 3ʹ-H and 5ʹ-H), 7.26 (1H, td, J 7.8, 
1.6 Hz, 4-H), 8.03 (1H, dd, J 7.8, 1.6 Hz, 6-H), 8.78 (1H, br s, NH), 11.4 (1H, br s, OH); δC 
(126 MHz, CDCl3) 18.4 (2 × CH3), 108.7 (C), 112.5 (CH), 114.9 (2 × CH, d, 
2JCF 21.9 Hz), 
115.9 (CH), 132.5 (CH), 132.7 (C, d, 4JCF 3.1 Hz), 135.7 (CH), 139.3 (2 × C, d, 
3JCF 8.4 
Hz), 150.7 (C), 161.0 (C, d, 1JCF 245.1 Hz), 173.5 (C); m/z (EI) 259.1011 (M+. C15H14FNO2 
requires 259.1009), 241 (74%), 226 (80), 212 (42), 198 (26), 106 (10), 77 (18), 51 (12). 
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6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxybenzoic acid (81) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.018 g, 0.44 mmol, 60% in mineral oil), methanol (0.8 mL), 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]benzoic acid (75) (0.050 g, 0.15 mmol) and copper powder (0.0040 
g, 0.060 mmol). The crude material was purified by flash column chromatography, eluting 
with 20% ethyl acetate in petroleum ether (40‒60) to afford 6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-2-methoxybenzoic acid (81) as a brown solid (0.031 g, 71%). Mp 
100‒101 °C; νmax/cm−1 (neat) 3246 (NH/OH), 2953 (CH), 1694 (CO), 1576 (C=C), 1464, 
1442, 1255, 1084, 806; δH (500 MHz, CDCl3) 2.15 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 4.05 (3H, s, 
OCH3), 5.91 (1H, dd, J 8.4, 0.9 Hz, 5-H), 6.25 (1H, dd, J 8.4, 0.9 Hz, 3-H), 6.83 (2H, d, J 
9.0 Hz, 3ʹ-H and 5ʹ-H), 7.13 (1H, t, J 8.4, 4-H), 9.90 (1H, br s, NH), 11.50 (1H, br s, OH); 
δC (126 MHz, CDCl3) 18.4 (2 × CH3), 56.9 (CH3), 98.0 (CH), 98.8 (C), 107.2 (CH), 114.8 (2 
× CH, d, 2JCF 21.9 Hz), 132.9 (C, d, 
4JCF 2.7 Hz), 134.4 (CH), 139.2 (2 × C, d, 
3JCF 8.9 Hz), 
152.7 (C), 159.9 (C), 160.9 (C, d, 1JCF 245.0 Hz), 169.0 (C); m/z (ESI) 312.0994 (MNa+. 
C16H16FNNaO3 requires 312.1006). 
6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-isobutoxybenzoic acid (82) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.018 g, 0.44 mmol, 60% in mineral oil), isobutanol (0.8 mL), 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]benzoic acid (75) (0.050 g, 0.15 mmol) and copper powder (0.0040 
g, 0.060 mmol). The crude material was purified by flash column chromatography, eluting 
with 20% ethyl acetate in petroleum ether (40‒60) to afford 6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-2-isobutoxybenzoic acid (82) as an orange solid (0.033 g, 68%). 
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Mp 74‒76 °C; νmax/cm−1 (neat) 3255 (NH/OH), 2966 (CH), 1695 (CO), 1577 (C=C), 1456, 
1407, 1252, 1057, 756; δH (500 MHz, CDCl3) 1.11 (6H, d, J 6.4 Hz, 2ʹʹ-CH3 and 3ʹʹ-H3), 
2.16 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.19‒2.29 (1H, m, 2ʹʹ-H), 3.99 (2H, d, J 6.4 Hz, 1ʹʹ-H2), 
5.89 (1H, d, J 8.3 Hz, 5-H), 6.22 (1H, d, J 8.3 Hz, 3-H), 6.83 (2H, d, J 9.1 Hz, 3ʹ-H and 5ʹ-
H), 7.10 (1H, t, J 8.3 Hz, 4-H), 9.90 (1H, br s, NH), 11.77 (1H, br s, OH); δC (126 MHz, 
CDCl3) 18.4 (2 × CH3), 19.2 (2 × CH3), 28.1 (CH), 76.7 (CH2), 98.9 (C), 98.9 (CH), 106.9 
(CH), 114.8 (2 × CH, d, 2JCF 21.6 Hz), 132.9 (C, d, 
4JCF 2.8 Hz), 134.4 (CH), 139.2 (2 × C, 
d, 3JCF 8.7 Hz), 152.6 (C), 159.5 (C), 160.9 (C, d, 
1JCF 244.6 Hz), 169.1 (C); m/z (ESI) 
354.1465 (MNa+. C19H22FNNaO3 requires 354.1476). 
2-n-Butoxy-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoic acid (83) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.018 g, 0.44 mmol, 60% in mineral oil), n-butanol (0.8 mL), 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]benzoic acid (75) (0.050 g, 0.15 mmol) and copper powder (0.0040 
g, 0.060 mmol). The crude material was purified by flash column chromatography, eluting 
with 20% ethyl acetate in petroleum ether (40‒60) to afford 2-n-butoxy-6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]benzoic acid (83) as a brown solid (0.033 g, 70%). Mp 77‒79 °C; 
νmax/cm−1 (neat) 3246 (NH/OH), 2963 (CH), 1694 (CO), 1578 (C=C), 1456, 1408, 1252, 
1219, 754; δH (500 MHz, CDCl3) 1.02 (3H, t, J 7.4 Hz, 4ʹʹ-H3), 1.49‒1.60 (2H, m, 3ʹʹ-H2), 
1.87‒1.95 (2H, m, 2ʹʹ-H2), 2.16 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 4.22 (2H, t, J 6.5 Hz, 1ʹʹ-H2), 
5.89 (1H, dd, J 8.3, 0.8 Hz, 5-H), 6.23 (1H, dd, J 8.3, 0.8 Hz, 3-H), 6.83 (2H, d, J 9.2 Hz, 
3ʹ-H and 5ʹ-H), 7.10 (1H, t, J 8.3 Hz, 4-H), 9.90 (1H, br s, NH), 11.78 (1H, br s, OH); δC 
(126 MHz, CDCl3) 13.7 (CH3), 18.4 (2 × CH3), 19.2 (CH2), 30.9 (CH2), 70.2 (CH2), 99.0 
(CH), 106.9 (CH), 114.8 (2 × CH, d, 2JCF 21.9 Hz), 126.4 (C), 132.9 (C, d, 
4JCF 2.7 Hz), 
134.4 (CH), 139.2 (2 × C, d, 3JCF 8.9 Hz), 152.6 (C), 159.4 (C), 160.9 (C, d, 
1JCF 244.6 
Hz), 169.1 (C); m/z (ESI) 354.1466 (MNa+. C19H22FNNaO3 requires 354.1476). 
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6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-(3ʹʹ-methyl-n-butoxy)benzoic acid (85) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.018 g, 0.44 mmol, 60% in mineral oil), 3-methyl-n-butanol (0.8 mL), 2-bromo-6-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoic acid (75) (0.050 g, 0.15 mmol) and copper 
powder (0.0040 g, 0.060 mmol). The crude material was purified by flash column 
chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 6-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-(3ʹʹ-methyl-n-butoxy)benzoic acid (85) as a brown 
viscous oil (0.020 g, 39%). νmax/cm−1 (neat) 3244 (NH/OH), 2959 (CH), 1694 (CO), 1578 
(C=C), 1458, 1408, 1252, 1217, 1076, 754; δH (400 MHz, CDCl3) 1.01 (6H, d, J 6.4 Hz, 3ʹʹ-
CH3 and 4ʹʹ-H3), 1.77‒1.91 (3H, m, 2ʹʹ-H2 and 3ʹʹ-H), 2.16 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 4.24 
(2H, t, J 6.5 Hz, 1ʹʹ-H2), 5.89 (1H, dd, J 8.3, 0.8 Hz, 5-H), 6.24 (1H, br d, J 8.3 Hz, 3-H), 
6.83 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 7.11 (1H, t, J 8.3 Hz, 4-H), 9.90 (1H, br s, NH), 11.69 
(1H, br s, OH); δC (126 MHz, CDCl3) 18.4 (2 × CH3), 22.5 (2 × CH3), 25.1 (CH), 37.7 
(CH2), 69.0 (CH2), 99.0 (CH), 99.0 (C), 107.0 (CH), 114.8 (2 × CH, d, 
2JCF 21.9 Hz), 133.0 
(C, d, 4JCF 2.7 Hz), 134.3 (CH), 139.2 (2 × C, d, 
3JCF 8.4 Hz), 152.6 (C), 159.4 (C), 160.9 
(C, d, 1JCF 244.8 Hz), 169.1 (C); m/z (ESI) 368.1620 (MNa+. C20H24FNNaO3 requires 
368.1632). 
2-(Allyloxy)-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoic acid (86) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.0532 g, 1.33 mmol, 60% in mineral oil), 3-fluoropropan-1-ol (0.134 mL, 11.8 mmol), 2-
bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoic acid (75) (0.150 g, 0.444 mmol), 
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tetrahydrofuran (1.6 mL) and copper powder (0.0113 g, 0.178 mmol). The crude material 
was purified by flash column chromatography, eluting with 20% ethyl acetate in petroleum 
ether (40‒60) to afford 2-(allyloxy)-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoic acid 
(86) as a brown viscous oil (0.0643 g, 46%). νmax/cm−1 (neat) 3258 (NH/OH), 2920 (CH), 
1694 (CO), 1576 (C=C), 1456, 1252, 1051, 806; δH (500 MHz, CDCl3) 2.15 (6H, s, 2ʹ-CH3 
and 6ʹ-CH3), 4.76 (2H, d, J 5.8 Hz, 1ʹʹ-H2), 5.45 (1H, dd, J 10.5, 0.8 Hz, 3ʹʹ-HH), 5.51 (1H, 
dd, J 17.0, 0.8 Hz, 3ʹʹ-HH), 5.91 (1H, d, J 8.2 Hz, 5-H), 6.12 (1H, ddt, J 17.0, 10.5, 5.8 Hz, 
2ʹʹ-H), 6.23 (1H, d, J 8.2 Hz, 3-H), 6.84 (2H, d, J 9.1 Hz, 3ʹ-H and 5ʹ-H), 7.10 (1H, t, J 8.2 
Hz, 4-H), 9.89 (1H, br s, NH), 11.60 (1H, br s, OH); δC (126 MHz, CDCl3) 18.3 (2 × CH3), 
71.2 (CH2), 99.2 (C), 99.4 (CH), 107.3 (CH), 114.8 (2 × CH, 
2JCF 21.8 Hz), 120.7 (CH2), 
131.0 (CH), 132.9 (C, d, 4JCF 2.7 Hz), 134.3 (CH), 139.1 (2 × C, d, 
3JCF 8.3 Hz), 152.7 (C), 
159.0 (C), 160.9 (C, d, 1JCF 245.0 Hz), 168.9 (C); m/z (ESI) 338.1151 (MNa+. 
C18H18FNNaO3 requires 338.1163). 
6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxy-3-methylbenzoic acid (87) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.017 g, 0.43 mmol, 60% in mineral oil), methanol (0.8 mL), 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-3-methylbenzoic acid (79) (0.050 g, 0.14 mmol) and copper 
powder (0.0040 g, 0.057 mmol). The crude material was purified by flash column 
chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 6-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxy-3-methylbenzoic acid (87) as an orange 
viscous oil (0.0307 g, 71%). νmax/cm−1 (neat) 3308 (NH/OH), 2926 (CH), 1700 (CO), 1574 
(C=C), 1504, 1216, 757; δH (500 MHz, CDCl3) 2.15 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.20 (3H, 
s, 3-CH3), 3.93 (3H, s, OCH3), 5.98 (1H, d, J 8.7 Hz, 5-H), 6.83 (2H, d, J 9.1 Hz, 3ʹ-H and 
5ʹ-H), 7.02 (1H, d, J 8.7 Hz, 4-H), 9.45 (1H, br s, NH), 11.94 (1H, br s, OH); δC (126 MHz, 
CDCl3) 15.1 (CH3), 18.3 (2 × CH3), 62.2 (CH3), 102.2 (C), 109.8 (CH), 114.8 (2 × CH, d, 
2JCF 21.7 Hz), 116.5 (C), 133.0 (C, d, 
4JCF 2.7 Hz), 137.2 (CH), 139.2 (2 × C, d, 
3JCF 8.9 
Hz), 150.3 (C), 158.2 (C), 160.9 (C, d, 1JCF 244.6 Hz), 168.7 (C); m/z (ESI) 326.1148 
(MNa+. C17H16FNNaO3 requires 326.1163). 
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6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-isobutoxy-3-methylbenzoic acid (88) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.034 g, 0.85 mmol, 60% in mineral oil), isobutanol (1.2 mL), 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-3-methylbenzoic acid (79) (0.10 g, 0.28 mmol) and copper powder 
(0.0070 g, 0.11 mmol). The crude material was purified by flash column chromatography, 
eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-2-isobutoxy-3-methylbenzoic acid (88) as an orange solid (0.073 g, 
74%). Mp 130‒132 °C; νmax/cm−1 (neat) 3294 (NH), 3125 (OH), 2963 (CH), 1705 (CO), 
1573 (C=C), 1504, 1404, 1227, 1034, 818; δH (400 MHz, CDCl3) 1.11 (6H, d, J 6.7 Hz, 2ʹʹ-
CH3 and 3ʹʹ-H3), 2.15 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.18 (3H, s, 3-CH3), 2.18‒2.28 (1H, m, 
2ʹʹ-H), 3.76 (2H, d, J 6.7 Hz, 1ʹʹ-H2), 5.97 (1H, d, J 8.7 Hz, 5-H), 6.83 (2H, d, J 9.1 Hz, 3ʹ-H 
and 5ʹ-H), 7.02 (1H, d, J 8.7 Hz, 4-H), 9.44 (1H, br s, NH), 12.25 (1H, br s, OH); δC (101 
MHz, CDCl3) 15.2 (CH3), 18.4 (2 × CH3), 19.0 (2 × CH3), 29.1 (CH), 82.1 (CH2), 102.6 (C), 
109.6 (CH), 114.9 (2 × CH, d, 2JCF 21.9 Hz), 116.8 (C), 133.0 (C, d, 
4JCF 2.7 Hz), 137.1 
(CH), 139.2 (2 × C, d, 3JCF 8.5 Hz), 150.3 (C), 157.2 (C), 160.9 (C, d, 
1JCF 244.8 Hz), 
168.7 (C); m/z (ESI) 368.1619 (MNa+. C20H24FNNaO3 requires 368.1632). 
2-Isopropoxy-6-(mesitylamino)benzamide (31)95 
 
The reaction was carried out according to general procedure D using 2-isopropoxy-6-
(mesitylamino)benzoic acid (60) (0.100 g, 0.319 mmol), 2-chloro-4,6-dimethoxy-1,3,5-
triazine (0.0673 g, 0.383 mmol) and N-methylmorpholine (0.105 mL, 0.957 mmol) in 
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tetrahydrofuran (1.0 mL). The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 2-
isopropoxy-6-(mesitylamino)benzamide (31) as a pale yellow solid (0.074 g, 74%). The 
spectroscopic data were consistent with the literature.95 Mp 215‒217 °C; δH (500 MHz, 
CDCl3) 1.43 (6H, d, J 6.1 Hz, OCH(CH3)2), 2.15 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.30 (3H, s, 4ʹ-
CH3), 4.69 (1H, sept, J 6.1 Hz, OCH(CH3)2), 5.60 (1H, br s, NH), 5.84 (1H, dd, J 8.3, 0.9 
Hz, 5-H), 6.17 (1H, br d, J 8.3 Hz, 3-H), 6.93 (2H, s, 3ʹ-H and 5ʹ-H), 6.99 (1H, t, J 8.3 Hz, 
4-H), 8.14 (1H, br s, NH), 10.13 (1H, br s, NH); δC (101 MHz, CDCl3) 18.2 (2 × CH3), 20.9 
(CH3), 22.3 (2 × CH3), 72.0 (CH), 100.5 (CH), 103.1 (C), 106.2 (CH), 129.0 (2 × CH), 
132.5 (CH), 135.5 (C), 135.6 (C), 136.6 (2 × C), 152.2 (C), 158.2 (C), 171.6 (C); m/z (EI) 
312 (M+. 95%) 295 (25), 253 (100), 252 (55), 238 (68). 
6-(Mesitylamino)-2-methoxybenzamide (97)95 
 
The reaction was carried out according to general procedure D using 6-(mesitylamino)-2-
methoxybenzoic acid (96) (1.62 g, 5.68 mmol), 2-chloro-4,6-dimethoxy-1,3,5-triazine (1.20 
g, 6.81 mmol) and N-methylmorpholine (1.87 mL, 17.0 mmol) in tetrahydrofuran (20 mL). 
The crude material was purified by flash column chromatography, eluting with 20% ethyl 
acetate in petroleum ether (40‒60) to afford 6-(mesitylamino)-2-methoxybenzamide (97) 
as a white solid (1.56 g, 97%). The spectroscopic data were consistent with the 
literature.95 Mp 180‒182 °C; δH (500 MHz, CDCl3) 2.15 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.29 
(3H, s, 4ʹ-CH3), 3.89 (3H, s, OCH3), 5.88 (1H, dd, J 8.3, 0.9 Hz, 5-H), 6.09 (1H, br s, NH), 
6.17 (1H, dd, J 8.3, 0.9 Hz, 3-H), 6.92 (2H, s, 3ʹ-H and 5ʹ-H), 7.01 (1H, t, J 8.3 Hz, 4-H), 
7.90 (1H, br s, NH), 10.18 (1H, br s, NH); δC (126 MHz, CDCl3) 18.2 (2 × CH3), 20.9 (CH3), 
55.9 (CH3), 98.0 (CH), 102.0 (C), 106.6 (CH), 129.0 (2 × CH), 132.6 (CH), 135.4 (C), 
135.6 (C), 136.5 (2 × C), 152.1 (C), 159.9 (C), 171.5 (C); m/z (ESI) 307 (MNa+. 100%). 
164 
6-[(2ʹ,6ʹ-Dimethylphenyl)amino]-2-isopropoxybenzamide (67) 
 
The reaction was carried out according to general procedure D using 6-[(2ʹ,6ʹ-
dimethylphenyl)amino]-2-isopropoxybenzoic acid (70) (0.0670 g, 0.224 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (0.0472 g, 0.269 mmol) and N-methylmorpholine (0.0739 mL, 
0.672 mmol) in tetrahydrofuran (1.0 mL). The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 6-
[(2ʹ,6ʹ-dimethylphenyl)amino]-2-isopropoxybenzamide (67) as a pale yellow solid (0.0613 
g, 92%). Mp 180‒182 °C; νmax/cm−1 (neat) 3433 (NH), 2980 (CH), 1643 (CO), 1584 (C=C), 
1456, 1248, 1111; δH (400 MHz, CDCl3) 1.43 (6H, d, J 6.1 Hz, OCH(CH3)2), 2.20 (6H, s, 
2ʹ-CH3 and 6ʹ-CH3), 4.69 (1H, sept, J 6.1 Hz, OCH(CH3)2), 5.76 (1H, br s, NH), 5.83 (1H, 
dd, J 8.3, 0.9 Hz, 5-H), 6.19 (1H, br d, J 8.3 Hz, 3-H), 7.00 (1H, t, J 8.3 Hz, 4-H), 7.05‒
7.16 (3H, m, 3ʹ-H, 4ʹ-H and 5ʹ-H), 8.15 (1H, br s, NH), 10.20 (1H, br s, NH); δC (101 MHz, 
CDCl3) 18.3 (2 × CH3), 22.3 (2 × CH3), 72.0 (CH), 100.7 (CH), 103.1 (C), 106.2 (CH), 
126.1 (CH), 128.3 (2 × CH), 132.5 (CH), 136.8 (2 × C), 138.2 (C), 151.9 (C), 158.2 (C), 
171.6 (C); m/z (ESI) 321.1565 (MNa+. C18H22N2NaO2 requires 321.1573). 
6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-isopropoxybenzamide (66) 
 
The reaction was carried out according to general procedure D using 6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-2-isopropoxybenzoic acid (80) (0.0400 g, 0.126 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (0.0265 g, 0.151 mmol) and N-methylmorpholine (0.0416 mL, 
0.378 mmol) in tetrahydrofuran (0.5 mL). The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 6-[(4ʹ-
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fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-isopropoxybenzamide (66) as a pale yellow solid 
(0.0392 g, 98%). Mp 204‒206 °C; νmax/cm−1 (neat) 3444 (NH), 3188 (NH), 2982 (CH), 
1638 (CO), 1584 (C=C), 1456, 1250, 1111, 1044; δH (400 MHz, CDCl3) 1.43 (6H, d, J 6.1 
Hz, OCH(CH3)2), 2.18 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 4.70 (1H, sept, J 6.1 Hz, OCH(CH3)2), 
5.65 (1H, br s, NH), 5.80 (1H, dd, J 8.3, 0.9 Hz, 5-H), 6.20 (1H, br d, J 8.3 Hz, 3-H), 6.82 
(2H, d, J 9.2 Hz, 3ʹ-H and 5ʹ-H), 7.01 (1H, t, J 8.3 Hz, 4-H), 8.16 (1H, br s, NH), 10.14 (1H, 
br s, NH); δC (126 MHz, CDCl3) 18.5 (2 × CH3), 22.3 (2 × CH3), 72.0 (CH), 100.9 (CH), 
103.2 (C), 105.9 (CH), 114.6 (2 × CH, d 2JCF 21.8 Hz), 132.6 (CH), 134.0 (C, d, 
4JCF 2.7 
Hz), 139.1 (2 × C, d, 3JCF 8.2 Hz), 152.1 (C), 158.3 (C), 160.6 (C, d, 
1JCF 244.0 Hz), 171.5 
(C); m/z (ESI) 339.1465 (MNa+. C18H21FN2NaO2 requires 339.1479). 
6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxybenzamide (89) 
 
The reaction was carried out according to general procedure D using 6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-2-methoxybenzoic acid (81) (0.0300 g, 0.104 mmol), 2-chloro-4,6-
dimethoxy-1,3,5-triazine (0.0219 g, 0.125 mmol) and N-methylmorpholine (0.0412 mL, 
0.375 mmol) in tetrahydrofuran (0.5 mL). The crude material was purified by flash column 
chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 6-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxybenzamide (89) as a pale yellow solid 
(0.0201 g, 67%). Mp 171‒173 °C; νmax/cm−1 (neat) 3462 (NH), 3186 (NH), 2924 (CH), 
1638 (CO), 1580 (C=C), 1458, 1250, 1128, 752; δH (400 MHz, CDCl3) 2.17 (6H, s, 2ʹ-CH3 
and 6ʹ-CH3), 3.92 (3H, s, OCH3), 5.77 (1H, br s, NH), 5.84 (1H, dd, J 8.4, 0.9 Hz, 5-H), 
6.22 (1H, dd, J 8.4, 0.9 Hz, 3-H), 6.82 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 7.05 (1H, t, J 8.4 
Hz, 4-H), 7.94 (1H, br s, NH), 10.17 (1H, br s, NH); δC (101 MHz, CDCl3) 18.4 (CH3), 18.5 
(CH3), 56.0 (CH3), 98.4 (CH), 102.1 (C), 106.4 (CH), 114.6 (2 × CH, d, 
2JCF 21.8 Hz), 
132.8 (CH), 133.9 (C, d, 4JCF 2.6 Hz), 139.1 (2 × C, d, 
3JCF 8.7 Hz), 152.0 (C), 160.0 (C), 
160.6 (C, d, 1JCF 245.0 Hz), 171.3 (C); m/z (ESI) 311.1158 (MNa+. C16H17FN2NaO2 
requires 311.1166). 
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6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-isobutoxybenzamide (90) 
 
The reaction was carried out according to general procedure D using 6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-2-isobutoxybenzoic acid (82) (0.0300 g, 0.0905 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (0.0191 g, 0.109 mmol) and N-methylmorpholine (0.0300 mL, 
0.273 mmol) in tetrahydrofuran (0.5 mL). The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 6-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-isobutoxybenzamide (90) as an orange solid (0.0294 
g, 98%). Mp 152‒154 °C; νmax/cm−1 (neat) 3455 (NH), 3181 (NH), 2922 (CH), 1636 (CO), 
1582 (C=C), 1493, 1449, 1398, 1246, 1060, 864, 754; δH (500 MHz, CDCl3) 1.08 (6H, d, J 
6.7 Hz, 2ʹʹ-CH3 and 3ʹʹ-H3), 2.13‒2.21 (1H, m, 2ʹʹ-H), 2.17 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 3.86 
(2H, d, J 6.4 Hz, 1ʹʹ-H2), 5.73 (1H, br s, NH), 5.82 (1H, dd, J 8.5, 0.8 Hz, 5-H), 6.19 (1H, br 
d, J 8.5 Hz, 3-H), 6.82 (2H, d, J 9.1 Hz, 3ʹ-H and 5ʹ-H), 7.02 (1H, t, J 8.5 Hz, 4-H), 8.06 
(1H, br s, NH), 10.14 (1H, br s, NH); δC (126 MHz, CDCl3) 18.5 (CH3), 18.5 (CH3), 19.5 (2 
× CH3), 28.3 (CH), 75.7 (CH2), 99.3 (CH), 102.1 (C), 106.1 (CH), 114.6 (2 × CH, d, 
2JCF 
21.4 Hz), 132.8 (CH), 133.9 (C, d, 4JCF 2.7 Hz), 139.1 (2 × C, d, 
3JCF 8.4 Hz), 152.0 (C), 
159.5 (C), 160.6 (C, d, 1JCF 243.6 Hz), 171.4 (C); m/z (ESI) 353.1623 (MNa+. 
C19H23FN2NaO2 requires 353.1636). 
2-n-Butoxy-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzamide (91) 
 
The reaction was carried out according to general procedure D using 2-butoxy-6-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoic acid (83) (0.0300 g, 0.0905 mmol), 2-chloro-
4,6-dimethoxy-1,3,5-triazine (0.0191 g, 0.109 mmol) and N-methylmorpholine (0.0300 mL, 
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0.273 mmol) in tetrahydrofuran (0.5 mL). The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 2-n-
butoxy-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino] benzamide (91) as a pale orange solid 
(0.0244 g, 81%). Mp 156‒158 °C; νmax/cm−1 (neat) 3460 (NH), 3181 (NH), 2932 (CH), 
1645 (CO), 1570 (C=C), 1491, 1445, 1248, 752; δH (500 MHz, CDCl3) 1.00 (3H, t, J 7.5 
Hz, 4ʹʹ-H3), 1.47‒1.57 (2H, m, 3ʹʹ-H2), 1.81‒1.90 (2H, m, 2ʹʹ-H2), 2.17 (6H, s, 2ʹ-CH3 and 6ʹ-
CH3), 4.09 (2H, t, J 6.5 Hz, 1ʹʹ-H2), 5.70 (1H, br s, NH), 5.82 (1H, dd, J 8.5, 0.8 Hz, 5-H), 
6.20 (1H, dd, J 8.5, 0.8 Hz, 3-H), 6.81 (2H, d, J 9.1 Hz, 3ʹ-H and 5ʹ-H), 7.01 (1H, t, J 8.5 
Hz, 4-H), 8.06 (1H, br s, NH), 10.16 (1H, br s, NH); δC (126 MHz, CDCl3) 13.8 (CH3), 18.4 
(2 × CH3), 19.4 (CH2), 31.3 (CH2), 69.0 (CH2), 99.3 (CH), 102.1 (C), 106.1 (CH), 114.6 (2 
× CH, d, 2JCF 21.7 Hz), 132.8 (CH), 134.0 (C, d, 
4JCF 2.8 Hz), 139.1 (C, d, 
3JCF 8.4 Hz), 
152.0 (C), 159.5 (C), 160.6 (C, d, 1JCF 243.9 Hz), 171.4 (C); m/z (ESI) 353.1623 (MNa+. 
C19H23FN2NaO2 requires 353.1636). 
6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-(3ʹʹ-methyl-n-butoxy)benzamide (92) 
 
The reaction was carried out according to general procedure D using 6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-2-(3ʹʹ-methyl-n-butoxy)benzoic acid (85) (0.020 g, 0.058 mmol), 2-
chloro-4,6-dimethoxy-1,3,5-triazine (0.012 g, 0.070 mmol) and N-methylmorpholine (0.019 
mL, 0.17 mmol) in tetrahydrofuran (0.5 mL). The crude material was purified by flash 
column chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to 
afford 6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-(3ʹʹ-methyl-n-butoxy)benzamide (92) as a 
pale yellow solid (0.014 g, 67%). Mp 143‒145 °C; νmax/cm−1 (neat) 3467 (NH), 3200 (NH), 
2960 (CH), 1641 (CO), 1580 (C=C), 1451, 1245, 1216, 754; δH (500 MHz, CDCl3) 0.99 
(6H, d, J 6.4 Hz, 3ʹʹ-CH3 and 4ʹʹ-H3), 1.73‒1.87 (3H, m, 2ʹʹ-H2 and 3ʹʹ-H), 2.17 (6H, s, 2ʹ-
CH3 and 6ʹ-CH3), 4.11 (2H, t, J 6.6 Hz, 1ʹʹ-H2), 5.65 (1H, br s, NH), 5.82 (1H, dd, J 8.5, 0.8 
Hz, 5-H), 6.21 (1H, br d, J 8.5 Hz, 3-H), 6.81 (2H, d, J 9.1 Hz, 3ʹ-H and 5ʹ-H), 7.02 (1H, t, J 
8.5 Hz, 4-H), 8.05 (1H, br s, NH), 10.16 (1H, br s, NH); δC (126 MHz, CDCl3) 18.5 (CH3), 
18.5 (CH3), 22.6 (2 × CH3), 25.3 (CH), 38.1 (CH2), 67.8 (CH2), 99.3 (CH), 102.2 (C), 106.2 
(CH), 114.6 (2 × CH, d, 2JCF 21.4 Hz), 132.8 (CH), 133.9 (C, d, 
4JCF 2.7 Hz), 139.1 (2 × C, 
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d, 3JCF 8.8 Hz), 152.1 (C), 159.5 (C), 160.6 (C, d, 
1JCF 243.7 Hz), 171.4 (C); m/z (ESI) 
367.1771 (MNa+. C20H25FN2NaO2 requires 367.1792). 
2-(Allyloxy)-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzamide (93) 
 
The reaction was carried out according to general procedure D using 2-(allyloxy)-6-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoic acid (86) (0.0500 g, 0.149 mmol), 2-chloro-4,6-
dimethoxy-1,3,5-triazine (0.0314 g, 0.179 mmol) and N-methylmorpholine (0.0491 mL, 
0.447 mmol) in tetrahydrofuran (0.5 mL). The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 2-
(allyloxy)-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzamide (93) as a pale yellow solid 
(0.0445 g, 95%). Mp 176‒178 °C; νmax/cm−1 (neat) 3443 (NH), 3181 (NH), 2920 (CH), 
1647 (CO), 1605 (C=C), 1582 (C=C), 1451, 1238, 1053, 810; δH (500 MHz, CDCl3) 2.17 
(6H, s, 2ʹ-CH3 and 6ʹ-CH3), 4.63 (2H, d, J 5.6 Hz, 1ʹʹ-H2), 5.36 (1H, dd, J 10.5, 1.2 Hz, 3ʹʹ-
HH), 5.46 (1H, dd, J 17.2, 1.2 Hz, 3ʹʹ-HH), 5.75 (1H, br s, NH), 5.84 (1H, dd, J 8.2, 0.8 Hz, 
5-H), 6.11 (1H, ddt, J 17.2, 10.5, 5.6 Hz, 2ʹʹ-H), 6.20 (1H, br d, J 8.2 Hz, 3-H), 6.82 (2H, d, 
J 9.1 Hz, 3ʹ-H and 5ʹ-H), 7.02 (1H, t, J 8.2 Hz, 4-H), 7.99 (1H, br s, NH), 10.12 (1H, br s, 
NH); δC (126 MHz, CDCl3) 18.4 (CH3), 18.5 (CH3), 70.1 (CH2), 99.7 (CH), 102.5 (C), 106.5 
(CH), 114.6 (2 × CH, 2JCF 21.4 Hz), 119.2 (CH2), 132.4 (CH), 132.7 (CH), 133.9 (C, d, 
4JCF 
2.7 Hz), 139.1 (2 × C, d, 3JCF 8.4 Hz), 152.0 (C), 159.0 (C), 160.6 (C, d, 
1JCF 244.1 Hz), 
171.3 (C); m/z (ESI) 337.1313 (MNa+. C18H19FN2NaO2 requires 337.1323). 
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6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxy-3-methylbenzamide (94) 
 
The reaction was carried out according to general procedure D using 6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-2-methoxy-3-methylbenzoic acid (87) (0.030 g, 0.099 mmol), 2-
chloro-4,6-dimethoxy-1,3,5-triazine (0.021 g, 0.12 mmol) and N-methylmorpholine (0.033 
mL, 0.30 mmol) in tetrahydrofuran (0.5 mL). The crude material was purified by flash 
column chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to 
afford 6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxy-3-methylbenzamide (94) as a 
pale yellow solid (0.016 g, 55%). Mp 136‒138 °C; νmax/cm−1 (neat) 3464 (NH), 3226 (NH), 
2923 (CH), 1623 (CO), 1569 (C=C), 1496, 1404, 1368, 1257, 1130, 1046, 1020, 865, 702; 
δH (500 MHz, CDCl3) 2.17 (3H, s, 3-CH3), 2.17 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 3.78 (3H, s, 
OCH3), 5.74 (1H, br s, NH), 5.91 (1H, d, J 8.6 Hz, 5-H), 6.81 (2H, d, J 9.1 Hz, 3ʹ-H and 5ʹ-
H), 6.94 (1H, d, J 8.6 Hz, 4-H), 7.95 (1H, br s, NH), 9.36 (1H, br s, NH); δC (126 MHz, 
CDCl3) 15.2 (CH3), 18.5 (2 × CH3), 61.2 (CH3), 106.9 (C), 109.0 (CH), 114.6 (2 × CH, d, 
2JCF 21.8 Hz), 117.7 (C), 134.0 (C, d, 
4JCF 2.7 Hz), 135.1 (CH), 139.0 (2 × C, d, 
3JCF 8.5 
Hz), 149.2 (C), 158.2 (C), 160.5 (C, d, 1JCF 243.7 Hz), 170.8 (C); m/z (ESI) 325.1315 
(MNa+. C17H16FNNaO3 requires 325.1323). 
6-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-isobutoxy-3-methylbenzamide (95) 
 
The reaction was carried out according to general procedure D using 6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-2-isobutoxy-3-methylbenzoic acid (88) (0.0720 g, 0.208 mmol), 2-
chloro-4,6-dimethoxy-1,3,5-triazine (0.0438 g, 0.250 mmol) and N-methylmorpholine 
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(0.0687 mL, 0.625 mmol) in tetrahydrofuran (0.5 mL). The crude material was purified by 
flash column chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) 
to afford 6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-2-isobutoxy-3-methylbenzamide (95) as 
a white solid (0.059 g, 82%). Mp 125‒127 °C; νmax/cm−1 (neat) 3449 (NH), 3233 (NH), 
2963 (CH), 1651 (CO), 1574 (C=C), 1497, 1258, 1042; δH (400 MHz, CDCl3) 1.06 (6H, d, 
J 6.7 Hz, 2ʹʹ-CH3 and 3ʹʹ-H3), 2.06‒2.22 (1H, m, 2ʹʹ-H), 2.15 (3H, s, 3-CH3), 2.17 (6H, s, 2ʹ-
CH3 and 6ʹ-CH3), 3.62 (2H, d, J 6.7 Hz, 1ʹʹ-H2), 5.90 (1H, d, J 8.6 Hz, 5-H), 5.92 (1H, br s, 
NH), 6.81 (2H, d, J 9.1 Hz, 3ʹ-H and 5ʹ-H), 6.93 (1H, d, J 8.6 Hz, 4-H), 7.93 (1H, br s, NH), 
9.23 (1H, br s, NH); δC (101 MHz, CDCl3) 15.4 (CH3), 18.5 (CH3), 18.5 (CH3), 19.3 (2 × 
CH3), 29.3 (CH), 80.7 (CH2), 107.7 (C), 108.8 (CH), 114.6 (2 × CH, d, 
2JCF 21.7 Hz), 118.0 
(C), 134.0 (C, d, 4JCF 2.8 Hz), 135.0 (CH), 139.0 (2 × C, d, 
3JCF 8.6 Hz), 148.9 (C), 157.1 
(C), 160.5 (C, d, 1JCF 243.7 Hz), 171.0 (C); m/z (ESI) 367.1781 (MNa+. C20H25FN2NaO2 
requires 367.1792). 
3-Bromo-2-isopropoxy-6-(mesitylamino)benzamide (72) 
 
The reaction was carried out according to general procedure E using iron(III) chloride 
(0.0016 g, 0.010 mmol), [BMIM]NTf2 (0.12 mL, 0.40 mmol), 2-isopropoxy-6-
(mesitylamino)benzamide (67) (0.060 g, 0.20 mmol) and N-bromosuccinimide (0.098 g, 
0.55 mmol) in dichloromethane (0.5 mL). The crude material was purified by flash column 
chromatography, eluting with 10% diethyl ether in petroleum ether (40‒60) to afford 3-
bromo-2-isopropoxy-6-(mesitylamino)benzamide (72) as a white solid (0.073 g, 94%). Mp 
205‒207 °C; νmax/cm−1 (neat) 3435 (NH), 3185 (NH), 2976 (CH), 1647 (CO), 1564 (C=C), 
1487, 1406, 1258, 1098; δH (500 MHz, CDCl3) 1.39 (6H, d, J 6.2 Hz, OCH(CH3)2), 2.14 
(6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.30 (3H, s, 4ʹ-CH3), 4.56 (1H, sept, J 6.2 Hz, OCH(CH3)2), 
5.73 (1H, br s, NH), 5.90 (1H, d, J 9.0 Hz, 5-H), 6.93 (2H, s, 3ʹ-H and 5ʹ-H), 7.20 (1H, d, J 
9.0 Hz, 4-H), 7.57 (1H, br s, NH), 9.18 (1H, br s, NH); δC (126 MHz, CDCl3) 18.2 (2 × 
CH3), 20.9 (CH3), 21.9 (2 × CH3), 78.2 (CH), 102.9 (C), 110.3 (CH), 110.8 (C), 129.1 (2 × 
CH), 134.7 (C), 136.0 (C), 136.1 (CH), 136.4 (2 × C), 149.6 (C), 154.0 (C), 170.2 (C); m/z 
(ESI) 413.0824 (MNa+. C19H2379BrN2NaO2 requires 413.0835). 
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3-Bromo-6-(mesitylamino)-2-methoxybenzamide (98) 
 
The reaction was carried out according to general procedure E using iron(III) chloride 
(0.0446 g, 0.275 mmol), [BMIM]NTf2 (2.30 mL, 11.0 mmol), 2-methoxy-6-
(mesitylamino)benzamide (97) (1.56 g, 5.49 mmol) and N-bromosuccinimide (0.980 g, 
5.49 mmol) in dichloromethane (14 mL). The crude material was purified by flash column 
chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 3-
bromo-6-(mesitylamino)-2-methoxybenzamide (98) as a white solid (1.54 g, 77%). Mp 
184‒186 °C; νmax/cm−1 (neat) 3456 (NH), 3256 (NH), 2924 (CH), 1651 (CO), 1566 (C=C), 
1489, 1404, 1258, 1042, 818; δH (400 MHz, CDCl3) 2.14 (2ʹ-CH3 and 6ʹ-CH3), 2.30 (3H, s, 
4ʹ-CH3), 3.89 (3H, s, OCH3), 5.90 (1H, br s, NH), 5.94 (1H, d, J 9.1, Hz, 5-H), 6.93 (2H, s, 
3ʹ-H and 5ʹ-H), 7.22 (1H, d, J 9.1 Hz, 4-H), 7.82 (1H, br s, NH), 9.55 (1H, br s, NH); δC 
(126 MHz, CDCl3) 18.1 (2 × CH3), 20.9 (CH3), 61.8 (CH3), 101.9 (C), 108.1 (C), 110.9 
(CH), 129.2 (2 × CH), 134.6 (C), 136.1 (C), 136.3 (2 × C), 136.3 (CH), 150.6 (C), 156.6 
(C), 169.9 (C); m/z (ESI) 385.0512 (MNa+. C17H1979BrN2NaO2 requires 385.0522). 
3-Iodo-2-isopropoxy-6-(mesitylamino)benzamide (73) 
 
To a dry flask under argon was added iron(III) choride (0.0016 g, 0.010 mmol) and 
[BMIM]NTf2 (0.12 mL, 0.40 mmol) and the mixture stirred for 0.5 h. 2-Isopropoxy-6-
(mesitylamino)benzamide (67) (0.060 g, 0.20 mmol) was then added as a solution in 
dichloromethane (0.5 mL) and N-iodosuccinimide (0.045 g, 0.20 mmol) was added slowly 
to the mixture. After 16 h of stirring at 36 °C, N-iodosuccinimide (0.018 g, 0.080 mmol) 
was added and the reaction mixture stirred for a further 3 h. The mixture was diluted with 
ethyl acetate (10 mL) and filtered through a short pad of silica. The filtrate was then 
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washed with 1 M sodium thiosulfate (10 mL) and brine (10 mL). The solution was dried 
(MgSO4), filtered and concentrated in vacuo. The resulting residue was then purified by 
flash column chromatography, eluting with 15% diethyl ether in petroleum ether (40‒60) to 
afford 3-iodo-2-isopropoxy-6-(mesitylamino)benzamide (73) as a white solid (0.028 g, 
31%). Mp 215‒217 °C; νmax/cm−1 (neat) 3447 (NH), 3198 (NH), 2972 (CH), 1643 (CO), 
1560 (C=C), 1485, 1256, 758; δH (400 MHz, CDCl3) 1.40 (6H, d, J 6.2 Hz, OCH(CH3)2), 
2.14 (2ʹ-CH3 and 6ʹ-CH3), 2.30 (3H, s, 4ʹ-CH3), 4.53 (1H, sept, J 6.2 Hz, OCH(CH3)2), 5.81 
(1H, d, J 9.0 Hz, 5-H), 5.83 (1H, br s, NH), 6.92 (2H, s, 3ʹ-H and 5ʹ-H), 7.40 (1H, d, J 9.0 
Hz, 4-H), 7.47 (1H, br s, NH), 9.11 (1H, br s, NH); δC (101 MHz, CDCl3) 18.1 (2 × CH3), 
20.9 (CH3), 22.0 (2 × CH3), 75.0 (C), 78.4 (CH), 110.9 (C), 111.3 (CH), 129.2 (2 × CH), 
134.7 (C), 136.0 (C), 136.3 (2 × C), 141.9 (CH), 150.3 (C), 156.4 (C), 170.2 (C); m/z (ESI) 
461.0689 (MNa+. C19H23IN2NaO2 requires 461.0696). 
3-(4ʹʹ-Fluorophenyl)-6-(mesitylamino)-2-methoxybenzamide (101) 
 
The reaction was carried out according to general procedure F using 3-bromo-6-
(mesitylamino)-2-methoxybenzamide (98) (0.100 g, 0.275 mmol), 4-fluorophenylboronic 
acid (0.0616 g, 0.440 mmol), [1,1ʹ-bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
(1:1) (0.0113 g, 0.0138 mmol) and caesium carbonate (0.270 g, 0.825 mmol) in 1,4-
dioxane (4.0 mL) and water (0.30 mL). The crude material was purified by flash column 
chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 3-(4ʹʹ-
fluorophenyl)-6-(mesitylamino)-2-methoxybenzamide (101) as a white solid (0.0738 g, 
71%). Mp 209‒211 °C; νmax/cm−1 (neat) 3449 (NH), 3225 (NH), 2924 (CH), 1651 (CO), 
1489, 1250, 1227, 1042, 818, 756; δH (400 MHz, CDCl3) 2.18 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 
2.31 (3H, s, 4ʹ-CH3), 3.45 (3H, s, OCH3), 5.82 (1H, br s, NH), 6.08 (1H, d, J 8.8 Hz, 5-H), 
6.95 (2H, s, 3ʹ-H and 5ʹ-H), 7.05 (1H, d, J 8.8 Hz, 4-H), 7.07 (2H, t, J 8.7 Hz, 3ʹʹ-H and 5ʹʹ-
H), 7.45 (2H, dd, J 8.7, 5.5 Hz, 2ʹʹ-H and 6ʹʹ-H), 8.07 (1H, br s, NH), 9.72 (1H, br s, NH); δC 
(101 MHz, CDCl3) 18.3 (2 × CH3), 21.0 (CH3), 61.3 (CH3), 106.6 (C), 109.6 (CH), 115.1 (2 
× CH, d, 2JCF 21.2 Hz), 121.2 (C), 129.1 (2 × CH), 130.6 (2 × CH, d, 
3JCF 7.8 Hz), 134.4 
(C, d, 4JCF 3.4 Hz), 134.6 (CH), 135.0 (C) 135.9 (C), 136.4 (2 × C), 150.8 (C), 157.6 (C), 
161.7 (C, d, 1JCF 245.6 Hz), 170.9 (C); m/z (ESI) 401.1623 (MNa+. C23H23FN2NaO2 
requires 401.1636). 
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3-(4ʹʹ-Methoxyphenyl)-6-(mesitylamino)-2-methoxybenzamide (103) 
 
The reaction was carried out according to general procedure F using 3-bromo-6-
(mesitylamino)-2-methoxybenzamide (98) (0.100 g, 0.275 mmol), 4-
methoxyphenylboronic acid (0.0669 g, 0.440 mmol), [1,1ʹ-bis(diphenylphosphino) 
ferrocene]dichloropalladium(II) (1:1) (0.0113 g, 0.0138 mmol) and caesium carbonate 
(0.270 g, 0.825 mmol) in 1,4-dioxane (4.0 mL) and water (0.30 mL). The crude material 
was purified by flash column chromatography, eluting with 20% ethyl acetate in petroleum 
ether (40‒60) to afford 3-(4ʹʹ-methoxyphenyl)-6-(mesitylamino)-2-methoxybenzamide 
(103) as a white solid (0.0873 g, 81%). Mp 184‒185 °C; νmax/cm−1 (neat) 3449 (NH), 3194 
(NH), 2932 (CH), 1643 (CO), 1489, 1242, 1042, 756; δH (400 MHz, CDCl3) 2.19 (6H, s, 2ʹ-
CH3 and 6ʹ-CH3), 2.31 (3H, s, 4ʹ-CH3), 3.45 (3H, s, 2-OCH3), 3.83 (3H, s, 4ʹʹ-OCH3), 5.81 
(1H, br s, NH), 6.07 (1H, d, J 8.7 Hz, 5-H), 6.93 (2H, d, J 8.3 Hz, 3ʹʹ-H and 5ʹʹ-H), 6.94 (2H, 
s, 3ʹ-H and 5ʹ-H), 7.07 (1H, d, J 8.7 Hz, 4-H), 7.41 (2H, d, J 8.3 Hz, 2ʹʹ-H and 6ʹʹ-H), 8.11 
(1H, br s, NH), 9.70 (1H, br s, NH); δC (101 MHz, CDCl3) 18.3 (2 × CH3), 21.0 (CH3), 55.3 
(CH3), 61.1 (CH3), 106.6 (C), 109.5 (CH), 113.7 (2 × CH), 121.9 (C), 129.1 (2 × CH), 
130.1 (2 × CH), 130.9 (C), 134.7 (CH), 135.2 (C), 135.8 (C), 136.4 (2 × C), 150.4 (C), 
157.6 (C), 158.4 (C), 171.1 (C); m/z (ESI) 413.1819 (MNa+. C24H26N2NaO3 requires 
413.1836). 
3-(2ʹʹ-Fluorophenyl)-6-(mesitylamino)-2-methoxybenzamide (105) 
 
The reaction was carried out according to general procedure F using 3-bromo-6-
(mesitylamino)-2-methoxybenzamide (98) (0.100 g, 0.275 mmol), 2-fluorophenylboronic 
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acid (0.0616 g, 0.440 mmol), [1,1ʹ-bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
(1:1) (0.0113 g, 0.0138 mmol) and caesium carbonate (0.270 g, 0.825 mmol) in 1,4-
dioxane (4.0 mL) and water (0.30 mL). The crude material was purified by flash column 
chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 3-(2ʹʹ-
fluorophenyl)-6-(mesitylamino)-2-methoxybenzamide (105) as a white solid (0.0698 g, 
67%). Mp 219‒221 °C; νmax/cm−1 (neat) 3464 (NH), 3264 (NH), 2916 (CH), 1620 (CO), 
1481, 1396, 1373, 1242, 1034, 748; δH (400 MHz, CDCl3) 2.20 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 
2.30 (3H, s, 4ʹ-CH3), 3.47 (3H, s, OCH3), 5.88 (1H, br s, NH), 6.08 (1H, d, J 8.7 Hz, 5-H), 
6.94 (2H, s, 3ʹ-H and 5ʹ-H), 7.04 (1H, d, J 8.7 Hz, 4-H), 7.07‒7.20 (2H, m, ArH), 7.24‒7.34 
(1H, m, ArH), 7.37 (1H, t, J 7.5 Hz, ArH), 8.11 (1H, br s, NH), 9.70 (1H, br s, NH); δC (101 
MHz, CDCl3) 18.3 (2 × CH3), 20.9 (CH3), 61.6 (CH3), 106.4 (C), 109.3 (CH), 115.7 (CH, d, 
2JCF 22.8 Hz), 116.2 (C), 123.9 (CH, d, 
3JCF 3.6 Hz), 126.0 (C, d, 
2JCF 15.7 Hz), 128.7 (CH, 
d, 3JCF 8.1 Hz), 129.1 (2 × CH), 132.1 (CH, d, 
4JCF 3.1 Hz), 135.0 (C), 135.1 (CH), 135.9 
(C), 136.4 (2 × C), 151.2 (C), 158.3 (C), 160.0 (C, d, 1JCF 246.4 Hz), 170.9 (C); m/z (ESI) 
401.1621 (MNa+. C23H23FN2NaO2 requires 401.1636). 
3-(2ʹʹ-Methoxyphenyl)-6-(mesitylamino)-2-methoxybenzamide (104) 
 
The reaction was carried out according to general procedure F using 3-bromo-6-
(mesitylamino)-2-methoxybenzamide (98) (0.100 g, 0.275 mmol), 2-
methoxyphenylboronic acid (0.0669 g, 0.440 mmol), [1,1ʹ-bis(diphenylphosphino) 
ferrocene]dichloropalladium(II) (1:1) (0.0113 g, 0.0138 mmol) and caesium carbonate 
(0.270 g, 0.825 mmol) in 1,4-dioxane (4.0 mL) and water (0.30 mL). The crude material 
was purified by flash column chromatography, eluting with 20% ethyl acetate in petroleum 
ether (40‒60) to afford 3-(2ʹʹ-methoxyphenyl)-6-(mesitylamino)-2-methoxybenzamide 
(104) as a white solid (0.0518 g, 48%). Mp 240‒241 °C; νmax/cm−1 (neat) 3456 (NH), 3217 
(NH), 2916 (CH), 1620 (CO), 1481, 1242, 1034, 748; δH (400 MHz, CDCl3) 2.20 (6H, s, 2ʹ-
CH3 and 6ʹ-CH3), 2.30 (3H, s, 4ʹ-CH3), 3.44 (3H, s, 2-OCH3), 3.77 (3H, s, 2ʹʹ-OCH3), 5.64 
(1H, br s, NH), 6.05 (1H, d, J 8.7 Hz, 5-H), 6.94 (2H, s, 3ʹ-H and 5ʹ-H), 6.95‒7.00 (2H, m, 
3ʹʹ-H and 5ʹʹ-H), 7.02 (1H, d, J 8.7 Hz, 4-H), 7.26‒7.34 (2H, m, 4ʹʹ-H and 6ʹʹ-H), 8.06 (1H, 
br s, NH), 9.74 (1H, br s, NH); δC (101 MHz, CDCl3) 18.4 (2 × CH3), 20.9 (CH3), 55.7 
(CH3), 61.3 (CH3), 106.3 (C), 108.9 (CH), 111.2 (CH), 118.8 (C), 120.4 (CH), 127.4 (C), 
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128.4 (CH), 129.0 (2 × CH), 131.9 (CH), 135.3 (C), 135.6 (C), 135.7 (CH), 136.5 (2 × C), 
150.7 (C), 157.1 (C), 158.1 (C), 171.1 (C); m/z (ESI) 413.1819 (MNa+. C24H26FN2NaO3 
requires 413.1836). 
3-(2ʹʹ-Fluoro-4ʹʹ-methoxyphenyl)-6-(mesitylamino)-2-methoxybenzamide (102) 
 
The reaction was carried out according to general procedure (General Procedure F) using 
3-bromo-6-(mesitylamino)-2-methoxybenzamide (98) (0.100 g, 0.275 mmol), 2-fluoro-4-
methoxyphenylboronic acid (0.0748 g, 0.440 mmol), [1,1ʹ-bis(diphenylphosphino) 
ferrocene]dichloropalladium(II) (1:1) (0.0113 g, 0.0138 mmol) and caesium carbonate 
(0.270 g, 0.825 mmol) in 1,4-dioxane (4.0 mL) and water (0.30 mL). The crude material 
was purified by flash column chromatography, eluting with 20% ethyl acetate in petroleum 
ether (40‒60) and then triturated with 10% ethyl acetate in petroleum ether (40‒60) to 
afford 3-(2ʹʹ-fluoro-4ʹʹ-methoxyphenyl)-6-(mesitylamino)-2-methoxybenzamide (102) as a 
white solid (0.0573 g, 51%). Mp 206‒210 °C; νmax/cm−1 (neat) 3466 (NH), 2913 (CH), 1624 
(CO), 1557 (C=C), 1489, 1373, 1257, 1040, 951, 823; δH (400 MHz, CDCl3) 2.19 (6H, s, 
2ʹ-CH3 and 6ʹ-CH3), 2.30 (3H, s, 4ʹ-CH3), 3.47 (3H, s, 2-OCH3), 3.83 (3H, s, 4ʹʹ-OCH3), 
5.79 (1H, br s, NH), 6.07 (1H, d, J 8.6 Hz, 5-H), 6.65‒6.77 (2H, m, 5ʹʹ-H and 6ʹʹ-H), 6.94 
(2H, s, 3ʹ-H and 5ʹ-H), 7.02 (1H, d, J 8.6 Hz, 4-H), 7.19‒7.36 (1H, m, 3ʹʹ-H), 8.04 (1H, br s, 
NH), 9.75 (1H, br s, NH); δC (101 MHz, CDCl3) 18.3 (2 × CH3), 20.9 (CH3), 55.6 (CH3), 
61.5 (CH3), 101.7 (CH, d, 2JCF 26.6 Hz), 106.4 (C), 109.2 (CH), 109.8 (CH, d, 4JCF 3.0 Hz), 
116.1 (C), 118.1 (C, d, 2JCF 16.2 Hz), 129.1 (2 × CH), 132.3 (CH, d, 3JCF 5.2 Hz), 135.1 
(C), 135.3 (CH), 135.8 (C), 136.4 (2 × C), 151.0 (C), 158.3 (C), 160.0 (C, d, 3JCF 10.8 Hz), 
160.5 (C, d, 1JCF 246.2 Hz), 170.9 (C); m/z (ESI) 431.1721 (MNa+. C24H25FN2NaO3 
requires 431.1741). 
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3-(2ʹʹ-Fluoro-5ʹʹ-methoxyphenyl)-6-(mesitylamino)-2-methoxybenzamide (107) 
 
The reaction was carried out according to general procedure F using 3-bromo-6-
(mesitylamino)-2-methoxybenzamide (98) (0.100 g, 0.275 mmol), 2-fluoro-5-
methoxyphenylboronic acid (0.0748 g, 0.440 mmol), [1,1ʹ-bis(diphenylphosphino) 
ferrocene]dichloropalladium(II) (1:1) (0.0113 g, 0.0138 mmol) and caesium carbonate 
(0.270 g, 0.825 mmol) in 1,4-dioxane (4.0 mL) and water (0.30 mL). The crude material 
was purified by flash column chromatography, eluting with 20% ethyl acetate in petroleum 
ether (40‒60) and then triturated with 10% ethyl acetate in petroleum ether (40‒60) to 
afford 3-(2ʹʹ-fluoro-5ʹʹ-methoxyphenyl)-6-(mesitylamino)-2-methoxybenzamide (107) as a 
white solid (0.0694 g, 62%). Mp 196‒198 °C; νmax/cm−1 (neat) 3456 (NH), 2934 (CH), 1647 
(CO), 1564 (C=C), 1489, 1404, 1245, 1206, 1038, 752; δH (400 MHz, CDCl3) 2.19 (6H, s, 
2ʹ-CH3 and 6ʹ-CH3), 2.31 (3H, s, 4ʹ-CH3), 3.51 (3H, s, 2-OCH3), 3.80 (3H, s, 5ʹʹ-OCH3), 
5.68 (1H, br s, NH), 6.08 (1H, d, J 8.8 Hz, 5-H), 6.81 (1H, dt, J 8.8, 3.5 Hz, 4ʹʹ-H), 6.90 
(1H, dd, J 6.0, 3.5 Hz, 6ʹʹ-H), 6.94 (2H, s, 3ʹ-H and 5ʹ-H), 7.00‒7.07 (1H, m, 3ʹʹ-H), 7.02 
(1H, d, J 8.8 Hz, 4-H), 8.03 (1H, br s, NH), 9.78 (1H, br s, NH); δC (101 MHz, CDCl3) 18.3 
(2 × CH3), 21.0 (CH3), 55.8 (CH3), 61.7 (CH3), 106.4 (C), 109.2 (CH), 113.7 (CH, d, 3JCF 
8.0 Hz), 116.1 (CH, d, 2JCF 28.7 Hz), 116.2 (C), 116.7 (CH, d, 3JCF 3.1 Hz), 126.6 (C, d, 
2JCF 17.5 Hz), 129.1 (2 × CH), 135.0 (C), 135.1 (CH), 135.9 (C), 136.4 (2 × C), 151.3 (C), 
154.5 (C, d, 1JCF 238.9 Hz), 155.4 (C, d, 4JCF 2.0 Hz), 158.2 (C), 170.8 (C); m/z (ESI) 
431.1723 (MNa+. C24H25FN2NaO3 requires 431.1741). 
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3-(2ʹʹ-Fluoropyridin-3ʹʹ-yl)-6-(mesitylamino)-2-methoxybenzamide (106) 
 
The reaction was carried out according to general procedure F using 3-bromo-6-
(mesitylamino)-2-methoxybenzamide (98) (0.100 g, 0.275 mmol), 2-fluoropyridin-3-
ylboronic acid (0.0620 g, 0.440 mmol), [1,1ʹ-bis(diphenylphosphino) 
ferrocene]dichloropalladium(II) (1:1) (0.0113 g, 0.0138 mmol) and caesium carbonate 
(0.270 g, 0.825 mmol) in 1,4-dioxane (4.0 mL) and water (0.30 mL). The crude material 
was purified by flash column chromatography, eluting with 30% ethyl acetate in petroleum 
ether (40‒60) followed by recrystallisation from diethyl ether to afford 3-(2ʹʹ-fluoropyridin-
3ʹʹ-yl)-6-(mesitylamino)-2-methoxybenzamide (106) as a white solid (0.0190 g, 18%). Mp 
214‒216 °C; νmax/cm−1 (neat) 3441 (NH), 3233 (NH), 3163 (CH), 1667 (CO), 1566 (C=C), 
1427, 1258, 1034, 825, 756; δH (400 MHz, CDCl3) 2.18 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.31 
(3H, s, 4ʹ-CH3), 3.49 (3H, s, OCH3), 5.76 (1H, br s, NH), 6.10 (1H, br d, J 8.8 Hz, 5-H), 
6.95 (2H, s, 3ʹ-H and 5ʹ-H), 7.06 (1H, dd, J 8.8, 1.3 Hz, 4-H), 7.23 (1H, ddd, J 7.3, 4.8, 1.7 
Hz, 5ʹʹ-H), 7.85 (1H, ddd, J 9.5, 7.3, 1.9 Hz, 6ʹʹ-H), 7.93 (1H, br s, NH), 8.18 (1H, ddd, J 
4.8, 1.9, 1.1 Hz, 4ʹʹ-H), 9.77 (1H, br s, NH); δC (101 MHz, CDCl3) 18.2 (2 × CH3), 21.0 
(CH3), 61.9 (CH3), 106.5 (C), 109.5 (CH), 114.3 (C, d, 
3JCF 4.5 Hz), 120.8 (C, d, 
2JCF 30.4 
Hz), 121.3 (CH, d, 4JCF 4.3 Hz), 129.2 (2 × CH), 134.7 (C), 134.7 (CH, 
4JCF 2.1 Hz), 136.1 
(C), 136.4 (2 × C), 142.3 (CH, d, 3JCF 4.4 Hz), 146.1 (CH, d, 
3JCF 14.5 Hz), 151.7 (C), 
158.3 (C), 160.9 (C, d, 1JCF 239.5 Hz), 170.5 (C); m/z (ESI) 402.1578 (MNa+. 
C22H22FN3NaO2 requires 402.1588). 
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Methyl 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoate (108) 
 
Trimethylsilyldiazomethane (0.0740 mL, 0.148 mmol, 2.0 M in diethyl ether) was added 
dropwise at 0 °C to a solution of 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoic 
acid (75) (1.52 g, 4.50 mmol) in methanol (20 mL) and tetrahydrofuran (60 mL) in an oven 
dried flask under argon. The reaction mixture was allowed to warm to room temperature 
and stirred for 24 h. Acetic acid (6.0 mL) was added and the reaction mixture stirred for 
0.1 h. The mixture was diluted with ethyl acetate (20 mL) and the organic layer washed 
with water (20 mL), brine (20 mL) and saturated aqueous sodium bicarbonate (20 mL). 
The organic layer was dried (MgSO4) and concentrated in vacuo to afford a brown 
residue. The crude material was purified by flash column chromatography eluting with 
2.5% ethyl acetate in petroleum ether (40‒60) to afford methyl 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]benzoate (108) as a brown solid (1.03 g, 65%). Mp 84‒88 °C; 
νmax/cm−1 (neat) 3379 (NH), 2955 (CH), 1697 (CO), 1566 (C=C), 1489, 1443, 1296, 1230, 
1103, 895, 772; δH (400 MHz, CDCl3) 2.16 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 3.98 (3H, s, OCH3), 
6.10 (1H, dd, J 7.4, 1.4 Hz, 5-H), 6.83 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 6.90‒6.98 (2H, m, 
3-H and 4-H), 7.10 (1H, br s, NH); δC (101 MHz, CDCl3) 18.3 (CH3), 18.4 (CH3), 52.1 
(CH3), 111.5 (CH), 115.0 (2 × CH, d, 
2JCF 21.9 Hz), 116.8 (C), 122.3 (C), 122.7 (CH), 
132.5 (CH), 132.8 (C, d, 4JCF 2.8 Hz), 138.7 (2 × C, d, 
3JCF 8.7 Hz), 148.2 (C), 160.8 (C, d, 
1JCF 244.8 Hz), 168.3 (C); m/z (ESI) 374.0147 (MNa+. C16H1579BrFNNaO2 requires 
374.0162). 
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Methyl 2-acetyl-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoate (110) 
 
Methyl 2-bromo-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoate (108) (1.03 g, 2.92 
mmol), tributyl(1-ethoxyvinyl)tin (1.48 mL, 4.39 mmol, 2.0 M in diethyl ether) and 
tetrakis(triphenylphosphine)palladium(0) (0.169 g, 0.146 mmol, 5 mol%) were added to 
1,4-dioxane (14 mL) in an oven dried flask under argon. The reaction mixture was stirred 
at 90 °C for 5 h before further addition of tetrakis(triphenylphosphine)palladium(0) (0.169 
g, 0.146 mmol, 5 mol%). The mixture was stirred for a further 18 h. The reaction mixture 
was filtered through Celite®, diluted with ethyl acetate (20 mL) and washed with water (20 
mL), brine (20 mL) and saturated aqueous sodium bicarbonate (20 mL). The organic layer 
was dried (MgSO4) and concentrated in vacuo to afford a yellow residue. The residue was 
dissolved in tetrahydrofuran (14 mL) and a 1.0 M aqueous solution of hydrochloric acid 
(7.0 mL) was added. The mixture was stirred at room temperature for 18 h before being 
concentrated in vacuo. The crude material was purified by flash column chromatography 
eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford a yellow oil. The 
product was further purified by flash column chromatography using 10% potassium 
carbonate (w/w) in silica, eluting with 10% ethyl acetate in petroleum ether (40‒60) to 
afford methyl 2-acetyl-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoate (110) as a yellow 
solid (0.830 g, 90%). Mp 222‒226 °C; νmax/cm−1 (neat) 3338 (NH), 2952 (CH), 1689 (CO), 
1606 (C=C), 1496, 1464, 1436, 1304, 1259, 1238, 1180, 1138, 1019, 807; δH (400 MHz, 
CDCl3) 2.16 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.49 (3H, s, COCH3), 3.87 (3H, s, OCH3), 6.23 
(1H, dd, J 8.5, 1.0 Hz, 5-H), 6.58 (1H, dd, J 7.3, 1.0 Hz, 3-H), 6.84 (2H, d, J 9.0 Hz, 3ʹ-H 
and 5ʹH), 7.19 (1H, ddd, J 8.5, 7.3, 0.5 Hz, 4-H), 8.43 (1H, br s, NH); δC (101 MHz, CDCl3) 
18.4 (CH3), 18.4 (CH3), 30.3 (CH3), 51.9 (CH3), 107.9 (C), 114.0 (CH), 114.1 (CH), 115.0 
(2 × CH, d, 2JCF 21.9 Hz), 132.6 (C, d, 
4JCF 2.8 Hz), 133.4 (CH), 139.0 (2 × C, d, 
3JCF 8.7 
Hz), 145.8 (C), 149.2 (C), 160.9 (C, d, 1JCF 245.1 Hz), 168.4 (C), 203.7 (C); m/z (ESI) 
338.1151 (MNa+. C18H18FNNaO3 requires 338.1163). 
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8-[(4ʹ-Fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (111) 
 
To a solution of methyl 2-acetyl-6-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]benzoate (110) 
(0.830 g, 2.63 mmol) in ethanol (15 mL) was added hydrazine monohydrate (0.260 mL, 
5.26 mmol). The reaction mixture was stirred at 95 °C for 16 h and then cooled to room 
temperature. The reaction mixture was concentrated in vacuo to afford 8-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (111) as a yellow solid (0.696 g, 
89%). Mp 120‒124 °C; νmax/cm−1 (neat) 3257 (NH), 3052 (CH), 1640 (CO), 1606 (C=C), 
1588, 1563, 1500, 1473, 1299, 1273, 810; δH (400 MHz, CDCl3) 2.21 (6H, s, 2ʹ-CH3 and 
6ʹ-CH3), 2.50 (3H, s, 4-CH3), 6.30 (1H, dd, J 8.4, 0.9 Hz, 7-H), 6.86 (2H, d, J 9.0 Hz, 3ʹ-H 
and 5ʹ-H), 6.90 (1H, dd, J 7.8, 0.9 Hz, 5-H), 7.44 (1H, dd, J 8.4, 7.8 Hz, 6-H), 10.09 (1H, br 
s, NH), 10.16 (1H, br s, NH); δC (101 MHz, CDCl3) 18.4 (CH3), 18.5 (CH3), 19.3 (CH3), 
110.3 (C), 111.5 (CH), 112.1 (CH), 114.9 (2 × CH, d, 2JCF 21.8 Hz), 132.2 (C), 132.7 (C, d, 
4JCF 2.8 Hz), 134.9 (CH), 139.1 (2 × C, d, 
3JCF 8.7 Hz), 145.7 (C), 149.7 (C), 161.0 (C, d, 
1JCF 244.9 Hz), 163.6 (C); m/z (ESI) 320.1161 (MNa+. C17H16FN3NaO requires 320.1170). 
5-Bromo-8-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone 
(114) 
 
The reaction was carried out according to general procedure E using iron(III) chloride 
(0.0190 g, 0.117 mmol), [BMIM]NTf2 (1.36 mL, 4.68 mmol), 8-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (111) (0.695 g, 2.34 mmol) and N-
bromosuccinimide (0.980 g, 5.49 mmol) in dichloromethane (6.0 mL). The crude material 
was purified by flash column chromatography, eluting with 5% ethyl acetate in 
dichloromethane to afford 5-bromo-8-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-
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1(2H)-phthalazinone (114) as a white solid (0.695 g, 94%). Mp 200‒204 °C; νmax/cm−1 
(neat) 3242 (NH), 3012 (CH), 1636 (CO), 1484, 1314, 1274, 1216, 1128, 1020, 819, 753; 
δH (400 MHz, CDCl3) 2.19 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.89 (3H, s, 4-CH3), 6.15 (1H, d, J 
9.1 Hz, 7-H), 6.86 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 7.64 (1H, d, J 9.1 Hz, 6-H), 10.59 (1H, 
br s, NH), 10.99 (1H, br s, NH); δC (101 MHz, CDCl3) 18.4 (CH3), 18.4 (CH3), 26.1 (CH3), 
103.1 (C), 112.3 (C), 113.4 (CH), 115.1 (2 × CH, d, 2JCF 21.9 Hz), 130.8 (C), 132.3 (C, d, 
4JCF 2.9 Hz), 139.0 (2 × C, d, 3JCF 8.7 Hz), 142.0 (CH), 144.9 (C), 149.8 (C), 161.1 (C, d, 
1JCF 245.4 Hz), 163.3 (C); m/z (ESI) 398.0269 (MNa+. C17H1579BrFN3NaO requires 
398.0275). 
5-Phenyl-8-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone 
(115) 
 
The reaction was carried out according to general procedure F using 5-bromo-8-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (114) (0.100 g, 0.266 
mmol), benzeneboronic acid (0.0518 g, 0.425 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1:1) (0.0109 g, 0.0133 mmol) and 
caesium carbonate (0.260 g, 0.798 mmol) in 1,4-dioxane (4.0 mL) and water (0.30 mL). 
The crude material was purified by flash column chromatography, eluting with 20% ethyl 
acetate in petroleum ether (40‒60) to afford 5-phenyl-8-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (115) as a white solid (0.073 g, 
74%). Mp 280‒284 °C; νmax/cm−1 (neat) 3246 (NH), 3021 (CH), 1639 (CO), 1485, 1256, 
1128, 1018, 758, 702; δH (400 MHz, CDCl3) 1.84 (3H, s, 4-CH3), 2.24 (6H, s, 2ʹ-CH3 and 
6ʹ-CH3), 6.30 (1H, d, J 8.6 Hz, 7-H), 6.88 (2H, d, J 9.1 Hz, 3ʹ-H and 5ʹ-H), 7.09‒7.31 (3H, 
m, 6-H, 3ʹʹ-H and 5ʹʹ-H), 7.35‒7.61 (3H, m, 2ʹʹ-H, 4ʹʹ-H and 6ʹʹ-H), 10.21 (1H, br s, NH), 
10.47 (1H, br s, NH); δC (101 MHz, CDCl3) 18.5 (CH3), 18.5 (CH3), 24.8 (CH3), 110.5 (C), 
111.3 (CH), 115.0 (2 × CH, d, 2JCF 21.8 Hz), 127.3 (CH), 127.4 (C), 127.9 (2 × CH), 130.0 
(2 × CH), 129.8 (C), 132.8 (C, d, 4JCF 2.8 Hz), 138.5 (CH), 139.1 (2 × C, d, 
3JCF 8.7 Hz), 
142.7 (C), 145.9 (C), 149.4 (C), 160.9 (C, d, 1JCF 244.9 Hz), 163.6 (C); m/z (ESI) 396.1471 
(MNa+. C23H20FN3NaO requires 396.1483). 
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5-(4ʹʹ-Bromophenyl)-8-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-
phthalazinone (116) 
 
The reaction was carried out according to general procedure F using 5-bromo-8-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (114) (0.043 g, 0.16 
mmol), 4-bromophenylboronic acid (0.050 g, 0.25 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1:1) (0.0064 g, 0.0078 mmol) and 
caesium carbonate (0.15 g, 0.47 mmol) in 1,4-dioxane (2.0 mL) and water (0.2 mL). The 
crude material was purified by flash column chromatography, eluting with 10‒15% ethyl 
acetate in petroleum ether (40‒60) to afford 5-(4ʹʹ-bromophenyl)-8-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (116) as a yellow viscous oil (0.015 
g, 21%). νmax/cm−1 (neat) 3256 (NH), 3013 (CH), 1643 (CO), 1483, 1252, 1128, 1011, 819, 
754; δH (400 MHz, CDCl3) 1.87 (3H, s, 4-CH3), 2.23 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 6.29 (1H, 
d, J 8.6 Hz, 7-H), 6.87 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 7.14 (2H, d, J 7.6 Hz, 2ʹʹ-H and 6ʹʹ-
H), 7.21 (1H, d, J 8.6 Hz, 6-H), 7.51 (2H, d, J 7.6 Hz, 3ʹʹ-H and 5ʹʹ-H), 10.28 (1H, br s, NH), 
10.49 (1H, br s, NH); δC (101 MHz, CDCl3) 18.5 (CH3), 18.5 (CH3), 25.1 (CH3), 110.6 (C), 
111.4 (CH), 115.0 (2 × CH, d, 2JCF 21.8 Hz), 121.6 (C), 125.8 (C), 129.8 (C), 131.1 (2 × 
CH), 131.6 (2 × CH), 132.6 (C, d, 4JCF 2.9 Hz), 138.4 (CH), 139.1 (2 × C, d, 3JCF 8.7 Hz), 
141.6 (C), 145.5 (C), 149.7 (C), 161.0 (C, d, 1JCF 245.0 Hz), 163.5 (C); m/z (ESI) 474.0568 
(MNa+. C23H1979BrFN3NaO requires 474.0588). 
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5-(4ʹʹ-Methoxyphenyl)-8-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-
phthalazinone (117) 
 
The reaction was carried out according to general procedure F using 5-bromo-8-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (114) (0.100 g, 0.266 
mmol), 4-methoxyphenylboronic acid (0.0646 g, 0.425 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1:1) (0.0119 g, 0.0133 mmol) and 
caesium carbonate (0.260 g, 0.798 mmol) in 1,4-dioxane (4.0 mL) and water (0.3 mL). 
The crude material was purified by flash column chromatography, eluting with 20% ethyl 
acetate in petroleum ether (40‒60) to afford 5-(4ʹʹ-methoxyphenyl)-8-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (117) as a pale yellow solid (0.127 
g, 79%). Mp 222‒226 °C; νmax/cm−1 (neat) 3163 (NH), 2995 (CH), 1637 (CO), 1494 (C=C), 
1292, 1250, 1030, 862, 760; δH (400 MHz, CDCl3) 1.86 (3H, s, 4-CH3), 2.24 (6H, s, 2ʹ-CH3 
and 6ʹ-CH3), 3.86 (3H, s, OCH3), 6.28 (1H, d, J 8.6 Hz, 7-H), 6.87 (2H, d, J 9.0 Hz, 3ʹ-H 
and 5ʹ-H), 6.91 (2H, d, J 7.4 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.16 (2H, d, J 7.4 Hz, 2ʹʹ-H and 6ʹʹ-H), 
7.25 (1H, d, J 8.6 Hz, 6-H), 10.07 (1H, br s, NH), 10.45 (1H, br s, NH); δC (101 MHz, 
CDCl3) 18.5 (CH3), 18.5 (CH3), 24.8 (CH3), 55.3 (CH3), 110.5 (C), 111.4 (CH), 113.4 (2 × 
CH), 115.0 (2 × CH, d, 2JCF 21.8 Hz), 127.1 (C), 130.0 (C), 131.0 (2 × CH), 132.8 (C, d, 
4JCF 2.8 Hz), 134.9 (C), 138.8 (CH), 139.1 (2 × C, d, 3JCF 8.7 Hz), 146.1 (C), 149.3 (C), 
159.0 (C), 160.9 (C, d, 1JCF 244.8 Hz), 163.6 (C); m/z (ESI) 426.1575 (MNa+. 
C24H22FN3NaO2 requires 426.1588). 
  
184 
5-(Thiophen-3ʹʹ-yl)-8-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-
phthalazinone (118) 
 
The reaction was carried out according to general procedure F using 5-bromo-8-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (114) (0.100 g, 0.266 
mmol), 3-thienylboronic acid (0.0544 g, 0.425 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1:1) (0.0119 g, 0.0133 mmol) and 
caesium carbonate (0.260 g, 0.798 mmol) in 1,4-dioxane (4.0 mL) and water (0.3 mL). 
The crude material was purified by flash column chromatography, eluting with 5% ethyl 
acetate in dichloromethane to afford 5-(thiophen-3ʹʹ-yl)-8-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (118) as a pale yellow solid (0.079 
g, 79%). Mp 279‒281 °C; νmax/cm−1 (neat) 3158 (NH), 3019 (NH), 2920 (CH), 1638 (CO), 
1499, 1261, 837, 770, 675; δH (400 MHz, CDCl3) 1.94 (3H, s, 4-CH3), 2.23 (6H, s, 2ʹ-CH3 
and 6ʹ-CH3), 6.28 (1H, d, J 8.6 Hz, 7-H), 6.87 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 7.02 (1H, 
dd, J 4.9, 1.3 Hz, 4ʹʹ-H), 7.11 (1H, dd, J 3.0, 1.3 Hz, 2ʹʹ-H), 7.28 (1H, d, J 8.6 Hz, 6-H), 
7.34 (1H, dd, J 4.9, 3.0 Hz, 5ʹʹ-H), 10.02 (1H, br s, NH), 10.48 (1H, br s, NH); δC (101 
MHz, CDCl3) 18.5 (CH3), 18.5 (CH3), 23.6 (CH3), 110.6 (C), 111.3 (CH), 115.0 (CH, d, 
2JCF 
21.8 Hz), 121.6 (C), 123.5 (CH), 125.0 (CH), 130.2 (CH), 130.5 (C), 132.7 (C, d, 4JCF 2.8 
Hz), 138.7 (CH), 139.1 (C, d, 3JCF 8.7 Hz), 142.3 (C), 145.9 (C), 149.6 (C), 161.0 (C, d, 
1JCF 244.9 Hz), 163.5 (C); m/z (EI) 379.1151 (M+. C21H18FN3OS requires 379.1155) 364 
(7%), 226 (5). 
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5-(4ʹʹ-Ethoxycarbonylphenyl)-8-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-
1(2H)-phthalazinone (119) 
 
The reaction was carried out according to general procedure F using 5-bromo-8-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (114) (0.065 g, 0.17 
mmol), 4-ethoxycarbonylphenylboronic acid (0.054 g, 0.28 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1:1) (0.0074 g, 0.0090 mmol) and 
caesium carbonate (0.17 g, 0.52 mmol) in 1,4-dioxane (3.0 mL) and water (0.2 mL). The 
crude material was purified by flash column chromatography, eluting with 5% ethyl acetate 
in dichloromethane to afford 5-(4ʹʹ-ethoxycarbonylphenyl)-8-[(4ʹ-fluoro-2ʹ,6ʹ-
dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (119) as a pale yellow solid (0.034 
g, 44%). Mp 206‒208 °C; νmax/cm−1 (neat) 3198 (NH), 2924 (CH), 1717 (CO), 1639 (CO), 
1495, 1271, 1101, 1020, 775; δH (400 MHz, CDCl3) 1.42 (3H, t, J 7.1 Hz, OCH2CH3), 1.85 
(3H, s, 4-CH3), 2.24 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 4.41 (2H, q, J 7.1 Hz, OCH2CH3), 6.31 
(1H, d, J 8.6 Hz, 7-H), 6.88 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 7.24 (1H, d, J 8.6 Hz, 6-H), 
7.36 (2H, d, J 8.0 Hz, 2ʹʹ-H and 6ʹʹ-H), 8.07 (2H, d, J 8.0 Hz, 3ʹʹ-H and 5ʹʹ-H), 10.53 (1H, br 
s, NH), 10.60 (1H, br s, NH); δC (101 MHz, CDCl3) 14.4 (CH3), 18.5 (CH3), 18.5 (CH3), 
25.0 (CH3), 61.1 (CH2), 110.6 (C), 111.3 (CH), 115.0 (2 × CH, d, 
2JCF 21.8 Hz), 126.0 (C), 
129.2 (2 × CH), 129.5 (C), 129.8 (C), 130.0 (2 × CH), 132.6 (C, d, 4JCF 2.8 Hz), 138.2 
(CH), 139.1 (2 × C, d, 3JCF 8.7 Hz), 145.5 (C), 147.4 (C), 149.8 (C), 161.0 (C, d, 
1JCF 245.1 
Hz), 163.6 (C), 166.4 (C); m/z (ESI) 468.1673 (MNa+. C26H24FN3NaO3 requires 468.1694). 
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5-[3ʹʹ-(Trifluoromethyl)phenyl]-8-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-
1(2H)-phthalazinone (120) 
 
The reaction was carried out according to general procedure F using 5-bromo-8-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (114) (0.060 g, 0.16 
mmol), 3-(trifluoromethyl)phenylboronic acid (0.048 g, 0.26 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1:1) (0.0065 g, 0.0080 mmol) and 
caesium carbonate (0.16 g, 0.48 mmol) in 1,4-dioxane (2.0 mL) and water (0.2 mL). The 
crude material was purified by flash column chromatography, eluting with 20% ethyl 
acetate in petroleum ether (40‒60) to afford 5-[3ʹʹ-(trifluoromethyl)phenyl]-8-[(4ʹ-fluoro-
2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (120) as a pale yellow solid 
(0.034 g, 49%). Mp 104‒106 °C; νmax/cm−1 (neat) 3190 (NH), 2924 (CH), 1639 (CO), 1485, 
1329, 1167, 1128, 714; δH (400 MHz, CDCl3) 1.81 (3H, s, 4-CH3), 2.25 (6H, s, 2ʹ-CH3 and 
6ʹ-CH3), 6.31 (1H, d, J 8.6 Hz, 7-H), 6.88 (2H, d, J 9.0 Hz, 3ʹ-H and 5ʹ-H), 7.24 (1H, d, J 
8.6 Hz, 6-H), 7.45‒7.54 (2H, m, 5ʹʹ-H and 6ʹʹ-H), 7.55 (1H, s, 2ʹʹ-H), 7.64 (1H, d, J 7.4 Hz, 
4ʹʹ-H), 10.69 (1H, br s, NH), 10.55 (1H, br s, NH); δC (101 MHz, CDCl3) 18.5 (2 × CH3), 
25.2 (CH3), 110.6 (C), 111.3 (CH), 115.0 (CH, d, 
2JCF 21.9 Hz), 115.1 (CH, d, 
2JCF 21.9 
Hz), 124.0 (C, q, 1JCF 272.5 Hz), 124.1 (CH, q, 
3JCF 3.8 Hz), 125.3 (C), 126.8 (CH, q, 
3JCF 
3.8 Hz), 128.5 (CH), 129.9 (C), 130.4 (C, q, 2JCF 32.5 Hz), 132.5 (C, d, 
4JCF 2.8 Hz), 133.2 
(CH), 138.4 (CH), 139.0 (C, d, 3JCF 8.7 Hz), 139.1 (C, d, 
3JCF 8.7 Hz), 143.4 (C), 145.2 (C), 
149.9 (C), 161.0 (C, d, 1JCF 245.1 Hz), 163.7 (C); m/z (ESI) 464.1341 (MNa+. 
C24H19F4N3NaO requires 464.1356). 
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5-(3ʹʹ-Chloro-4ʹʹ-methoxyphenyl)-8-[(4ʹ-fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-
1(2H)-phthalazinone (121) 
 
The reaction was carried out according to general procedure F using 5-bromo-8-[(4ʹ-
fluoro-2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (114) (0.055 g, 0.15 
mmol), 3-chloro-4-methoxyphenylboronic acid (0.044 g, 0.23 mmol), [1,1ʹ-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1:1) (0.0060 g, 0.0073 mmol) and 
caesium carbonate (0.14 g, 0.44 mmol) in 1,4-dioxane (2.0 mL) and water (0.2 mL). The 
crude material was purified by flash column chromatography, eluting with 20% ethyl 
acetate in petroleum ether (40‒60) to afford 5-(3ʹʹ-chloro-4ʹʹ-methoxyphenyl)-8-[(4ʹ-fluoro-
2ʹ,6ʹ-dimethylphenyl)amino]-4-methyl-1(2H)-phthalazinone (121) as a pale yellow solid 
(0.043 g, 66%). Mp 217‒219 °C; νmax/cm−1 (neat) 3183 (NH), 3009 (NH), 2926 (CH), 1638 
(CO), 1487, 1285, 1250, 1064, 756; δH (400 MHz, CDCl3) 1.90 (3H, s, 4-CH3), 2.24 (6H, s, 
2ʹ-CH3 and 6ʹ-CH3), 3.95 (3H, s, OCH3), 6.28 (1H, d, J 8.6 Hz, 7-H), 6.87 (2H, d, J 9.0 Hz, 
3ʹ-H and 5ʹ-H), 6.94 (1H, d, J 8.4 Hz, 5ʹʹ-H), 7.11 (1H, dd, J 8.4, 2.2 Hz, 6ʹʹ-H), 7.23 (1H, d, 
J 8.6 Hz, 6-H), 7.29 (1H, d, J 2.2 Hz, 2ʹʹ-H), 10.50 (1H, br s, NH), 10.60 (1H, br s, NH); δC 
(101 MHz, CDCl3) 18.5 (CH3), 18.5 (CH3), 25.1 (CH3), 56.2 (CH3), 110.5 (C), 111.3 (CH), 
111.4 (CH), 115.0 (CH, d, 2JCF 21.8 Hz), 115.0 (CH, d, 
2JCF 21.8 Hz), 121.9 (C), 125.4 (C), 
129.2 (CH), 130.0 (C), 131.6 (CH), 132.7 (C, d, 4JCF 2.8 Hz), 135.8 (C), 138.7 (CH), 139.0 
(C, d, 3JCF 8.5 Hz), 139.1 (C, d, 
3JCF 8.5 Hz), 145.6 (C), 149.6 (C), 154.4 (C), 161.0 (C, d, 
1JCF 245.0 Hz), 163.7 (C); m/z (ESI) 460.1185 (MNa+. C24H2135ClFN3NaO2 requires 
460.1199). 
  
188 
2-Bromo-6-(mesitylamino)-3-methylbenzoic acid (122)95 
 
The reaction was carried out according to general procedure B using 2-bromo-6-fluoro-3-
methylbenzoic acid (77) (2.00 g, 8.58 mmol) and 2,4,6-trimethylaniline (2.60 mL, 17.2 
mmol) in tetrahydrofuran (50 mL), followed by treatment with lithium 
bis(trimethylsilyl)amide (25.7 mL, 25.7 mmol, 1.0 M in tetrahydrofuran). The crude 
material was purified by flash column chromatography, eluting with 20‒40% ethyl acetate 
in petroleum ether (40‒60) to afford 2-bromo-6-(mesitylamino)-3-methylbenzoic acid (122) 
as a brown solid (2.93 g, 98%). The spectroscopic data were consistent with the 
literature.95 Mp 142‒144 °C; δH (400 MHz, CDCl3) 2.17 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.33 
(6H, br s, 3-CH3 and 4ʹ-CH3), 6.14 (1H, d, J 8.5 Hz, 5-H), 6.96 (2H, s, 3ʹ-H and 5ʹ-H), 7.00 
(1H, d, J 8.5 Hz, 4-H), 9.26 (1H, br s, OH); δC (101 MHz, CDCl3) 18.1 (2 × CH3), 20.9 
(CH3), 22.9 (CH3), 112.2 (CH), 117.3 (C), 123.9 (C), 127.5 (C), 129.3 (2 × CH), 133.7 
(CH), 134.5 (C), 135.9 (2 × C), 135.9 (C), 146.1 (C), 173.4 (C); m/z (ESI) 370 (MNa+. 
100%). 
6-(Mesitylamino)-2-methoxy-3-methylbenzoic acid (123)95 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.474 g, 11.8 mmol, 60% in mineral oil), methanol (10 mL), 2-bromo-6-(mesitylamino)-3-
methylbenzoic acid (122) (0.820 g, 2.37 mmol) and copper powder (0.0602 g, 0.947 
mmol). The crude material was purified by flash column chromatography, eluting with 20% 
ethyl acetate in petroleum ether (40‒60) to afford 6-(mesitylamino)-2-methoxy-3-
methylbenzoic acid (123) as an orange solid (0.695 g, 98%). The spectroscopic data were 
consistent with the literature.95 Mp 97‒99 °C; δH (400 MHz, CDCl3) 2.12 (6H, s, 2ʹ-CH3 and 
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6ʹ-CH3), 2.19 (3H, s, 3-CH3), 2.30 (3H, s, 4ʹ-CH3), 3.92 (3H, s, OCH3), 6.02 (1H, d, J 8.8 
Hz, 5-H), 6.94 (2H, s, 3ʹ-H and 5ʹ-H), 6.99 (1H, d, J 8.8 Hz, 4-H), 9.48 (1H, br s, NH), 
12.06 (1H, br s, OH); δC (101 MHz, CDCl3) 15.1 (CH3), 18.1 (2 × CH3), 21.0 (CH3), 62.2 
(CH3), 102.0 (C), 110.1 (CH), 116.0 (C), 129.2 (2 × CH), 134.5 (C), 136.3 (C), 136.6 (2 × 
C), 137.1 (CH), 150.6 (C), 158.2 (C), 168.6 (C); m/z (ESI) 322 (MNa+. 100%). 
6-(Mesitylamino)-2-methoxy-3-methylbenzamide (33)95 
 
The reaction was carried out according to general procedure D using 6-(mesitylamino)-2-
methoxy-3-methylbenzoic acid (123) (0.690 g, 2.30 mmol), 2-chloro-4,6-dimethoxy-1,3,5-
triazine (0.485 g, 2.76 mmol) and N-methylmorpholine (0.759 mL, 6.90 mmol) in 
tetrahydrofuran (11 mL). The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 6-
(mesitylamino)-2-methoxy-3-methylbenzamide (33) as a white solid (0.565 g, 82%). The 
spectroscopic data were consistent with the literature.95 Mp 131‒133 °C; δH (400 MHz, 
CDCl3) 2.16 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.17 (3H, s, 3-CH3), 2.31 (3H, s, 4ʹ-CH3), 3.78 
(3H, s, OCH3), 5.90 (1H, br s, NH), 5.97 (1H, d, J 8.6 Hz, 5-H), 6.89‒6.97 (2H, m, 4-H, 3ʹ-
H and 5ʹ-H), 7.93 (1H, br s, NH), 9.38 (1H, br s, OH); δC (101 MHz, CDCl3) 15.2 (CH3), 
18.2 (2 × CH3), 20.9 (CH3), 61.1 (CH3), 106.8 (C), 109.3 (CH), 117.3 (C), 129.0 (2 × CH), 
134.9 (CH), 135.4 (C), 135.5 (C), 136.4 (2 × C), 149.3 (C), 158.1 (C), 170.9 (C); m/z (ESI) 
321 (MNa+. 100%). 
2-Bromo-6-(mesitylamino)-3-methylbenzamide (127) 
 
The reaction was carried out according to general procedure D using 2-bromo-6-
(mesitylamino)-3-methylbenzoic acid (122) (0.0500 g, 0.144 mmol), 2-chloro-4,6-
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dimethoxy-1,3,5-triazine (0.0302 g, 0.172 mmol) and N-methylmorpholine (0.0474 mL, 
0.431 mmol) in tetrahydrofuran (1.0 mL). The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 2-
bromo-6-(mesitylamino)-3-methylbenzamide (127) as a white solid (0.0499 g, 100%). Mp 
138‒140 °C; νmax/cm−1 (neat) 3364 (NH), 2916 (CH), 1658 (CO), 1604 (C=C), 1489, 1257, 
756; δH (400 MHz, CDCl3) 2.13 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.28 (6H, br s, 3-CH3 and 4ʹ-
CH3), 6.07 (1H, d, J 8.4 Hz, 5-H), 6.10 (1H, br s, NH), 6.33 (1H, br s, NH), 6.49 (1H, br s, 
NH), 6.90 (2H, s, 3ʹ-H and 5ʹ-H), 6.92 (1H, d, J 8.4 Hz, 4-H); δC (101 MHz, CDCl3) 18.1 (2 
× CH3), 20.9 (CH3), 22.6 (CH3), 111.8 (CH), 121.6 (C), 122.7 (C), 126.7 (C), 129.2 (2 × 
CH), 132.0 (CH), 134.8 (C), 135.6 (C), 135.7 (2 × C), 144.1 (C), 170.5 (C); m/z (EI) 
346.0688 (M+. C17H1979BrN2O requires 346.0681), 329 (93%), 314 (52), 250 (69). 
5-Allyl-2-(mesitylamino)-5-methyl-6-oxocyclohexa-1,3-dienecarboxylic acid (126) 
 
Sodium hydride (0.028 g, 0.72 mmol, 60% in mineral oil) was added to a dry flask under 
argon and cooled to 0 °C. Allyl alcohol (1.0 mL) was added to the reaction vessel 
dropwise over 0.1 h and then stirred for 0.5 h. 2-Bromo-6-(mesitylamino)-3-
methylbenzamide (122) (0.050 g, 0.14 mmol) and copper powder (0.0040 g, 0.058 mmol) 
were then added and the reaction mixture stirred at 80 °C for 24 h. The reaction mixture 
was cooled to room temperature and filtered through a pad of Celite®. The filtrate was 
concentrated in vacuo and taken up in water (2 mL). The mixture was acidified to pH 2 
using 10% aqueous hydrochloric acid and extracted with dichloromethane (3 × 10 mL). 
The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The crude 
material was purified by flash column chromatography, eluting with 20% ethyl acetate in 
petroleum ether (40‒60) to afford 5-allyl-2-(mesitylamino)-5-methyl-6-oxocyclohexa-1,3-
dienecarboxylic acid (126) as a pale orange solid (0.036 g, 77%). Mp 99‒100 °C; 
νmax/cm−1 (neat) 3460 (OH), 2972 (CH), 2920 (NH), 1670 (CO), 1551 (C=C), 1441, 1414, 
1381, 1209, 922, 827; δH (400 MHz, CDCl3) 1.33 (3H, s, 5-CH3), 2.12 (3H, s, 2ʹ-CH3), 2.15 
(3H, s, 6ʹ-CH3), 2.27 (1H, dd, J 13.4, 7.4 Hz, 1ʹʹ-HH), 2.32 (3H, s, 4ʹ-CH3), 2.73 (1H, dd, J 
13.4, 7.4 Hz, 1ʹʹ-HH), 4.99 (1H, br d, J 9.8 Hz, 3ʹʹ-HH), 5.00 (1H, br d, J 17.2 Hz, 3ʹʹ-HH), 
5.50 (1H, ddt, J 17.2, 9.8, 7.4 Hz, 2ʹʹ-H), 6.00 (1H, d, J 10.2 Hz, 3-H), 6.49 (1H, dd, J 10.2 
Hz, 4-H), 6.96 (2H, s, 3ʹ-H and 5ʹ-H), 12.42 (1H, br s, NH), 15.79 (1H, s, OH); δC (101 
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MHz, CDCl3) 18.2 (CH3), 18.2 (CH3), 21.0 (CH3), 24.9 (CH3), 44.7 (CH2), 48.5 (C), 95.3 
(C), 115.9 (CH), 118.8 (CH2), 129.3 (CH), 129.4 (CH), 131.2 (C), 132.2 (CH), 134.9 (C), 
135.0 (C), 138.6 (C), 153.4 (CH), 163.9 (C), 172.3 (C), 200.5 (C); m/z (EI) 325.1681 (M+. 
C20H23NO3 requires 325.1678), 307 (72%), 281 (100), 266 (87), 238 (50), 91 (50). 
2-(Mesitylamino)-5-(4ʹʹ-methoxybenzyl)-5-methyl-6-oxocyclohexa-1,3-
dienecarboxylic acid (130) 
 
To a suspension of sodium hydride (0.017 g, 0.43 mmol, 60% in mineral oil) in 
tetrahydrofuran (1.0 mL) at 0 °C under argon was added dropwise 4-methoxybenzyl 
alcohol (0.054 mL, 0.43 mmol) and the resulting solution stirred for 0.5 h. 2-Bromo-6-
(mesitylamino)-3-methylbenzamide (122) (0.050 g, 0.14 mmol) and copper powder 
(0.0040 g, 0.058 mmol) were then added and the reaction mixture stirred at 80 °C for 24 
h. The reaction mixture was cooled to room temperature and filtered through a pad of 
Celite®. The filtrate was concentrated in vacuo and water (2 mL) was added. The mixture 
was acidified to pH 2 using 10% aqueous hydrochloric acid and extracted with 
dichloromethane (3 × 10 mL). The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo. The crude material was purified by flash column chromatography, 
eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 2-(mesitylamino)-5-(4ʹʹ-
methoxybenzyl)-5-methyl-6-oxocyclohexa-1,3-dienecarboxylic acid (130) as a white solid 
(0.023 g, 40%). Mp 105‒107 °C; νmax/cm−1 (neat) 2926 (CH), 1667 (CO), 1557 (C=C), 
1510, 1477, 1435, 1383, 1246, 1034, 827, 733; δH (400 MHz, CDCl3) 1.41 (3H, s, 5-CH3), 
1.66 (3H, s, 2ʹ-CH3), 2.10 (3H, s, 6ʹ-CH3), 2.29 (3H, s, 4ʹ-CH3), 2.72 (1H, d, J 13.2 Hz, 
CHHAr), 3.35 (1H, d, J 13.2 Hz, CHHAr), 3.73 (3H, s, OCH3), 5.82 (1H, br d, J 10.1 Hz, 3-
H), 6.52 (1H, dd, J 10.1 Hz, 4-H), 6.68 (2H, d, J 8.8 Hz, 3ʹʹ-H and 5ʹʹ-H), 6.85‒6.93 (4H, m, 
3ʹ-H, 5ʹ-H, 2ʹʹ-H and 6ʹʹ-H), 12.22 (1H, br s, NH), 15.93 (1H, s, OH); δC (101 MHz, CDCl3) 
17.6 (CH3), 18.1 (CH3), 21.0 (CH3), 25.0 (CH3), 46.5 (CH2), 50.0 (C), 55.2 (CH3), 96.0 (C), 
113.3 (2 × CH), 116.1 (CH), 128.1 (C), 129.2 (CH), 129.2 (CH), 130.5 (2 × CH), 131.1 (C), 
134.8 (C), 135.1 (C), 138.4 (C), 153.3 (CH), 158.5 (C), 163.8 (C), 172.2 (C), 200.5 (C); 
m/z (ESI) 428.1816 (MNa+. C25H27NNaO4 requires 428.1832). 
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2-(Benzyloxy)-6-(mesitylamino)-3-methylbenzoic acid (131) 
 
To a suspension of sodium hydride (1.15 g, 28.7 mmol) in tetrahydrofuran (16 mL) at 0 °C 
under argon was added dropwise benzyl alcohol (2.96 mL, 28.7 mmol) and the resulting 
solution stirred for 0.5 h. 2-Bromo-6-(mesitylamino)-3-methylbenzamide (122) (2.00 g, 
5.74 mmol) and copper powder (0.146 g, 2.30 mmol) were then added and the reaction 
mixture stirred at 80 °C for 24 h. The reaction mixture was cooled to room temperature 
and filtered through a pad of Celite®. The filtrate was concentrated in vacuo and taken up 
in water (20 mL). The mixture was acidified to pH 2 using 10% aqueous hydrochloric acid 
and extracted with dichloromethane (3 × 30 mL). The organic layer was dried (MgSO4), 
filtered and concentrated in vacuo. The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 2-
(benzyloxy)-6-(mesitylamino)-3-methylbenzoic acid (131) as a brown solid (1.60 g, 74%). 
Mp 89‒91 °C; νmax/cm−1 (neat) 3294 (NH), 3032 (OH), 2916 (CH), 1697 (CO), 1501 (C=C), 
1396, 1381, 1223, 814, 698; δH (400 MHz, CDCl3) 2.13 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.28 
(3H, s, CH3), 2.31 (3H, s, CH3), 4.97 (2H, s, CH2Ph), 6.05 (1H, d, J 8.8 Hz, 5-H), 6.94 (2H, 
s, 3ʹ-H and 5ʹ-H), 7.03 (1H, d, J 8.8 Hz, 4-H), 7.36‒7.58 (5H, m, Ph), 9.47 (1H, br s, NH), 
12.09 (1H, br s, OH); δC (101 MHz, CDCl3) 15.4 (CH3), 18.1 (2 × CH3), 21.0 (CH3), 77.6 
(CH2), 102.7 (C), 110.2 (CH), 116.4 (C), 129.0 (2 × CH), 129.0 (2 × CH), 129.2 (2 × CH), 
129.3 (CH), 134.4 (C), 134.4 (C), 136.3 (C), 136.6 (2 × C), 137.0 (CH), 150.6 (C), 156.6 
(C), 168.6 (C); m/z (ESI) 398.1712 (MNa+. C24H25NNaO3 requires 398.1727). 
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2-(Benzyloxy)-6-(mesitylamino)-3-methylbenzamide (132) 
 
The reaction was carried out according to general procedure D using 2-(benzyloxy)-6-
(mesitylamino)-3-methylbenzoic acid (131) (1.60 g, 4.26 mmol), 2-chloro-4,6-dimethoxy-
1,3,5-triazine (0.897 g, 5.11 mmol) and N-methylmorpholine (1.41 mL, 12.8 mmol) in 
tetrahydrofuran (20 mL). The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 2-
(benzyloxy)-6-(mesitylamino)-3-methylbenzamide (132) as a white solid (1.37 g, 92%). Mp 
122‒124 °C; νmax/cm−1 (neat) 3451 (NH), 3260 (NH), 2916 (CH), 1651 (CO), 1574 (C=C), 
1495, 1366, 1261, 1040, 912, 743; δH (400 MHz, CDCl3) 2.17 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 
2.22 (3H, s, CH3), 2.30 (3H, s, CH3), 4.87 (2H, s, CH2Ph), 5.65 (1H, br s, NH), 5.99 (1H, d, 
J 8.6 Hz, 5-H), 6.93 (2H, s, 3ʹ-H and 5ʹ-H), 6.95 (1H, d, J 8.6 Hz, 4-H), 7.33‒7.54 (5H, m, 
Ph), 7.86 (1H, br s, NH), 9.32 (1H, br s, NH); δC (101 MHz, CDCl3) 15.5 (CH3), 18.2 (2 × 
CH3), 20.9 (CH3), 76.1 (CH2), 107.3 (C), 109.5 (CH), 117.6 (C), 128.1 (2 × CH), 128.5 
(CH), 128.7 (2 × CH), 129.0 (2 × CH), 134.9 (CH), 135.4 (C), 135.6 (C), 136.4 (2 × C), 
136.5 (C), 149.3 (C), 156.6 (C), 170.8 (C); m/z (ESI) 397.1871 (MNa+. C24H26N2NaO2 
requires 397.1886). 
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2-Hydroxy-6-(mesitylamino)-3-methylbenzamide (124) 
 
 
To a solution of 2-(benzyloxy)-6-(mesitylamino)-3-methylbenzamide (132) (1.36 g, 3.63 
mmol) in tetrahydrofuran (100 mL) was added 10% palladium on carbon (0.770 g) and the 
reaction mixture purged under hydrogen gas for 1 h, before stirring at room temperature 
under a hydrogen atmosphere for a further 1 h. The reaction mixture was then filtered 
through Celite®, washed with ethyl acetate (50 mL) and the filtrate was concentrated in 
vacuo. The crude material was purified by flash column chromatography, eluting with 10‒
20% ethyl acetate in petroleum ether (40‒60) to afford 2-hydroxy-6-(mesitylamino)-3-
methylbenzamide (124) as a white solid (0.900 g, 87%). Mp 145‒147 °C; νmax/cm−1 (neat) 
3298 (OH), 3177 (NH), 2914 (CH), 1645 (CO), 1612, 1587 (C=C), 1483, 1377, 1244, 
1225, 1040, 912, 802, 741; δH (400 MHz, CDCl3) 2.13 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.15 
(3H, s, 3-CH3), 2.30 (3H, s, 4ʹ-CH3), 5.24 (1H, br s, NH), 5.87 (1H, d, J 8.1 Hz, 5-H), 6.92 
(2H, s, 3ʹ-H and 5ʹ-H), 6.94 (1H, d, J 8.1 Hz, 4-H), 7.49 (2H, br s, NH), 12.72 (1H, s, OH); 
δC (101 MHz, CDCl3) 15.5 (CH3), 18.1 (2 × CH3), 20.8 (CH3), 105.2 (C), 108.1 (CH), 119.9 
(C), 129.6 (2 × CH), 132.7 (2 × C), 134.6 (CH), 134.7 (C), 136.2 (C), 144.1 (C), 161.2 (C), 
173.5 (C); m/z (ESI) 307.1409 (MNa+. C17H20N2NaO2 requires 307.1417). 
2-Bromo-6-[(2ʹ,6ʹ-dimethylphenyl)amino]-3-methylbenzoic acid (137) 
 
The reaction was carried out according to general procedure B using 2-bromo-6-fluoro-3-
methylbenzoic acid (77) (2.00 g, 8.58 mmol) and 2,4,6-trimethylaniline (2.10 mL, 17.2 
mmol) in tetrahydrofuran (50 mL), followed by treatment with lithium 
bis(trimethylsilyl)amide (25.7 mL, 25.7 mmol, 1.0 M in tetrahydrofuran). The crude 
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material was purified by flash column chromatography, eluting with 20‒40% ethyl acetate 
in petroleum ether (40‒60) to afford 2-bromo-6-[(2ʹ,6ʹ-dimethylphenyl)amino]-3-
methylbenzoic acid (137) as a brown solid (2.74 g, 95%). Mp 126‒128 °C; νmax/cm−1 (neat) 
3389 (NH), 2918 (OH/CH), 1690 (CO), 1661, 1489, 1234, 773; δH (500 MHz, CDCl3) 2.20 
(6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.34 (3H, s, 3-CH3), 6.14 (1H, d, J 8.5 Hz, 5-H), 7.02 (1H, d, J 
8.5 Hz, 4-H), 7.07‒7.17 (3H, m, 3ʹ-H, 4ʹ-H and 5ʹ-H), 10.29 (1H, br s, OH); δC (126 MHz, 
CDCl3) 18.2 (2 × CH3), 23.0 (CH3), 112.5 (CH), 116.9 (C), 124.0 (C), 126.4 (CH), 128.0 
(C), 128.6 (2 × CH), 134.0 (CH), 136.0 (2 × C), 137.1 (C), 146.0 (C), 173.4 (C); m/z (ESI) 
356.0250 (MNa+. C16H1679BrNNaO2 requires 356.0257). 
6-[(2ʹ,6ʹ-Dimethylphenyl)amino]-2-methoxy-3-methylbenzoic acid (138) 
 
The reaction was carried out according to general procedure C using sodium hydride 
(0.896 g, 22.4 mmol, 60% in mineral oil), methanol (27 mL), 2-bromo-6-[(2ʹ,6ʹ-
dimethylphenyl)amino]-3-methylbenzoic acid (137) (2.50 g, 7.48 mmol) and copper 
powder (0.190 g, 2.99 mmol). The crude material was purified by flash column 
chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 6-
[(2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxy-3-methylbenzoic acid (138) as a brown solid 
(1.51 g, 71%). Mp 92‒94 °C; νmax/cm−1 (neat) 3289 (NH), 3094 (OH), 2945 (CH), 1699 
(CO), 1570 (C=C), 1501, 1414, 1385, 1223, 1040, 818, 770; δH (500 MHz, CDCl3) 2.18 
(6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.20 (3H, s, 3-CH3), 3.93 (3H, s, OCH3), 6.03 (1H, d, J 8.7 Hz, 
5-H), 7.01 (1H, d, J 8.7 Hz, 4-H), 7.06‒7.18 (3H, m, 3ʹ-H, 4ʹ-H and 5ʹ-H), 9.59 (1H, br s, 
NH), 12.15 (1H, br s, OH); δC (126 MHz, CDCl3) 15.1 (CH3), 18.2 (2 × CH3), 62.2 (CH3), 
102.1 (C), 110.0 (CH), 116.3 (C), 126.7 (CH), 128.5 (2 × CH), 136.7 (2 × C), 137.1 (C), 
137.1 (CH), 150.2 (C), 158.2 (C), 168.7 (C); m/z (ESI) 308.1248 (MNa+. C17H19NNaO3 
requires 308.1257). 
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6-[(2ʹ,6ʹ-Dimethylphenyl)amino]-2-methoxy-3-methylbenzamide (134) 
 
The reaction was carried out according to general procedure D using 6-[(2ʹ,6ʹ-
dimethylphenyl)amino]-2-methoxy-3-methylbenzoic acid (138) (1.40 g, 4.91 mmol), 2-
chloro-4,6-dimethoxy-1,3,5-triazine (1.03 g, 5.89 mmol) and N-methylmorpholine (1.62 
mL, 14.7 mmol) in tetrahydrofuran (28 mL). The crude material was purified by flash 
column chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to 
afford 6-[(2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxy-3-methylbenzamide (134) as a white 
solid (1.29 g, 92%). Mp 116‒118 °C; νmax/cm−1 (neat) 3443 (NH), 3184 (NH), 2936 (CH), 
1645 (CO), 1570 (C=C), 1497, 1366, 1261, 1047, 816, 731; δH (400 MHz, CDCl3) 2.18 
(3H, s, 3-CH3), 2.21 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 3.79 (3H, s, OCH3), 5.96 (1H, d, J 8.6 Hz, 
5-H), 6.04 (1H, br s, NH), 6.94 (1H, d, J 8.6 Hz, 4-H), 7.03‒7.19 (3H, m, 3ʹ-H, 4ʹ-H and 5ʹ-
H), 7.93 (1H, br s, NH), 9.47 (1H, br s, NH); δC (101 MHz, CDCl3) 15.2 (CH3), 18.4 (2 × 
CH3), 61.1 (CH3), 107.0 (C), 109.3 (CH), 117.5 (C), 126.0 (CH), 128.3 (2 × CH), 134.9 
(CH), 136.6 (2 × C), 138.1 (C), 148.9 (C), 158.1 (C), 170.9 (C); m/z (ESI) 307.1409 
(MNa+. C17H20N2NaO2 requires 307.1417). 
6-[(4ʹ-Iodo-2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxy-3-methylbenzamide (135) 
 
To a dry flask under argon was added iron(III) choride (0.0029 g, 0.018 mmol) and 
[BMIM]NTf2 (0.21 mL, 0.70 mmol) and the mixture stirred for 0.5 h. 6-[(2ʹ,6ʹ-
Dimethylphenyl)amino]-2-methoxy-3-methylbenzamide (134) (0.10 g, 0.35 mmol) was 
then added as a solution in tetrahydrofuran (1.5 mL) and N-iodosuccinimide (0.16 g, 0.70 
mmol) was added slowly to the mixture. After 16 h of stirring at 70 °C, N-iodosuccinimide 
(0.080 g, 0.35 mmol) was added and the reaction mixture stirred for a further 4 h. After 
cooling to ambient temperature, the reaction was filtered through a short pad of Celite®, 
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washed with ethyl acetate (5 mL) and the filtrate was concentrated in vacuo. The crude 
material was purified by flash column chromatography, eluting with 10% ethyl acetate in 
petroleum ether (40‒60) to afford 6-[(4ʹ-iodo-2ʹ,6ʹ-dimethylphenyl)amino]-2-methoxy-3-
methylbenzamide (135) as a white solid (0.0073 g, 5%). Mp 143‒144 °C; νmax/cm−1 (neat) 
3333 (NH), 3181 (NH), 2938 (CH), 1655 (CO), 1591 (C=C), 1458, 1418, 1231, 1213, 
1167, 970, 756, 732, 611; δH (400 MHz, CDCl3) 2.16 (6H, s, 2ʹ-CH3 and 6ʹ-CH3), 2.17 (3H, 
s, 3-CH3), 3.78 (3H, s, OCH3), 5.65 (1H, br s, NH), 5.92 (1H, d, J 8.6 Hz, 5-H), 6.95 (1H, 
d, J 8.6 Hz, 4-H), 7.10 (2H, s, 3ʹ-H and 5ʹ-H), 7.93 (1H, br s, NH), 9.40 (1H, br s, NH); δC 
(101 MHz, CDCl3) 15.2 (CH3), 18.3 (2 × CH3), 61.2 (CH3), 90.8 (C), 107.2 (C), 109.2 (CH), 
118.0 (C), 128.1 (2 × CH), 131.0 (C), 135.0 (CH), 138.5 (2 × C), 148.6 (C), 158.2 (C), 
170.7 (C); m/z (ESI) 433.0379 (MNa+. C17H19N2NaO2 requires 433.0383). 
Radiosynthesis of 6-(mesitylamino)-2-[11C]methoxy-3-methylbenzamide ([11C]33) 
 
Radiochemistry was carried out on a Synthra Wolpertinger synthesiser and [11C]CO2 was 
produced via the 14N(p,α)11C nuclear reaction by cyclotron irradiation of a target containing 
[14N]N2. The [11C]CO2 was trapped in a stainless steel loop at −180 °C and rinsed with He 
gas. Conversion to [11C]CH4 took place at 425 °C in an oven coated with an activated Zn 
catalyst and was then passed through an Ascarite® trap. The [11C]CH4 was trapped on 
activated carbon at −120 °C and rinsed with He to remove residual H2 gas. The 
conversion to [11C]MeI took place by passing the [11C]CH4 through an iodine oven heated 
to 95 °C, then passing through a high temperature oven at 730 °C. The [11C]MeI was 
separated by trapping on a Porapak Q column and any residual [11C]CH4 was circulated in 
a loop, repeating this process. The [11C]MeI was de-adsorbed and bubbled into a mixture 
of 2-hydroxy-6-(mesitylamino)-3-methylbenzamide (124) (5.0 mg, 0.017 mmol) and tetra-
n-butylammonium fluoride (20 μL, 0.020 mmol; 1 M solution in tetrahydrofuran) in 
cyclohexanone (0.5 mL) at 120 °C for 3 min at a flow rate of 2 mL min−1. The reaction 
mixture was then diluted with acetonitrile (0.62 mL) and water (0.38 mL) and loaded onto 
a C18 Synergi Hydro-RP 80 Å, 150×10 mm, 4 µm column (Phenomenex, UK). A 62% 
solution of acetonitrile in water was used as the mobile phase at a flow rate of 5.5 mL 
min−1. The radiolabelled product was detected by the HPLC gamma-detector and eluted at 
approximately 32 min. The collected fraction was diluted with water (26 mL) and then 
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transferred onto a Sep-Pak® Plus Light HLB cartridge. This was rinsed with water (10 mL) 
and the product eluted with ethanol (0.5 mL) then saline (12 mL). This provided a 4% 
ethanol/saline formulation of the product in a total synthesis time of 63 min. The 
radiolabelled product was isolated with a radiochemical yield of 13% and a radiochemical 
purity of >99%. 
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3.3 HPLC Methods for Physicochemical Analysis122 
All physicochemical analyses were performed using a Dionex Ultimate 3000 series and 
data acquisition and processing performed using Chromeleon 6.8 Chromatography 
software. Standard and test compounds were dissolved in 1:1 organic/aqueous phases 
and prepared to a concentration of 0.25 mg/mL. The HPLC system was set to 25 °C and 
UV detection achieved using a diode array detector (190‒800 nm). Analysis was 
performed using 5 µL sample injections. 
C18 chromatography for determination of lipophilicity (log P)122 
Log P values were determined using a Phenomenex Luna® 5 µm C18 100 Å (50 × 3 mm) 
column. The retention time for each compound was measured using filtered acetonitrile 
and 0.01 mM phosphate buffered saline (PBS) as the mobile phase at pH 4.0, pH 7.4 and 
pH 10.0. The pH was adjusted by the addition of concentrated hydrochloric acid or 0.05 M 
aqueous sodium hydroxide solution, respectively. The mobile phase flow rate was set at 
1.0 mL min−1. Chromatographic hydrophobicity index (CHI) values for all compounds were 
determined by measuring the compound retention time (tr) under the following conditions: 
0‒10.5 min, 0‒100% acetonitrile; 10.5‒11.5 min, 100% acetonitrile; 11.5‒12.0 min, 100‒
0% acetonitrile; 12.0‒15.0 min, 0% acetonitrile. System calibration was achieved using 
the following compounds and plotting their mean CHI values against the measured tr 
under all three pH conditions: theophylline (CHI = 15.76), phenyltetrazole (CHI = 20.18), 
benzimidazole (CHI = 30.71), colchicine (CHI = 41.37), acetophenone (CHI = 64.90), 
indole (CHI = 69.15), butyrophenone (CHI = 88.49) and valerophenone (CHI = 97.67). 
Using the calibration curves obtained and the following equations from a validated study, 
the log P of the compounds was calculated using Excel 2016 software. 
CHI log D = 0.054CHI− 1.467 
Where CHI log D is the CHI value projected to the logarithmic scale. 
log P = 0.047CHIN + 0.036HBC − 1.10 
Where CHIN is the gradient chromatographic hydrophobicity index of the non-ionised 
compound and HBC is the hydrogen bond donor count. 
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Immobilised artificial membrane (IAM) chromatography for determination of 
membrane permeability (Pm) and membrane partition coefficient (Km)122 
Pm and Km values were determined using previously developed methodology on a 
Registech IAM.PC.DD2 (150 × 4.6 mm) column. Acetonitrile and 0.01 mM PBS at pH 7.4 
was used as the mobile phase, with a flow rate of 1.0 mL min−1. The tr of each compound 
was measured under an isocratic mobile phase, with the percentage of acetonitrile 
ranging from 30‒70%. The retention time of citric acid as an unretained compound, under 
an isocratic mobile phase of 100% PBS was used for system corrections. The following 
equations were used to calculate Pm and Km of the compounds of interest using Excel 
2016 software. 
kIAM =
tr − t0
t0
 
Where kIAM = solute capacity factor on the column, tr = retention time of compound and t0 
= tr of unretained compound. 
kIAM = (
Vs
Vm
) × Km 
Where Vs = volume of the IAM interphase created by the immobilised phospholipids, Vm = 
total volume of the solvent within the IAM column and Km = membrane partition coefficient. 
Vm =
WPhC
δPhC
+
WC10
δC10
+
WC3
δC3
 
Where the specific weight of PhC (δPhC) = 1.01779 gmL−1 and C10/C3 (δC10/C3) = 0.86 
gmL−1; WPhC = 133 mg, WC10 = 12.73 mg and WC3 = 2.28 mg. 
Vm = fr × t0 
Where fr = flow rate. 
Pm =
Km
MW
 
Where Pm = permeability and MW = molecular weight. 
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Human serum albumin (HSA) chromatography for determination of percentage of 
plasma protein binding (%PPB)122 
A ChromTech HSA 5 µm (3.0 × 50 mm) column was used for determination of %PPB, 
using previously developed methodology. Isopropanol and 0.01 mM PBS at pH 7.4 was 
used as the mobile phase, with a flow rate of 1.8 mL min−1. The retention time of each 
compound was measured under the following mobile phase conditions: 0‒3 min, 0‒30% 
isopropanol; 3‒10 min, 30% isopropanol; 10.5‒11.0 min, 30‒0% isopropanol; 11.0‒15.0 
min, 0% isopropanol. System calibration was achieved using the following reference 
compounds: warfarin (%PPB = 98.0), nizatidine (%PPB = 35.0), bromazepam (%PPB = 
60.0), carbamazepine (%PPB = 75.0), nicardipine (%PPB = 95.0), ketoprofen (%PPB = 
98.7), indomethacin (%PPB = 99.0) and diclofenac (%PPB = 99.8). The %PPB for the 
reference compounds were converted to the linear free energy related log k values, which 
when plotted against the tr on the HSA column, afforded a line equation from which the log 
k values of the unknown compounds could be extracted. The log k values could then be 
converted to %PPB. Log k and subsequent %PPB calculations for the compounds of 
interest were performed using Excel 2016 software. 
log k = log 
%PPB
101 −%PPB
  
%PPB = [
(101 − 10logk)
(1 + 10logk)
] 
  
202 
3.4 Procedure for the [35S]GTPγS Binding Assay159 
The assay buffer was prepared from HEPES (20 mM), NaCl (100 mM), MgCl2 (10 mM) 
and fatty acid-free BSA (0.1%) at pH 7.4. ChemiScreenTM S1P1‒3,5 lysophospholipid 
receptor membrane preparations were obtained from Eurofins. The membrane 
preparation was diluted to 0.4 g mL−1 with assay buffer and mixed 1:1 (v/v) with a 0.4 mg 
mL−1 solution of saponin in assay buffer. Nine concentrations of the compounds to be 
tested were prepared (10 µM, 1 µM, 100 nM, 10 nM, 1 nM, 100 pM, 10 pM, 1 pM, 100 fM). 
MerckTM Multiscreen® HTS 96 well filter plates were pre-wet with 70% aqueous EtOH (50 
µL/well) for 30 seconds and then washed twice with assay buffer (200 µL/well). To each 
well was added membrane preparation (25 µL), GDP in assay buffer (25 µL, 2 µM), 
[35S]GTPγS in assay buffer (25 µL, 1.2 nM) and test compound (25 µL). For total binding, 
S1P solution in assay buffer (25 µL, 10 µM) was added and for basal, assay buffer (25 µL) 
was added. The assay plate was incubated at 30 °C for 30 min before the addition of cold 
assay buffer (100 µL/well) to stop the reaction. The plate was filtered using a Millipore 
vacuum manifold, with a pressure between 600‒800 mbar and then dried at 50 °C for 1‒2 
h. Betaplate Scint Scintillation Cocktail (30 µL/well) was added and the disintegrations per 
minute were determined using a Wallac 1450 Microbeta Trilux liquid scintillation and 
luminescence couter. EC50 values were derived from non-linear regression analysis using 
GraphPad Prism Version 6 (GraphPad Software Inc). 
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3.5 TSPO Experimental 
Diethyl 4-phenylquinoline-2,3-dicarboxylate (148)162 
 
Indium(III) chloride (0.680 g, 3.07 mmol) was added to 2-aminobenzophenone (5.00 g, 
15.3 mmol) and diethyl acetylenedicarboxylate (2.95 mL, 18.4 mmol), and the neat 
mixture stirred at 80 °C for 3 h. On cooling to ambient temperature, water (50 mL) was 
added and the mixture extracted using ethyl acetate (3 × 50 mL). The organic layer was 
then washed with water (100 mL) and brine (100 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude material was purified by flash column chromatography, 
eluting with 15% ethyl acetate in petroleum ether (40‒60) to afford diethyl 4-
phenylquinoline-2,3-dicarboxylate (148) as a yellow solid (5.36 g, 100%). Mp 89‒91 °C, 
lit.162 95‒96 °C; δH (400 MHz, CDCl3) 0.99 (3H, t, J 7.2 Hz, OCH2CH3), 1.47 (3H, t, J 7.2 
Hz, OCH2CH3), 4.09 (2H, q, J 7.2 Hz, OCH2CH3), 4.54 (2H, q, J 7.2 Hz, OCH2CH3), 7.34‒
7.40 (2H, m, 2 × ArH), 7.47‒7.53 (3H, m, 3 × ArH), 7.57 (1H, ddd, J 8.4, 6.4, 1.6 Hz, ArH), 
7.63 (1H, ddd, J 8.4, 1.6, 0.6 Hz, ArH), 7.81 (1H, ddd, J 8.4, 6.4, 1.6 Hz, ArH), 8.38 (1H, 
ddd, J 8.4, 1.6, 0.6 Hz, ArH); δC (101 MHz, CDCl3) 13.6 (CH3), 14.2 (CH3), 61.6 (CH2), 
62.6 (CH2), 126.6 (CH), 127.1 (C), 127.5 (C), 128.2 (2 × CH), 128.7 (CH), 129.0 (CH), 
129.4 (2 × CH), 130.7 (CH), 130.9 (CH), 134.8 (C), 145.9 (C), 147.1 (C), 148.0 (C), 165.3 
(C), 167.2 (C); m/z (EI) 349 (M+. 100%), 305 (20), 276 (55), 205 (100), 204 (82), 165 (12), 
84 (5). 
9-Phenyl-1H,3H-furo[3,4-b]quinolin-1-ol (152)119 
 
A solution of diethyl 4-phenylquinoline-2,3-dicarboxylate (148) (4.72 g, 13.5 mmol) in 
tetrahydrofuran (50 mL) under argon was heated under reflux with vigorous stirring. 
Sodium borohydride (5.11 g, 135 mmol) was added slowly followed by methanol (50 mL), 
and the reaction mixture stirred under reflux for 15 h. After cooling to ambient 
temperature, the reaction was quenched by the dropwise addition of a saturated aqueous 
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solution of ammonium chloride (50 mL). The crude reaction mixture was extracted using 
dichloromethane (3 × 50 mL) and washed with water (2 × 50 mL), dried (MgSO4), filtered 
and concentrated in vacuo. Trituration with diethyl ether afforded 9-phenyl-1H,3H-furo[3,4-
b]quinolin-1-ol (152) as a pale yellow solid (2.77 g, 78%). Mp 208‒210 °C, lit.119 208‒210 
°C; δH (400 MHz, DMSO-d6) 4.87 (1H, dd, J 15.7, 0.8 Hz, CHHO), 4.98 (1H, br d, J 15.7 
Hz, CHHO), 5.02 (1H, br s, CHOH), 6.87‒6.94 (2H, m, 2 × ArH), 7.04 (1H, d, J 6.8 Hz, 
ArH), 7.10‒7.17 (2H, m, 2 × ArH), 7.18‒7.28 (4H, m, 4 × ArH), 10.0 (1H, br s, CHOH); δC 
(101 MHz, DMSO-d6) 65.0 (CH2), 95.2 (CH), 116.2 (CH), 123.1 (CH), 124.3 (C), 126.2 
(CH), 127.5 (CH), 127.6 (2 × CH), 128.3 (2 × CH), 128.7 (C), 130.8 (CH), 136.1 (C), 146.8 
(C), 158.5 (C), 172.0 (C); m/z (ESI) 286 (MNa+. 100%). 
9-Phenylfuro[3,4-b]quinolin-1(3H)-one (149)210 
 
To a solution of 9-phenyl-1H,3H-furo[3,4-b]quinolin-1-ol (152) (3.29 g, 12.5 mmol) in 
chloroform (150 mL) was added activated manganese(IV) oxide (32.6 g, 374 mmol) in one 
portion. The reaction mixture was stirred vigorously at room temperature for 4 h and then 
filtered through Celite®. After washing with chloroform (200 mL), the solvent was removed 
in vacuo to afford 9-phenylfuro[3,4-b]quinolin-1(3H)-one (149) as a white solid (2.72 g, 
83%). This was used without further purification. Mp 201‒203 °C, lit.210 203‒204 °C; δH 
(500 MHz, CDCl3) 5.45 (2H, s, OCH2), 7.43‒7.49 (2H, m, 2 × ArH), 7.57‒7.61 (4H, m, 4 × 
ArH), 7.89‒7.93 (2H, m, 2 × ArH), 8.19‒8.22 (1H, m, ArH); δC (126 MHz, CDCl3) 69.6 
(CH2), 113.5 (C), 127.1 (C), 127.4 (CH), 128.1 (CH), 128.3 (2 × CH), 129.4 (CH), 129.5 
(CH), 129.8 (2 × CH), 131.6 (C), 132.6 (CH), 151.3 (C), 51.5 (C), 163.6 (C), 167.9 (C); m/z 
(EI) 261 (M+. 100%), 232 (56), 204 (42), 203 (32), 176 (21), 151 (9), 131 (8), 91 (10). 
2,3-Bis(hydroxymethyl)-4-phenylquinoline (150)210 
 
A suspension of lithium aluminium hydride (3.90 g, 103 mmol) in diethyl ether (90 mL) 
under argon was cooled to 0 °C, and to this was added dropwise a solution of diethyl 4-
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phenylquinoline-2,3-dicarboxylate (148) (9.00 g, 26.0 mmol) in diethyl ether (90 mL). The 
temperature of the reaction mixture was maintained at 0 °C and stirred vigorously for 3 h. 
Water (4.0 mL) was added, followed by 15% aqueous sodium hydroxide (4.0 mL) and 
allowed to stir at 0 °C for 0.2 h. Water (12 mL) was then added and the reaction mixture 
allowed to reach room temperature followed by stirring with MgSO4 for 0.5 h. The reaction 
mixture was then filtered and concentrated in vacuo to afford a colourless residue which 
was dissolved in methanol (250 mL). 10% Palladium on carbon (0.90 g) was added to the 
reaction flask and the reaction mixture stirred at room temperature for 15 h. The 
suspension was then filtered through a pad of Celite®, washed with methanol and 
concentrated in vacuo. Trituration with diethyl ether afforded 2,3-bis(hydroxymethyl)-4-
phenylquinoline (150) as a white solid (4.50 g, 65%). Mp 171‒173 °C, lit.210 175‒177 °C; 
δH (400 MHz, CD3OD) 4.59 (2H, s, CH2OH), 5.11 (2H, s, CH2OH), 7.34‒7.38 (2H, m, 2 × 
ArH), 7.41 (1H, dd, J 8.4, 1.2 Hz, ArH), 7.44‒7.50 (1H, m, ArH), 7.51‒7.60 (3H, m, 3 × 
ArH), 7.73 (1H, ddd, J 8.4, 6.4, 1.2 Hz, ArH), 8.11 (1H, d, J 8.4 Hz, ArH); δC (101 MHz, 
CD3OD) 59.1 (CH2), 64.6 (CH2), 127.8 (CH), 127.9 (CH), 128.6 (C), 129.4 (CH), 129.5 
(CH), 129.5 (2 × CH), 130.0 (C), 130.8 (CH), 130.8 (2 × CH), 137.2 (C), 147.4 (C), 150.4 
(C), 160.9 (C); m/z (CI) 266 (MH+. 100%), 264 (50), 248 (42), 218 (21), 206 (4), 151 (3). 
9-Phenylfuro[3,4-b]quinolin-3(1H)-one (153)210 
 
To a solution of 2,3-bis(hydroxymethyl)-4-phenylquinoline (150) (0.780 g, 2.93 mmol) in 
chloroform (50 mL) was added activated manganese(IV) oxide (7.64 g, 87.9 mmol) in one 
portion. The reaction mixture was stirred vigorously at room temperature for 4 h and then 
filtered through Celite®. After washing with chloroform (100 mL), the solvent was removed 
in vacuo to afford 9-phenylfuro[3,4-b]quinolin-3(1H)-one (153) as a white solid (0.70 g, 
92%), which was used without further purification. Mp 188‒190 °C, lit.210 190‒192 °C; δH 
(400 MHz, CDCl3) 5.41 (2H, s, OCH2), 7.45 (2H, dd, J 8.0, 2.0 Hz, 2 × ArH), 7.57‒7.70 
(4H, m, 4 × ArH), 7.84‒7.90 (1H, m, ArH), 7.92 (1H, d, J 8.4 Hz, ArH), 8.46 (1H, d, J 8.4 
Hz, ArH); δC (101 MHz, CDCl3) 67.8 (CH2), 125.7 (CH), 127.9 (C), 128.9 (2 × CH), 129.3 
(2 × CH), 129.4 (CH), 129.6 (CH), 130.7 (CH), 131.5 (CH), 132.3 (C), 133.6 (C), 143.9 
(C), 144.4 (C), 150.7 (C), 168.7 (C); m/z (ESI) 284. (MNa+. 100%). 
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3-(Hydroxymethyl)-4-phenylquinoline-2-N-diethylcarboxamide (151)119 
 
To a solution of diethylamine (1.06 mL, 10.2 mmol) in dichloromethane (70 mL) under 
argon was added aluminium(III) chloride (1.36 g, 10.2 mmol), and the mixture stirred at 
room temperature for 0.3 h. A solution of 9-phenylfuro[3,4-b]quinolin-3(1H)-one (153) 
(0.890 g, 3.41 mmol) in dichloromethane (20 mL) was then added dropwise and the 
reaction mixture stirred at room temperature for 15 h. The reaction was quenched by the 
careful addition of a 1 M aqueous hydrochloric acid solution (25 mL) and the crude 
mixture extracted using dichloromethane (2 × 40 mL). The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo. The crude material was purified by flash 
column chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to 
afford 3-(hydroxymethyl)-4-phenylquinoline-2-N-diethylcarboxamide (151) as a pale yellow 
solid (1.00 g, 88%). Mp 117‒119 °C, lit.119 117‒119 °C; δH (400 MHz, CDCl3) 1.27 (3H, t, J 
7.2 Hz, NCH2CH3), 1.36 (3H, t, J 7.2 Hz, NCH2CH3), 3.42 (2H, q, J 7.2 Hz, NCH2CH3), 
3.68 (2H, q, J 7.2 Hz, NCH2CH3), 4.12 (1H, t, J 6.4 Hz, CH2OH), 4.39 (2H, d, J 6.4 Hz, 
CH2OH), 7.41‒7.58 (7H, m, 7 × ArH), 7.72 (1H, ddd, J 8.4, 6.8, 1.6 Hz, ArH), 8.12 (1H, 
ddd, J 8.4, 1.2, 0.8 Hz, ArH); δC (101 MHz, CDCl3) 12.9 (CH3), 14.2 (CH3), 40.3 (CH2), 
43.7 (CH2), 59.7 (CH2), 127.0 (CH), 127.4 (CH), 127.6 (C), 128.4 (3 × CH), 129.4 (C), 
129.6 (CH), 129.7 (CH), 129.9 (2 × CH), 135.2 (C), 146.1 (C), 149.3 (C), 155.1 (C), 169.8 
(C); m/z (ESI) 357 (MNa+. 100%). 
3-(Chloromethyl)-4-phenylquinoline-2-N-diethylcarboxamide (44)119 
 
To a solution of 3-(hydroxymethyl)-4-phenylquinoline-2-N-diethylcarboxamide (151) (0.450 
g, 1.35 mmol) in dichloromethane (45 mL) under argon was added thionyl chloride (2.94 
mL, 40.5 mmol) and the reaction mixture stirred under reflux for 24 h. On cooling to 
ambient temperature, the mixture was concentrated in vacuo and azeotroped with toluene 
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(3 × 30 mL). The crude material was purified by flash column chromatography, eluting with 
50% diethyl ether in petroleum ether (40‒60) to afford 3-(chloromethyl)-4-phenylquinoline-
2-N-diethylcarboxamide (44) as a colourless oil (0.423 g, 89%). The spectroscopic data 
were consistent with the literature.119 δH (500 MHz, CDCl3) 1.30 (3H, t, J 7.0 Hz, 
NCH2CH3), 1.35 (3H, t, J 7.5 Hz, NCH2CH3), 3.28 (2H, q, J 7.0 Hz, NCH2CH3), 3.68 (2H, 
q, J 7.5 Hz, NCH2CH3), 4.70 (2H, s, CH2Cl), 7.36‒7.40 (2H, m, 2 × ArH), 7.41‒7.59 (5H, 
m, 5 × ArH), 7.73 (1H, ddd, J 8.5, 6.5, 1.5 Hz, ArH), 8.13 (1H, d, J 8.5 Hz, ArH); δC (126 
MHz, CDCl3) 12.3 (CH3), 13.5 (CH3), 39.2 (CH2), 40.3 (CH2), 43.6 (CH2), 125.9 (C), 126.9 
(CH), 127.3 (C), 127.4 (CH), 128.6 (2 × CH), 128.7 (CH), 129.4 (2 × CH), 129.6 (CH), 
130.2 (CH), 134.9 (C), 146.4 (C), 149.4 (C), 155.6 (C), 168.1 (C); m/z (ESI) 375 (MNa+. 
100%). 
3-(Fluoromethyl)-4-phenylquinoline-2-N-diethylcarboxamide (45)119 
 
To a solution of 18-crown-6 (0.038 g, 0.140 mmol) in acetonitrile (2.5 mL) under argon 
was added potassium fluoride (0.041 g, 0.710 mmol) and the suspension stirred at room 
temperature for 0.5 h. A solution of 3-(chloromethyl)-4-phenylquinoline-2-N-
diethylcarboxamide (44) (0.050 g, 0.140 mmol) in acetonitrile (2.5 mL) was then added 
dropwise and the reaction mixture stirred under reflux for 24 h. On cooling to ambient 
temperature, water (10 mL) was added to the mixture and the product extracted using 
dichloromethane (3 × 15 mL). The combined organic layers were dried (MgSO4), filtered 
and concentrated in vacuo. The crude material was purified by flash column 
chromatography, eluting with 50% diethyl ether in petroleum ether (40‒60) to afford 3-
(fluoromethyl)-4-phenylquinoline-2-N-diethylcarboxamide (45) as a white solid (0.030 g, 
60%). The spectroscopic data were consistent with the literature.119 Mp 126‒128 °C; δH 
(400 MHz, CDCl3) 1.22 (3H, t, J 7.2 Hz, NCH2CH3), 1.34 (3H, t, J 7.2 Hz, NCH2CH3), 3.28 
(2H, q, J 7.2 Hz, NCH2CH3), 3.67 (2H, q, J 7.2 Hz, NCH2CH3), 5.38 (2H, d, J 47.8 Hz, 
CH2F), 7.32‒7.38 (2H, m, 2 × ArH), 7.46‒7.57 (5H, m, 5 × ArH), 7.73‒7.78 (1H, m, ArH), 
8.16 (1H, d, J 8.4 Hz, ArH); δC (101 MHz, CDCl3) 12.6 (CH3), 13.7 (CH3), 39.4 (CH2), 43.2 
(CH2), 79.2 (CH2, d, 
1JCF 162.2 Hz), 123.4 (C, d, 
2JCF 15.1 Hz), 127.0 (CH), 127.1 (C, d, 
4JCF 1.8 Hz), 127.4 (CH), 128.5 (2 × CH), 128.7 (CH), 129.6 (CH), 129.7 (2 × CH), 130.5 
(CH, d, 5JCF 1.5 Hz), 134.8 (C), 147.1 (C, d, 
3JCF 2.9 Hz), 150.7 (C, d, 
3JCF 4.9 Hz), 155.9 
(C, d, 4JCF 1.7 Hz), 168.2 (C); m/z (ESI) 359 (MNa+. 100%). 
208 
3-(Acetoxymethyl)-4-phenylquinoline-2-N-diethylcarboxamide (154) 
 
To a solution of 3-(hydroxymethyl)-4-phenylquinoline-2-N-diethylcarboxamide (151) (0.050 
g, 0.150 mmol) in dichloromethane (2.0 mL) was added triethylamine (0.031 mL, 0.225 
mmol), acetic anhydride (0.028 mL, 0.300 mmol) and 4-dimethylaminopyridine (0.002 g, 
0.015 mmol) and the reaction mixture stirred under argon at room temperature for 16 h. 
The reaction mixture was dissolved in ethyl acetate (10 mL) and washed with saturated 
aqueous sodium bicarbonate (10 mL), water (10 mL) and brine (10 mL). The organic layer 
was then dried (MgSO4), filtered and concentrated in vacuo. The crude material was 
purified by flash column chromatography, eluting with 40% ethyl acetate in petroleum 
ether (40‒60) to afford 3-(acetoxymethyl)-4-phenylquinoline-2-N-diethylcarboxamide (154) 
as a colourless oil (0.047 g, 83%). νmax/cm-1 (neat) 2978 (CH), 1736 (CO), 1636 (CO), 
1558 (C=C), 1481, 1227, 1072, 1026, 772; δH (400 MHz, CDCl3) 1.26 (3H, t, J 7.1 Hz, 
NCH2CH3), 1.31 (3H, t, J 7.1 Hz, NCH2CH3), 1.96 (3H, s, OCOCH3), 3.30 (2H, q, J 7.1 Hz, 
NCH2CH3), 3.65 (2H, q, J 7.1 Hz, NCH2CH3), 5.10 (2H, s, CH2OAc), 7.30‒7.35 (2H, m, 2 × 
ArH), 7.43‒7.57 (5H, m, 5 × ArH), 7.69‒7.78 (1H, m, ArH), 8.15 (1H, d, J 8.4 Hz, ArH); δC 
(101 MHz, CDCl3) 12.7 (CH3), 13.8 (CH3), 20.7 (CH3), 39.4 (CH2), 43.1 (CH2), 61.3 (CH2), 
123.0 (C), 126.7 (CH), 127.3 (C), 127.3 (CH), 128.5 (2 × CH), 128.6 (CH), 129.4 (2 × CH), 
129.6 (CH), 130.1 (CH), 135.1 (C), 146.7 (C), 150.4 (C), 155.6 (C), 168.2 (C), 169.9 (C); 
m/z (ESI) 399.1672 (MNa+. C23H24N2NaO3 requires 399.1679). 
(R)-(N-sec-Butyl)-3-(hydroxymethyl)-4-phenylquinoline-2-carboxamide (159) 
 
To a stirred suspension of aluminium(III) chloride (0.770 g, 5.74 mmol) in dichloromethane 
(18 mL) under argon was added (R)-sec-butylamine (0.580 mL, 5.74 mmol) dropwise and 
the mixture stirred for 0.5 h at room temperature. A solution of 9-phenylfuro[3,4-b]quinolin-
3(1H)-one (153) (0.500 g, 1.91 mmol) in dichloromethane (18 mL) was added and the 
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reaction mixture was stirred at 40 °C for 16 h. The mixture was then filtered through a 
short pad of Celite®, washed with ethyl acetate (50 mL) and the filtrate was concentrated 
in vacuo. The crude material was purified by flash column chromatography, eluting with 
20% ethyl acetate in petroleum ether (40‒60) to afford (R)-(N-sec-butyl)-3-
(hydroxymethyl)-4-phenylquinoline-2-carboxamide (159) as a white solid (0.482 g, 75%). 
Mp 133‒134 °C; νmax/cm−1 (neat) 3387 (OH), 2961 (NH), 1651 (CO), 1518, 1402, 1161, 
1015; [α]D30 −24.8 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.04 (3H, t, J 7.5 Hz, CH2CH3), 
1.35 (3H, d, J 6.6 Hz, CHCH3), 1.65‒1.76 (2H, m, CH2CH3), 4.10‒4.23 (1H, m, CHCH3), 
4.67 (2H, d, J 7.6 Hz, 3-CH2), 5.39 (1H, t, J 7.6 Hz, OH), 7.34‒7.38 (2H, m, ArH), 7.47‒
7.56 (5H, m, ArH), 7.68‒7.77 (1H, m, ArH), 8.13 (1H, dt, J 8.4, 0.9 Hz, ArH), 8.28 (1H, d, J 
8.4 Hz, NH); δC (101 MHz, CDCl3) 10.7 (CH3), 20.5 (CH3), 29.9 (CH2), 47.3 (CH), 59.9 
(CH2), 127.2 (CH), 128.2 (CH), 128.4 (CH), 128.6 (CH), 128.6 (CH), 128.7 (C), 129.7 
(CH), 129.9 (CH), 130.0 (CH), 130.0 (CH), 131.5 (C), 136.0 (C), 145.5 (C), 149.8 (C), 
150.1 (C), 166.4 (C); m/z (ESI) 357.1563 (MNa+. C21H22N2NaO2 requires 357.1573). 
(R)-(N-sec-Butyl)-3-(chloromethyl)-4-phenylquinoline-2-carboxamide (163) 
 
To a solution of (R)-N-(sec-butyl)-3-(hydroxymethyl)-4-phenylquinoline-2-carboxamide 
(159) (0.223 g, 0.667 mmol) in dichloromethane (20 mL) under argon was added thionyl 
chloride (1.45 mL, 20.0 mmol). The resultant solution was stirred at room temperature for 
16 h. The reaction mixture was concentrated in vacuo and subsequently azeotroped with 
toluene to yield an off-white solid. The crude material was purified by trituration (Et2O) to 
afford (R)-(N-sec-butyl)-3-(chloromethyl)-4-phenylquinoline-2-carboxamide (163) as a 
white solid (0.200 g, 85%). Mp 218‒219 °C; νmax/cm−1 (neat) 3277 (CH), 2965 (NH), 1651 
(CO), 1637, 1541, 1277, 1163; [α]D30 −28.3 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.04 (3H, 
t, J 7.4 Hz, CH2CH3), 1.35 (3H, d, J 6.6 Hz, CHCH3), 1.62‒1.77 (2H, m, CH2CH3), 4.12‒
4.25 (1H, m, CHCH3), 5.18 (1H, d, J 10.4 Hz, 3-CHH), 5.24 (1H, d, J 10.4 Hz, 3-CHH), 
7.33‒7.41 (3H, m, ArH), 7.46‒7.52 (1H, m, ArH), 7.53‒7.60 (3H, m, ArH), 7.73 (1H, t, J 
8.1 Hz, ArH), 7.88 (1H, d, J 8.1 Hz, NH), 8.17 (1H, d, J 8.4 Hz, ArH); δC (101 MHz, 
CDCl3); 10.7 (CH3), 20.5 (CH3), 29.9 (CH2), 40.6 (CH2), 47.2 (CH), 127.1 (CH), 128.3 
(CH), 128.5 (C), 128.6 (C), 128.7 (2 × CH), 128.8 (CH), 129.5 (CH), 129.5 (CH), 129.6 
(CH), 130.5 (CH), 135.2 (C), 145.5 (C), 149.2 (C), 151.3 (C), 165.1 (C); m/z (ESI) 
375.1220 (MNa+. C21H2135ClN2NaO requires 375.1235). 
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(R)-(N-sec-Butyl)-3-(fluoromethyl)-4-phenylquinoline-2-carboxamide (164) 
 
To a solution of 18-crown-6 (0.180 g, 0.680 mmol) in acetonitrile (13 mL) under argon was 
added potassium fluoride (0.200 g, 3.40 mmol) and the suspension stirred at room 
temperature for 0.5 h. A solution of (R)-(N-sec-butyl)-3-(chloromethyl)-4-phenylquinoline-
2-carboxamide (163) (0.240 g, 0.680 mmol) in acetonitrile (13 mL) and dichloromethane 
(6.5 mL) was then added dropwise and the reaction mixture stirred under reflux for 24 h. 
On cooling to ambient temperature, water (20 mL) was added to the mixture and the 
product extracted using dichloromethane (3 × 20 mL). The combined organic extracts 
were dried (MgSO4), filtered and concentrated in vacuo. The crude material was purified 
by flash column chromatography, eluting with 30% ethyl acetate in petroleum ether (40‒
60) to afford (R)-(N-sec-butyl)-3-(fluoromethyl)-4-phenylquinoline-2-carboxamide (164) as 
a white solid (0.214 g, 92%). Mp 176‒177 °C; νmax/cm−1 (neat) 3283 (CH), 2965 (NH), 
1640 (CO), 1539, 1452, 1402, 1207, 1157, 980; [α]D30 −25.5 (c 0.5, CHCl3); δH (400 MHz, 
CDCl3) 1.03 (3H, t, J 7.4 Hz, CH2CH3), 1.34 (3H, d, J 6.6 Hz, CHCH3), 1.62‒1.76 (2H, m, 
CH2CH3), 4.12‒4.23 (1H, m, CHCH3), 5.80 (1H, dd, J 11.4, 9.8 Hz, 3-CHH), 5.90, (1H, dd, 
J 11.4, 9.8 Hz, 3-CHH), 7.29‒7.36 (2H, m, ArH), 7.45‒7.57 (5H, m, ArH), 7.74‒7.79 (1H, 
m, ArH), 7.90 (1H, d, J 8.1 Hz, NH), 8.16 (1H, d, J 8.5 Hz, ArH); δC (101 MHz, CDCl3) 10.5 
(CH3), 20.4 (CH3), 29.8 (CH2), 46.9 (CH), 78.5 (CH2, d, 
1JCF 162.9 Hz), 125.5 (C, d, 
2JCF 
15.4 Hz), 127.1 (CH), 128.1 (CH), 128.3 (C, d, 4JCF 1.9 Hz), 128.4 (2 × CH), 128.6 (CH), 
129.7 (CH), 129.7 (2 × CH), 130.5 (CH, d, 5JCF 0.9 Hz), 135.2 (C), 146.2 (C, d, 
3J CF 2.4 
Hz), 150.0 (C), 152.5 (C, d, 3J CF 4.9 Hz), 165.1 (C); m/z (ESI) 359.1514 (MNa+. 
C21H21FN2NaO requires 359.1530). 
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(±)-3-(Acetoxymethyl)-(N-sec-butyl)-4-phenylquinoline-2-carboxamide (160) 
 
To a solution of (±)-(N-sec-butyl)-3-(hydroxymethyl)-4-phenylquinoline-2-carboxamide 
(159) (0.10 g, 0.30 mmol) in dichloromethane (4.0 mL) was added triethylamine (0.062 
mL, 0.45 mmol), acetic anhydride (0.057 mL, 0.60 mmol) and 4-dimethylaminopyridine 
(0.0040 g, 0.030 mmol) and the reaction mixture was stirred under argon at room 
temperature for 1 h. The reaction mixture was dissolved in ethyl acetate (20 mL) and 
washed with saturated aqueous sodium bicarbonate (20 mL), water (20 mL) and brine (20 
mL). The organic layer was then dried (MgSO4), filtered and concentrated in vacuo. The 
crude material was purified by flash column chromatography, eluting with 20% ethyl 
acetate in petroleum ether (40‒60) to afford (±)-3-(acetoxymethyl)-(N-sec-butyl)-4-
phenylquinoline-2-carboxamide (160) as a white solid (0.10 g, 89%). Mp 138‒140 °C; 
νmax/cm-1 (neat) 3337 (NH), 2967 (CH), 1740 (CO), 1667 (CO), 1514 (C=C), 1487, 1236, 
1028, 768; δH (400 MHz, CDCl3) 1.03 (3H, t, J 7.4 Hz, CH2CH3), 1.32 (3H, d, J 6.7 Hz, 
CHCH2), 1.59‒1.76 (2H, m, CH2CH3), 1.97 (3H, s, OCOCH3), 4.10‒4.20 (1H, m, CHCH3), 
5.48 (1H, d, J 15.8 Hz, 3-CHH), 5.50 (1H, d, J 15.8 Hz, 3-CHH), 7.24‒7.32 (2H, m, ArH), 
7.39‒7.56 (5H, m, ArH), 7.74 (1H, ddd, J 7.0, 6.7, 1.5 Hz, ArH), 7.84 (1H, d, J 8.6 Hz, 
NH), 8.15 (1H, d, J 8.5 Hz, ArH); δC (101 MHz, CDCl3) 10.5 (CH3), 20.5 (CH3), 20.8 (CH3), 
29.8 (CH2), 46.8 (CH), 61.2 (CH2), 125.7 (C), 126.8 (CH), 128.0 (CH), 128.3 (C), 128.4 (2 
× CH), 128.5 (CH), 129.42 (CH), 129.44 (CH), 129.6 (CH), 130.2 (CH), 135.4 (C), 145.9 
(C), 150.2 (C), 151.9 (C), 165.2 (C), 170.2 (C); m/z (ESI) 399.1666 (MNa+. C23H24N2NaO3 
requires 399.1679). 
Ethyl 4-hydroxy-3-methylquinoline-2-carboxylate (170)170 
 
To a solution of aniline (2.25 mL, 24.7 mmol) and diethyl oxalpropionate (4.67 mL, 24.7 
mmol) in cyclohexane (200 mL) under argon was added p-toluenesulfonic acid (0.0300 g, 
0.170 mmol) and the reaction mixture heated under reflux at 120 °C using a Dean-Stark 
condenser for 72 h. After cooling to ambient temperature, the reaction mixture was 
212 
filtered, washed with hexane (100 mL) and the filtrate concentrated in vacuo. To this crude 
product was added polyphosphoric acid (20.0 g) and the mixture stirred at 120 °C for 1 h. 
After cooling to ambient temperature, a 2.4 M aqueous sodium carbonate solution (100 
mL) was added slowly and the resulting yellow precipitate filtered. The crude material was 
purified by flash column chromatography, eluting with 50% ethyl acetate in petroleum 
ether (40‒60) to afford ethyl 4-hydroxy-3-methylquinoline-2-carboxylate (170) as a pale 
yellow solid (3.41 g, 60%). Mp 176‒178 °C, lit.170 176‒178 °C; δH (400 MHz, CDCl3) 1.48 
(3H, t, J 7.2 Hz, OCH2CH3), 2.49 (3H, s, 3-CH3), 4.52 (2H, q, J 7.2 Hz, OCH2CH3), 7.31‒
7.37 (2H, m, ArH), 7.62 (1H, ddd, J 8.4, 5.5, 1.5 Hz, ArH), 8.35 (1H, J 8.4 Hz, ArH), 9.04 
(1H, s, OH); δC (101 MHz, CDCl3) 11.7 (CH3), 14.2 (CH3), 63.3 (CH2), 117.5 (CH), 122.8 
(C), 123.7 (C), 123.8 (CH), 126.6 (CH), 132.7 (CH), 132.8 (C), 138.3 (C), 164.4 (C), 179.7 
(C); m/z (EI) 231 (M+. 100%), 202 (100), 157 (98), 129 (46), 84 (41). 
Ethyl 4-bromo-3-methylquinoline-2-carboxylate (171)170 
 
To a solution of ethyl 4-hydroxy-3-methylquinoline-2-carboxylate (170) (3.40 g, 14.7 
mmol) in acetonitrile (187 mL) under argon was added phosphorous oxybromide (12.6 g, 
44.1 mmol) and potassium carbonate (6.10 g, 44.1 mmol) and the reaction mixture heated 
under reflux for 2 h. After cooling to ambient temperature, the reaction mixture was 
concentrated in vacuo. Water (100 mL) was added to the residue and the product was 
extracted with ethyl acetate (3 × 100 mL), dried (MgSO4), filtered and concentrated in 
vacuo to afford ethyl 4-bromo-3-methylquinoline-2-carboxylate (171) as a brown solid 
(3.71 g, 86%). Mp 48‒50 °C, lit.170 48‒50 °C; δH (400 MHz, CDCl3) 1.48 (3H, t, J 7.1 Hz, 
OCH2CH3), 2.72 (3H, s, 3-CH3), 4.55 (2H, q, J 7.1 Hz, OCH2CH3), 7.68 (1H, ddd, J 8.3, 
6.9, 1.4 Hz, ArH), 7.75 (1H, ddd, J 8.3, 6.9, 1.4 Hz, ArH), 8.18 (1H, br d, J 8.3 Hz, ArH), 
8.25 (1H, br d, J 8.3 Hz, ArH); δC (101 MHz, CDCl3) 14.2 (CH3), 19.8 (CH3), 62.3 (CH2), 
126.8 (CH), 128.5 (C), 129.2 (CH), 129.4 (C), 129.9 (CH), 130.2 (CH), 137.3 (C), 146.0 
(C), 151.1 (C), 166.5 (C); m/z (EI) 293 (M+. 100%), 264 (39), 221 (73), 140 (100), 114 
(21), 84 (81). 
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Ethyl 3-methyl-4-phenylquinoline-2-carboxylate (172)210 
 
To a solution of ethyl 4-bromo-3-methylquinoline-2-carboxylate (171) (3.70 g, 12.6 mmol) 
in N,N-dimethylformamide (200 mL) was added benzeneboronic acid (2.00 g, 16.4 mmol) 
and potassium phosphate tribasic (3.48 g, 16.4 mmol) and the reaction mixture degassed 
under argon for 0.2 h. To this solution was added tetrakis(triphenylphosphine)palladium(0) 
(0.440 g, 0.378 mmol) and the reaction stirred under reflux for 16 h. After cooling to 
ambient temperature, the reaction mixture was filtered through a short pad of Celite®, 
washing with ethyl acetate (500 mL) and the filtrate washed with water (3 × 500 mL) and 
brine (500 mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo. 
The crude material was purified by flash column chromatography, eluting with 20% ethyl 
acetate in petroleum ether (40‒60) and recrystallised from hexane to afford ethyl 3-
methyl-4-phenylquinoline-2-carboxylate (172) as white crystals (2.88 g, 78%). Mp 110‒
112 °C, lit.210 114‒115 °C; δH (400 MHz, CDCl3) 1.48 (3H, t, J 7.2 Hz, OCH2CH3), 2.32 
(3H, s, 3-CH3), 4.55 (2H, q, J 7.2 Hz, OCH2CH3), 7.23‒7.27 (2H, m, ArH), 7.37‒7.56 (5H, 
m, ArH), 7.67 (1H, ddd, J 8.3, 6.7, 1.4 Hz, ArH), 8.19 (1H, br d, J 8.3 Hz, ArH); δC (101 
MHz, CDCl3) 14.3 (CH3), 16.8 (CH3), 62.1 (CH2), 126.0 (CH), 126.2 (C), 127.7 (CH), 128.1 
(CH), 128.2 (C), 128.7 (2 × CH), 129.0 (CH), 129.2 (2 × CH), 129.8 (CH), 136.7 (C), 145.6 
(C), 148.7 (C), 151.5 (C), 167.4 (C); m/z (CI) 292 (MH+. 100%), 220 (48), 137 (3), 113 (9), 
85 (19). 
3-Methyl-4-phenylquinoline-2-carboxylic acid (173)210 
 
To a solution of ethyl 3-methyl-4-phenylquinoline-2-carboxylate (172) (2.88 g, 9.88 mmol) 
in 50% aqueous ethanol (200 mL) was added sodium hydroxide (1.58 g, 39.5 mmol) and 
the reaction mixture heated at 80 °C for 1.5 h. After cooling to ambient temperature, the 
ethanol was removed in vacuo and the reaction mixture acidified to pH 1 with a 1 M 
aqueous hydrochloric acid solution. The product was extracted into dichloromethane (3 × 
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100 mL) and washed with water (100 mL) and brine (100 mL). The organic extracts were 
dried (MgSO4), filtered and concentrated in vacuo to afford 3-methyl-4-phenylquinoline-2-
carboxylic acid (173) as a white solid (2.54 g, 98%). The spectroscopic data were 
consistent with the literature.210 Mp 130‒132 °C; δH (400 MHz, CDCl3) 2.65 (3H, s, 3-CH3), 
7.23‒7.25 (2H, m, ArH), 7.43 (1H, br d, J 8.3 Hz, ArH), 7.50‒7.60 (4H, m, ArH), 7.75 (1H, 
ddd, J 8.3, 6.9, 1.2 Hz, ArH), 8.14 (1H, br d, J 8.3 Hz, ArH); δC (101 MHz, CDCl3) 17.4 
(CH3), 126.5 (CH), 128.4 (CH), 128.8 (2 × CH), 129.0 (CH), 129.1 (CH), 129.2 (2 × CH), 
129.7 (C), 129.8 (CH), 130.2 (C), 136.4 (C), 143.6 (C), 144.2 (C), 151.4 (C), 164.4 (C); 
m/z (CI) 264 (MH+.100%), 220 (19), 188 (3), 85 (27). 
(R)-(N-sec-Butyl)-3-methyl-4-phenylquinoline-2-carboxamide (174)174 
 
To a solution of 3-methyl-4-phenylquinoline-2-carboxylic acid (173) (2.54 g, 9.65 mmol) in 
anhydrous N,N-dimethylformamide (250 mL) was added O-(benzotriazol-1-yl)-N,N,Nʹ,Nʹ-
tetramethyluronium hexafluorophosphate (5.49 g, 14.5 mmol) and N,Nʹ-
diisopropylethylamine (3.40 mL, 19.3 mmol). The reaction mixture was stirred at room 
temperature for 0.5 h before the addition of (R)-(−)-sec-butylamine (1.10 mL, 10.6 mmol). 
The reaction mixture was then heated at 50 °C for 4 h. The reaction mixture was cooled to 
room temperature, diluted with ethyl acetate (300 mL) and washed with water (3 × 200 
mL) and brine (200 mL). The organic layer was dried (MgSO4), filtered and concentrated 
in vacuo to give a brown oil. The crude material was purified by flash column 
chromatography, eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford (R)-
(N-sec-butyl)-3-methyl-4-phenylquinoline-2-carboxamide (174) as a white solid (2.81 g, 
91%). Mp 152‒154 °C, lit.174 157‒158 °C; [α]D25 −26.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 
1.03 (3H, t, J 7.4 Hz, CH2CH3), 1.33 (3H, d, J 6.6 Hz, CHCH3), 1.61‒1.75 (2H, m, 
CH2CH3), 2.56 (3H, s, 3-CH3), 4.07‒4.21 (1H, m, CHCH3), 7.21–7.25 (2H, m, ArH), 7.35 
(1H, br d, J 8.3 Hz, ArH), 7.40–7.55 (4H, m, ArH), 7.65 (1H, ddd, J 8.3, 6.8, 1.4 Hz, ArH), 
7.90 (1H, d, J 8.3 Hz, NH), 8.09 (1H, br d, J 8.3 Hz, ArH); δC (101 MHz, CDCl3) 10.6 
(CH3), 17.6 (CH3), 20.5 (CH3), 29.9 (CH2), 46.8 (CH), 126.1 (CH), 127.5 (CH), 127.9 (CH), 
128.6 (C), 128.6 (2 × CH), 128.7 (CH), 128.8 (C), 129.3 (2 × CH), 129.5 (CH), 137.3 (C), 
144.7 (C), 149.5 (C), 150.1 (C), 166.2 (C); m/z (CI) 319 (MH+. 100%), 220 (19), 202 (5), 
148 (6), 113 (16), 85 (77). 
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(R)-(N-sec-Butyl)-N-methyl-3-methyl-4-phenylquinoline-2-carboxamide (167)174 
 
To a solution of (R)-(N-sec-butyl)-3-methyl-4-phenylquinoline-2-carboxamide (174) (2.81 
g, 8.82 mmol) in tetrahydrofuran (176 mL) was added sodium hydride (0.710 g, 17.6 
mmol, 60% dispersion in mineral oil) and the reaction mixture stirred under argon at room 
temperature for 0.5 h. Iodomethane (2.75 mL, 44.1 mmol) was then added and the 
reaction mixture stirred at room temperature for a further 3 h. The reaction was quenched 
by the addition of water (20 mL) and the tetrahydrofuran was removed in vacuo. The 
aqueous phase was extracted with diethyl ether (3 × 50 mL) and the combined organic 
layers were washed with a 1 M aqueous solution of sodium thiosulfate (100 mL), brine 
(100 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude material was 
purified by flash column chromatography, eluting with 25% ethyl acetate in petroleum 
ether (40‒60) to afford (R)-(N-sec-butyl)-N-methyl-3-methyl-4-phenylquinoline-2-
carboxamide (167) as a white solid (2.75 g, 94%). Mp 114‒117 °C, lit.174 117‒118 °C; 
[α]D23 −6.3 (c 1.0, CHCl3); NMR spectra showed a 1:1 mixture of rotamers. Signals for 
both rotamers are recorded. δH (400 MHz, CDCl3) 0.86 (3H, t, J 7.3 Hz, CH2CH3), 1.03 
(3H, t, J 7.3 Hz, CH2CH3), 1.24 (3H, d, J 6.6 Hz, CHCH3), 1.28 (3H, d, J 6.6 Hz, CHCH3), 
1.36‒1.49 (2H, m, CH2CH3), 1.53‒1.74 (2H, m, CH2CH3), 2.21 (3H, s, 3-CH3), 2.23 (3H, s, 
3-CH3), 2.73 (3H, s, NCH3), 3.04 (3H, s, NCH3), 3.43‒3.55 (1H, m, CHCH3), 4.83‒4.95 
(1H, m, CHCH3), 7.23‒7.31 (4H, m, ArH), 7.38‒7.44 (4H, m, ArH), 7.45‒7.57 (6H, m, 
ArH), 7.60‒7.67 (2H, m, ArH), 8.09 (1H, d, J 8.3 Hz, ArH), 8.12 (1H, d, J 8.3 Hz, ArH); δC 
(101 MHz, CDCl3) 11.2 (CH3), 11.3 (CH3), 16.0 (CH3), 16.4 (CH3), 17.3 (CH3), 18.6 (CH3), 
25.5 (CH3), 26.5 (CH2), 27.2 (CH2), 29.3 (CH3), 49.6 (CH), 55.8 (CH), 124.6 (C), 125.3 (C), 
125.9 (CH), 126.0 (CH), 126.8 (CH), 126.8 (CH), 127.4 (C), 127.4 (C), 128.0 (2 × CH), 
128.6 (CH), 128.6 (2 × CH), 128.7 (CH), 128.7 (CH), 129.2 (CH), 129.2 (4 × CH), 129.4 
(CH), 129.4 (CH), 136.7 (C), 136.8 (C), 145.8 (C), 146.1 (C), 148.0 (C), 148.1 (C), 156.1 
(C), 156.6 (C), 169.4 (C), 169.7 (C); m/z (CI) 333 (MH+. 100%), 291 (48), 250 (41), 220 
(14), 86 (23). 
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(R)-3-Bromomethyl-(N-sec-butyl)-N-methyl-4-phenylquinoline-2-carboxamide (168) 
 
A solution of (R)-(N-sec-butyl)-N-methyl-3-methyl-4-phenylquinoline-2-carboxamide (167) 
(2.70 g, 8.12 mmol) in chloroform (300 mL) was degassed under argon for 0.2 h. To this 
was added N-bromosuccinimide (2.17 g, 12.2 mmol) and dibenzoyl peroxide (0.200 g, 
0.812 mmol) and the solution heated under reflux for 6 h. A further portion of N-
bromosuccinimide (1.00 g, 5.62 mmol) was then added and the solution heated under 
reflux for a further 16 h. After cooling to ambient temperature, the reaction mixture was 
filtered, and the solvent removed in vacuo. The crude residue was then diluted with ethyl 
acetate (100 mL) and washed with water (3 × 100 mL). The organic layer was dried 
(MgSO4), filtered and concentrated in vacuo. The crude material was purified by flash 
column chromatography, eluting with 0‒5% ethyl acetate in dichloromethane to afford (R)-
3-bromomethyl-(N-sec-butyl)-N-methyl-4-phenylquinoline-2-carboxamide (168) as a pale 
yellow solid (2.76 g, 83%). Mp 160‒164 °C; νmax/cm-1 (KBr) 2970 (CH), 1631 (CO), 1484, 
1397, 1046, 766; [α]D28 −9.0 (c 1.0, CHCl3); NMR spectra showed a 2:1 mixture of 
rotamers. Only signals for the major rotamer are recorded. δH (400 MHz, CDCl3) 1.09 (3H, 
t, J 7.4 Hz, CH2CH3), 1.32 (3H, d, J 6.8 Hz, CHCH3), 1.51‒1.80 (2H, m, CH2CH3), 2.86 
(3H, s, NCH3), 4.60 (1H, d, J 10.2 Hz, 3-CHH), 4.67 (1H, d, J 10.2 Hz, 3-CHH), 4.81‒4.94 
(1H, m, CHCH3), 7.37‒7.48 (4H, m, ArH), 7.51‒7.59 (3H, m, ArH), 7.70 (1H, ddd, J 8.3, 
6.7, 1.5 Hz, ArH), 8.12 (1H, d, J 8.8 Hz, ArH); δC (101 MHz, CDCl3) 11.1 (CH3), 17.1 
(CH3), 26.6 (CH2), 27.7 (CH2), 30.5 (CH3), 50.1 (CH), 126.3 (C), 126.7 (2 × CH), 127.3 
(C), 127.4 (CH), 128.6 (2 × CH), 128.7 (CH), 129.1 (CH), 129.5 (CH), 130.1 (CH), 134.9 
(C), 146.4 (C), 149.3 (C), 156.0 (C), 168.4 (C); m/z (EI) 410.0992 (M+. C22H2379BrN2O 
requires 410.0994), 298 (15%), 296 (14), 217 (57), 189 (28), 151 (10), 86 (100). 
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(R)-(N-sec-Butyl)-3-chloromethyl-N-methyl-4-phenylquinoline-2-carboxamide (184) 
 
To a solution of (R)-3-bromomethyl-(N-sec-butyl)-N-methyl-4-phenylquinoline-2-
carboxamide (168) (0.500 g, 1.22 mmol) in tetrahydrofuran (10 mL) under argon was 
added lithium chloride (0.160 g, 3.66 mmol) and the reaction mixture stirred at room 
temperature for 16 h. The reaction was quenched with water (30 mL) and the mixture was 
extracted into ethyl acetate (3 × 30 mL). The organic layers were combined and washed 
with brine (90 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude material 
was purified by flash column chromatography, eluting with 5% ethyl acetate in 
dichloromethane to afford (R)-(N-sec-butyl)-3-chloromethyl-N-methyl-4-phenylquinoline-2-
carboxamide (184) as a white solid (0.327 g, 73%). Mp 140–142 °C; νmax/cm-1 (neat) 2970 
(CH), 1620 (CO), 1481, 1404, 1219, 748; [α]D28 –11.6 (c 1.0, CHCl3); NMR spectra 
showed a 1.5:1 mixture of rotamers. Only signals for the major rotamer are recorded. δH 
(400 MHz, CDCl3) 1.08 (3H, t, J 7.4 Hz, CH2CH3), 1.30 (3H, d, J 6.8 Hz, CHCH3), 1.49‒
1.79 (2H, m, CH2CH3), 2.84 (3H, s, NCH3), 4.67 (1H, d, J 10.6 Hz, 3-CHH), 4.72 (1H, d, J 
10.6 Hz, 3-CHH), 4.81‒4.93 (1H, m, CHCH3), 7.34‒7.61 (7H, m, ArH), 7.69‒7.75 (1H, m, 
ArH), 8.13 (1H, d, J 8.4 Hz, ArH); δC (101 MHz, CDCl3) 11.1 (CH3), 17.1 (CH3), 26.6 
(CH2), 30.4 (CH3), 40.4 (CH2), 50.1 (CH), 125.8 (C), 126.8 (CH), 127.2 (C), 127.4 (CH), 
128.5 (2 × CH), 128.7 (CH), 129.4 (CH), 129.6 (2 × CH), 130.1 (CH), 134.9 (C), 146.6 (C), 
149.5 (C), 156.1 (C), 168.5 (C); m/z (ESI) 389.1381 (MNa+. C22H2335ClN2NaO requires 
389.1391). 
(R)-(N-sec-Butyl)-3-(fluoromethyl)-N-methyl-4-phenylquinoline-2-carboxamide (155) 
 
To a solution of 18-crown-6 (0.032 g, 0.12 mmol) in acetonitrile (2.5 mL) under argon was 
added potassium fluoride (0.036 g, 0.61 mmol) and the suspension stirred at ambient 
temperature for 0.5 h. A solution of (R)-(N-sec-butyl)-3-bromomethyl-N-methyl-4-
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phenylquinoline-2-carboxamide (168) (0.050 g, 0.122 mmol) in acetonitrile (6.0 mL) and 
dichloromethane (3.0 mL) was then added dropwise to the reaction mixture. The mixture 
was stirred under reflux for 72 h. On cooling to ambient temperature, water (20 mL) was 
added to the mixture and the product extracted using dichloromethane (3 × 20 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The 
crude material was purified by flash column chromatography, eluting with 30% ethyl 
acetate in petroleum ether (40‒60) to afford (R)-(N-sec-butyl)-3-(fluoromethyl)-N-methyl-4-
phenylquinoline-2-carboxamide (155) as a white solid (0.023 g, 53%). Mp 146‒148 °C; 
νmax/cm-1 (neat) 2972 (CH), 1628 (CO), 1559, 1485, 1398, 1049, 970; [α]D30 −12.6 (c 0.5, 
CHCl3); NMR spectra showed a 3:1 mixture of rotamers. Only signals for the major 
rotamer are recorded. δH (400 MHz, CDCl3) 1.05 (3H, t, J 7.4 Hz, CH2CH3), 1.29 (3H, d, J 
6.8 Hz, CHCH3), 1.41‒1.78 (2H, m, CH2CH3), 2.77 (3H, s, NCH3), 4.84‒4.95 (1H, m, 
CHCH3), 5.35 (1H, dd, J 48.0, 10.5 Hz, 3-CHH), 5.40 (1H, dd, J 48.0, 10.5 Hz, 3-CHH), 
7.31‒7.40 (2H, m, ArH), 7.43‒7.58 (5H, m, ArH), 7.74 (1H, t, J 7.6 Hz, ArH), 8.17 (1H, d, J 
8.4 Hz, ArH); δC (101 MHz, CDCl3) 10.9 (CH3), 17.4 (CH3), 26.5 (CH3), 29.9 (CH2), 50.0 
(CH), 79.2 (CH2, 
1JCF 162.8 Hz), 123.0 (C, 
2JCF 15.1 Hz), 127.0 (CH), 127.1 (C, 
4JCF 2.3 
Hz), 127.4 (CH, 5JCF 1.2 Hz), 128.5 (2 × CH), 128.7 (CH), 129.6 (2 × CH), 129.7 (CH), 
130.4 (CH), 134.8 (C, 4JCF 1.5 Hz), 147.4 (C, 
3JCF 2.5 Hz), 150.8 (C, 
3JCF 4.7 Hz), 156.6 
(C, 5JCF 2.1 Hz), 168.8 (C); m/z (ESI) 373.1670 (MNa+. C22H23FN2NaO requires 373.1687); 
Enantiomeric excess was determined by HPLC analysis with a Chiralcel AD-H column 
(hexane:iPrOH 97.5:2.5, flow rate 1.0 mL/min), tmajor = 30.68 and 32.22 min, tminor = 27.15 
and 38.38 min; er = 99.5:0.5. 
Radiosynthesis of (R)-(N-sec-Butyl)-3-([18F]fluoromethyl)-N-methyl-4-
phenylquinoline-2-carboxamide ([18F]155) 
 
Radiofluorination was carried out on a GE TRACERlab FXFN synthesiser. [18F]Fluoride 
was produced by cyclotron irradiation of a target containing [18O]water via the 18O(p,n)18F 
nuclear reaction. After trapping on a Sep-Pak® Light QMA cartridge, the activity was 
eluted into the reaction vial using a solution of Kryptofix® 222 (16 mg) and potassium 
carbonate (2.9 mg) in acetonitrile (1.7 mL) and water (0.3 mL). Azeotropic drying took 
place using acetonitrile (1.0 mL), (R)-(N-sec-butyl)-3-chloromethyl-N-methyl-4-
phenylquinoline-2-carboxamide (184) (5.0 mg) in acetonitrile (1.0 mL) was added and the 
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reaction heated to 110 °C for 5 min. The reaction mixture was then diluted with acetonitrile 
(0.5 mL) and water (2.5 mL) and loaded onto a C18 Synergi Hydro-RP 80 Å, 150×10 mm, 
4 µm column (Phenomenex, UK). A 70% solution of acetonitrile in water was used as the 
mobile phase at a flow rate of 3 mL min−1. The radiolabelled product was detected by the 
HPLC gamma-detector and eluted at approximately 10 min. The collected fraction was 
diluted with water (20 mL) and then transferred onto a Sep-Pak® Plus Light C18 cartridge. 
This was rinsed with water (1 mL) and the product eluted with ethanol (0.25 mL) then 
saline (4.75 mL). This provided a 5% ethanol/saline formulation of the product in a total 
synthesis time of 32 min. The radiolabelled product was isolated with a radiochemical 
yield of 32% ± 2.9% and a specific activity of 144 ± 20 GBq mg−1 (n = 4). The 
radiochemical purity was >99%. 
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3.6 Benzotriazoles Experimental 
General procedure for the preparation of polymer-supported nitrite181 
The polymer-supported nitrite reagent was prepared by the addition of Amberlyst® A26 
hydroxide form resin (10.0 g, 40.0 mmol) to a solution of sodium nitrite (5.50 g, 80.0 
mmol) in water (200 mL). The mixture was stirred at room temperature for 0.5 h. The 
polymer-supported nitrite was filtered and washed with water until the pH of the filtrate 
became neutral. The content of the polymer-supported nitrite was 3.5 mmol of NO2− per 
g.181 
(2S)-3-Amino-2-[(benzyloxycarbonyl)amino]propionic acid (193)193 
 
To a suspension of Nα-(benzyloxycarbonyl)-L-asparagine (10.0 g, 37.6 mmol) in 
acetonitrile (19.2 mL), ethyl acetate (19.2 mL) and water (9.6 mL) was added 
(diacetoxyiodo)benzene (14.6 g, 45.1 mmol) and the reaction mixture cooled to between 
10‒15 °C and stirred for 0.75 h at this temperature. The reaction mixture was then allowed 
to reach room temperature over 0.75 h and heated to 70 °C for 0.1 h before allowing to 
cool to ambient temperature. The reaction mixture was filtered and the resulting solid 
washed with diethyl ether (100 mL) to afford (2S)-3-amino-2-
[(benzyloxycarbonyl)amino]propionic acid (193) as a white solid (8.96 g, 100%). Mp 208‒
210 °C; [α]D23 −7.9 (c 1.2, 1 M NaOH), lit.193 [α]D23 −7.7 (c 0.4, 1 M NaOH); δH (400 MHz, 
DMSO-d6/TFA) 2.99‒3.06 (1H, m, 3-HH), 3.21‒3.28 (1H, m, 3-HH), 4.30 (1H, dt, J 8.9, 4.6 
Hz, 2-H), 5.07 (2H, s, OCH2Ph), 7.28‒7.37 (5H, m, Ph), 7.70 (1H, d, J 8.9 Hz, NH), 7.91 
(2H, s, NH2); δC (101 MHz, DMSO-d6/TFA) 40.4 (CH2), 51.9 (CH), 66.0 (CH2), 127.95 (2 × 
CH), 128.0 (CH), 128.5 (2 × CH), 136.8 (C), 156.4 (C), 170.9 (C); m/z (ESI) 261 (MNa+. 
100%). 
Methyl (2S)-3-amino-2-[(benzyloxycarbonyl)amino]propanoate hydrochloride 
(191)194 
 
To a suspension of (2S)-3-amino-2-[(benzyloxycarbonyl)amino]propionic acid (193) (8.96 
g, 37.6 mmol) in methanol (144 mL) at 0 °C under argon was added dropwise thionyl 
chloride (4.12 mL, 56.4 mmol). The reaction mixture was allowed to reach room 
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temperature and stirred for 16 h. The solution was then concentrated in vacuo and 
azeotroped with toluene (3 × 50 mL) to remove excess thionyl chloride. The resulting 
residue was triturated with diethyl ether to afford methyl (2S)-3-amino-2-
[(benzyloxycarbonyl)amino]propanoate hydrochloride (191) as a white solid (9.48 g, 
100%). Mp 165‒168 °C, lit.211 165‒167 °C; [α]D22 −41.4 (c 1.1, MeOH), lit.211 [α]D20 −42.5 (c 
1.0, MeOH); δH (400 MHz, CD3OD) 3.23 (1H, dd, J 13.2, 8.8 Hz, 3-HH), 3.45 (1H, dd, J 
13.2, 5.1 Hz, 3-HH), 3.78 (3H, s, OCH3), 4.51 (1H, dd, J 8.8, 5.1 Hz, 2-H), 5.14 (2H, s, 
OCH2Ph), 7.30‒7.40 (5H, m, PhH); δC (101 MHz, CD3OD) 41.3 (CH2), 53.1 (CH), 53.4 
(CH3), 68.2 (CH2), 129.0 (2 × CH), 129.2 (CH), 129.5 (2 × CH), 137.8 (C), 158.7 (C), 
170.9 (C); m/z (ESI) 275 (MNa+. 100%). 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino]propanoate 
(189) 
 
To a solution of methyl (2S)-3-amino-2-[(benzyloxycarbonyl)amino]propanoate 
hydrochloride (191) (0.250 g, 0.991 mmol) in acetonitrile (7.5 mL) under argon was added 
2-fluoronitrobenzene (0.310 mL, 2.97 mmol) and triethylamine (0.410 mL, 2.97 mmol) and 
the reaction mixture stirred under reflux for 16 h. After cooling the reaction to ambient 
temperature, the solvent was removed in vacuo. The resulting residue was dissolved in 
ethyl acetate (50 mL), washed with water (3 × 50 mL) and brine (50 mL). The organic 
layer was dried (MgSO4), filtered and concentrated in vacuo. Crude material was purified 
by flash column chromatography, eluting with 0‒20% ethyl acetate in dichloromethane to 
afford methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino]propanoate 
(189) as a yellow solid (0.330 g, 89%). Mp 82‒84 °C; νmax/cm−1 (neat) 3348 (NH), 2956 
(CH), 1721 (CO), 1620, 1512 (C=C), 1265, 1234, 741; [α]D25 +50.8 (c 0.3, CHCl3); δH (400 
MHz, CDCl3) 3.64‒3.74 (5H, m, 3-H2 and OCH3), 4.57 (1H, dt, J 6.7, 5.7 Hz, 2-H), 5.04 
(2H, s, OCH2Ph), 5.63 (1H, d, J 6.7 Hz, NH), 6.69 (1H, br t, J 8.6 Hz, 4ʹ-H), 6.98 (1H, d, J 
8.7 Hz, 6ʹ-H), 7.27‒7.51 (6H, m, Ph and 5ʹ-H), 8.16 (1H, dd, J 8.6, 1.2 Hz, 3ʹ-H), 8.22 (1H, 
t, J 5.6 Hz, NH); δC (101 MHz, CDCl3) 44.6 (CH2), 53.1 (CH3), 53.6 (CH), 67.4 (CH2), 
113.7 (CH), 116.3 (CH), 127.0 (CH), 128.3 (2 × CH), 128.4 (CH), 128.7 (2 × CH), 132.8 
(C), 136.0 (C), 136.4 (CH), 144.9 (C), 155.9 (C), 170.8 (C); m/z (ESI) 396.1158 (MNa+. 
C18H19N3NaO6 requires 396.1166). 
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Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-{[2ʹ-nitro-4ʹ-
(trifluoromethyl)phenyl]amino}propanoate (196) 
 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-{[2ʹ-nitro-4ʹ-
(trifluoromethyl)phenyl]amino}propanoate (196) was synthesised as described for methyl 
(2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino]propanoate (189) using 
methyl (2S)-3-amino-2-[(benzyloxycarbonyl)amino]propanoate hydrochloride (191) (0.200 
g, 0.793 mmol), 2-fluoro-5-(trifluoromethyl)-1-nitrobenzene (0.333 mL, 2.38 mmol) and 
triethylamine (0.332 mL, 2.38 mmol) in acetonitrile (6.0 mL). The crude material was 
purified by flash column chromatography, eluting with 0‒20% ethyl acetate in 
dichloromethane to afford methyl (2S)-2-(benzyloxycarbonyl)amino]-3-{ [2ʹ-nitro-4ʹ-
(trifluoromethyl)phenyl]amino}propanoate (196) as a yellow solid (0.295 g, 84%). Mp 84‒
86 °C; νmax/cm−1 (neat) 3356 (NH), 2955 (CH), 1713 (CO), 1636 (CO), 1535 (C=C), 1435, 
1319, 1227, 1111, 756, 694; [α]D23 +25.9 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 3.75‒3.82 
(4H, m, 3-HH and OCH3), 3.85 (1H, ddd, J 13.8, 5.8, 5.4 Hz, 3-HH), 4.65 (1H, dt, J 6.9, 
5.4 Hz, 2-H), 5.09 (1H, d, J 12.1 Hz, OCHHPh), 5.14 (1H, d, J 12.1 Hz, OCHHPh), 5.83 
(1H, d, J 6.9 Hz, NH), 7.08 (1H, d, J 9.0 Hz, 6ʹ-H), 7.27‒7.43 (5H, m, Ph), 7.56 (1H, d, J 
9.0 Hz, 5ʹ-H), 8.42 (1H, s, 3ʹ-H), 8.48 (1H, t, J 5.8 Hz, NH); δC (126 MHz, CDCl3) 44.5 
(CH2), 53.2 (CH3), 53.5 (CH), 67.4 (CH2), 114.5 (CH), 118.2 (C, q, 
2JCF 34.4 Hz), 123.5 (C, 
q, 1JCF 271.0 Hz), 125.0 (CH, q, 
3JCF 4.3 Hz), 128.3 (2 × CH), 128.5 (CH), 128.6 (2 × CH), 
131.6 (C), 132.3 (CH, q, 3JCF 3.2 Hz), 135.9 (C), 146.6 (C), 156.0 (C), 170.4 (C); m/z (ESI) 
464.1040 (MNa+. C19H18F3N3NaO6 requires 464.1040). 
3-Fluoro-4-nitroanisole (195)212 
 
To a solution of 3-fluoro-4-nitrophenol (1.00 g, 6.37 mmol) in acetone (14 mL) under argon 
was added potassium carbonate (1.76 g, 12.7 mmol) and iodomethane (0.790 mL, 12.7 
mmol). The reaction was stirred at room temperature for 0.1 h before heating under reflux 
for 3 h. The reaction mixture was then filtered, washed with dichloromethane (20 mL) and 
the solvent removed in vacuo. Dichloromethane (40 mL) was added and the organic layer 
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washed with water (3 × 40 mL) and brine (40 mL), dried (MgSO4), filtered and the solvent 
removed in vacuo. The resulting residue was purified by flash column chromatography, 
eluting with 20% ethyl acetate in petroleum ether (40‒60) to afford 3-fluoro-4-nitroanisole 
(195) as a white solid (1.06 g, 97%). Mp 59‒61 °C, lit.212 61 °C; δH (400 MHz, CDCl3) 3.90 
(3H, s, OCH3), 6.73 (1H, dd, J 12.8, 2.6 Hz, 2-H), 6.76 (1H, ddd, J 9.2, 2.6, 1.0 Hz, 6-H), 
8.09 (1H, dd, J 9.2, 8.7 Hz, 5-H); δC (101 MHz, CDCl3) 56.4 (CH3), 103.2 (CH, d, 
2JCF 24.2 
Hz), 110.4 (CH, d, 3JCF 3.1 Hz), 127.9 (CH, d, 
4JCF 1.6 Hz), 130.7 (C, d, 
2JCF 7.6 Hz), 157.5 
(C, d, 1JCF 265.0 Hz), 165.2 (C, d, 
3JCF 11.0 Hz); m/z (ESI) 194 (MNa+. 100%). 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-methoxy-2ʹ-
nitrophenyl)amino]propanoate (200) 
 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-methoxy-2ʹ-nitrophenyl)amino]propanoate 
(200) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-
nitrophenyl)amino]propanoate (189) using methyl (2S)-3-amino-2-
[(benzyloxycarbonyl)amino]propanoate hydrochloride (200) (0.200 g, 0.793 mmol), 3-
fluoro-4-nitroanisole (195) (0.407 g, 2.38 mmol) and triethylamine (0.332 mL, 2.38 mmol) 
in acetonitrile (6.0 mL). The crude material was purified by flash column chromatography, 
eluting with 0‒20% ethyl acetate in dichloromethane to afford methyl (2S)-2-
(benzyloxycarbonyl)amino]-3-[(5ʹ-methoxy-2ʹ-nitrophenyl)amino]propanoate (200) as a 
yellow solid (0.277 g, 87%). Mp 82‒84 °C; νmax/cm−1 (neat) 3356 (NH), 2955 (CH), 1713 
(CO), 1620 (CO), 1582 (C=C), 1497, 1226, 1221, 748; [α]D23 +20.7 (c 1.0, CHCl3); δH (400 
MHz, CDCl3) 3.73 (1H, ddd, J 13.7, 6.2, 5.7 Hz, 3-HH), 3.77 (1H, ddd, J 13.7, 6.2, 5.7 Hz, 
3-HH), 3.80 (3H, s, OCH3), 3.87 (3H, s, OCH3), 4.64 (1H, dt, J 6.9, 6.2 Hz, 2-H), 5.13 (2H, 
s, CH2Ph), 5.63 (1H, d, J 6.9 Hz, NH), 6.27 (1H, dd, J 9.5, 2.5 Hz, 4ʹ-H), 6.43 (1H, d, J 2.5 
Hz, 6ʹ-H), 7.28‒7.42 (5H, m, Ph), 8.14 (1H, d, J 9.5 Hz, 3ʹ-H), 8.52 (1H, t, J 5.7 Hz, NH); 
δC (101 MHz, CDCl3) 44.6 (CH2), 53.1 (CH3), 53.2 (CH), 55.9 (CH3), 67.3 (CH2), 95.4 
(CH), 105.6 (CH), 127.0 (C), 128.2 (2 × CH), 128.4 (CH), 128.6 (2 × CH), 129.3 (CH), 
135.9 (C), 147.3 (C), 155.7 (C), 166.2 (C), 170.7 (C); m/z (ESI) 426.1266 (MNa+. 
C19H21N3NaO7 requires 426.1272). 
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Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(4ʹ,5ʹ-dichloro-2ʹ-
nitrophenyl)amino]propanoate (198) 
 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(4ʹ,5ʹ-dichloro-2ʹ-
nitrophenyl)amino]propanoate (198) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino]propanoate (189) using methyl (2S)-
3-amino-2-[(benzyloxycarbonyl)amino]propanoate hydrochloride (191) (0.400 g, 1.59 
mmol), 2-fluoro-4,5-dichloro-1-nitrobenzene (0.628 mL, 4.77 mmol) and triethylamine 
(0.665 mL, 4.77 mmol) in acetonitrile (12 mL). The crude material was purified by flash 
column chromatography, eluting with 0‒20% ethyl acetate in dichloromethane to afford 
methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(4ʹ,5ʹ-dichloro-2ʹ-nitrophenyl)amino] 
propanoate (198) as a yellow solid (0.599 g, 85%). Mp 94‒96 °C;νmax/cm−1 (neat) 3358 
(NH), 2953 (CH), 1716 (CO), 1612 (CO), 1521 (C=C), 1485, 1223, 759; [α]D23 +28.4 (c 
1.0, CHCl3); δH (400 MHz, CDCl3) 3.72 (1H, ddd, J 13.6, 5.6, 5.0 Hz, 3-HH) , 3.76 (1H, 
ddd, J 13.6, 5.6, 5.0 Hz, 3-HH), 3.81 (3H, s, OCH3), 4.64 (1H, dt, J 6.1, 5.6 Hz, 2-H), 5.13 
(2H, s, CH2Ph), 5.71 (1H, d, J 6.1 Hz, NH), 7.13 (1H, s, 6ʹ-H), 7.27‒7.44 (5H, m, Ph), 8.18 
(1H, t, J 5.0 Hz, NH), 8.26 (1H, s, 3ʹ-H); δC (101 MHz, CDCl3) 44.8 (CH2), 53.2 (CH3), 53.4 
(CH), 67.6 (CH2), 115.1 (CH), 119.7 (C), 127.9 (CH), 128.2 (2 × CH), 128.4 (CH), 128.6 (2 
× CH), 131.2 (C), 135.7 (C), 141.3 (C), 143.6 (C), 155.9 (C), 170.3 (C); m/z (ESI) 
464.0373 (MNa+. C18H1735Cl2N3NaO6 requires 464.0387). 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-chloro-4ʹ-methyl-2ʹ-
nitrophenyl)amino]propanoate (199) 
 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-chloro-4ʹ-methyl-2ʹ-
nitrophenyl)amino]propanoate (199) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino]propanoate (189) using methyl (2S)-
3-amino-2-[(benzyloxycarbonyl)amino]propanoate hydrochloride (191) (0.400 g, 1.59 
mmol), 1-chloro-5-fluoro-2-methyl-4-nitrobenzene (0.904 g, 4.77 mmol) and triethylamine 
(0.665 mL, 4.77 mmol) in acetonitrile (12 mL). The crude material was purified by flash 
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column chromatography, eluting with 0‒20% ethyl acetate in dichloromethane to afford 
methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-chloro-4ʹ-methyl-2ʹ-nitrophenyl)amino] 
propanoate (199) as a yellow oil (0.643 g, 96%). νmax/cm−1 (neat) 3360 (NH), 2951 (CH), 
1738 (CO), 1726 (CO), 1626, 1501 (C=C), 1228, 1217, 978; [α]D23 +23.5 (c 1.0, CHCl3); δH 
(400 MHz, CDCl3) 2.28 (3H, s, 4ʹ-CH3), 3.71 (1H, ddd, J 13.6, 5.7, 5.3 Hz, 3-HH), 3.75 
(1H, ddd, J 13.6, 5.7, 5.3 Hz, 3-HH), 3.80 (3H, s, OCH3), 4.65 (1H, dt, J 6.3, 5.3 Hz, 2-H), 
5.13 (2H, s, CH2Ph), 5.70 (1H, d, J 6.3 Hz, NH), 7.00 (1H, s, 6ʹ-H), 7.27‒7.39 (5H, m, Ph), 
8.03 (1H, s, 3ʹ-H), 8.08 (1H, t, J 5.7 Hz, NH); δC (101 MHz, CDCl3) 18.9 (CH3), 44.7 (CH2), 
53.1 (CH3), 53.5 (CH), 67.4 (CH2), 113.8 (CH), 124.2 (C), 128.1 (CH), 128.2 (2 × CH), 
128.3 (CH), 128.6 (2 × CH), 131.0 (C), 135.9 (C), 143.6 (C), 143.6 (C), 155.9 (C), 170.5 
(C); m/z (ESI) 444.0916 (MNa+. C19H2035ClN3NaO6 requires 444.0933). 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(4ʹ-bromo-2ʹ-
nitrophenyl)amino]propanoate (197) 
 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(4ʹ-bromo-2ʹ-nitrophenyl)amino]propanoate 
(197) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-
nitrophenyl)amino]propanoate (189) using methyl (2S)-3-amino-2-
[(benzyloxycarbonyl)amino]propanoate hydrochloride (191) (3.97 g, 13.8 mmol), 5-bromo-
2-fluoro-1-nitrobenzene (5.10 mL, 41.3 mmol) and triethylamine (5.90 mL, 41.3 mmol) in 
acetonitrile (50 mL). The crude material was purified by flash column chromatography, 
eluting with 0‒20% ethyl acetate in dichloromethane to afford methyl (2S)-2-
(benzyloxycarbonyl)amino]-3-[(4ʹ-bromo-2ʹ-nitrophenyl)amino]propanoate (197) as a 
yellow solid (5.75 g, 92%). Mp 86‒89 °C; νmax/cm−1 (neat) 3364 (NH), 2955 (CH), 1721 
(CO), 1612 (CO), 1504 (C=C), 1227, 1065; [α]D25 +14.3 (c 1.1, CHCl3); δH (400 MHz, 
CDCl3) 3.60‒3.76 (5H, m, 3-H2 and OCH3), 4.60 (1H, dt, J 6.9, 5.8 Hz, 2-H), 5.06 (1H, d, J 
12.2 Hz, OCHHPh), 5.11 (1H, d, J 12.2 Hz, OCHHPh), 6.06 (1H, d, J 6.9 Hz, NH), 6.81 
(1H, d, J 9.1 Hz, 6ʹ-H), 7.20‒7.30 (5H, m, Ph), 7.36 (1H, dd, J 9.1, 1.5 Hz, 5ʹ-H), 8.16 (1H, 
d, J 1.5 Hz, 3ʹ-H), 8.19 (1H, t, J 6.0 Hz, NH); δC (101 MHz, CDCl3) 44.2 (CH2), 52.8 (CH3), 
53.2 (CH), 67.0 (CH2), 107.0 (C), 115.3 (CH), 127.9 (2 × CH), 128.1 (CH), 128.3 (2 × CH), 
128.6 (CH), 132.5 (C), 135.8 (C), 138.7 (CH), 143.6 (C), 155.9 (C), 170.4 (C); m/z (ESI) 
474.0276 (MNa+. C18H1879BrN3NaO6 requires 474.0271). 
226 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (187) 
 
To a solution of (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino]propanoate 
(189) (0.320 g, 0.857 mmol) in methanol (12 mL) was added tin(II) dichloride dihydrate 
(0.970 g, 4.29 mmol) and the reaction mixture stirred under reflux for 20 h. After cooling 
the reaction to ambient temperature, the solvent was removed in vacuo and the resulting 
residue dissolved in ethyl acetate (50 mL) and mixed with a saturated solution of aqueous 
sodium hydrogen carbonate (30 mL). The biphasic mixture was filtered through a pad of 
Celite® and the organic layer separated from the aqueous layer. The product was further 
extracted from the aqueous layer with ethyl acetate (2 × 30 mL) and the combined organic 
layers were washed with brine (50 mL), dried (MgSO4), filtered and concentrated in vacuo. 
The crude material was purified by flash column chromatography, eluting with 10% ethyl 
acetate in dichloromethane to afford methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-
aminophenyl)amino]propanoate (188) as a white solid (0.244 g, 83%). This material was 
then used immediately in the following step. To a solution of methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[(2ʹ-aminophenyl)amino]propanoate (188) (0.244 g, 0.711 
mmol) in acetonitrile (12 mL) at −10 °C was added p-toluenesulfonic acid (0.405 g, 2.13 
mmol) and polymer-supported nitrite (0.609 g, containing 2.13 mmol of NO2−) and the 
reaction mixture stirred at this temperature for 3 h. The reaction mixture was filtered, and 
the resin washed with dichloromethane (50 mL). The organic layers were washed with a 
saturated solution of aqueous sodium hydrogen carbonate (50 mL) and brine (50 mL), 
dried (MgSO4), filtered and concentrated in vacuo. The crude material was purified by 
flash column chromatography, eluting with 10% ethyl acetate in dichloromethane to afford 
methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate 
(187) as a white solid (0.148 g, 59%). Mp 82‒85 °C; νmax/cm−1 (neat) 3325 (NH), 2955 
(CH), 1713 (CO), 1504 (C=C), 1211, 1057, 741; [α]D25 +37.0 (c 0.4, CHCl3); δH (400 MHz, 
CDCl3) 3.75 (3H, s, OCH3), 4.88 (1H, dt, J 7.0, 4.4 Hz, 2-H), 5.05‒5.18 (4H, m, 3-H2 and 
OCH2Ph), 5.66 (1H, d, J 7.0 Hz, NH), 7.29‒7.45 (8H, m, Ph, 5ʹ-H, 6ʹ-H and 7ʹ-H), 8.03 
(1H, br d, J 8.0, 4ʹ-H); δC (101 MHz, CDCl3) 48.7 (CH2), 53.3 (CH3), 54.4 (CH), 67.4 (CH2), 
109.2 (CH), 120.2 (CH), 124.2 (CH), 127.9 (CH), 128.3 (2 × CH), 128.5 (CH), 128.7 (2 × 
CH), 133.9 (C), 136.0 (C), 145.8 (C), 155.8 (C), 169.5 (C); m/z (ESI) 377.1223 (MNa+. 
C18H18N4NaO4 requires 377.1220). 
227 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(trifluoromethyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (200) 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(trifluoromethyl)-1H-benzo[d][1.2.3]triazol-
1ʹ-yl]propanoate (200) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (187) using 
methyl (2S)-2-(benzyloxycarbonyl)amino]-3-{[2ʹ-nitro-4ʹ-
(trifluoromethyl)phenyl]amino}propanoate (196) (0.290 g, 0.657 mmol), tin(II) dichloride 
dihydrate (0.742 g, 3.29 mmol) in methanol (9.0 mL). The crude material was purified by 
flash column chromatography, eluting with 0‒20% ethyl acetate in dichloromethane to 
afford methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-{[2ʹ-amino-4ʹ-
(trifluoromethyl)phenyl]amino}propanoate as a white solid (0.229 g, 85%). The next step 
was carried out as described previously using methyl (2S)-2-(benzyloxycarbonyl)amino]-3-
{[2ʹ-amino-4ʹ-(trifluoromethyl)phenyl]amino}propanoate (0.229 g, 5.57 mmol), p-
toluenesulfonic acid (0.313 g, 1.67 mmol) and polymer-supported nitrite (0.477 g, 
containing 1.67 mmol of NO2−) in acetonitrile (9.0 mL). The crude material was purified by 
flash column chromatography, eluting with 20‒40% ethyl acetate in petroleum ether (40‒
60) to afford methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(trifluoromethyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (200) as a white solid (0.129 g, 57%). Mp 130‒132; 
νmax/cm−1 (neat) 3333 (NH), 2957 (CH), 1742 (CO), 1717 (CO), 1526 (C=C), 1331, 1209, 
1123; [α]D23 +12.7 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 3.79 (3H, s, OCH3), 4.85 (1H, dt, J 
6.4, 4.4 Hz, 2-H), 5.05 (1H, d, J 4.4 Hz, 3-HH), 5.16 (1H, d, J 4.4 Hz, 3-HH), 5.18 (2H, s, 
OCH2Ph), 5.65 (1H, d, J 6.4 Hz, NH), 7.27‒7.43 (5H, m, Ph), 7.48 (1H, d, J 8.7 Hz, 7ʹ-H), 
7.52 (1H, d, J 8.7 Hz, 6ʹ-H), 8.33 (1H, s, 4ʹ-H); δC (126 MHz, CDCl3) 48.6 (CH2), 53.4 
(CH3), 54.3 (CH), 67.4 (CH2), 110.2 (CH), 118.4 (CH, q, 
3JCF 4.4 Hz), 124.0 (C, q, 
1JCF 272 
Hz), 124.5 (CH, q, 3JCF 3.0 Hz), 126.8 (C, q, 
2JCF 32.9 Hz), 128.4 (2 × CH), 128.5 (CH), 
128.6 (2 × CH), 135.3 (C), 135.8 (C), 144.8 (C), 155.6 (C), 169.1 (C); m/z (ESI) 445.1095 
(MNa+. C19H17F3N4NaO4 requires 445.1094). 
  
228 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(6ʹ-methoxy-1H-benzo[d][1.2.3]triazol-
1ʹ-yl)propanoate (201) 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(6ʹ-methoxy-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (201) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (187) using 
methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-methoxy-2ʹ-nitrophenyl)amino]propanoate 
(200) (0.270 g, 0.669 mmol), tin(II) dichloride dihydrate (0.756 g, 3.35 mmol) in methanol 
(9.0 mL). The crude material was purified by flash column chromatography, eluting with 0‒
20% ethyl acetate in dichloromethane to afford methyl (2S)-2-[(benzyloxycarbonyl)amino]-
3-[(5ʹ-methoxy-2ʹ-aminophenyl)amino]propanoate as a brown solid (0.147 g, 59%). The 
next step was carried out as described previously using methyl (2S)-2-
(benzyloxycarbonyl)amino]-3-[(5ʹ-methoxy-2ʹ-aminophenyl)amino]propanoate (0.147 g, 
0.394 mmol), p-toluenesulfonic acid (0.224 g, 1.18 mmol) and polymer-supported nitrite 
(0.338 g, containing 1.18 mmol of NO2−) in acetonitrile (6.0 mL). The crude material was 
purified by flash column chromatography, eluting with 0‒20% ethyl acetate in 
dichloromethane to afford methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(6ʹ-methoxy-1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (201) as a brown oil (0.056 g, 39%). νmax/cm−1 
(neat) 3333 (NH), 2953 (CH), 1717 (CO), 1622 (CO), 1505 (C=C), 1233, 1020, 698; [α]D23 
+17.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.73 (3H, s, OCH3), 3.80 (3H, s, OCH3), 4.88 
(1H, dt, J 7.6, 4.4 Hz, 2-H), 4.99 (1H, dd, J 14.5, 4.4 Hz, 3-HH), 5.08 (1H, dd, J 14.5, 4.4 
Hz, 3-HH), 5.11 (2H, s, OCH2Ph), 5.79 (1H, d, J 7.6 Hz, NH), 6.80 (1H, d, J 2.2 Hz, 7ʹ-H), 
6.98 (1H, dd, J 9.0, 2.2 Hz, 5ʹ-H), 7.22‒7.40 (5H, m, Ph), 7.85 (1H, d, J 9.0 Hz, 4ʹ-H); δC 
(101 MHz, CDCl3) 48.4 (CH2), 53.2 (CH3), 54.1 (CH), 55.7 (CH3), 67.2 (CH2), 89.4 (CH), 
116.6 (CH), 120.7 (CH), 128.0 (2 × CH), 128.3 (CH), 128.6 (2 × CH), 134.9 (C), 135.8 (C), 
141.0 (C), 155.7 (C), 160.3 (C), 169.5 (C); m/z (ESI) 407.1324 (MNa+. C19H20N4NaO5 
requires 407.1326). 
  
229 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ,6ʹ-dichloro-1H-benzo[d][1.2.3]triazol-
1ʹ-yl)propanoate (202) 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ,6ʹ-dichloro-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (202) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (187) using 
methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(4ʹ,5ʹ-dichloro-2ʹ-
nitrophenyl)amino]propanoate (198) (0.440 g, 0.669 mmol), tin(II) dichloride dihydrate 
(1.10 g, 4.98 mmol) in methanol (14 mL). The crude material was purified by flash column 
chromatography, eluting with 0‒20% ethyl acetate in dichloromethane to afford methyl 
(2S)-2-[(benzyloxycarbonyl)amino]-3-[(4ʹ,5ʹ-dichloro-2ʹ-aminophenyl)amino]propanoate as 
a brown oil (0.365 g, 89%). The next step was carried out as described previously using 
methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-methoxy-2ʹ-
aminophenyl)amino]propanoate (0.365 g, 0.889 mmol), p-toluenesulfonic acid (0.508 g, 
2.67 mmol) and polymer-supported nitrite (0.762 g, containing 2.67 mmol of NO2−) in 
acetonitrile (14 mL). The crude material was purified by flash column chromatography, 
eluting with 0‒20% ethyl acetate in dichloromethane to afford methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ,6ʹ-dichloro-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate 
(202) as a white solid (0.297 g, 80%). Mp 98‒100 °C; νmax/cm−1 (neat) 3322 (NH), 2957 
(CH), 1709 (CO), 1514 (C=C), 1434, 1208, 751; [α]D23 +11.2 (c 1.0, CHCl3); δH (400 MHz, 
CDCl3) 3.76 (3H, s, OCH3), 4.84 (1H, dt, J 7.0, 4.5 Hz, 2-H), 4.97‒5.15 (4H, m, 3-H2 and 
OCH2Ph), 6.00‒6.13 (1H, m, NH), 7.21‒7.36 (5H, m, Ph), 7.67 (1H, s, 7ʹ-H), 8.01 (1H, s, 
4ʹ-H); δC (101 MHz, CDCl3) 48.8 (CH2), 53.3 (CH3), 54.2 (CH), 67.5 (CH2), 110.7 (CH), 
120.8 (CH), 128.0 (2 × CH), 128.3 (CH), 128.6 (2 × CH), 128.9 (C), 132.9 (2 × C), 135.7 
(C), 144.3 (C), 155.8 (C), 169.2 (C); m/z (ESI) 445.0432 (MNa+. C18H1635Cl2N4NaO4 
requires 445.0441). 
  
230 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(6ʹ-chloro-5ʹ-methyl-1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (203) 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(6ʹ-chloro-5ʹ-methyl-1H-benzo[d][1.2.3]triazol-
1ʹ-yl)propanoate (203) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (187) using 
methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-chloro-4ʹ-methyl-2ʹ-
nitrophenyl)amino]propanoate (199) (0.520 g, 1.23 mmol), tin(II) dichloride dihydrate (1.40 
g, 6.15 mmol) in methanol (17 mL). The crude material was purified by flash column 
chromatography, eluting with 0‒20% ethyl acetate in dichloromethane to afford methyl 
(2S)-2-[(benzyloxycarbonyl)amino]-3-[(5ʹ-chloro-4ʹ-methyl-2ʹ-
aminophenyl)amino]propanoate as a brown oil (0.315 g, 65%). The next step was carried 
out as described previously using methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-chloro-
4ʹ-methyl-2ʹ-aminophenyl)amino]propanoate (0.315 g, 0.803 mmol), p-toluenesulfonic acid 
(0.458 g, 2.41 mmol) and polymer-supported nitrite (0.689 g, containing 2.41 mmol of 
NO2−) in acetonitrile (13 mL). The crude material was purified by flash column 
chromatography, eluting with 0‒20% ethyl acetate in dichloromethane to afford methyl 
(2S)-2-[(benzyloxycarbonyl)amino]-3-(6ʹ-chloro-5ʹ-methyl-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (203) as a white solid (0.247 g, 78%). Mp 86‒88 °C; νmax/cm−1 (neat) 3310 
(NH), 2955 (CH), 1747 (CO), 1713 (CO), 1516 (C=C), 1437, 1213, 754; [α]D23 +13.7 (c 
1.0, CHCl3); δH (500 MHz, CDCl3) 2.40 (3H, s, 5ʹ-CH3), 3.74 (3H, s, OCH3), 4.84 (1H, dt, 
7.4, 4.8 Hz, 2-H), 5.03 (2H, br d, J 4.8 Hz, 3-H2), 5.08 (2H, s, OCH2Ph), 6.08‒6.23 (1H, m, 
NH), 7.18‒7.38 (5H, m, Ph), 7.52 (1H, s, 4ʹ-H), 7.70 (1H, s, 7ʹ-H); δC (101 MHz, CDCl3) 
20.7 (CH3), 48.5 (CH2), 53.1 (CH3), 54.2 (CH), 67.3 (CH2), 109.2 (CH), 120.3 (CH), 128.1 
(2 × CH), 128.3 (CH), 128.5 (2 × CH), 132.5 (C), 132.9 (C), 135.3 (C), 135.8 (C), 144.4 
(C), 155.8 (C), 169.4 (C); m/z (ESI) 425.0975 (MNa+. C19H1935ClN4NaO4 requires 
425.0987). 
  
231 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (204) 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (204) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (187) using 
methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-bromo-2ʹ-nitrophenyl)amino]propanoate 
(197) (9.00 g, 19.9 mmol), tin(II) dichloride dihydrate (22.0 g, 99.5 mmol) in methanol (100 
mL). The crude material was purified by flash column chromatography, eluting with 0‒20% 
ethyl acetate in dichloromethane to afford methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-
bromo-2ʹ-aminophenyl)amino]propanoate as a brown oil (6.42 g, 76%). The next step was 
carried out as described previously using methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-
bromo-2ʹ-aminophenyl)amino]propanoate (6.30 g, 14.9 mmol), p-toluenesulfonic acid 
(8.50 g, 44.7 mmol) and polymer-supported nitrite (12.8 g, containing 44.7 mmol of NO2−) 
in acetonitrile (200 mL). The crude material was purified by flash column chromatography, 
eluting with 0‒20% ethyl acetate in dichloromethane to afford methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (204) 
as a white solid (4.25 g, 66%). Mp 110‒114 °C; νmax/cm−1 (neat) 3321 (NH), 2954 (CH), 
1717 (CO), 1512 (C=C), 1211, 1057, 752; [α]D22 −22.2 (c 1.0, CHCl3); δH (500 MHz, 
CDCl3) 3.77 (3H, s, OCH3), 4.84 (1H, dt, J 6.6, 4.5 Hz, 2-H), 5.00‒5.20 (4H, m, 3-H2 and 
OCH2Ph), 5.69 (1H, d, J 6.6 Hz, NH), 7.22‒7.47 (7H, m, Ph, 6ʹ-H and 7ʹ-H), 8.15 (1H, d, J 
1.0 Hz, 4ʹ-H); δC (126 MHz, CDCl3) 48.6 (CH2), 53.3 (CH3), 54.2 (CH), 67.3 (CH2), 110.4 
(CH), 117.4 (C), 122.6 (CH), 128.3 (2 × CH), 128.4 (CH), 128.6 (2 × CH), 131.2 (CH), 
132.8 (C), 135.8 (C), 146.7 (C), 155.6 (C), 169.1 (C); m/z (ESI) 455.0325 (MNa+. 
C18H1779BrN4NaO4 requires 455.0325). 
 (2S)-2-Amino-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (186) 
 
A solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (187) (0.0830 g, 0.236 mmol) in 6 M aqueous hydrochloric acid solution (10 
mL) was heated under reflux for 20 h. After cooling to ambient temperature, the reaction 
232 
mixture was concentrated in vacuo and the resulting residue recrystallised from methanol 
and diethyl ether to afford (2S)-2-amino-3-(1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid 
hydrochloride (186) as a pale brown solid (0.054 g, 94%). Mp 190‒192 °C; νmax/cm−1 
(neat) 2893 (NH/CH), 2739 (OH), 1728 (CO), 1234, 1165, 756; [α]D24 +11.9 (c 0.7, 
MeOH); δH (400 MHz, CD3OD) 4.79 (1H, dd, J 5.8, 4.1 Hz, 2-H), 5.26 (1H, dd, J 15.5, 4.1 
Hz, 3-HH), 5.37 (1H, dd, J 15.5, 5.8 Hz, 3-HH), 7.49 (1H, ddd, J 8.4, 7.0, 0.9 Hz, 5ʹ-H), 
7.63 (1H, ddd, J 8.5, 7.0, 0.9 Hz, 6ʹ-H), 7.84 (1H, dt, J 8.5, 0.9 Hz, 7ʹ-H), 8.05 (1H, dt, J 
8.4, 0.9 Hz, 4ʹ-H); δC (101 MHz, CD3OD) 48.0 (CH2), 53.5 (CH), 111.1 (CH), 120.3 (CH), 
126.0 (CH), 129.5 (CH), 134.9 (C), 146.8 (C), 168.9 (C); m/z (ESI) 229.0706 (MNa+. 
C9H10N4NaO2 requires 229.0696). 
(2S)-2-Amino-3-[5ʹ-(trifluoromethyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (205) 
 
(2S)-2-Amino-3-[5ʹ-(trifluoromethyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (205) was synthesised as described for (2S)-2-amino-3-(1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (186) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[5ʹ-(trifluoromethyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl]propanoate (200) (0.120 g, 0.284 mmol) in 6 M aqueous hydrochloric acid solution (20 
mL). The crude material was purified by recrystallisation from methanol and diethyl ether 
to afford (2S)-2-amino-3-[5ʹ-(trifluoromethyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid 
hydrochloride (205) as a pale brown solid (0.046 g, 59%). Mp 185‒187 °C (dec); νmax/cm−1 
(neat) 3381 (NH), 2916 (OH/CH), 1743 (CO), 1331, 1215, 1125, 816; [α]D24 +2.0 (c 1.0, 
MeOH); δH (400 MHz, CD3OD) 4.83 (1H, br t, J 4.7 Hz, 2-H), 5.36 (1H, dd, J 15.5, 4.7 Hz, 
3-HH), 5.45 (1H, dd, J 15.5, 4.7 Hz, 3-HH), 7.88 (1H, dd, J 8.8, 0.9 Hz, 6ʹ-H), 8.09 (1H, d, 
J 8.8 Hz, 7ʹ-H), 8.42 (1H, br s, 4ʹ-H); δC (101 MHz, CD3OD) 47.0 (CH2), 52.2 (CH), 111.6 
(CH), 117.3 (CH, q, 3JCF 4.5 Hz), 124.2 (C, q, 
1JCF 271 Hz), 124.3 (CH, q, 
3JCF 3.2 
Hz),126.8 (C, q, 2JCF 32.7 Hz), 135.2 (C), 144.7 (C), 167.6 (C); m/z (ESI) 297.0574 (MNa+. 
C10H9F3N4NaO2 requires 297.0570). 
233 
(2S)-2-Amino-3-(6ʹ-methoxy-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid 
hydrochloride (209) 
 
(2S)-2-Amino-3-(6ʹ-methoxy-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride 
(209) was synthesised as described for (2S)-2-amino-3-(1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoic acid hydrochloride (186) using methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-
(6ʹ-methoxy-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (201) (0.056 g, 0.146 mmol) in 6 M 
aqueous hydrochloric acid solution (11 mL). The crude material was purified by 
recrystallisation from methanol and diethyl ether to afford (2S)-2-amino-3-(6ʹ-methoxy-1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (209) as a pale brown solid (0.023 
g, 67%). Mp 179‒180 °C (dec); νmax/cm−1 (neat) 3403 (NH), 2895 (OH/CH), 1746 (CO), 
1624 (C=C), 1506, 1236, 820; [α]D24 +7.3 (c 1.0, MeOH); δH (400 MHz, CD3OD) 4.77 (1H, 
dd, J 5.4, 4.2 Hz, 2-H), 5.21 (1H, dd, J 15.4, 4.2 Hz, 3-HH), 5.31 (1H, dd, J 15.4, 5.4 Hz, 
3-HH), 7.08 (1H, dd, J 9.1, 2.2 Hz, 5ʹ-H), 7.25 (1H, d, J 2.2 Hz, 7ʹ-H), 7.86 (1H, d, J 9.1 
Hz, 4ʹ-H); δC (101 MHz, CD3OD) 46.4 (CH2), 52.2 (CH), 55.2 (CH3), 89.9 (CH), 117.3 
(CH), 119.5 (CH), 134.9 (C), 140.6 (C), 160.9 (C), 167.7 (C); m/z (ESI) 259.0808 (MNa+. 
C10H12N4NaO3 requires 259.0802). 
(2S)-2-Amino-3-(5ʹ,6ʹ-dichloro-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid 
hydrochloride (207) 
 
(2S)-2-Amino-3-(5ʹ,6ʹ-dichloro-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride 
(207) was synthesised as described for (2S)-2-amino-3-(1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoic acid hydrochloride (186) using methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-
(5ʹ,6ʹ-dichloro-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (202) (0.290 g, 0.685 mmol) in 6 
M aqueous hydrochloric acid solution (48 mL). The crude material was purified by 
recrystallisation from methanol and diethyl ether to afford (2S)-2-amino-3-(5ʹ,6ʹ-dichloro-
1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (207) as a pale brown solid 
(0.167 g, 88%). Mp 180‒182 °C (dec); νmax/cm−1 (neat) 3381 (NH), 2875 (OH/CH), 1740 
(CO), 1507, 1434, 1214, 822; [α]D23 +11.4 (c 1.0, MeOH); δH (400 MHz, CD3OD) 4.81 (1H, 
br t, J 4.8 Hz, 2-H), 5.29 (1H, dd, J 15.5, 4.8 Hz, 3-HH), 5.38 (1H, dd, J 15.5, 4.8 Hz, 3-
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HH), 8.18 (1H, s, 7ʹ-H), 8.24 (1H, s, 4ʹ-H); δC (101 MHz, CD3OD) 47.0 (CH2), 52.1 (CH), 
111.8 (CH), 120.1 (CH), 128.9 (C), 132.6 (C), 132.7 (C), 144.4 (C), 167.5 (C); m/z (ESI) 
296.9915 (MNa+. C9H835Cl2N4NaO2 requires 296.9917). 
(2S)-2-Amino-3-(6ʹ-chloro-5ʹ-methyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid 
hydrochloride (208) 
 
(2S)-2-Amino-3-(6ʹ-chloro-5ʹ-methyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid 
hydrochloride (208) was synthesised as described for (2S)-2-amino-3-(1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (186) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(6ʹ-chloro-5ʹ-methyl-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoate (203) (0.240 g, 0.596 mmol) in 6 M aqueous hydrochloric acid solution (42 
mL). The crude material was purified by recrystallisation from methanol and diethyl ether 
to afford (2S)-2-amino-3-(6ʹ-chloro-5ʹ-methyl-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid 
hydrochloride (208) as a pale brown solid (0.139 g, 92%). Mp 199‒201 °C (dec); νmax/cm−1 
(neat) 3376 (NH), 2951 (OH/CH), 1744 (CO), 1454, 1228, 1001, 865; [α]D23 +11.1 (c 1.0, 
MeOH); δH (400 MHz, CD3OD) 2.53 (3H, s, 5ʹ-CH3), 4.78 (1H, dd, J 5.5, 4.2 Hz, 2-H), 5.22 
(1H, dd, J 15.5, 4.2 Hz, 3-HH), 5.32 (1H, dd, J 15.5, 5.5 Hz, 3-HH), 7.94 (1H, s, 7ʹ-H), 7.95 
(1H, s, 4ʹ-H); δC (101 MHz, CD3OD) 19.4 (CH3), 46.7 (CH2), 52.1 (CH), 110.0 (CH), 119.6 
(CH), 132.7 (C), 133.3 (C), 135.5 (C), 144.5 (C), 167.5 (C); m/z (ESI) 255.0651 (MH+. 
C10H1235ClN4O2 requires 255.0643). 
(2S)-2-Amino-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid 
hydrochloride (206) 
 
(2S)-2-Amino-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride 
(206) was synthesised as described for (2S)-2-amino-3-(1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoic acid hydrochloride (186) using methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-
(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (204) (0.200 g, 0.462 mmol) in 6 M 
aqueous hydrochloric acid solution (20 mL). The crude material was purified by 
recrystallisation from methanol and diethyl ether to afford (2S)-2-amino-3-(5ʹ-bromo-1H-
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benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (206) as a pale brown solid (0.103 
g, 78%). Mp 168‒172 °C; νmax/cm−1 (neat) 3387 (NH), 2847 (OH/CH), 1744 (CO), 1474, 
1211, 802; [α]D22 +9.1 (c 0.7, MeOH); δH (500 MHz, CD3OD) 4.74 (1H, dd, J 5.9, 4.0 Hz, 2-
H), 5.24 (1H, dd, J 15.5, 4.0 Hz, 3-HH), 5.34 (1H, dd, J 15.5, 5.9 Hz, 3-HH), 7.73 (1H, dd, 
J 8.8, 1.7 Hz, 6ʹ-H), 7.78 (1H, dd, J 8.8, 0.5 Hz, 7ʹ-H), 8.26 (1H, dd, J 1.7, 0.5 Hz, 4ʹ-H); δC 
(126 MHz, CD3OD) 48.3 (CH2), 53.6 (CH), 112.9 (CH), 119.0 (C), 123.1 (CH), 132.7 (CH), 
134.0 (C), 148.1 (C), 169.0 (C); m/z (ESI) 284.9978 (MH+. C9H1079BrN4O2 requires 
284.9982). 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(7ʹ-bromo-6ʹ-methoxy-1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (210) 
 
To a dry flask under argon was added iron(III) choride (0.0030 g, 0.018 mmol) and 
[BMIM]NTf2 (0.21 mL, 0.73 mmol) and the mixture stirred for 0.5 h. Methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(6ʹ-methoxy-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate 
(201) (0.14 g, 0.36 mmol) was then added as a solution in dichloromethane (5.0 mL), 
followed by N-bromosuccinimide (0.065 g, 0.36 mmol). After 1 h of stirring at room 
temperature, the mixture was diluted with ethyl acetate (20 mL) and filtered through a 
short pad of silica. The filtrate was washed with a 1 M aqueous solution of sodium 
thiosulfate (2 × 20 mL) and brine (20 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The crude material was purified by flash column chromatography, eluting with 10% 
ethyl acetate in dichloromethane to afford methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(7ʹ-
bromo-6ʹ-methoxy-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (210) as a white solid (0.14 
g, 85%). Mp 122‒124 °C; νmax/cm−1 (neat) 3331 (NH), 2953 (CH), 1724 (CO), 1501 (C=C), 
1261, 1065; [α]D23 −5.4 (c 1.0, CHCl3); δH (500 MHz, CDCl3) 3.76 (3H, s, OCH3), 4.00 (3H, 
s, OCH3), 4.96‒5.12 (3H, m, 2-H and OCH2Ph), 5.28 (1H, dd, J 14.4, 6.9 Hz, 3-HH), 5.47 
(1H, dd, J 14.4, 4.8 Hz, 3-HH), 5.68 (1H, d, J 8.1 Hz, NH), 7.09 (1H, d, J 9.0 Hz, 5ʹ-H), 
7.24‒7.36 (5H, m, Ph), 7.95 (1H, d, J 9.0 Hz, 4ʹ-H); δC (126 MHz, CDCl3) 49.8 (CH2), 53.0 
(CH3), 54.4 (CH), 57.5 (CH3), 67.2 (CH2), 90.1 (C), 111.2 (CH), 119.8 (CH), 128.1 (2 × 
CH), 128.2 (CH), 128.5 (2 × CH), 132.9 (C), 135.9 (C), 142.3 (C), 155.7 (C), 156.2 (C), 
169.7 (C); m/z (ESI) 485.0430 (MNa+. C19H1979BrN4NaO5 requires 485.0430). 
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Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[6ʹ-methoxy-7ʹ-(4ʹʹ-methoxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (211) 
 
To a solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-(7ʹ-bromo-6ʹ-methoxy-1H-
benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (210) (0.140 g, 0.302 mmol) in 1,4-dioxane (3.0 
mL) and water (0.23 mL) was added 4-methoxyphenylboronic acid (0.0734 g, 0.483 
mmol), potassium fluoride (0.0526 g, 0.906 mmol) and [1,1ʹ-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1:1) (0.0186 g, 0.0227 mmol). The 
mixture was degassed under argon for 0.25 h before heating to 80 °C for 24 h. The 
reaction was then cooled to ambient temperature and filtered through a pad of Celite®, 
diluted with ethyl acetate (20 mL) and washed with water (3 × 20 mL) and brine (20 mL). 
The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The crude 
material was purified by flash column chromatography, eluting with 10% ethyl acetate in 
dichloromethane to afford methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[6ʹ-methoxy-7ʹ-(4ʹʹ-
methoxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (211) as a pale orange oil 
(0.0979 g, 66%). νmax/cm−1 (neat) 3350 (NH), 2954 (CH), 1748 (CO), 1723 (CO), 1519 
(C=C), 1497, 1288, 1065, 1028, 752; [α]D20 −26.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 
3.62 (3H, s, OCH3), 3.83 (3H, s, OCH3), 3.88 (3H, s, OCH3), 4.31 (1H, dd, J 13.8, 3.6 Hz, 
3-HH), 4.43‒4.58 (2H, m, 2-H and 3-HH), 4.98 (2H, s, OCH2Ph), 5.57 (1H, d, J 8.6 Hz, 
NH), 6.97‒7.07 (2H, m, 3ʹʹ-H and 5ʹʹ-H), 7.17 (1H, d, J 9.1 Hz, 5ʹ-H), 7.21‒7.38 (7H, m, Ph, 
2ʹʹ-H and 6ʹʹ-H), 8.00 (1H, d, J 9.1 Hz, 4ʹ-H); δC (101 MHz, CDCl3) 49.9 (CH2), 52.7 (CH3), 
53.6 (CH), 55.3 (CH3), 57.2 (CH3), 67.1 (CH2), 111.2 (CH), 111.8 (C), 114.0 (CH), 114.2 
(CH), 119.7 (CH), 124.5 (C), 127.9 (2 × CH), 128.1 (CH), 128.5 (2 × CH), 131.7 (CH), 
131.8 (CH), 133.0 (C), 136.0 (C), 141.7 (C), 155.6 (C), 156.7 (C), 159.6 (C), 169.6 (C); 
m/z (EI) 490.1831 (M+. C26H26N4O6 requires 490.1852), 382 (90%), 240 (94), 227 (42), 
212 (37), 108 (52), 91 (100), 79 (49). 
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(2S)-2-Amino-3-(6ʹ-methoxy-7ʹ-(4ʹʹ-methoxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoic acid hydrochloride (212) 
 
To a solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[6ʹ-methoxy-7ʹ-(4ʹʹ-
methoxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (211) (0.097 g, 0.198 mmol) in 
methanol (7.0 mL) and water (3.0 mL) was added caesium carbonate (0.084 g, 0.257 
mmol) and the reaction stirred at room temperature for 16 h. The reaction mixture was 
concentrated in vacuo and dissolved in water (5.0 mL), before the addition of 1 M 
aqueous hydrochloric acid solution (10 mL). The product was extracted with 
dichloromethane (3 × 20 mL), dried (MgSO4), filtered and concentrated in vacuo to afford 
(2S)-2-[(benzyloxycarbonyl)amino]-3-[6ʹ-methoxy-7ʹ-(4ʹʹ-methoxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid as a yellow foam (0.089 g, 94%). This material 
was then used immediately in the following step. To a solution of (2S)-2-
[(benzyloxycarbonyl)amino]-3-[6ʹ-methoxy-7ʹ-(4ʹʹ-methoxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoic acid (0.044 g, 0.092 mmol) in tetrahydrofuran (5 mL) 
was added 10% palladium on carbon (0.019 g) and the reaction mixture purged under 
hydrogen gas for 1 h, before stirring at room temperature under a hydrogen atmosphere 
for 16 h. The reaction mixture was then treated with a 1 M aqueous solution of 
hydrochloric acid (0.50 mL), filtered through Celite®, washed with methanol (10 mL) and 
the filtrate was concentrated in vacuo. The resulting residue was recrystallised from 
methanol and diethyl ether to afford (2S)-2-amino-3-(6ʹ-methoxy-7ʹ-(4ʹʹ-methoxyphenyl)-
1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid hydrochloride (212) as a white solid (0.023 
g, 73%). Mp 130‒132 °C; νmax/cm−1 (neat) 3698 (NH), 2931 (OH/CH), 1686 (CO), 1595 
(C=C), 1354, 1252, 1169, 984; [α]D19 −6.2 (c 0.1, MeOH); δH (400 MHz, CD3OD) 3.83 (3H, 
s, OCH3), 3.85‒3.97 (4H, m, OCH3 and 2-H), 4.43 (1H, dd, J 15.2, 9.6 Hz, 3-HH), 4.57 
(1H, dd, J 15.2, 2.5 Hz, 3-HH), 7.00‒7.12 (2H, m, 3ʹʹ-H and 5ʹʹ-H), 7.23‒7.34 (2H, m, 2ʹʹ-H 
and 6ʹʹ-H), 7.37 (1H, d, J 9.1 Hz, 5ʹ-H), 7.99 (1H, d, J 9.1 Hz, 4ʹ-H); δC (126 MHz, CD3OD) 
50.8 (CH2), 55.1 (CH), 55.8 (CH3), 57.7 (CH3), 113.5 (CH), 113.9 (C), 115.2 (CH), 115.3 
(CH), 120.0 (CH), 125.6 (C), 132.8 (CH), 133.2 (CH), 134.3 (C), 142.7 (C), 158.6 (C), 
161.3 (C), 170.2 (C); m/z (ESI) 365.1210 (MNa+. C17H18N4NaO4 requires 365.1220). 
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tert-Butyl-(3-fluoro-4-nitrophenoxy)dimethylsilane (220) 
 
To a solution of 3-fluoro-4-nitrophenol (2.00 g, 12.7 mmol) in dichloromethane (50 mL) 
under argon was added tert-butyldimethylsilyl chloride (2.30 g, 15.3 mmol), imidazole 
(1.70 g, 25.4 mmol) and 4-dimethylaminopyridine (0.155 g, 1.27 mmol). The reaction 
mixture was stirred for 16 h at room temperature. The mixture was then diluted with 
dichloromethane (50 mL) and washed with water (3 × 50 mL) and brine (100 mL), dried 
(MgSO4), filtered and the solvent removed in vacuo. The crude material was purified by 
flash column chromatography, eluting with 5% ethyl acetate in petroleum ether (40‒60) to 
afford tert-butyl-(3-fluoro-4-nitrophenoxy)dimethylsilane (220) as a yellow oil (3.24 g, 
94%). νmax/cm−1 (neat) 2931 (CH), 1597 (C=C), 1328, 1284, 1093, 982, 824, 783; δH (400 
MHz, CDCl3) 0.27 (6H, s, OSi(CH3)2), 0.98 (9H, s, C(CH3)3), 6.64‒6.72 (2H, m, 2-H and 6-
H), 8.03 (1H, dd, J 9.5, 8.9 Hz, 5-H); δC (101 MHz, CDCl3) −4.4 (2 × CH3), 18.2 (C), 25.4 
(3 × CH3), 109.3 (CH, d, 
2JCF 21.9 Hz), 116.0 (CH, d, 
3JCF 3.1 Hz), 127.7 (CH, d, 
4JCF 1.5 
Hz), 131.4 (C, d, 2JCF 6.3 Hz), 157.2 (C, d, 
1JCF 265.6 Hz), 162.3 (C, d, 
3JCF 11.5 Hz); m/z 
(ESI) 294.0924 (MNa+. C12H18FNNaO3Si requires 294.0932). 
3-Fluoro-1-(methoxymethoxy)-4-nitrobenzene (224) 
 
To a solution of 3-fluoro-4-nitrophenol (1.00 g, 6.37 mmol) in dichloromethane (35 mL) at 
0 °C under argon was added N,N-diisopropylethylamine (1.70 mL, 9.56 mmol) and stirred 
for 0.1 h. Bromomethyl methyl ether (0.570 mL, 7.01 mmol) was then added and the 
reaction mixture stirred for 0.5 h before heating under reflux for 2 h. The reaction was 
taken up in water (50 mL) and extracted with dichloromethane (15 mL) and then ethyl 
acetate (2 × 50 mL). The combined organic layers were dried (MgSO4), filtered and the 
solvent removed in vacuo. The crude material was purified by flash column 
chromatography, eluting with 10% ethyl acetate in petroleum ether (40‒60) to afford 3-
fluoro-1-(methoxymethoxy)-4-nitrobenzene (224) as a yellow oil (1.27 g, 99%). νmax/cm−1 
(neat) 2940 (CH), 1605 (C=C), 1520 (C=C), 1342, 1273, 1150, 1072, 988, 748, 733; δH 
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(400 MHz, CDCl3) 3.45 (3H, s, OCH3), 5.21 (2H, s, OCH2), 6.82‒6.90 (2H, m, 2-H and 6-
H), 8.01 (1H, br t, J 9.0 Hz, 5-H); δC (101 MHz, CDCl3) 56.7 (CH3), 94.6 (CH2), 105.4 (CH, 
d, 2JCF 24.3 Hz), 112.2 (CH, d, 
3JCF 3.2 Hz), 127.8 (CH, d, 
4JCF 1.7 Hz), 131.4 (C, d, 
2JCF 
6.7 Hz), 157.3 (C, d, 1JCF 264.6 Hz), 163.0 (C, d, 
3JCF 11.1 Hz); m/z (ESI) 224.0324 
(MNa+. C8H8FNNaO4 requires 224.0330). 
3-Fluoro-1-(4ʹ-methoxybenzyloxy)-4-nitrobenzene (227) 
 
To a solution of 3-fluoro-4-nitrophenol (1.00 g, 6.37 mmol) in acetone (20 mL) under argon 
was added 4-methoxybenzyl chloride (0.950 mL, 7.01 mmol), potassium carbonate (1.80 
g, 12.7 mmol) and tetrabutylammonium iodide (0.24 g, 0.637 mmol) and the reaction 
stirred under reflux for 2 h. The solvent was removed in vacuo and the residue dissolved 
in ethyl acetate (50 mL) and washed with water (3 × 50 mL). The combined organic layers 
were dried (MgSO4), filtered and the solvent removed in vacuo. The crude material was 
purified by flash column chromatography, eluting with dichloromethane and subsequently 
recrystallised from hexane to afford 3-fluoro-1-(4ʹ-methoxybenzyloxy)-4-nitrobenzene 
(227) as white crystals (1.64 g, 93%). Mp 101‒103 °C; νmax/cm−1 (neat) 2940 (CH), 1605 
(C=C), 1512 (C=C), 1342, 1296, 1250, 1173, 1096, 833; δH (400 MHz, CDCl3) 3.82 (3H, s, 
OCH3), 5.06 (2H, s, OCH2Ar), 6.79 (1H, dd, J 12.7, 2.7 Hz, 2-H), 6.82 (1H, ddd, J 9.0, 2.7, 
0.9 Hz, 6-H), 6.94 (2H, d, J 8.6 Hz, 3ʹ-H and 5ʹ-H), 7.35 (2H, d, J 8.6 Hz, 2ʹ-H and 6ʹ-H), 
8.07 (1H, dd, J 9.2, 9.0 Hz, 5-H); δC (101 MHz, CDCl3) 55.4 (CH3), 71.0 (CH2), 104.1 (CH, 
d, 2JCF 24.2 Hz), 111.1 (CH, d, 
3JCF 3.1 Hz), 114.3 (2 × CH), 126.9 (C), 127.9 (CH, d, 
4JCF 
1.5 Hz), 129.5 (2 × CH), 130.8 (C, d, 2JCF 6.8 Hz), 157.4 (C, d, 
1JCF 265.0 Hz), 160.0 (C), 
164.5 (C, d, 3JCF 11.0 Hz); m/z (ESI) 300.0633 (MNa+. C14H12FNNaO4 requires 300.0643). 
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Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-hydroxy-2ʹ-
nitrophenyl)amino]propanoate (221) 
 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-[(5ʹ-hydroxy-2ʹ-nitrophenyl)amino]propanoate 
(221) was synthesised as described for methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[(2ʹ-
nitrophenyl)amino]propanoate (189) using methyl (2S)-3-amino-2-
[(benzyloxycarbonyl)amino]propanoate hydrochloride (191) (0.050 g, 0.20 mmol), 3-fluoro-
4-nitrophenol (0.093 g, 0.59 mmol) and triethylamine (0.083 mL, 0.59 mmol) in acetonitrile 
(3.0 mL). The crude material was purified by flash column chromatography, eluting with 
5% ethyl acetate and 1% tetrahydrofuran in dichloromethane to afford methyl (2S)-2-
(benzyloxycarbonyl)amino]-3-[(5ʹ-hydroxy-2ʹ-nitrophenyl)amino]propanoate (221) as a 
yellow solid (0.023 g, 49%). Mp 85‒87 °C; νmax/cm−1 (neat) 3348 (NH), 2924 (CH), 1701 
(CO), 1620 (CO), 1516 (C=C), 1227, 1061; [α]D22 +18.8 (c 1.0, CHCl3); δH (400 MHz, 
CDCl3) 3.69 (2H, br t, J 6.5 Hz, 3-H2), 3.80 (3H, s, OCH3), 4.63 (1H, dt, J 6.7, 6.1 Hz, 2-H), 
5.14 (2H, s, CH2Ph), 5.71 (1H, d, J 6.7 Hz, NH), 6.17 (1H, dd, J 9.3, 2.3 Hz, 4ʹ-H), 6.37 
(1H, d, J 2.3 Hz, 6ʹ-H), 6.72 (1H, br s, OH), 7.29‒7.41 (5H, m, Ph), 8.10 (1H, d, J 9.3 Hz, 
3ʹ-H), 8.44 (1H, t, J 6.5 Hz, NH); δC (101 MHz, CDCl3) 44.6 (CH2), 53.1 (CH3), 53.1 (CH), 
67.6 (CH2), 97.6 (CH), 106.3 (CH), 127.2 (C), 128.1 (2 × CH), 128.5 (CH), 128.7 (2 × CH), 
129.9 (CH), 135.6 (C), 147.2 (C), 156.1 (C), 163.2 (C), 170.6 (C); m/z (ESI) 412.1111 
(MNa+. C18H19N3NaO7 requires 412.1115). 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-{[5ʹ-(methoxymethoxy)-2ʹ-
nitrophenyl]amino}propanoate (225) 
 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-{[5ʹ-(methoxymethoxy)-2ʹ-
nitrophenyl]amino}propanoate (225) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino]propanoate (189) using methyl (2S)-
3-amino-2-[(benzyloxycarbonyl)amino]propanoate hydrochloride (191) (0.400 g, 1.59 
mmol), 3-fluoro-1-(methoxymethoxy)-4-nitrobenzene (0.960 g, 4.77 mmol) and 
triethylamine (0.665 mL, 4.77 mmol) in acetonitrile (12 mL). The crude material was 
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purified by flash column chromatography, eluting with 0‒20% ethyl acetate in 
dichloromethane to afford methyl (2S)-2-(benzyloxycarbonyl)amino]-3-{[5ʹ-
(methoxymethoxy)-2ʹ-nitrophenyl]amino}propanoate (225) as a yellow oil (0.572 g, 83%). 
νmax/cm−1 (neat) 3356 (NH), 2955 (CH), 1721 (CO), 1620 (CO), 1497 (C=C), 1211, 748; 
[α]D23 +17.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.47 (3H, s, OCH2OCH3), 3.72 (2H, br t, 
J 5.9 Hz, 3-H2), 3.79 (3H, s, OCH3), 4.65 (1H, dt, J 6.9, 5.7 Hz, 2-H), 5.12 (2H, s, CH2Ph), 
5.21 (1H, d, J 6.8 Hz, OCHH2OCH3), 5.24 (1H, d, J 6.8 Hz, OCHH2OCH3), 5.68 (1H, d, J 
6.9 Hz, NH), 6.37 (1H, dd, J 9.5, 2.5 Hz, 4ʹ-H), 6.53 (1H, d, J 2.5 Hz, 6ʹ-H), 7.28‒7.42 (5H, 
m, Ph), 8.14 (1H, d, J 9.5 Hz, 3ʹ-H), 8.42 (1H, t, J 5.9 Hz, NH); δC (101 MHz, CDCl3) 44.7 
(CH2), 53.0 (CH3), 53.3 (CH), 56.5 (CH3), 67.4 (CH2), 94.2 (CH2), 98.2 (CH), 106.2 (CH), 
127.7 (C), 128.1 (2 × CH), 128.3 (CH), 128.6 (2 × CH), 129.3 (CH), 135.9 (C), 147.0 (C), 
155.8 (C), 163.7 (C), 170.7 (C); m/z (ESI) 456.1365 (MNa+. C20H23N3NaO8 requires 
456.1377). 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-{[5ʹ-(4ʹʹ-methoxybenzyloxy)-2ʹ-
nitrophenyl]amino}propanoate (228) 
 
Methyl (2S)-2-(benzyloxycarbonyl)amino]-3-{[5ʹ-(4ʹʹ-methoxybenzyloxy)-2ʹ-
nitrophenyl]amino}propanoate (228) was synthesised as described for methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-[(2ʹ-nitrophenyl)amino]propanoate (189) using methyl (2S)-
3-amino-2-[(benzyloxycarbonyl)amino]propanoate hydrochloride (191) (0.400 g, 1.59 
mmol), 3-fluoro-1-(4-methoxybenzyloxy)-4-nitrobenzene (1.32 g, 4.77 mmol) and 
triethylamine (0.665 mL, 4.77 mmol) in acetonitrile (12 mL). The crude material was 
purified by flash column chromatography, eluting with 0‒20% ethyl acetate in 
dichloromethane to afford methyl (2S)-2-(benzyloxycarbonyl)amino]-3-{[5ʹ-(4ʹʹ-
methoxybenzyloxy)-2ʹ-nitrophenyl]amino}propanoate (228) as a yellow oil (0.694 g, 86%). 
Mp 79‒81 °C; νmax/cm−1 (neat) 3356 (NH), 2955 (CH), 1721 (CO), 1613 (CO), 1497 (C=C), 
1219, 903, 725; [α]D22 +13.6 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 3.63‒3.74 (2H, m, 3-H2), 
3.76 (3H, s, OCH3), 3.79 (3H, s, OCH3), 4.62 (1H, dt, J 7.0, 6.1 Hz, 2-H), 5.04 (1H, d, J 
11.3 Hz, CHHAr), 5.07 (1H, d, J 11.3 Hz, CHHAr), 5.08 (1H, d, J 12.2 Hz, CHHPh), 5.12 
(1H, d, J 12.2 Hz, CHHPh), 5.77 (1H, d, J 7.0 Hz, NH), 6.30 (1H, dd, J 9.5, 2.5 Hz, 4ʹ-H), 
6.49 (1H, d, J 2.5 Hz, 6ʹ-H), 6.91 (2H, d, J 8.7 Hz, 3ʹʹ-H and 5ʹʹ-H), 7.25‒7.38 (5H, m, Ph), 
7.33 (2H, d, J 8.7 Hz, 2ʹʹ-H and 6ʹʹ-H), 8.10 (1H, d, J 9.5 Hz, 3ʹ-H), 8.49 (1H, t, J 5.8 Hz, 
NH); δC (101 MHz, CDCl3) 44.5 (CH2), 53.0 (CH3), 53.2 (CH), 55.3 (CH3), 67.3 (CH2), 70.3 
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(CH2), 96.4 (CH), 106.1 (CH), 114.1 (2 × CH), 127.0 (C), 127.8 (C), 128.1 (2 × CH), 128.3 
(CH), 128.5 (2 × CH), 129.2 (CH), 129.4 (2 × CH), 135.9 (C), 147.2 (C), 155.8 (C), 159.7 
(C), 165.3 (C), 170.7 (C); m/z (ESI) 532.1677 (MNa+. C26H27N3NaO8 requires 532.1690). 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(2ʹʹ-hydroxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (229) 
 
Methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(2ʹʹ-hydroxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (229) was synthesised as described for methyl 
(2S)-2-[(benzyloxycarbonyl)amino]-3-[6ʹ-methoxy-7ʹ-(4ʹʹ-methoxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (211) using methyl (2S)-2-
[(benzyloxycarbonyl)amino]-3-(5ʹ-bromo-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoate (204) 
(0.400 g, 0.920 mmol), 2-hydroxyphenylboronic acid (0.200 g, 1.47 mmol), potassium 
fluoride (0.160 g, 2.76 mmol) and [1,1ʹ-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1:1) (0.0566 g, 0.0690 mmol) in 
1,4-dioxane (8.0 mL) and water (0.60 mL). The crude material was purified by flash 
column chromatography, eluting with 10% ethyl acetate in dichloromethane to afford 
methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(2ʹʹ-hydroxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (229) as a pale orange solid (0.380 g, 93%). Mp 
55‒56 °C; νmax/cm−1 (neat) 3337 (NH/OH), 2953 (CH), 1695 (CO), 1510 (C=C), 1454, 
1211, 1057, 752; [α]D19 +15.4 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 4.69 (3H, s, OCH3), 
4.82 (1H, dt, J 7.1, 4.4 Hz, 2-H), 4.95‒5.15 (4H, m, 3-H2 and OCH2Ph), 5.86 (1H, d, J 7.1 
Hz, NH), 6.95 (1H, br t, J 7.9 Hz, 5ʹʹ-H), 7.03 (1H, d, 7.8 Hz, 3ʹʹ-H), 7.20 (1H, ddd, J 7.9, 
7.8, 1.6 Hz, 4ʹʹ-H), 7.22‒7.32 (6H, m, Ph and 6ʹʹ-H), 7.37 (1H, d, J 8.6 Hz, 7ʹ-H), 7.55 (1H, 
s, OH), 7.56 (1H, dd, J 8.6, 1.3 Hz, 6ʹ-H), 8.18 (1H, br s, 4ʹ-H); δC (101 MHz, CDCl3) 48.6 
(CH2), 53.2 (CH3), 54.2 (CH), 67.3 (CH2), 109.0 (CH), 116.5 (CH), 119.9 (CH), 120.6 (CH), 
127.4 (C), 128.2 (2 × CH), 128.3 (CH), 128.5 (2 × CH), 129.2 (CH), 130.1 (CH), 130.8 
(CH), 132.9 (C), 134.8 (C), 135.8 (C), 145.6 (C), 153.4 (C), 155.8 (C), 169.3 (C); m/z (ESI) 
469.1477 (MNa+. C24H22N4NaO5 requires 469.1482). 
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(2S)-2-Amino-3-(5ʹ-(2ʹʹ-hydroxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-yl)propanoic acid 
hydrochloride (231) 
 
To a solution of methyl (2S)-2-[(benzyloxycarbonyl)amino]-3-[5ʹ-(2ʹʹ-hydroxyphenyl)-1H-
benzo[d][1.2.3]triazol-1ʹ-yl]propanoate (229) (0.100 g, 0.224 mmol) in 1,4-dioxane (1.0 
mL) was added 6 M aqueous hydrochloric acid solution (5 mL). The reaction mixture was 
heated under reflux for 4 h. After cooling to ambient temperature, the reaction mixture was 
concentrated in vacuo and the resulting residue recrystallised from methanol and diethyl 
ether to afford (2S)-2-amino-3-(5ʹ-(2ʹʹ-hydroxyphenyl)-1H-benzo[d][1.2.3]triazol-1ʹ-
yl)propanoic acid hydrochloride (231) as a pale brown solid (0.065 g, 97%). Mp 198‒200 
°C; νmax/cm−1 (neat) 3165 (NH), 2945 (OH/CH), 1746 (CO), 1603 (C=C), 1485, 1238, 754; 
[α]D19 +9.4 (c 1.0, MeOH); δH (500 MHz, CD3OD) 4.81 (1H, dd, J 5.7, 4.1 Hz, 2-H), 5.29 
(1H, dd, J 15.5, 4.1 Hz, 3-HH), 5.38 (1H, dd, J 15.5, 5.7 Hz, 3-HH), 6.90‒6.98 (2H, m, 3ʹʹ-
H and 5ʹʹ-H), 7.21(1H, ddd, J 8.9, 7.5, 1.6 Hz, 4ʹʹ-H), 7.33 (1H, dd, J 7.8, 1.6 Hz, 6ʹʹ-H), 
7.83 (1H, d, J 8.7 Hz, 7ʹ-H), 7.87 (1H, dd, J 8.7, 1.3 Hz, 6ʹ-H), 8.16 (1H, br s, 4ʹ-H); δC (126 
MHz, CD3OD) 46.7 (CH2), 52.2 (CH), 108.8 (CH), 115.6 (CH), 118.7 (CH), 119.7 (CH), 
127.3 (C), 128.7 (CH), 130.5 (CH), 130.6 (CH), 132.5 (C), 136.4 (C), 145.8 (C), 154.2 (C), 
167.6 (C); m/z (ESI) 299.1135 (MH+. C15H15N4O3 requires 299.1139). 
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